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          Development of Bisamides as Kappa Opioid Receptor Agonists. The structure-activity 
relationship (SAR) expansion was carried out on bisamides KOR agonists. Previous four-step 
linear synthetic route was replaced by Ugi multicomponent reaction, affording final compound in 
one step. Parallel synthesis was adopted using Bohdan MiniBlock synthesis platform in 
combination with subsequent purification with MS-directed HPLC. A total of 80 analogues with 
diverse substitutions were prepared, including three pairs of enantiomers obtained by chiral HPLC 
separation of racemic precursors. All of the final compounds were tested in [35S]GTPγS functional 
assay. Enantiopure analogues were also accessed by arrestin2 imaging assay. Several analogues 
with improved potency and bias toward G-protein signaling were obtained. A useful SAR was 
established based on the biological results obtained, which would direct the study of this 
chemotype in future. 
          Potency Enhancement of Sulfonamide-based Kappa Opioid Receptor Antagonists. 
Structural modification on a sulfonamide-based KOR antagonists was accomplished. A total of 34 
analogues were prepared through linker replacement, constraint manipulation, and substitution 
introduction. All of the final compounds were assayed using a DiscoveRx PathHunter -arrestin 
assay platform. One compound with four-fold increase of potency (IC50 = 18.9 ± 4 nM) was 
obtained, compared with the lead compound (IC50 = 83.5 ± 20.3 nM). A putative binding mode of 
sulfonamide analogues with the KOR were generated based on the data obtained previously and 
this study. The enriched SAR and putative binding mode provide insights into the interactions 
between sulfonamide analogues and the KOR which will direct further study on this chemotype. 
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          Asymmetric Acyl Transfer Reactions Catalyzed by a Cyclic Peptide. Kinetic resolution 
of secondary alcohols by a cyclic peptide was described. The cyclic peptide was designed as a 
modified version of Miller’s peptide catalyst, which was synthesized in five steps. Single crystal 
X-ray experiments demonstrated that it adopted a conformation close to type II -turn. Selectivity 
of this proposed catalyst was examined on five secondary alcohols, with best selectivity factor as 
about 24.  
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Development of Bisamides as Kappa Opioid Receptor Agonists. 
Introduction 
A Brief History of Opium and Opioid 
          Opioid receptors are important targets for the treatment of pain. Clinically used analgesics 
like morphine (Figure 1.1), which was isolated originally from opium, act primarily through the 
mu opioid receptor (MOR) and remain the gold standard for the treatment of severe pain. Humans 
have been utilizing opium for religious or therapeutic purposes for a long time.1 It is believed that 
the Sumerians, inhabiting what is presently Iraq, cultivated poppies and isolated opium from their 
seed capsules at the end of the third millennium B.C. 
They called opium “gil,” the word for joy, and the 
poppy “hul gil,” plant for joy. It is suggested that 
opium originated from Sumeria then spread to the 
other parts of the old world. Opium was brought to India2 and China3 as early as the eighth century 
A.D., and then spread to all parts of Europe from Anatolia. Originally opium may have been 
ingested, taken by mouth or inhaled from heated vessel, at religious rituals.1 It was also used along 
with hemlock to help people die quickly and painlessly, owning to its known euphoric effect after 
administration. In addition, it was even used as a remedy to prevent excessive crying of children, 
in a cautious manner.4 Nevertheless, opioid drug abuse and tolerance were described in 
manuscripts in Turkey, Egypt, Germany, and England starting from 16th century. Nowhere was 
the problem of addiction greater than in China, where smoking opium became popular during the 
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mid of 17th century.3 Unfortunately, the reason and mechanism causing tolerance and dependence 
were completely unknown at that time.  
 
          It was not until 1806 that the active ingredient was isolated from opium by Sertürner and 
named morphine, after the Greek god of dreams, Morpheus.4 Shortly after its discovery, morphine 
was used for minor surgical procedures, postoperatives and chronic pain. In addition to morphine, 
a number of morphine related compounds were identified from opium, including codeine (Figure 
1.1) which is a methylated version of morphine used for pain management. Thereafter, medicinal 
chemistry efforts in the search for non-addictive analgesics yielded thousands of morphine 
analogues and structurally distinct opioids, including oxycodone, hydrocodone, pethidine, and 
fentanyl (Figure 1.2). These opioids are all MOR agonists and remain the most prescribed 
analgesics for the management of pain presently, though high abuse potential remains a concern.  
 
Opioid Receptor Subtypes 
          Opioid receptors belong to the G protein-coupled receptor superfamily. There are four 
subtypes of opioid receptors, including mu (), kappa (), delta (DOR), and 
nociceptin (NOP) opioid receptors. In 1973, three independent teams demonstrated the existence 
of opioid receptors in the nervous system. Pert and Snyder showed that tritiated naloxone 
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specifically bound to opioid receptors in both mammalian brain and guinea pig intestine, which 
supported that the opioid receptor was expressed in the nervous system, although at that time it 
was unknown which subtype.5 Soon after that, Simon and coworkers reported the stereospecific 
binding of tritiated etorphine to rat-brain homogenate.6 Additionally, Terenius and coworkers 
reported the stereospecific interaction between tritiated dihydromorphine and synaptic plasma 
membrane fraction of rat cerebral cortex.7 These three reports collectively lent strong support to 
the existence of a specific opioid receptor. A few years later, three distinct opioid receptor types 
were identified based on physiological observations.8-9 Each receptor was named after the drug or 
assay system with which it was characterized:  for morphine, KOR for ketocyclazocine, and 
the DOR for the mouse vas deferens. However, the opioid receptors were solely classified 
according to the physiology response until the first DOR was cloned in 1992.10 Though all 
subtypes of opioid receptors belong to GPCR family and share similar signaling pathways, their 
outcomes upon agonist binding are different. Activation of the MOR lead to a series of 
physiological responses including pain relief, euphoria, respiratory depression, immune 
suppression, and constipation.11-13 Similarly, activation of the KOR by endogenous ligands 
dynorphin, typically dynorphin A, could also lead to pain relief and anti-pruritus effect, but 
dysphoria is another negative effect of its activation.13-16 The  activation of the DOR by its 
endogenous ligands called enkephalins leads to analgesia, immune stimulation, and respiratory 
depression,13,17,18 while the most recently discovered nociceptin receptor regulates a wide range of 
physiological functions including sensations of pain, food intake, and memory processes.19-22 
 
Pain Management and KOR as a Target for Pain Treatments 
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          Pain is usually associated with a wide range of injuries and diseases, and can be considered 
a disease itself. Acute pain is usually a normal sensation triggered in the nervous system to alert 
people of possible injury. In other words, acute pain is a necessary and helpful pain and prevents 
people from further injury.23 However, chronic pain persists and keeps firing signals in the nervous 
system for a longer than useful or helpful duration of time.24 Pain is such a universal response that 
millions of American people suffer from acute or chronic pain annually.25 Chronic unrelieved pain 
often results in longer hospital stays, rehospitalization, and increased outpatient visits. As a result, 
approximately $635 billion are cost due to pain related problems besides low work productivity. 
Currently, the analgesics used to alleviate pain can be categorized into two general classes: 
nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. 
 
          NSAIDs, represented by aspirin and ibuprofen (Figure 1.3), are amongst the most commonly 
used drugs for the treatment of pain associated with inflammation. The target of NSAIDs was 
identified as the cyclooxygenase (COX) enzyme that was essential in the synthesis of 
prostaglandin.26 Thus far, two isoforms of COX are identified in human, which are COX-1 and 
COX-2.27,28 Interestingly, COX-1 is expressed constitutively while COX-2 is found in low levels 
under normal conditions but overexpressed during inflammation.29 Thus, non-selective inhibition 
of COX-1/2 for a prolonged period with traditional NSAIDs like aspirin or ibuprofen, is not 
5 
 
preferred and could result in ulcers due to the reduced production of protective prostaglandin found 
in the stomach lining.30 COX-2-selective NSAIDs, represented by celecoxib (Figure 1.3), are 
favored in terms of minimal gastrointestinal side effects. 
 
 
          The opioid class of analgesics has been used for the treatment of pain since the discovery of 
morphine, and remains the “gold standard” for pain management. However, the use of most opioid 
analgesics is limited by side effects including addiction potentials, respiratory depression, and 
constipation.31 Moreover, use of opioid analgesics leads to development of tolerance and 
dependence after patients are exposed to these drugs for a long period of time. In the past several 
decades, tremendous efforts have been spent toward the understanding and development of opioid 
analgesics with less side effects.32-36 KOR agonists are of great interest in terms of development 
of pain-relief treatment without addiction potential, since they do not activate the dopamine reward 
pathway. KOR agonists alleviated pain with good potency in a wide variety of visceral pain models 
in which rank order of analgesic potencies were consistent with the results from cloned 
receptors.37-39 Furthermore, the analgesic effects of KOR agonists could be blocked by peripherally 
restricted KOR antagonists, indicating that these KOR agonists exert analgesic effects through 
periphery neuronal system.40-43 However, KOR agonists produced side effects like dysphoria, 
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sedation, and diuresis, which led to the discontinuation of several clinical trials (ICI199441, 
spiradoline, Figure 1.4.).44-46 Thereafter, research focus shifted to investigation of peripherally 
selective KOR agonists that would avoid side effects like sedation and dysphoria by not crossing 
the blood brain barrier.44 Another attempt to develop analgesics with an ideal pharmacological 
profile was the development of mixed-efficacy KOR/MOR agonists, which could produce strong 
analgesic effects devoid of side effects like euphoria and dysphoria. For instance, nalbuphine 
(Figure 1.4), a mixed-efficacy KOR/MOR agonist, exhibited significant analgesic effects when 
compared with placebo in a female patient group.47 However, the difference of analgesic effects 
between nalbuphine and placebo were not dose dependent in the male group. Furthermore, in this 
experiment, greater analgesic effects of nalbuphine were observed in female group compared with 
the male group at all dose levels. Nalbuphine is indicated for the moderate to severe pain, and is 
the treatment of choice especially in obstetrical analgesia during labor and delivery. Overall, the 
KOR remains an attractive target in terms of the development of effective analgesic with less side 
effects, especially less addiction potential. 
 
KOR Potential for the Treatment of Pruritus/Uremic Pruritus 
          Pruritus is defined as an unpleasant sensation that provokes the desire to scratch, which is 
the predominant symptom of skin disease and can be caused by a variety of dermatological 
conditions or systemic disorders like uremia, chronic hepatic obstruction, and haematological 
disorders, etc.48-49 However, the pathophysiology of pruritus is still poorly understood, there is no 
universally accepted therapy and the development of new effective treatment for pruritus is 
challenging. Uremic pruritus is a common complication of end-stage renal disease (ESRD), which 
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is observed in about one-third of dialysis patients. The pathogenesis of uremic pruritus is 
multifaceted and may include uremia-related abnormalities (particularly involving calcium, and 
phosphorus levels and parathyroid hormone metabolism), accumulation of uremic toxins, systemic 
inflammation, cutaneous xerosis, and common co-morbidities, such as diabetes mellitus and viral 
hepatitis. Though the understanding about pathophysiology of uremic pruritus is still not complete, 
topical and systemic agents, as well as broadband ultraviolet phototherapy, are proven to be 
beneficial.50  
          The use of antihistamines as systemic agents, especially H1-receptor antagonists, are 
supported by an old trial for the treatment of uremic pruritus.51 However, no significant difference 
was found between H1-receptor inverse agonist loratadine and placebo.
52 In clinical setting, 
antihistamines are still used as first-line therapy for uremic pruritus though frustrating results are 
often observed and further clinical trials are needed to confirm the effectiveness of this class of 
drugs.49  
 
          A relatively new hypothesis that has received increased attention is that balance between 
MOR and KOR can regulate pruritus. This hypothesis was developed based on two main 
phenomena: (a) itch was induced by central MOR in mice experiments by injecting morphine;54 
(b) dynorphin suppressed itch by binding and activating KOR. In addition, naltrexone as a MOR 
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antagonist is proven to be effective for the treatment of cholestatic pruritus.15 In an attempt to 
develop new analgesics, a synthetic opioid called nalfurafine (Figure 1.5) was discovered.55-56 In 
Phase II clinical trials of treating patients of postoperative surgery, nalfurafine possessed sufficient 
analgesic effect but an insufficient safety margin.55 However, nalfurafine was shown to suppress 
the histamine-induced scratching behavior in mice.56-57 Moreover, this compound was proven to 
be effective in treating morphine induced scratching behavior in mice, which was resistant to the 
treatment of antihistamine drugs.58 Taken together, it is suggested that nalfurafine is more effective 
than antihistamines at treating opioid-derived pruritus. Thus, nalfurafine was moved to clinical 
trials aiming at the development of antipruritus agent, followed by confirmation on various animal 
itching models. It was reported that nalfurafine is significantly effective than placebo in the 
treatment of uremic pruritus. In addition, only mild to moderate adverse drug reactions (e.g. 
insomnia) were observed in a Phase III clinical trial, which were transient and readily resolved. 
Thus, nalfurafine was considered as effective and safe in the treatment of uremic pruritus. A one-
year open-label study about nalfurafine hydrochloride was carried out, during which neither 
tolerance or dependence was observed. In 2009, nalfurafine was approved for clinical use in Japan 
and have become the first KOR agonist on the market for the treatment of pruritus. In conclusion, 
the KOR is steadily rising as target for the treatment of uremic pruritus. Further research and 
investigations are needed for a complete understanding of role of the KOR and KOR agonist in 
pruritus. 
 
KOR Potential for the Treatment of Depression 
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          Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. 
Depression can be classified into several subcategories including major depression, persistent 
depressive disorder, seasonal affective disorder, and perinatal depression, and psychotic 
depression. According to World Health Organization, more than 300 million people worldwide 
suffer from depression.59 National Institute of Mental Health estimated that approximately 16 
million adults in United States had at least one major depressive episode in 2012.60 Currently, most 
prescribed antidepressants (Figure 1.6) are divided into subclasses including tricyclics 
antidepressants (TCAs, e.g. imipramine), monoamine inhibitors (MOAIs, e.g. selegiline), selective 
serotonin reuptake inhibitors (SSRIs, e.g. fluoxetine), and serotonin–norepinephrine reuptake 
inhibitors (SNRIs, e.g. venlafaxine). Despite the availability of antidepressants, it is still 
challenging to treat depression and avoid relapse. Unfortunately, stress is a prominent trigger in 
depression relapse and is one of the most common experiences in daily life. In fact, the rate of 
depression relapse is about 80%.61 
 
 
          The opioid system modulates dopaminergic signaling in the brain. Opposing effects on 
mesolimbic dopamine system were observed via activation of MOR and KOR, with MOR agonists 
increasing dopamine levels while KOR agonists decreasing levels of dopamine.62 In addition, 
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activation of  the MOR produced euphoria, whereas KOR activation led to dysphoria and 
psychotomimetic effects in human.63 Furthermore, anhedonia-, dysphoria-, and anxiety-like 
effects were observed in rodents upon activation of the KOR.64-65 The location of KOR and 
distribution of dynorphin in the brain are critical for the physiological response of KOR 
activation.66-68  
          KOR activation by acute stress can facilitate the motivation to escape from threats. However, 
sustained KOR activation resulting from chronic stress can have adverse effects such as increased 
risk of depression, increased propensity to participate in drug-seeking behaviors, and increased 
drug-craving.65 These adverse effects are believed to occur via a mechanism involving increased 
levels of dynorphin.69 Cyclic adenosine monophosphate (cAMP) response element binding protein 
(CREB) function in the nucleus accumbens (NAc) could be increased by rewarding and stressful 
stimuli.70 In addition, subsequently increased dynorphin level resulting from activation of CREB 
after stress stimuli could contribute to symptoms of emotional numbing.71 Furthermore, elevated 
CREB function in NAc elicited the equivalent signs of major depression in rodents according to 
several studies.72-73 Stress as a trigger for addictive as well as depressive disorders, was shown to 
activate CREB in the NAc.73 In contrast, antidepressant-like effects indistinguishable from 
standard antidepressants was observed by disruption of CREB function in NAc.70 In summation, 
activation of CREB in NAc mediates aversive or depressive-like symptoms. 
          The profound influence on behavior by the KOR agonists are 
thought to reflect motivational and emotional states in animal 
models of depression and anxiety, which lead to interest in use of 
selective KOR antagonists as potential therapies for treating mood 
disorders.75-76 KOR antagonist nor-BNI (Figure 1.7) produced 
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antidepressant-like effects in the forced-swim tests (FST) in rats, which was followed up by other 
studies with similar findings.69 In addition, KOR antagonists inhibited stress-induced, but not 
cocaine-primed, reinstatement of cocaine-associated conditioned place preference (CCP) in 
mice.77-78 Furthermore, this stress-induced reinstatement of CPP in mice was abolished by genetic 
deletion of the KOR or prodynorphin.80 Overall, KOR antagonists were demonstrated to be 
potential therapies of stress-induced depression and stress triggered relapse of drug addiction.  
 
KOR Agonists 
          Numerous of KOR agonists have been reported to date, which can be roughly classified in 
several categories. The first category is morphine-derived KOR agonists, which feature a 
morphinan scaffold, like 6´-guanidinonaltrindole (6´-GNTI, Figure 1.8) or nalfurafine (discussed 
above). Compound 6´-GNTI, as a DOR-KOR heteromer-selective agonist,79 produced a prolonged 
antinociceptive response in a rat behavioral model of thermal allodynia.80 In addition, 6´-GNTI 
was a potent partial agonist at the KOR for G-protein activation (EC50 = 1.6 ± 1.3 nM,  Emax = 64 
± 6%) while it did not recruit arrestin to the KOR.81 Considering arrestin recruitment is an essential 
step in GPCR downregulation (responsible for tolerance) and induction of an array of kinase 
activation and signaling (believed to be responsible for side effects), 6´-GNTI is an attractive 
candidate to undergo further investigation as a KOR agonist.  
          The second scaffold category consists of arylacetamides, including U-50,488, U69,593 
(Figure 1.8), and, as previously described, spiradoline. U69,593 was originally prepared as 
[3H]U69,593 for the in vitro studies as a standard in 1985 as no tritiated ligand selective for KOR 
was available prior to its discovery.82 This tritiated ligand was active on the mouse  tail flick test 
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with an ED50 of 3.6 mg/kg, which was close to its analogue U50,488 and morphine (ED50 = 2.7 
and 1.6 mg/kg, respectively). In cross-tolerance studies, the EC50 of U69,693 was lightly increased 
to 7.0 mg/kg by chronic administration of morphine. In comparison the EC50 of U69,693 was 
increased from 3.6 to 50 mg/kg, by chronic dosing of U50,488, indicating U69,693  exerted its 
analgesic effects through KOR rather than MOR.82 The binding affinity of U69,693 to the KOR 
was much higher than that with MOR and DOR (approximately 100- and 2830-fold, 
respectively).83 Thus, this compound has been predominantly used as a tool compound in research 
owning to its high selectivity for the KOR over the MOR and DOR. In addition, this compound 
produced analgesic effect in animal models using rhesus monkeys. However, U69,593 suppressed 
respiration of rhesus monkeys in a dose-related manner.83 Despite the good selectivity for KOR 
and effectiveness in analgesic studies using animals, the development of U69,593 as analgesic 
therapy was hindered by its side effects.  
 
          The third scaffold category is neoclerodane diterpenes isolated from the ethnomedical plant 
Salvia divinorum. As a representative in this category, salvinorin A was the first reported 
nonnitrogenous opioid receptor agonist, demonstrated to be a powerful hallucinogen in humans.84 
Salvinorin A is unique from several aspects: (a) it is the first plant-derived KOR agonist with high 
13 
 
selectivity over the MOR and DOR; (b) it has no structural resemblance to any previously known 
KOR agonist; (c) the hallucination effect is not mediated by 5-HT2A like typical hallucinogen. 
Salvinorin A was shown to be highly selective for the KOR (Ki = 4.3 nM) over the MOR and DOR 
(both Ki > 5,000 nM) in radioligand binding assays.
85 Sedative-like and locomotor-decreasing 
effects were observed in rodent and non-human primate models after admiministration of 
salvinorin A. In addition, the effects of salvinorin A in humans could be blocked by naltrexone, 
confirming the hallucination effect was mediated by the KOR.86 Besides hallucination, salvinorin 
A suffers from a very short duration of action. Thus, efforts were carried out to improve 
pharmacological profile and phamarcokinetics of salvinorin A.87-88 
          The last scaffold category is peptide-derived analogues. Peptides are interesting in terms of 
their high hydrophilicity, which intrinsically prohibit them from crossing biological membranes 
passively.89 Thus, it is believed that peptides possess the potential to be developed as peripherally 
selective KOR agonist to avoid side effects caused by activation of KOR in CNS. A tetrapeptide 
named CR665 (Figure 1.8), identified as a KOR agonist, consist of all D-amino acids.89-90 
Interestingly, this peptide is not structurally related to KOR endogenous ligands. CR665 was 
shown to be highly selective for the KOR (Ki = 0.24 nM) over the MOR and DOR (approximately 
17,000- and 85,000-fold, respectively) in radioligand binding assays. In addition, high potency and 
efficacy (EC50 = 0.03 nM, Emax = 130%) was demonstrated in [
35S]GTPS binding assays.  More 
importantly, higher doses of this compound were required to induce centrally-mediated effects in 
the rotarod assay (548-fold higher dose), and antinociception determined in the mouse tail-flick 
assay (>1429-fold higher dose) after peripheral administration, indicating its peripheral selectivity. 
With the satisfying results of preclinical studies, CR665 was tested in Phase I clinical trials.91 This 
peptide significantly increased the pain rating threshold to esophageal distension (a type of visceral 
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pain model), but reduced the pain tolerance threshold to skin pinching. The side effect was mainly 
limited to mild pruritus at the site of administration and to mild facial tingling which was believed 
to be associated with KOR activation. Further updates about this peptide in clinical trials are not 
currently available. 
 
Discovery and Synthesis of Bisamide KOR Agonists 
          To search for novel KOR modulators with novel scaffold and therapeutic potential, a high 
throughput screening (HTS) campaign was initiated by collaborative efforts of Specialized 
Chemistry Center (the University of Kansas) and Sanford-Burnham Medical Research Center 
(California). In this HTS campaign, the bisamide class (chemotype I) KOR agonists was 
discovered, along with three other new classes of KOR agonists (Figure 1.9). 92 
 
          ML139 is attractive in terms of: (a) good selectivity for the KOR over the MOR and DOR, 
and no measurable affinity for other 41 CNS-relevant targets; (b) a novel scaffold without any 
resemblance to previously known opioid modulators; (c) modular structure allowing for selective 
improvement of unfavorable properties while retaining the positive attributes. Thus, bisamide class 
15 
 
was prioritized for optimization toward probe molecule nomination. The probe discovery efforts 
were carried out with a four-step linear synthetic route (Scheme 1.1). For instance, the synthesis 
of hit molecule ML139 began with DCC-promoted amide coupling between N-boc amino acid and 
cyclohexylamine, which afforded an N-boc amino amide intermediate. Then, the boc group was 
removed with a 1:1 mix of TFA and DCM, yielding a free amine. Then, the free amine was 
alkylated by reductive amination with thiophene-2-carboxaldehyde, followed by acylation to 
afford the desired compound. By using this route, 10 analogues were prepared. However, none of 
them possess higher potency than ML139. In addition, the purity profiles are not obtained for 
majority of these analogues.92 Thus, it is not convincing to draw a structure activity relationship 
(SAR) based on the preliminary studies on this class until enough analogues with decent purity 
would be available. 
 
 
Results and Discussion 
Design and synthesis of analogues 
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          In the preliminary study on this bisamide class of KOR agonists, a four-step linear synthetic 
route was established which afforded 10 analogues. My goal on this project is to streamline the 
synthesis of the bisamide class of KOR agonists and provide analogues with new structural 
elements to expand the SAR.   
          Multicomponent reactions (MCRs) are one pot reactions in which more than two starting 
materials react to form a final product.93-94 This convergent transformation is attractive in terms of 
atom economy that the majority if not all of the atoms of starting materials are incorporated in the 
product. In addition, MCRs are efficient, since it takes one step to install multicomponent into one 
molecule rather than several steps. The efficient and easy access to biologically relevant 
compounds by MCRs makes them useful in drug discovery. With this concept in mind, we noticed 
the scaffold of bisamide class of KOR agonists can be accessed by Ugi multicomponent reaction 
which use ketone, amine, carboxylic acid, and isocyanide as starting materials.95 To fully take 
advantage of this one-step transformation and make the analogue synthesis more efficient, the 
reaction conditions were modified for parallel synthesis on the Bohdan MiniBlock synthesis 
platform, followed by MS-directed HPLC purification. Then quenching methods (TFA vs 
Amberlyst 15) and purification methods were briefly surveyed based on a model reaction. (Figure 
1.10). Both methods were efficient enough to quench the uncomsumed isocyanide and remove its 
unpleasant smell. However, TFA was chosen as the reagent to quench the reaction, since it gave 




          Once the reaction condition and workup method were finalized, the first set of analogues 
was proposed with diverse building blocks (Figure 1.11). Cyclohexanone and cyclopentanone 
were chosen as ketone components to briefly survey how a 5- vs 6-membered ring ketone impacts 
the biological activity.  Four amines were selected as amine components, with furfurylamine and 
benzylamine as bioisosterie of 2-thiophenemethylamine to probe their influence on bioactivity and 
to potentially bypass metabolic liability issues associated thiophene moiety, with 
tetrahydrofurfurylamine, cyclohexanemethylamine as saturated version of furfurylamine and 
benzylamine for comparison and to evaluate if there would be pi interactions between ligand and 
receptor. Three carboxylic acid components were chosen including picolinic acid, nicotinic acid, 
and isonicotinic acid in order to survey the influence on the bioactivity by the position of nitrogen 
atom on pyridine ring. Lastly, cyclohexyl isocyanide and 2,6-dimethylphenyl isocyanide were 
nominated as isocyanide components to compare impacts by aromatic ring and aliphatic ring on 
18 
 
bioactivity. By every possible combination, 48 reactions were set up using two Bohdan 
MiniBlocks, each one accommodating 24 reaction tubes. The reactions were run at room 
temperature for 24 h in methanol with agitation from a shaker station. Then each reaction was 
quenched with TFA, followed by 30 min of shaking on the shaker station. Mixtures of each 
reaction was concentrated under N2 and was then submitted for purification by MS-directed HPLC. 
A total of 47 analogues (Figure 1.12) were obtained with high purity (43 analogues with 95% and 
above purity, 4 analogues with 90%-94% purity), which were suitable for biological assays. The 
only failed reaction was due to the leaking of the reaction tube. 
  
          With the success of synthesis and purification of first set of analogues, a second set was 
proposed to explore the ketone/aldehyde scope, by fixing the carboxylic acid, amine and 
isocyanide while using a different ketone or aldehyde component (Figure 1.12) for each reaction. 
The setup of reaction and subsequent purification were the same with that of the first set. A total 
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of 13 compounds out of 22 reactions 
were obtained from the second set with 
satisfying purity (see experimental 
section). However, products were not 
isolated from reactions using sterically 
hindered ketones (Q, U, and V), 1,1,1-
trifluoroacetone (T), and aliphatic 
aldehydes (R and S) due to the low 
percentage of product in the crude 
sample. Two products were obtained in 
reaction with ketone G. In contrast, only 
one product was isolated from each 
reaction (using ketones B, C, D, E, F) 
although two products were expected. 
The reason causing this phenomena was not quite understood.  It may be caused by 
diastereoselectivity or one of the products was lost during MS-directed HPLC purification. After 
obtaining some interesting bioassay results of this set of analogues, four reactions (using ketones 
C, E, F, and G) were revisited on relatively larger scale, which all afforded two diastereomeric 
products after challenging but successful chromatography separations. The relative 
stereochemistry of each of the four pairs of diastereomers were determined by single crystal X-ray 
diffraction experiments.  
          Nine one-off analogues were designed and synthesized separately in flasks rather than 
Bohdan MiniBlocks (Figure 1.14). The first two analogues (1.60 and 1.61) in this set were 
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designed to replace the thiophene or furan ring by a metabolically more stable 2-fluorophenyl ring 
while another two analogues (1.62 and 1.63) contained an n-butyl group on the spiro amide 
nitrogen to compare the effects of aliphatic chain with that of aromatic or aliphatic rings used 
previously. The next four analogous (1.64 to 1.67) were designed to see the effects of chain length 
between the phenyl ring and nitrogen atom. Another two analogues (1.68 and 1.69) were designed 
to further explore the ketone component. The last analogue (1.70) was obtained as a hydrolyzed 





          When using a non-symmetric ketone as starting material, a stereogenic center is formed at 
the amino acid carbon. To explore how the absolute configuration of this stereogenic center would 
influence the bioactivity, three pairs of 
enantiomers were designed as a set 
(Figure 1.14). By gradually increasing the 
size of R1 while fixing R2 as methyl 
group, the difference of biological 
activities between the two enantiomers (eudismic ratio) would be explored.   The three racemic 
compounds was synthesized using Ugi reaction, each of which was then separated with chiral 
HPLC to afford a pair of enantiomers. Then, one enantiomer from each pair was randomly selected 
for single crystal X-ray experiments. The absolute configuration was unambiguously determined 
by anomalous scattering of Cu X-rays by the bromine atoms. The activity and eudismic ratio will 
be discussed in the biological assay section. 
 
In Vitro Assay Studies 
          To assess the biological activity of bisamide compounds (1.1 to 1.73), two assay methods 
were employed, with [35S]GTPbinding assays as the primary screening method and arrestin2 
imaging assays as the secondary method for specific interesting compounds. In [35S]GTPbinding 
assays, cellular membranes expressed with KOR receptor were collected, then treated with drug 
molecules in the presence of radioactive non-hydrolyzable [35S]GTP. Membranes were washed 
to remove the non-bound [35S]GTP, then radioactivity of membranes were measured to determine 
the KOR activation as a function of [35S]GTPbinding. The arrestin2 imaging assays were run 
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in 384 well plates. The U2OS-hKOR-arrestin2-GFP cells were expressed the KOR and GFP-
tagged arrestin2 which upon recruitment to the receptor will form small fluorescent aggregates 
(spots). The spot count per cell was determined and used as a measure of the KOR activation. 
          In the first set of bisamide library, 47 compounds (1.1 to 1.47) were synthesized using two 
Bohdan MiniBlocks, in which compound 1.1 which was made previously during the previous SAR 
study and used as starting point in this set. All of the bioactivity data from this set are listed in the 
Table 1.1. When the 2-pyridyl group of 1.1 is replaced with a 3- or 4-pyridyl group, the resulting 
compound were completely inactive (1.3 and 1.5). Bioactivity was also lost when replacing 2-
pyridyl group on 1.2 with 3- or 4-pyridyl group (1.4 and 1.6). This trend was observed again in 
another subset (1.36, 1.38, and 1.40), suggesting the nitrogen atom on 2-pyridyl group was 
interacting with receptor. When the furan group on 1.1 was replaced with an aromatic phenyl group, 
decreased potency was observed (1.36, EC50 = 140.4 ± 35.7 nM). However, aliphatic rings 
(cyclohexyl group) replacement of furan were not tolerated (1.42). Similar phenomena were 
observed in another subset (1.2, 1.7, and 1.43), indicating that the furan could be involved in pi 
interactions with the receptor which could not be established by aliphatic rings. Replacing the left 
cyclohexyl group on 1.1 by an aromatic 2,6-dimethylphenyl group led to decreased activity (about 
3-fold). The ketone effects on bioactivity were mild, which somehow were dependent on other 
components (1.1 vs 1.2, 1.12 vs 1.13, and 1.36 vs 1.37).  





R1 R2 R3 








55 ± 10 
(n = 3) 
97 ± 1 
1.3 2-furyl 3-pyridyl 11210 77 
1.5 2-furyl 4-pyridyl NC  
1.8 2-tetrahydrofuryl 3-pyridyl NC  




480 ± 104 
(n = 4) 
96 ± 2 
1.14 phenyl 3-pyridyl NC  
1.16 phenyl 4-pyridyl NC  
1.18 cyclohexyl 2-pyridyl 15120 84 
1.20 cyclohexyl 3-pyridyl NC  
1.22 cyclohexyl 4-pyridyl NC  
1.24 2-furyl 2-pyridyl 
153 ± 29 
(n = 4) 
97 ± 0 
1.26 2-furyl 3-pyridyl NC  
1.28 2-furyl 4-pyridyl NC  
1.30 2-tetrahydrofuryl 2-pyridyl NC  
1.32 2-tetrahydrofuryl 3-pyridyl NC  




140 ± 36 
(n = 3) 
98 ± 1 
1.38 phenyl 3-pyridyl NC  
1.40 phenyl 4-pyridyl NC  
1.42 cyclohexyl 2-pyridyl >10000  
1.44 cyclohexyl 3-pyridyl NC  





R1 R2 R3 






58 ± 15 
(n = 3) 
99 ± 1 
1.4 2-furyl 3-pyridyl bNC  
1.6 2-furyl 4-pyridyl bNC  
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1.7 2-tetrahydrofuryl 2-pyridyl 12410 106 
1.9 2-tetrahydrofuryl 3-pyridyl bNC  
1.11 
 
2-tetrahydrofuryl 4-pyridyl bNC  
1.13 phenyl 2-pyridyl 
281 ± 51 
(n = 4) 
95 ± 2 
1.15 phenyl 3-pyridyl bNC  
1.17 phenyl 4-pyridyl bNC  
1.19 cyclohexyl 2-pyridyl bNC  
1.21 cyclohexyl 3-pyridyl bNC  
1.23 cyclohexyl 4-pyridyl bNC  
1.25 2-furyl 2-pyridyl 
150 ± 21 
(n = 3) 
95 ± 0 
1.27 2-furyl 3-pyridyl bNC  
1.29 2-furyl 4-pyridyl bNC  
1.31 2-tetrahydrofuryl 2-pyridyl bNC  
1.33 2-tetrahydrofuryl 3-pyridyl bNC  




67 ± 7 
(n = 4) 
98 ± 1 
1.39 phenyl 3-pyridyl bNC  
1.41 phenyl 4-pyridyl bNC  
1.43 cyclohexyl 2-pyridyl bNC  
1.45 cyclohexyl 3-pyridyl bNC  
1.47 cyclohexyl 4-pyridyl bNC  
a [35S]GTP functional assay (Membrane G protein Signaling) with n = 1 unless noted, 




          In the second set of bisamide library, 16 compounds (1.48 to 1.59, including four pairs of 
diastereomers) were synthesized, in order to expand the ketone scope of the reaction and explore 
their effects on bioactivity (Table 1.2). The first compound 1.48 was a methylated version of 
compound 1.2 (from first set). However, the relative stereochemistry was not assigned and a 
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decreased bioactivity (about 2-fold) was observed by this methylation. Effects of substituents on 
cyclohexanone moiety of 1.1 were explored by compounds 1.49 to 1.54. Two diastereomeric 
compounds (trans-1.49 and cis-1.49) were methylated version of 1.1 at the C-2 position, 
demonstrating increased bioactivity with trans-methylation (trans-1.49, relative to spiro amide 
nitrogen on C-1 positon) and decreased bioactivity with cis-methylation (cis-1.49). Similarly, 
methylations at the C-4 position of ketone moiety of 1.1 resulted in 5-fold increase of potency for 
trans-1.51 and 2-fold decrease of potency for cis-1.51. By increasing the size of substituents at C-
4 position, trans-tert-butyl group and trans-phenyl groups led to decreased bioactivity compared 
with cis-methylation (trans-1.51 vs trans-1.52, trans-1.51 vs trans-1.53). Not surprisingly, the 
cis-tert-butyl group and cis-phenyl group were not favored (cis-1.52 and cis-1.53) compared with 
the corresponding trans-diastereomers (trans-1.52 and trans-1.53). The methylation at C-3 
position (1.51) resulted in much lower bioactivity (16-fold) compared with 1.1, whose 
stereochemistry was not assigned. Tetramethylation at 3- and 5-position (1.54) was detrimental to 
the bioactivity. Expanding of the ring size of ketone moiety to 7-member (1.55) led to a slightly 
increased bioactivity (2-fold). But further expanding the ring size to 8-member (1.56) resulted in 
an equally potent compound compared with 1.1. Heterocycle replacements afforded 3 compounds 
(1.57 to 1.59), with slightly increased bioactivity for 1.57 and decreased bioactivity for 1.58 and 
1.59. 















9 ± 4 
(n = 2) 









10 ± 5 
(n = 2) 















371 ± 126 
(n = 2) 






24.4 ± 7.7 
(n = 3) 






32.4 ± 8.9 
(n = 2) 





197.2 ± 56.1 
(n = 2) 
99 ± 0 
1.59 
 
87 ± 9 
(n = 3) 
96 ± 1 
a [35S]GTP functional assay (membrane G protein signaling) with n = 1 unless noted, 
compared to U69,693 (EC50 = 35 ± 4 nM). 
 
 
          A total of 11 compounds in the one-off set were prepared, with their bioactivity data listed 
in the Table 1.3. The replacement of the furan ring on 1.1 with a 2-fluorophenyl group was shown 
to benefit the bioactivity (1.60, 2-fold increase). Not surprisingly, replacing 2-pyridyl of 1.60 by 
4-pyridyl was shown to be detrimental to bioactivity. Similarly, the next two analogues (1.62 and 
1.63) were not active, containing 3- and 4-pyridyl groups, respectively. The compounds 1.64 was 
designed with increased length (two carbon away) between the aromatic ring and nitrogen atom, 
which turned out to be detrimental to bioactivity. Not surprisingly, replacing 2-pyridyl of 1.64 with 
3- or 4-pyridyl (1.65 and 1.66) did not restore the bioactivity. In contrast, compound 1.67 was 
designed by attach the phenyl ring directly on the nitrogen atom, which resulted in complete loss 
of bioactivity. Another two analogues (1.68 and 1.69) were designed to further explore the ketone 
component, both of which possessed much lower activity compared with a similar compound 1.1. 
Lastly, compound 1.70, the byproduct obtained during the preparation of 1.69, was shown to had 
similar activity as its precursor.  
 
                        Table 1.3. Bioactivities of One-Off Bisamide Series 
cmpd.# Structure 
KOR ([35S]GTP) 








































a[35S]GTP functional assay (membrane G protein signaling) with n = 1, 
compared to U69,693 (EC50 = 35 ± 4 nM); bNC: non-convergent curve 
caused by insignificant activity. 
 
          A total of three pairs of enantiomers were prepared in this set, which were all screened in 
both [35S]GTP binding assay (membrane G protein signaling) and arrestin2 imaging assay 
(Table 1.4). All of these compounds have two alkyl substitution at the stereogenic center, which 
are a methyl group and a larger one. Interestingly, there was a general trend that the compound 
with R-configuration was more potent than its corresponding enantiomer which possessed S-
configuration ((R)-1.71 vs (S)-1.71, (R)-1.72 vs (S)-1.72, and (R)-1.73 vs (S)-1.73). In addition, 
eudismic ratio (potency difference between two enantiomers) was dependent on the differences of 
the size of two alkyl substitutions on the stereogenic center. Furthermore, it appeared that 
compound with smaller substitutions ((R)-1.71 vs (S)-1.71) were more potent in the biological 
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assay. Compared to the canonical KOR agonist U69,693, this set of bisamide compounds 
demonstrated biased activity toward G-protein signaling. It has been proposed that the 
physiological effects of KOR activation result from different signaling cascades, with analgesia 
being G protein-mediated and dysphoria being mediated through βarrestin2 recruitment.96 Thus, 
these enantiopure bisamide analogues are promising in terms of the development of analgesics 
with little dysphoric effect. 







aEC50 ± SEM 
(nM) 
Emax± SEM 
bEC50 ± SEM 
(nM) 
Emax± SEM 
(S)-1.71 Et Me 11 ± 1 95 ± 3 252 ± 78 73 ± 16 4 
(R)-1.71 Me Et 10 ± 1 98 ± 2 219 ± 49 64 ± 20 5 
(S)-1.72 iso-Bu Me 
165 ± 32 
(n = 4) 
95 ± 1 
16705 ± 
10553 
(n = 5) 
33 ± 17 16 
(R)-1.72 Me iso-Bu 
21 ± 4 
(n = 4) 
97 ± 1 
1307 ± 324 
(n = 5) 
53 ± 6 13 
(S)-1.73 n-Bu Me 
170 ± 26 
(n = 4) 
93 ± 1 
10136 ± 
3197 
(n = 3) 
20 ± 3 18 
(R)-1.73 Me n-Bu 57 ± 13 95 ± 3 2172 ± 561 65 ± 18 8 
a[35S]GTP functional assay (membrane G protein signaling) with n = 3 unless otherwise noted, compared to 
U69,693 (EC50 = 35 ± 4 nM); bArrestin2 imaging assay with n = 2 unless otherwise noted, compared to 





          In this study, the original four-step synthetic route for bisamide chemotype KOR agonists 
was replaced by a one-step Ugi multicomponent reaction, which streamlined the SAR study of this 
chemotype. In addition, parallel synthesis was employed using Bohdan MiniBlock synthesis 
platform in combination with subsequent MS-directed HPLC purification, which further facilitated 
the generation of bisamide KOR agonists. A total of 80 bisamide compounds were synthesized, 
which had diverse substitutions on the bisamide scaffold. All of the bisamide compounds were 
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Potency Enhancement of Sulfonamide-based Kappa Opioid Receptor Antagonists 
Introduction 
KOR Antagonists 
          Selective KOR antagonists, initially developed as tools for studying properties of KOR 
agonists in the 1980s, are receiving increased attention as potential pharmacotherapies for 
treatment of mood disorders and drug addictions.1-2 The first KOR antagonist named TENA 
(Figure 2.1), was reported by Portoghese and co-workers in 1982.3 However, the selectivity of 
TENA for the KOR over the MOR and DOR was about 4- and 2.5-fold, respectively. Thus, it was 
not developed into a very useful compound for studying the KOR. In 1987, nor-BNI (Figure 2.1) 
was reported by Portoghese and co-workers as a potent and selective KOR antagonist in animal 
studies, which featured a slow onset and long duration (28 days).4-9 Another KOR antagonist, 
GNTI (Figure 2.1), reported by Portoghese and co-workers, showed higher selectivity and better 
potency.10-13 Like nor-BNI, however, GNTI also suffers a slow onset and long duration of action 
as demonstrated in studies with rhesus monkeys.12 Moreover, GNTI was not active when 
administered systemically, which was attributed to its basic guanidine moiety.14 In addition to the 
KOR antagonists mentioned above, there are numerous  morphine-derived compounds developed 
in the 1980s and 1990s. Collectively, these ligands demonstrated the therapeutic potentials of 





          In efforts to seek non-morphine-derived KOR antagonists, a series of N-substituted trans-
3,4-dimethyl-4 (3-hydroxyphenyl)-piperidines were identified as KOR antagonists.15 As a 
representative of this series, JDTic (Figure 2.2) was reported by Carroll and co-workers in 2001, 
and shown to be a 
selective and potent KOR 
antagonist.16 JDTic 
entered into Phase Ι 
clinical trials for the 
treatment of cocaine 
abuse, but was 
discontinued due to 
ventricular tachycardia.17 
In 2012, an X-ray 
crystallographic study of 
the human KOR complexed with JDTic was reported by Raymond and collaborators. Thiswhich 




          In addition to small molecules, peptides have also been KOR antagonists. For example, 
zyklophin (Figure 2.2) is a dynorphin A-based peptide KOR antagonist, reported by Aldrich and 
co-workers in 2005.19 Zyklophin is highly selective for the KOR over the MOR and DOR (Ki = 
30.3, 5880, and > 10000 nM, respectively). More importantly, It was shown that zyklophin was 
able to antagonize the nociception induced by the selective KOR agonist U50,488 in C57BL/6J 
mice tested in the 55 °C warm water tail withdrawal assay in a dose-dependent manner.20 
Additionally, this peptide showed no effect on antinociception mediated by morphine or SNC-80 
(a DOR agonist), implying its selectivity for the KOR over the MOR and DOR in vivo. Lastly, 
there have been other cyclic peptide small molecules identified as novel KOR antagonist by 
different groups.21-22 
          Several antagonists, including JDTic as mentioned previously, have entered clinical trials. 
PF-04455242 (Figure 2.2) was reported to have Ki values of 3 and 65 nM in radioligand binding 
assay using CHO cell membranes expressing human KOR and MOR, respectively.23 This 
compound antagonized the effects of U50,488 and morphine with AD50 values of 0.67 and  12.03 
mg/kg, respectively.24 In addition, PF-04455242 proved to be effective in a series of animal models 
including the rat tail-flick test, social deficit stress assay, and cocaine CPP experiments.23 Thus, 
clinical trials of PF-04455242 were initiated for the treatment of bipolar disorder, depression and 
substance abuse. However, the clinical trials were halted due to toxicity demonstrated in animals 
after three months of drug exposure in 2010.25 Another KOR antagonist that entered clinical trials 
is LY2456302 (Figure 2.2) from Eli Lilly. This primary amide-bearing compound had a Ki value 
of 0.949 nM at the KOR and modest selectivity over the MOR and DOR (24- and 175-fold, 
respectively). In addition, decreased ethanol consumption was observed after administration of 
LY2456302 in an ethanol-drinking maintenance test using female P rat. LY2456302 also reduced 
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immobility of experiment mice at 10 mg/kg, po, in Porsolt forced swimming test.26 This compound 
was further pursued in Phase II clinical trials (under the new developmental code name of CERC-
501) for nicotine withdrawal. Hence are still ongoing as of this writing.27 
 
Sulfonamide KOR Antagonists 
          The sulfonamide chemotype KOR antagonist was originally discovered via a high 
throughput screening (HTS) campaign, along with three other new classes of KOR antagonists 
(Figure 2.3).28 In this HTS campaign, 290,000 compounds were evaluated on KOR activity and 
selectivity: the KOR DiscoveRx β-arrestin PathHunter assay and an imaging based β-arrestin 
translocation assay for confirmatory and selectivity assays. The sulfonamide compound ML140 
was deemed due to its little structural similarity relative to known opioid ligands. Although modest 
at potency (IC50 = 0.91 M) at the KOR, ML140 had good selectivity over MOR and DOR (IC50 > 




          Initial SAR studies were carried out via a modular synthetic route, which involved the 
preparation of carboxylic acid intermediate and diamine intermediates (Scheme 2.1). The synthesis 
of the carboxylic acid intermediate began with the coupling between a sulfonyl chloride and an 
ester-bearing amine, which afforded a sulfonamide ester. Subsequent hydrolysis of the ester 
afforded the carboxylic acid intermediate. The diamine synthesis began with reductive amination 
followed by a nucleophilic substitution reaction with chloroacetonitrile. Reduction with LiAlH4 
provided the diamine intermediate. With both intermediates in hand, the carboxylic acid was 
converted to the corresponding acyl chloride (with SOCl2), which was then coupled with diamine 




          Initial SAR studies focused on the diamine portion of the molecule by varying the 
substitutions on, and introducing constraint to, the basic nitrogen. It appeared that bulkier aliphatic 
substitution was preferred on this basic nitrogen (t-Bu > iPr > Et), while aromatic benzyl group 
was not tolerated (Figure 
2.4). Several constraints (five 
and six member ring) on the 
basic nitrogen were 
introduced, all of which turned out to be detrimental to bioactivity (Figure 2.5). Additional efforts 
were directed toward the modification of the central phenyl fragment of sulfonamide antagonists. 
Employing the constraint strategy again, a tetrahydroisoquinoline core was introduced as a tethered 
phenyl ring, resulting in further potency enhancement (Figure 2.5). Through combining the tert-
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butyl and tetrahydroisoquinoline modification, a number of analogues with single digit nanomolar 
IC50 were obtained based on the [
35S]GTPγS functional assay which measures the level of G 
protein activation following agonist occupation of a GPCR by determining the binding of the non-
hydrolyzable analog [35S]GTPγS to G alpha subunits.).  
 
          Through the SAR studies described above, compound 2.1 (IC50 = 1.6 ± 0.47 nM in 
GTPassay, IC50 = 83.5 ± 20.3 nM in DiscoveRx Pathhunter -Arrestin assay) was chosen as lead 
compound for further optimization and SAR study. The synthesis of 2.1 employed same sequence 





Results and Discussion 
Design and Synthesis of Analogues 
          Our initial goal on optimization of analogue 2.1 is to reduce unnecessary portions of the 
molecule to simpler structures with retention of biological action, with the idea that 
pharmacophore which is responsible for drug-target interaction could be a small portion of the 
molecule.29 Thus, it was interesting to test if the carboxylic acid or diamine portions of analogue 
2.1 were part of the pharmacophore and thus essential for the biological effect. To address this 
question, analogues 2.2, 2.3 and 2.4 were designed, replacing acid or diamine moiety of 2.1 with 
a simple and smaller chemical group (Figure 2.6). The synthesis of these three analogues employed 
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common intermediates (either acid or diamine) to couple with a simple amide coupling partner 
(see Experimental Section).  
 
          Linker modification is common in medicinal chemistry, which help extend SAR and give 
useful information about ligand receptor interactions. At this stage, none of the analogues made 
by us contained linkers other than the sulfonamide bond. Thus, to determine whether this 
sulfonamide moiety is replaceable or not, we made analogues without sulfonamide linker. 
 
          Analogue 2.5 and its urea derivative 2.6 (Figure 2.7) were proposed to probe the necessity 
of sulfonamide linker. The synthesis of compound 2.5 followed a route similar to that used in the 
sulfonamide series except a minor difference in the preparation of carboxylic acid intermediate 
(Scheme 2.3).  To form the amide bond containing acid intermediate 2.5.1, p-toluoyl chloride was 
reacted with tetrahydroisoquinoline core fragment followed by ester hydrolysis. Then HATU 
promoted amide coupling between 2.5.1 and 2.1.5 afforded the final compound 2.5.  The 
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preparation of analogue 2.6 started with the reaction between p-tolyl isocynate and the 
tetrahydroisoquinoline core, which followed by hydrolysis to afford the intermediate 2.6.1. With 
urea linker intermediate 2.6.1, HATU promoted amide coupling with diamine 2.1.5 afforded the 
final compound 2.6 smoothly. 
      
          Introducing constraint has proven to be an effective strategy to improve potency in medicinal 
chemistry. Though the tetrahydroisoquinoline core was originally introduced as a constraint to the 
molecule that enhanced potency, the possible effect of a hydrophobic contribution to potency 
warranted further investigation. Thus compound 2.7 was designed as an analogue could involve 
similar hydrophobic interaction to the tetrahydroisoquinoline moiety. The synthesis of this 
analogue started with sulfonamide coupling between sulfonyl chloride and ester-bearing amine to 
afford intermediate 2.7.1. Subsequent hydrolysis by aqueous NaOH gave acid intermediate 2.7.2. 
HATU promoted amide coupling between this acid intermediate 2.7.2 and diamine 2.1.5 afforded 




           As discussed previously, introduction of central tetrahydroisoquinoline resulted in potency 
enhancement. Following the same strategy, compound 2.8 was proposed in which another 
tetrahydroisoquinoline moiety was introduced as a new constraint on compound 2.1, to explore 
this class (Figure 2.8).  The synthesis of compound 2.8 started with Fischer esterification of (R)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 
which afforded compound 2.8.1. (Scheme 2.5) 
Subsequent reductive amination installed the 
isopropyl group on nitrogen atom, yielding 
compound 2.8.2. Then transamination in aqueous 
NH3 at 60 °C and 90 °C for 1 h respectively, yielded 
the amide intermediate 2.8.3. However, the stereogenic carbon on tetrahydroisoquinoline 
racemized under these conditions, which was shown by chiral HPLC (see experiment part). Then 
this racemate was reduced to a primary amine 2.8.4 with LiAlH4. Subsequent HATU promoted 
amide coupling between obtained primary amine 2.8.4 and acid intermediate 2.1.2 afforded the 




          As mentioned previously, JDTic discovered by F. Ivy Carroll and his colleagues, is a 
selective and potent KOR antagonist.16 Our sulfonamide opioids and JDTic share some common 
features. First, they both possess a diamine moiety in which the two nitrogen atom are separated 
by an ethylene fragment. Secondly, they both contain aromatic rings at either end of molecule. In 
previous work, we have not explored substitutions on the diamine linker (like isopropyl on JDTic) 
nor introduced a hydroxyl substituent on the two aromatic rings. Thus, two groups of analogues 




          However, the first group of analogues could not be synthesized via the general route above. 
To prepare this group of analogues, a synthetic strategy similar to that utilized in the preparation 
of JDTic and its related analogues was first attempted.30 This route started with amide coupling 
between Boc-protected amino acid and amine, which was followed by reduction of amide by BH3 
to afford Boc-protected diamine intermediate. Then Boc deprotection followed by amide synthesis 
would yield the final product (Scheme 2.6). The first step of this synthetic route failed when 
coupling between Boc-L-valine and intermediate 2.1.3 was attempted using a number of coupling 
reagents (HATU, CDI, PyBOP, etc.) at varied temperatures. The sluggishness of this 




     
          In light of this failure, two reductive amination approaches were examined (Scheme 2.7), 
given the idea that an electronic aldehyde would be much smaller and easier accessed by amine, 
compared with the activated ester as electrophile in amide coupling.31 Satisfyingly, one approach 
(with aliphatic aldehyde) offered the desired product. The other approch (with aromatic aldehyde) 
failed, which could be potentially caused by the relatively low reactivity of 4-chlorobenzyldehyde. 
After the success of reductive amination with most steric hindered reactants in this series, all other 
Boc-diamine linkers were prepared via this method (Scheme 2.8). Once this intermediate was 
obtained, Boc-deprotection with TFA and subsequent HATU promoted amide coupling with acid 
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2.1.2, afforded the final sulfonamide product (Scheme 2.8). 
 
The synthesis of second group of analogues followed the same sequence discovered during the 
preparation of first group, except employing different building blocks as needed (Scheme 2.9). 





          Eleven compounds (2.19 to 2.29) were proposed to explore the effects of substitutions on 
the right phenyl ring as well as replacement of this phenyl ring with pyridine (Figure 2.10). 
Methylthio, dimethylamino, methoxymethyl, hydroxymethyl, acetamido, and ethyl group (2.19 to 
2.22, 2.25, and 2.26) were chosen to be incorporated into the para-position of phenyl ring, as direct 
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comparison with 2.1 and 2.14. Dioxine and dioxole moiety were introduced as constrained oxygen-
bearing substitutions on the phenyl ring (2.23 and 2.24). Pyridine was a common moiety found in 
drug molecules, and often employed at early stage of drug discovery to adjust cLogP of small 
molecule. Thus three compounds (2.27, 2.28, and 2.29) with pyridine substitutions were proposed, 
which possess much lower cLogP (~ 4) compared compound 2.1 (5.8). It is worth noting that 
protonation of pyridine containing compounds under physiological condition would result in even 
lower cLogD and better solubility in aqueous meida. 
 
The successive reductive amination strategy was again employed to prepare this set (Scheme 2.10). 
Two successive reductive amination afforded the Boc-diamine intermediate. Then, deprotection 
of Boc-diamine, followed by amide bond formation promoted by HATU, afforded the final product. 
For the pyridine containing compounds, the two successive reductive aminations were carried out 
in one pot with only one workup and one purification to yield stable Boc-diamine intermediates 





          Finally, a new diamine with bigger alkyl substitution on nitrogen was prepared to test the 
role of overall hydrophobicity at this position. This diamine was incorporated into final analogues 





In Vitro Assay Studies 
          The sulfonamide final compounds were assayed using a DiscoveRx PathHunter® -arrestin 
GPCR assay platform.32 This in vitro assay method uses U2OS cells expressing human KOR in an 
enzyme complementation system designed for detecting recruitment of β-arrestin to the KOR. In this 
system, KOR is fused in frame with the small 42 amino acid fragment of -galactosidase (-gal) called 
Pro-linkTM and co-expressed with cells stably expressing a fusion protein of -arrestin and the larger, 
N-terminal deletion mutant of -gal (called enzyme acceptor or EA). Upon the activation of KOR, 
-arrestin binds to the receptor which promotes the complementation of two enzyme fragments, 
resulting in active -gal enzyme. This leads to an increase of enzyme activity which is measured by 
chemiluminescent reagent (Figure 2.11). Briefly, plates loaded with U2OS cells were incubated at 
37 °C overnight, and then treated with increasing concentrations of antagonists in the presence of 1 
M U69,593 for 1 h and 30 min at 37 °C. Detection reagent was added for 1 h and luminescent counts 




          Compound 2.2 and 2.3, designed by replacement of acid fragment of compound 2.1 with acetyl 
and benzoyl moieties, turned out to be inactive as KOR antagonists (Table 2.1). Similarly, the 
replacement of diamine fragment of 2.1 with an isopropyl group, as in 2.4, resulted in complete loss of 
KOR antagonist activity (Table 2.1). Together, these attempts offer a message that both fragments of 
lead compound 2.1 are critical.  
Table 2.1. KOR Antagonist Activity of Simplified Series 
 
Entry Compound aIC50 (nM) ± SEM Imax (%) ± SEM 
1 2.1 83.5 ± 20.3 101.2 ± 4.9 
2 2.2 NCb 12.4 ± 3.4 
3 2.3 > 10,000 60.5 ± 1.5 
4 2.4 NCb -4.9 ± 2.2 
a DiscoveRx Pathhunter -arrestin assay with n = 3 unless noted, compared to NorBNI (IC50 = 2.0 ± 0.1 nM); 
b 
NC: non-convergent curve caused by insignificant activity  
 
          Replacement of sulfonamide linker by amide or urea, turned out to be detrimental for KOR 
antagonist activity (2.5 and 2.6, Table 2.2).  
Table 2.2. KOR Antagonist Activity of Amide and Urea Linker Bearing Analogues 
 
Entry Compound aIC50 (nM) ± SEM Imax (%) ± SEM 
1 2.5 > 10,000 41.1 ± 2.8 
2 2.6 > 10,000 66.1 ± 3.4 
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a DiscoveRx Pathhunter -arrestin assay with n = 3 unless noted, compared to NorBNI (IC50 = 2.0 ± 0.1 nM) 
 
          Central fragment modification resulted in complete loss of KOR antagonist activity (2.7, 
Figure 2.3). Similarly, the introduction of another tetrahydroisoquinoline as a constraint on the 
right fragment led to dramatic decrease of KOR antagonist activity (2.8, IC50 = 1126.0 ± 193.8 nM). 
Table 2.3. KOR Antagonist Activity of 2.7 and 2.8 
 
Entry Compound aIC50 (nM) ± SEM Imax (%) ± SEM 
1 2.7 NCb 12.6 ± 4.0 
2 2.8 1126.0 ± 193.8 106.6 ± 1.1 
a DiscoveRx Pathhunter -arrestin assay with n = 3 unless noted, compared to NorBNI (IC50 = 2.0 ± 0.1 nM); 
b 
NC: non-convergent curve caused by insignificant activity 
 
          Alkyl substitution on diamine linker of 2.1 (Me or iPr), of either S or R configuration, are 
not tolerated ((S)- and (R)-2.10, (S)- and (R)-2.11). Though (S)-2.10 demonstrated marginal 
antagonist activity at the KOR (IC50 = 6945.0 ± 3244.0 nM), it was about 80-fold less potent than 
2.1. By switching the tert-butyl group of (S)-2.10 to an iPr group, bioactivity was slightly regained 
((S)-2.9, IC50 = 3887.0 ± 945.8 nM). However, the enantiomer of (S)-2.9 was completely inactive 
((R)-2.9, Table 2.4). Thus, alkyl substitutions on the alpha-carbon of amide nitrogen are not 
tolerated.  




Entry Compound R1 R2 aIC50 (nM) ± SEM Imax (%) ± SEM 
1 (S)-2.9 (S)-Me iPr 3887.0 ± 945.8 73.2 ± 2.2 
2 (R)-2.9 (R)-Me iPr NCb 25.5 ± 12.3 
3 (S)-2.10 (S)-Me t-Bu 6945.0 ± 3244.0 70.4 ± 0.9 
4 (R)-2.10 (R)-Me t-Bu > 10,000 39.9 ± 2.7 
5 (S)-2.11 (S)- iPr t-Bu > 10,000 16.0 ± 4.7 
6 (R)-2.11 (R)- iPr t-Bu NCb -3.1 ± 8.6 
a DiscoveRx Pathhunter -arrestin assay with n = 3 unless noted, compared to NorBNI (IC50 = 2.0 ± 0.1 nM); 
b NC: non-convergent curve caused by insignificant activity 
 
Replacement of 4-methyl group on the left phenyl ring of 2.1 with p-hydroxyl group reduced 
potency (2.18, IC50 = 391.5 ± 89.9 nM) by about 5-fold, whereas moving the hydroxyl group to the 
m-position afforded compound 2.17 with comparable potency (IC50 = 361.6 ± 71.1 nM). Similarly, 
replacement of p-methyl group of 2.1 with methoxy group resulted in drastic decrease of potency 
(2.16, IC50 = 9417.0 ± 2720.0 nM). However, moving the methoxy group to m-position regained 
the bioactivity a bit (2.15, IC50 = 614.8 ± 280.3 nM). Interestingly, further replacement of p-chlorine 
on the right phenyl ring of 2.16 with methoxy group rescued the potency by about 14-fold (2.12, 
IC50 = 42.2 ± 2.9 nM), resulting in a compound with slightly better activity than 2.1. By retaining 
the right p-methoxy group and switching the left m-methoxy group back to original p-methyl group, 
the obtained compound 2.14 had even better potency (IC50 = 18.9 ± 4.4 nM). In contrast, one single 
change of 2.14 by moving p-methoxy group to the m-position led to drastically decreased potency 
(2.13, IC50 = 216.8 ± 64.3 nM). 




Entry Compound R3 R4 aIC50 (nM) ± SEM Imax (%) ± SEM 
1 2.12 m-OMe p-OMe 42.2 ± 2.9 100.6 ± 0.3 
2 2.13 p-Me m-OMe 216.8 ± 64.3 102.5 ± 0.6 
3 2.14 p-Me p-OMe 18.9 ± 4.4 104.0 ± 2.4 
4 2.15 m-OMe p-Cl 614.8 ± 280.3 104.5 ± 5.8 
5 2.16 p-OMe p-Cl 9417.0 ± 2720.0 91.2 ± 3.3 
6 2.17 m-OH p-Cl 361.6 ± 71.1 102.8 ± 1.2 
7 2.18 p-OH p-Cl 391.5 ± 89.9 90.5 ± 4.7 
a DiscoveRx Pathhunter -arrestin assay with n = 3 unless noted, compared to NorBNI (IC50 = 2.0 ± 0.1 
nM)  
 
          The bioisosterie replacement of the methoxy group on 2.14 with methylthio group and 
dimethylamino group, led to mild reduction of activity (2.19 and 2.20). Methoxylmethyl group 
(2.21) were tolerated, while hydroxymethyl group led to 7-fold reduction of activity (2.22). 
Dioxine and dioxole introduced as constrained oxygen-bearing group, could not increase potency 
but were well tolerated (2.23 and 2.24). Acetoamido and ethyl introduction led to reduction of 
potency (4-fold and 8-fold, respectively). Moving from various substituted phenyl ring to pyridine-
containing analogues led to drop in potency. Compounds with 2-pyridyl and 3-pyridyl group (2.27 
and 2.28) were 7-fold less potent than 2.14. Unfortunately, when 4-pyridyl group was employed, 
the potency decreased dramatically (2.29, IC50 = 1521.0 ± 308.0 nM). 




Entry Compound R aIC50 (nM) ± SEM Imax (%) ± SEM 
1 2.19 
   
142.0 ± 4.2 107.5 ± 4.8 
2 2.20 
   
56.1 ± 10.9 108.8 ± 5.6 
3 2.21 
   
45.8 ± 5.4 108.1 ± 6.4 
4 2.22  
   
131.7 ± 27.6 105.2 ± 2.9 
5 2.23 
   
56.0 ± 10.1 105.7 ± 4.5 
6 2.24 
   
34.0 ± 1.8 108.6 ± 7.7 
7 2.25 
   
80.3 ± 15.2 106.0 ± 3.8 
8 2.26 
   
150.8 ± 16.0 100 ± 1.5 
9 2.27 
   
138.4 ± 26.7 102.5 ± 2.7 
10 2.28 
   
137.7 ± 19.9 100.2 ± 1.9 
11 2.29 
   
1521.0 ± 308.0 102.7 ± 1.6 
a DiscoveRx Pathhunter -arrestin assay with n = 3 unless noted, compared to NorBNI (IC50 = 2.0 ± 0.1 
nM)  
 
Table 2.7. KOR Antagonist Activity of Miscellaneous Series 
 
Entry Compound aIC50 (nM) ± SEM Imax (%) ± SEM 
1 2.30 NCb 5.4 ± 1.1 
2 2.31 NCb -2.3 ± 2.5 
3 2.32 NCb 23.6 ± 2.6 
a DiscoveRx Pathhunter -arrestin assay with n = 3 unless noted, compared to NorBNI (IC50 = 2.0 ± 0.1 nM); 
b 




          Replacement of tert-butyl group of 2.1 with neopentyl group, resulted in complete loss of 
bioactivity (2.30). It is interesting that a carbon extension had such a detrimental effect, suggesting 
there is not enough room in the receptor to accommodate this further elongation of alkyl 
substitution. Lastly, switching the sulfonamide linker of 2.30 to urea or amide (2.31 and 2.32) 
could not restore the activity. 
 
Putative Binding Mode 
          Based on bioactivity data of analogues made previously and new data we obtained in this 
round of SAR exploration, modeling studies were carried out by Professor Phil Mosier from 
Virginia Commonwealth University.  
          Sulfonamide analogues were sketched using SYBYL-X 2.1.1 (Certara USA, Inc., Princeton, 
NJ) and energy minimization was carried out with the Tripos Force Field (TFF; Gasteiger–Hückel 
charges, distance-dependent dielectric constant ε = 4D/Å, nonbonded interaction cut-off = 8 Å, 
energy gradient termination = 0.05 kcal/(mol×Å) or 100,000 iterations). The KOR−JDTic co-
crystal structure (PDB: 4DJH)18 was prepared for docking through a series of process including 
extraction of the “B” chain (KOR protein only), removal of the JDTic ligand and addition of 
hydrogen atoms. Other crystal structures were prepared in an analogous fashion (vide infra). 
Additionally, to mitigate the bias imposed by the “imprint” caused by the original ligand and to 
explore alternative receptor conformational states, MODELLER 9.1633 was used to create a 
population of 100 KOR homology models for each of three different KOR and MOR templates: 
1) the antagonist-bound KOR–JDTic co-crystal structure (PDB: 4DJH; B chain), 2) the antagonist-
bound MOR–β-FNA co-crystal structure (PDB: 4DKL; A chain)34, and 3) the nanobody-stabilized 
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agonist-bound MOR–BU72 co-crystal structure (PDB: 5C1M; A chain).35 To facilitate 
comparison of ligand binding modes, each homology model was spatially aligned to its crystal 
structure template. 
          Ligands were flexibly docked to the KOR crystal structure (PDB: 4DJH) and to each 
member of the three KOR homology model populations with GOLD Suite 5.2 (Cambridge 
Crystallographic Data Centre, Cambridge, UK)36 in order to generate candidate binding modes. In 
each case, the Goldscore fitness function was employed, and cavity detection was enabled. In 
addition, the ligand binding site was defined to include all receptor amino acid residues within 15 
Å of the gamma carbon atom of D138(3.32), encompassing all amino acids within the orthosteric 
binding site. Free ring corners and pyrimidal nitrogens were allowed to flip. To facilitate the 
interactions between the cationic ligands and D138(3.32), a constraint was introduced that 
disfavored solutions in which the ligand did not form a hydrogen bond with either oxygen of the 
D138 side chain carboxylate group (fitness function lowered by 10 Goldscore units). 
          An in-house clustering algorithm37 was employed to facilitate the identification of common 
and disparate binding modes for the ligands. Briefly, each ligands was flexibly docked ten times 
into each of the spatially aligned homology models generated above. Then, the top scoring solution 
for each ligand at each receptor model was selected, which were subsequently clustered at a cutoff 
RMSD value of 2.0 Å to identify different binding modes for each ligand. The highest-scoring 
solution from each cluster (binding mode) was selected to represent that particular binding mode 
and referred to as the exemplar. All exemplars for all ligands were then combined and clustered 
based on the RMSD of their common scaffold structure to identify common binding modes among 
the series of compounds. The common binding modes were then manually evaluated for 
stereoelectronic complementarity and consistency with experimentally derived ligand SAR. A 
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commonly-shared binding mode among the ML140 analogues was identified in the KOR 
homology model population derived from the antagonist-bound MOR–β-FNA co-crystal structure 
(PDB: 4DKL); these solutions were selected for further refinement and analysis. In a few cases, 
manual modification of KOR side chains and ligand torsion angles were performed after 
completion of the automated docking routines to further optimize the proposed receptor–ligand 
interactions. The resulting receptor−ligand complexes were then energy-minimized in SYBYL-X 
2.1.1 using the Tripos Force Field (TFF; Gasteiger–Hückel charges, distance-dependent dielectric 
constant ε = 4D/Å, nonbonded interaction cut-off = 8 Å, energy gradient termination = 0.05 
kcal/(mol×Å) or 500 iterations). 
 
  
Figure 2.12. Putative binding mode of 2.1 with the KOR 
 
          Compound 2.1 was used to elucidate the putative binding mode between this chemotype and 
receptor (Figure 2.11). The western phenyl ring engages tight hydrophobic interactions with V2.63 
and edge-face aromatic interactions with Y2.64. This tight binding site explains why bulk or multi-
substitution on this phenyl ring decrease the potency. One oxygen in sulfonamide linker is involved 
in a hydrogen bond with the proton on an amide nitrogen of the backbone. The proton on central 
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amide moiety, together with protonated nitrogen on diamine fragment, is involved in two hydrogen 
bonds with side chain of D3.32, respectively.  This explains why the methylation of amide nitrogen 
lead to complete loss of activity. In addition, the tert-butyl group has hydrophobic interactions 
with Y3.33 and I6.55. The phenyl ring on the diamine fragment is sandwiched between W6.48 and 
Y7.43 via pi-stacking interactions. Lastly, the 2-carbon linker on isoquinoline rigidifies the ML140 
scaffold, which enhances the interactions mentioned previously. 
 
Conclusions 
          Structural modification centered on compound 2.1 afforded a total of 34 new analogues, 
which further enriched the SAR of sulfonamide 
chemotype (Figure 2.13). Compared with 
compound 2.1, several analogues with better 
potency were obtained. By collaborative efforts, a 
putative binding mode of this chemotype with the 
KOR were proposed (Figure 2.12), which would be 
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Chapter  3 
Asymmetric Acyl Transfer Reactions Catalyzed by a Cyclic Peptide 
Introduction 
          Kinetic resolution (KR), according to IUPAC’s 1996 recommendation, is “the achievement 
of partial or complete resolution by virtue of unequal rates of reaction of enantiomers in racemate 
with a chiral agent (reagent, catalyst, solvent, etc.)”.1 KR relies on the differences in reactivity 
between enantiomers in the presence of a chiral agent. In the simplest case, two competing 
diastereomeric transition states are generated by the interactions between the substrate enantiomers 
via interacting with a chiral agent respectively, and these two transition states possess different 
activation energies which govern the rate constants for the conversion of the enantiomers. Lastly, 
the product distribution is controlled by the ratio of rate constant kfast/kslow (equal to krel or 
enantioselectivity s), which describes how selective a KR is. With high krel and enough percentage 
of conversion, the majority of the fast-reacting enantiomer would be converted to product while 
slow-reacting enantiomer could be isolated in enantiopure form after the reaction (Figure 3.1).2  
 
          The earliest phenomenon of KR, observed in 1858 by Pasteur, was that the dextrorotatory 
isomer of racemic ammonium tartrate was selectively destroyed during the fermentation with 
penicillium glaucum.2 Though the structural basis was not yet known, Pasteur understood that the 
reactive and unreactive isomers were mirror image forms to one another. The first non-enzymatic 
KR was reported by Marckwald and Mckenzie. In this work, racemic mandelic acid was 
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enantioselectively esterified by 
(–)-menthol upon heating the 
reactants, with small amount of 
L-mandelic acid recovered 
after recrystallization.4 In 
1981, a milestone paper about 
KR of allylic alcohol substrates 
was reported by Sharpless and co-workers.5 In one of the best examples in this report, allylic 
alcohol (S)-3.1 was converted to epoxide products much faster than (R)-3.1 (s = 104). The 
unreacted alcohol was recovered with high ee (>96%), while the epoxy alcohol product with good 
erythro/threo ratio (97:3).  This significant work stimulated the development of chiral supports for 
HPLC and GC assays that could precisely measure enantiomeric ratios with 96–99.9% ee. 
          Synthetic oligopeptides as mimics of enzyme have been increasingly investigated as catalyst 
for asymmetric transformation in the past several decades.6-14 However, synthetic oligopeptides 
with high efficiency and low molecular weight are still in great demand. It is believed that the 
conformational rigidity is critical for a chiral 
inducing agent, which is also true for 
oligopeptide catalysts. Usually cyclic peptides 
possess reduced freedom of rotation, and are 
accordingly more rigid compared with liner peptides. For example, cyclic dipeptide 3.4 (Figure 
3.2), reported by Inoue and co-workers, catalyzed asymmetric hydrocyanation of benzaldehyde 
with 90% ee.15 In contrast, linear poly-L-alanine 3.5 (Figure 3.2) is a catalyst of the Julia-Colonna 
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epoxidation but can only afford excellent asymmetric induction when it is longer than 10-mer and 
form the stable -helix structure.16  
 
          Synthetic oligopeptides have been exploited as catalyst for KR. Starting from 1998, Miller’s 
research group reported a series of oligopeptides as catalysts for asymmetric acyl-transfer 
reactions.17-20 These oligopeptides contain a -turn motif, including an intra-main-chain hydrogen 
bond between carbonyl of residue i and NH of residue i + 3 (Figure 3.3). Tripeptide 3.6, reported 
in 1998, was the first in this series.17 As the described in this report, 3.6 (Figure 3.3) was shown to 
catalyze the acetylation of (S,S)-3.7 faster than (R,R)-3.7 (s = 13). Optimization of reaction 
conditions revealed that selectivity was enhanced with solvents which do not interrupt hydrogen 
bonding. For example, optimum selectivities were obtained with toluene while decreased 
selectivities were observed by using DCM, CHCl3, or CHCl3–t-BuOH (1:1) as solvent. 
Optimization of 3.6 afforded several oligopeptide catalysts with enhanced selectivities, including 
a tetrapeptide (3.8) and an octapeptide (3.9), which promoted the same reaction with s values of 
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28 and 51, respectively.18  Kinetic studies indicated the order of substrate (3.7) and catalyst (3.9) 
were each 1 under conditions of high dilution.  
 
          In 2011, a series of tetrapeptides were reported by Qu’s research group (Figure 3.4), which 
were designed by backbone modification of Miller’s catalyst 3.8.21 Thioamide replacement of 
amide at the i+1 residue (3.10) afforded a peptide capable of acylating (±)-3.7 with an s value of 
20. This could be increased to a value of 63 by adding 0.2 equiv of N,N-diisopropylethylamine 
(DIPEA) to the reaction. It was believed the thioamide could reinforce the intermolecular hydrogen 
bond between the catalyst and the substrate while the DIPEA could absorb the proton generated in 
the reaction and maintain the imidazole in a neutral status which was critical for the catalysis. The 
replacement of the Boc group on the i residue with a tosyl group afforded catalyst 3.11 which 
acylated (±)-3.7 with an s value of 40. This could be modestly elevated to a value of 44 by adding 
0.2 equiv of DIPEA in the reaction. It was believed that the introduction of tosyl group made the 
proton of NH on i residue more acidic, which resulted in a strengthened intramolecular hydrogen 
bond and a more rigid conformation for the catalyst. By introducing the thioamide and tosyl group 
at the same time, a tetrapeptide 3.12 that afforded the best selectivities (s = 109 on substrate (±)-




Results and Discussion  
          Employment of 6-aminocaproic acid (Aca) as a dipeptide linker was reported by Woody and 
Scheraga, who demonstrated that such macrocycles adopted a -turn around the dipeptide unit 
(Figure 3.5).22-23 They also pointed out that the conformation adopted by such macrocycles was 
quite dependent on the amino acid stereochemistry. In general, type I -turn was preferred by 
macrocycles derived from L,L-dipeptides, whereas type II subtype was favored by L,D-dieptides. 
Our research lab also observed this phenomena by employing similar linkers (Figure 3.5)24-25.  
 
          We proposed to replace the hydrogen bond between i and i +3 amino-acid residues of 3.8 
with an Aca linker, which afforded a cyclic peptide 3.13 (Figure 3.5). This Aca linker could 
possibly bring some degree of restriction rather than distortion of -turn conformation, which 




          Proposed catalyst 3.13 consists of two amino acid residues plus the Aca linker. We first 
attempted the synthesis of 3.13 with a macrolactamization route (Scheme 3.2). However, this route 
failed at the macrolactamization step, despite examining several coupling reagents (HATU, 
PyBOP, and DMAP) for this transformation. This difficult transformation may be caused by ring 
strain of the product.  
 
          To overcome the ring strain, a ring closing metathesis (RCM) strategy was conceived 
(Figure 3.6). The building block 3.19 was prepared in 6 steps (Scheme 3.2). Reaction between (R)-
4-benzyloxazolidinone and bromoacetyl bromide afforded 3.14, which was converted to 3.15 by 
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an Arbuzov reaction. Subsequent Horner-Wadsworth-Emmons reaction converted 3.15 to the 
alkene intermediate 3.16, which was readily hydrogenated to give intermediate 3.17. Then Evans 
chiral auxiliary reaction installed the allyl group to yield 3.18. Subsequent hydrolysis of 3.18 
removed the oxazolidinone moiety and afford compound 3.19.  
 
          With compound 3.19 in hand, the synthesis of cyclic peptide 3.1 was carried out in five steps 
(Scheme 3.4). HATU promoted amide coupling between 2-(Boc-amino)isobutyric acid and 
allylamine afforded 3.20. Subsequent Boc deprotection of 3.20 followed by amide coupling with 
Boc-L-proline gave intermediate 3.21. Then Boc-deprotection of 3.21 and amide coupling with 
3.19 provide diene 3.22 as its TFA salt after reverse phase flash column chromatography 
purification (0-100% CH3CN/0.5% TFA in H2O). RCM reaction of 3.22 catalyzed by Hoveyda-
Grubbs 2 catalyst afforded 3.23 as an inseparable mixture of cis/trans isomers. Subsequent 





          The single crystal X-ray structure of 3.13 was obtained for the analysis of its conformation 
(Figure 3.7).  Though 3.13 is not an acyclic peptide and consists of 3 amino-acid residues, the 
crystal structure clearly displayed its conformation is very close to type II -turn (ϕi+1 =  ̶̵ 67.8°, 
ψi+1 = +116.9°,  ϕi+2 = +59.8°, ψi+1 = +26.5°). The distance between carbonyl and NH of i residue 







Figure 3.7. X-ray crystal structure and conformation analysis of 3.13 
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          The substrate scope of the asymmetric acyl-transfer reaction using the cyclic peptide 3.13 
were examined (Table 3.1). The reactions were run under conditions of high dilution (0.128 mmol 
of substrate in 12.8 mL of toluene) with 2.5 mol % of catalyst, 0.2 equiv of DIPEA, and 8.3 equiv 
of Ac2O at 25 °C. After quench with CH3OH (10 mL), products and starting materials were isolated 
with reverse phase flash column chromatography. Then chiral HPLC was employed to obtain the 
ee (enantiomeric excess of staring material) and ee´ (enantiomeric excess of product). Conversion 






 , s = 
ln[1 − 𝐶(1 + 𝑒𝑒′)]
ln[1 − 𝐶(1 − 𝑒𝑒′)]
).26 
          Cyclic peptide 3.13 was shown to have slightly lower selectivity for six-membered-ring 
trans cyclic acetamide-functionalized alcohol (3.7) than Miller’s catalyst 3.8 which gave an s value 
of 28. The selectivity of 3.13 on seven-membered-ring functionalized alcohol (3.24) was higher 
than 3.8 which gave an s value of 17. For substrate 3.25, an eight-membered-ring functionalized 
alcohol, the selectivity was much lower compared with six- and seven-membered substrates. For 
substrate 3.26, the enantioselectivity of cyclic peptide catalyst was lower than six- and seven-
membered-ring substrates but higher than the eight-membered-ring one. For the last substrate 3.27, 
an acyclic functionalized alcohol, the catalyst demonstrated a negligible selectivity (s = 1.3). 
Table 3.1. Kinetic Resolutions with Cyclic Peptide 3.13 
 
cmpd. # substrates time eea. ee´
a Cb sb 
3.7 
 
2.5 h 70.3% 82.6% 46.0% 21.9 
3.24 
 
2.5 h 58.6% 86.1% 40.5% 24.3 
3.25 
 





2 h 28.9% 73.3% 28.3% 8.6 
3.27 
 
5 h 3.8% 11.4% 25.1% 1.3 
       





          Cyclic peptide 3.13 was synthesized in five steps, followed by the analysis of conformation 
and assessment of selectivities on five substrates. Cyclic peptide adopt a conformation close to 
type II -turn. The selectivities of this catalyst is comparable to Miller’s catalyst 3.8 (slightly 
higher on substrate 3.24, slightly lower on substrate 3.7) while it is less selective compared with 
Qu’s catalyst 3.12. Much work is still needed in terms of the optimization of structure of the cyclic 
peptide and conditions. In summary, we demonstrated that the cyclic peptide could be used as 
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General Information. All reactions were performed in glassware dried in an oven at 120 ºC 
overnight and cooled under a stream of argon. The stainless steel needles used for handling 
anhydrous solvents and reagents were oven dried and flushed with dry argon prior to use. Plastic 
syringes were flushed with dry argon before use. Methanol and THF were dried by passage through 
neutral alumina columns using a commercial solvent purification system prior to use. Anhydrous 
methylene chloride and anhydrous toluene were purchased from Sigma-Aldrich and used as 
received. All chemicals were used as received from commercial source without further purification. 
Reactions and chromatography was monitored by thin-layer chromatography (TLC) on 0.25 mm 
Analtech GHLF silica gel plates and visualized by UV light (254 nm) or Seebach’s stain by heating. 
Purification was achieved by flash chromatography on a CombiFlash Rf (automated flash 
chromatography) system. MS-directed HPLC purification was carried out by mass-directed 
fractionation (MDF) with gradient elution (a narrow CH3CN gradient was chosen based on the 
retention time of the target from LCMS analysis of the crude sample) on an Agilent 1200 
instrument with photodiode array detector, an Agilent 6120 quadrupole mass spectrometer, and a 
HTPAL LEAP autosampler. HPLC/MS analysis was carried out with gradient elution (5% CH3CN 
to 100% CH3CN) on an Agilent 1200 RRLC with a photodiode array UV detector (214 nm) and 
an Agilent 6224 TOF mass spectrometer (also used to produce high resolution mass spectra). 1H 
and 13C NMR spectra were acquired on a 600 MHz Bruker AVIII spectrometer equipped with a 
cryogenically-cooled carbon observe probe, or a 500 MHz Bruker AVIII spectrometer equipped 
with a cryogenically-cooled carbon observe probe, or a 400 MHz Bruker AVIIIHD spectrometer, 
or a 400 MHz Varian 400MR spectrometer. HRMS data were collected with a LCT Premier time-
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of-flight mass spectrometer and an electrospray ion source. IR spectra were acquired on a 
PerkinElmer Spectrum 100 FT-IR spectrometer or a Bruker Alpha FT-IR spectrometer.  
Procedure for Chapter 1 
General Procedure for the Ugi Multicomponent Reactoin in Bisamide Library Synthesis. On 
a 24-position Bohdan MiniBlock, reaction tubes were installed. Each reaction tube was charged 
with a suspension of carboxylic acid (0.4 mmol), amine (0.4 mmol), and ketone/aldehyde (0.4 
mmol) in methanol (0.5 mL), was added isocyanide (0.4 mmol) at room temperature. The Bohdan 
MiniBlock was agitated for 24 h on the shaker station. To each reaction tube, was added TFA (0.14 
mL) prior to 30 min of shaking at room temperature. Each reaction mixture was transferred to a 
CCT tube then concentrated under N2. The crude sample was purified via MS-directed HPLC to 
afford the title compound. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-(furan-2-ylmethyl)picolinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a white solid (0.086 mg, 0.210 mmol, 52% yield, 93.1% purity). Mp = 88–92 ºC; IR 
(neat) 2929, 1655 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.58 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 
7.80 (t, J = 7.6 Hz, 1H), 7.66–7.57 (m, 1H), 7.45–7.33 (m, 1H), 7.25 (dd, J = 1.8, 0.8 Hz, 1H), 
7.04 (d, J = 9.8 Hz, 1H), 6.20 (dd, J = 3.3, 1.8 Hz, 1H), 5.95 (dd, J = 3.2, 0.9 Hz, 1H), 4.78 (s, 2H), 
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3.71–3.58 (m, 1H), 2.23–2.11 (m, 3H), 1.78 (ddt, J = 19.3, 12.5, 7.0 Hz, 5H), 1.71–1.42 (m, 8H), 
1.40–1.05 (m, 6H); 13C NMR (151 MHz, CDCl3) δ 173.1, 172.0, 155.3, 151.4, 148.2, 141.9, 137.3, 
124.8, 124.3, 110.8, 108.3, 66.5, 47.9, 43.0, 33.0, 32.8, 25.9, 25.8, 24.8, 22.5; HRMS (ESI) m/z 
calcd for C24H32N3O3 [M + H]
+ 410.2438, found 410.2472. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclopentyl)-N-(furan-2-ylmethyl)picolinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as yellow solid (0.022 mg, 0.056 mmol, 14% yield, ≥ 99% purity). Mp = 126–130 ºC; IR 
(neat) 2931, 1655 (v br), 1514 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.55 (ddd, J = 4.9, 1.8, 1.0 Hz, 
1H), 7.76 (td, J = 7.7, 1.7 Hz, 1H), 7.54 (dt, J = 7.8, 1.1 Hz, 1H), 7.33 (ddd, J = 7.6, 4.9, 1.2 Hz, 
1H), 7.24 (dd, J = 1.9, 0.8 Hz, 1H), 6.89 (br, 1H), 6.21 (dd, J = 3.3, 1.8 Hz, 1H), 5.96 (d, J = 3.2 
Hz, 1H), 4.82 (s, 2H), 3.65 (tdt, J = 10.2, 7.9, 3.9 Hz, 1H), 2.57 (dd, J = 12.4, 7.3 Hz, 2H), 2.05–
1.95 (m, 2H), 1.90–1.85 (m, 1H), 1.84–1.62 (m, 8H), 1.60–1.51 (m, 1H), 1.39–1.27 (m, 2H), 1.26–
1.01 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 172.7, 171.0, 155.1, 151.4, 148.0, 141.9, 137.3, 
124.8, 124.2, 110.8, 108.3, 73.9, 48.0, 44.0, 36.4, 33.0, 25.8, 24.8, 23.9; HRMS (ESI) calcd for 
C23H30N3O3 [M + H]





          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-(furan-2-ylmethyl)nicotinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a yellow solid (0.109 g, 0.266 mmol, 67% yield, 98.6% purity). Mp = 136–139 ºC; IR 
(neat) 2929, 1652 (v br), 1520 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.77 (d, J = 2.2, 0.9 Hz, 1H), 
8.66 (dd, J = 4.9, 1.7 Hz, 1H), 7.85 (dt, J = 7.9, 2.0 Hz, 1H), 7.38 (ddd, J = 7.8, 4.9, 0.9 Hz, 1H), 
7.30 (dd, J = 1.9, 0.8 Hz, 1H), 7.08–7.02 (m, 1H), 6.26 (dd, J = 3.3, 1.8 Hz, 1H), 6.06 (dd, J = 3.2, 
0.9 Hz, 1H), 4.54 (d, J = 0.9 Hz, 2H), 3.63–3.52 (m, 1H), 2.35–2.27 (m, 2H), 2.16–2.07 (m, 2H), 
1.83–1.62 (m, 6H), 1.60–1.05 (m, 10H); 13C NMR (126 MHz, CDCl3) δ 172.7, 172.4, 150.7, 150.1, 
147.9, 142.4, 135.8, 133.9, 123.8, 111.0, 108.9, 66.4, 48.0, 44.3, 32.9, 32.5, 25.8, 25.6, 24.7, 22.4; 
HRMS (ESI) m/z calcd for C24H32N3O3 [M + H]
+ 410.2438, found 410.2433. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclopentyl)-N-(furan-2-ylmethyl)nicotinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a white solid (0.064 g, 0.162 mmol, 40% yield, 98.9% purity). Mp = 105–108 ºC; IR 
(neat) 2932, 1646 (v br), 1524 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.72 – 8.62 (m, 2H), 7.79 (dt, 
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J = 1.91, 7.85 Hz, 1H), 7.39 – 7.32 (m, 2H), 6.70 (d, J = 7.97 Hz, 1H), 6.31 (dd, J = 1.86, 3.28 Hz, 
1H), 6.09 (dd, J = 0.91, 3.31 Hz, 1H), 4.55 (s, 2H), 3.69–3.62 (m, 1H), 2.66–2.62 (m, 2H), 2.04–
1.94 (m, 2H), 1.87–1.63 (m, 8H), 1.62–1.53 (m, 1H), 1.41–1.29 (m, 2H), 1.23–1.06 (m, 3H); 13C 
NMR (126 MHz, CDCl3) δ 172.3, 171.4, 150.5, 150.3, 147.2, 142.4, 135.4, 133.5, 123.7, 111.1, 
108.6, 73.8, 48.1, 45.7, 36.3, 33.0, 25.8, 24.8, 23.6; HRMS (ESI) m/z calcd for C23H30N3O3 [M + 
H]+ 396.2282, found 396.2280. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-(furan-2-ylmethyl)isonicotinamide. 
Prepared according to the general procedure for ugi multicomponent reaction, the title compound 
was obtained as a white solid (0.100 g, 0.244 mmol, 61% yield, 98.9% purity). Mp = 98–100 ºC;  
IR (neat) 2932, 1648 (v br), 1537 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.71–8.65 (m, 2H), 7.37–
7.34 (m, 2H), 7.33 (dd, J = 1.9, 0.8 Hz, 1H), 6.82–6.77 (m, 1H), 6.29 (dd, J = 3.3, 1.9 Hz, 1H), 
6.09 (dd, J = 3.3, 0.9 Hz, 1H), 4.49 (s, 2H), 3.63 – 3.58 (m, 1H), 2.23–2.14 (m, 4H), 1.84–1.61 (m, 
6H), 1.53 (qt, J = 14.0, 4.0 Hz, 5H), 1.40–1.28 (m, 2H), 1.25–1.08 (m, 3H); 13C NMR (126 MHz, 
CDCl3) δ 172.4, 172.2, 150.2, 150.1, 145.4, 142.3, 121.4, 111.0, 108.8, 66.3, 48.0, 43.9, 32.9, 32.4, 
25.8, 25.6, 24.7, 22.6; HRMS (ESI) m/z calcd for C24H32N3O3 [M + H]





          N-(1-(Cyclohexylcarbamoyl)cyclopentyl)-N-(furan-2-ylmethyl)isonicotinamide. 
Prepared according to the general procedure for Ugi multicomponent reaction, the title compound 
was obtained as a yellow solid (0.111 g, 70% yield, 98.6% purity). Mp = 138–141 ºC; IR (neat) 
2927, 1658, 1624 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.67 (d, J = 4.8 Hz, 2H), 7.44–7.34 (m, 3H), 
6.57–6.43 (m, 1H), 6.34 (dd, J = 3.3, 1.8 Hz, 1H), 6.12 (dd, J = 3.1, 0.9 Hz, 1H), 4.50 (s, 2H), 
3.74–3.62 (m, 1H), 2.66–2.55 (m, 3H), 2.05–1.94 (m, 2H), 1.89–1.53 (m, 9H), 1.43–1.30 (m, 2H), 
1.29–1.04 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 172.1, 171.1, 150.4, 149.3, 145.8, 142.4, 121.5, 
111.2, 108.7, 73.7, 48.2, 45.4, 36.2, 33.1, 25.8, 24.8, 23.6; HRMS (ESI) m/z calcd for C23H30N3O3 
[M + H]+ 396.2282, found 396.2281. 
 
 
          (±)-N-(1-(Cyclohexylcarbamoyl)cyclopentyl)-N-((tetrahydrofuran-2-
yl)methyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a colorless film (0.009 g, 0.023 mmol, 6% yield, 96.0% 
purity). IR (neat) 2926, 1649 (v br)  cm-1; 1H NMR (500 MHz, CDCl3) δ 8.52 (ddd, J = 4.9, 1.8, 
0.9 Hz, 1H), 7.78 (td, J = 7.7, 1.8 Hz, 1H), 7.64–7.60 (m, 1H), 7.56 (dt, J = 7.9, 1.1 Hz, 1H), 7.29 
99 
 
(ddd, J = 7.6, 4.9, 1.3 Hz, 0H), 3.98 (p, J = 6.7, 5.3 Hz, 1H), 3.85–3.72 (m, 2H), 3.65 (d, J = 16.1 
Hz, 1H), 3.56 (dt, J = 8.4, 6.9 Hz, 1H), 3.40–3.27 (m, 1H), 2.64 (d, J = 25.9 Hz, 1H), 2.43 (d, J = 
10.3 Hz, 1H), 2.12–2.01 (m, 1H), 2.01–1.06 (m, 18H); 13C NMR (126 MHz, CDCl3) δ 173.7, 170.4, 
156.2, 147.7, 137.0, 124.8, 124.1, 73.5, 67.7, 50.4, 48.2, 37.5, 36.1, 33.1, 33.0, 29.1, 25.9, 25.8, 
24.9, 24.6, 24.3; HRMS (ESI) m/z calcd for C23H34N3O3 [M + H]
+ 400.2595, found 400.2616. 
 
 
          (±)-N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-((tetrahydrofuran-2-
yl)methyl)nicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a colorless film (0.033 g, 0.080 mmol, 20% yield, ≥ 
99% purity). IR (neat) 2927, 1641 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.65 (dd, J = 2.3, 0.9 
Hz, 1H), 8.62 (dd, J = 4.9, 1.7 Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.75 (dt, J = 7.8, 1.9 Hz, 1H), 
7.34 (ddd, J = 7.8, 4.9, 0.9 Hz, 1H), 3.99–3.90 (m, 1H), 3.81–3.70 (m, 1H), 3.59 (dt, J = 8.2, 6.6 
Hz, 1H), 3.50–3.34 (m, 3H), 2.77–2.69 (m, 1H), 2.19–2.05 (m, 2H), 1.99–1.61 (m, 10H), 1.60–
1.30 (m, 7H), 1.29–1.15 (m, 3H), 1.15–1.05 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 173.9, 173.0, 
150.6, 148.7, 135.9, 134.6, 123.5, 76.6, 67.7, 65.8, 52.2, 48.1, 32.8, 32.6, 32.5, 32.2, 29.2, 25.9, 
25.6, 24.7, 22.3, 22.3; HRMS (ESI) m/z calcd for C24H36N3O3 [M + H]





          (±)-N-(1-(Cyclohexylcarbamoyl)cyclopentyl)-N-((tetrahydrofuran-2-
yl)methyl)nicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a white solid (0.084 g, 0.210 mmol, 53% yield, ≥ 99% 
purity). Mp = 148–151 ºC;  IR (neat) 2929, 1637 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.62 
(dd, J = 4.9, 1.7 Hz, 1H), 8.59 (dd, J = 2.2, 0.9 Hz, 1H), 7.71 (dt, J = 7.8, 1.9 Hz, 1H), 7.65 (d, J 
= 8.0 Hz, 1H), 7.38 (ddd, J = 7.8, 4.9, 0.9 Hz, 1H), 4.09–4.01 (m, 1H), 3.81–3.72 (m, 1H), 3.69–
3.61 (m, 1H), 3.58–3.50 (m, 1H), 3.47–3.33 (m, 2H), 2.83–2.75 (m, 1H), 2.45–2.35 (m, 1H), 2.08–
1.98 (m, 1H), 1.97–1.75 (m, 7H), 1.76–1.64 (m, 4H), 1.63–1.51 (m, 2H), 1.45–1.31 (m, 2H), 1.26–
1.13 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 173.1, 170.9, 149.3, 147.4, 135.9, 134.6, 123.6, 76.7, 
73.3, 67.9, 52.2, 48.3, 37.7, 36.1, 33.0, 32.9, 29.1, 25.9, 25.9, 24.9, 24.8, 24.2, 23.9; HRMS (ESI) 
m/z calcd for C23H34N3O3 [M + H]
+ 400.2595, found 400.2608. 
 
 
           (±)-N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-((tetrahydrofuran-2-
yl)methyl)isonicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a colorless film (0.051 g, 0.123 mmol, 31% yield, ≥ 
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99% purity). IR (neat) 2927, 1638 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.69 (d, J = 3.4 Hz, 
2H), 7.75 (d, J = 8.4 Hz, 1H), 7.36–7.31 (m, 2H), 3.99–3.93 (m, 1H), 3.81–3.73 (m, 1H), 3.63 
(ddd, J = 8.2, 7.1, 6.2 Hz, 1H), 3.56–3.49 (m, 1H), 3.43 (dd, J = 15.3, 2.9 Hz, 1H), 3.30 (dd, J = 
15.4, 9.9 Hz, 1H), 2.19 (ddd, J = 14.6, 10.6, 3.8 Hz, 2H), 2.10–1.96 (m, 2H), 1.93–1.68 (m, 8H), 
1.67–1.53 (m, 3H), 1.52–1.32 (m, 5H), 1.23 (dddd, J = 19.3, 12.6, 10.2, 3.6 Hz, 3H), 1.15–1.07 
(m, 1H); 13C NMR (126 MHz, CDCl3) δ 173.5, 172.5, 149.5, 147.1, 122.3, 76.6, 67.8, 66.0, 51.9, 
48.2, 32.9, 32.7, 32.6, 32.3, 29.3, 25.9, 25.9, 25.6, 24.8, 22.5; HRMS (ESI) m/z calcd for 
C24H36N3O3 [M + H]
+ 414.2751, found 414.2740. 
 
 
          (±)-N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclopentyl)-N-((tetrahydrofuran-2-
yl)methyl)isonicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a colorless film (0.037 g, 0.088 mmol, 22% yield, ≥ 
99% purity). IR (neat) 2958, 1677, 1639 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.02 (s, 1H), 8.71–
8.65 (m, 2H), 7.25–7.21 (m, 2H), 7.06 (s, 3H), 4.16 (br s, 1H), 3.68–3.53 (m, 2H), 3.48 (dd, J = 
15.4, 2.9 Hz, 1H), 3.40 (dd, J = 15.4, 10.4 Hz, 1H), 2.96 (br s, 1H), 2.51 (br s, 1H), 2.29 (s, 6H), 
2.19-2.06 (m, 2H), 2.00–1.84 (m, 4H), 1.84–1.69 (m, 3H), 1.65–1.49 (m, 1H), 1.22 (ddq, J = 12.4, 
8.1, 6.9 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 172.0, 171.0, 150.2, 145.6, 135.5, 134.9, 128.2, 
126.6, 121.3, 73.7, 68.3, 51.8, 41.1, 37.6, 36.2, 29.2, 25.9, 24.4, 24.0, 18.7; HRMS (ESI) m/z calcd 
for C25H32N3O3 [M + H]





          N-Benzyl-N-(1-((2,6-dimethylphenyl)carbamoyl)cyclohexyl)picolinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a white solid (0.102 g, 0.231 mmol, 58% yield, ≥ 99% purity). Mp = 144–146 ºC; IR 
(neat) 2929, 1676, 1637 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.58 (br, 1H), 8.53 (ddd, J = 4.8, 1.8, 
0.9 Hz, 1H), 7.68 (td, J = 7.7, 1.7 Hz, 1H), 7.46 (dt, J = 7.9, 1.1 Hz, 1H), 7.31–7.13 (m, 6H), 7.11–
7.01 (m, 3H), 4.87 (s, 2H), 2.50–2.41 (m, 2H), 2.28–2.16 (m, 8H), 1.89–1.77 (m, 2H), 1.76–1.66 
(m, 2H), 1.63–1.52 (m, 1H), 1.48–1.37 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 172.3, 171.8, 
155.5, 148.2, 139.0, 137.2, 135.2, 134.5, 128.7, 128.3, 127.6, 127.4, 126.7, 124.7, 123.9, 67.7, 
50.5, 33.5, 25.7, 22.8, 19.1; HRMS (ESI) m/z calcd for C28H32N3O2 [M + H]




          N-Benzyl-N-(1-((2,6-dimethylphenyl)carbamoyl)cyclopentyl)picolinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a white solid (0.042 g, 0.098 mmol, 25% yield, 98.2% purity). Mp = 148–150 ºC; IR 
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(neat) 2959, 1672, 1636 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.50 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 
7.71 (td, J = 7.8, 1.7 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.33–7.16 (m, 6H), 7.11–7.02 (m, 3H), 
4.91 (s, 2H), 2.86–2.67 (br s, 2H), 2.20 (s, 6H), 2.13–1.99 (m, 2H), 1.86–1.64 (m, 4H); 13C NMR 
(126 MHz, CDCl3) δ 171.8, 171.5, 155.2, 148.1, 138.9, 137.3, 135.4, 134.4, 128.7, 128.3, 127.3, 
127.2, 126.9, 124.7, 123.8, 74.9, 52.0, 36.8, 23.6, 18.7; HRMS (ESI) m/z calcd for C27H30N3O2 [M 
+ H]+ 428.2333, found 428.2348. 
 
 
          N-Benzyl-N-(1-((2,6-dimethylphenyl)carbamoyl)cyclohexyl)nicotinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a white solid (0.066 g, 0.149 mmol, 37% yield, 97.6% purity). Mp = 200–203 ºC; IR 
(neat) 2936, 1668, 1634 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.80 – 8.75 (m, 1H), 8.62 (s, 1H), 
8.53 (dd, J = 5.1, 1.7 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.28 (ddd, J = 7.8, 5.0, 0.8 Hz, 1H), 7.23–
7.16 (m, 3H), 7.15–7.03 (m, 5H), 4.74 (s, 2H), 2.54–2.45 (m, 2H), 2.43–2.34 (m, 2H), 2.21 (s, 6H), 
1.87–1.79 (m, 2H), 1.73–1.64 (m, 2H), 1.63–1.57 (m, 1H), 1.57–1.52 (m, 1H); 13C NMR (126 
MHz, CDCl3) δ 172.0, 171.4, 149.4, 146.3, 138.1, 136.3, 134.9, 134.6, 134.5, 129.0, 128.5, 127.8, 
127.4, 126.8, 124.1, 67.7, 51.6, 33.2, 25.5, 22.9, 19.2; HRMS (ESI) m/z calcd for C28H32N3O2 [M 





          N-Benzyl-N-(1-((2,6-dimethylphenyl)carbamoyl)cyclopentyl)nicotinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a white solid (0.066 g, 0.154 mmol, 39% yield, 98.9% purity). Mp = 190–193 ºC; IR 
(neat) 2961, 1664, 1636 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.69 (dd, J = 2.2, 0.9 Hz, 1H), 8.54 
(dd, J = 5.0, 1.7 Hz, 1H), 8.07 (s, 1H), 7.71 (dt, J = 8.0, 1.9 Hz, 1H), 7.32 (dd, J = 8.1, 6.7 Hz, 2H), 
7.29–7.18 (m, 4H), 7.14–7.03 (m, 3H), 4.75 (s, 2H), 2.86 (dd, J = 13.0, 5.7 Hz, 2H), 2.27 (s, 6H), 
2.24–2.12 (m, 2H), 1.84 (dtd, J = 10.3, 5.9, 2.7 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 171.7, 
171.7, 149.4, 146.2, 138.6, 135.6, 135.3, 134.2, 133.8, 129.1, 128.4, 127.7, 127.2, 126.4, 123.8, 
74.7, 53.2, 36.8, 23.8, 18.8; HRMS (ESI) m/z calcd for C27H30N3O2 [M + H]




          N-Benzyl-N-(1-((2,6-dimethylphenyl)carbamoyl)cyclohexyl)isonicotinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a white solid (0.123 g, 0.279 mmol, 70% yield, 94.0% purity). Mp = 191–193 ºC; IR 
(neat) 2932, 1681, 1639 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.61–8.52 (m, 2H), 8.20 (s, 1H), 
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7.31–7.28 (m, 2H), 7.29–7.20 (m, 3H), 7.20–7.14 (m, 2H), 7.11–7.04 (m, 3H), 4.68 (s, 2H), 2.70–
2.50 (m, 2H), 2.35–2.16 (m, 8H), 1.89–1.77 (m, 2H), 1.77–1.59 (m, 3H), 1.54–1.39 (m, 1H); 13C 
NMR (126 MHz, CDCl3) δ 171.8, 170.9, 148.7, 146.6, 138.0, 134.8, 134.2, 129.0, 128.4, 127.7, 
126.9, 126.8, 121.2, 67.5, 50.9, 33.1, 25.3, 23.0, 19.1; HRMS (ESI) m/z calcd for C28H32N3O2 [M 
+ H]+ 442.2489, found 442.2495. 
 
 
          N-Benzyl-N-(1-((2,6-dimethylphenyl)carbamoyl)cyclopentyl)isonicotinamide. 
Prepared according to the general procedure for Ugi multicomponent reaction, the title compound 
was obtained as a colorless film (0.078 g, 0.182 mmol, 46% yield, 98.5% purity). IR (neat) 2963, 
1690, 1617 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.59 – 8.50 (m, 2H), 7.80 (s, 1H), 7.34 (dd, J = 
8.2, 6.7 Hz, 2H), 7.31–7.27 (m, 3H), 7.24–7.19 (m, 2H), 7.14–7.06 (m, 3H), 4.67 (s, 2H), 2.95–
2.78 (m, 2H), 2.28 (s, 6H), 2.25–1.60 (m, 6H); 13C NMR (126 MHz, CDCl3) δ 171.7, 148.8, 146.1, 
138.5, 135.4, 134.0, 129.2, 128.5, 127.8, 127.3, 126.2, 121.1, 74.6, 52.9, 36.7, 23.8, 18.8; HRMS 
(ESI) m/z calcd for C27H30N3O2 [M + H]





          N-(Cyclohexylmethyl)-N-(1-((2,6-dimethylphenyl)carbamoyl)cyclohexyl)picolinamide. 
Prepared according to the general procedure for Ugi multicomponent reaction, the title compound 
was obtained as a white foam (0.030 g, 0.067 mmol, 17% yield, 98.4% purity). Mp = 68–71 ºC; 
IR (neat) 2926, 1681, 1637 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.74–9.70 (br, 1H), 8.61 (ddd, J 
= 4.9, 1.7, 0.9 Hz, 1H), 7.82 (td, J = 7.7, 1.7 Hz, 1H), 7.61 (dt, J = 7.8, 1.1 Hz, 1H), 7.36 (ddd, J 
= 7.7, 4.8, 1.2 Hz, 1H), 7.06 (s, 3H), 3.46 (d, J = 6.3 Hz, 2H), 2.53 (br, 2H), 2.30 (m, 7H), 1.89–
1.76 (m, 2H), 1.73–1.58 (m, 7H), 1.57–1.47 (m, 4H), 1.19–1.06 (m, 2H), 1.00–0.87 (m, 1H), 0.57–
0.45 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 173.5, 172.8, 155.9, 148.6, 137.2, 135.0, 134.8, 
128.3, 126.5, 124.8, 124.8, 66.6, 54.1, 37.5, 33.0, 31.1, 26.2, 25.8, 25.5, 22.6, 19.3; HRMS (ESI) 
m/z calcd for C28H38N3O2 [M + H]
+ 448.2959, found 448.2981. 
 
 
          N-(Cyclohexylmethyl)-N-(1-((2,6-
dimethylphenyl)carbamoyl)cyclopentyl)picolinamide. Prepared according to the general 
procedure for Ugi multicomponent reaction, the title compound was obtained as a white solid 
(0.027 g, 0.062 mmol, 16% yield, 98.9% purity). Mp = 101–103 ºC; IR (neat) 2924, 1678, 1633 
cm-1; 1H NMR (500 MHz, CDCl3) δ 9.38 (br, 1H), 8.57 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.82 (td, J 
= 7.7, 1.7 Hz, 1H), 7.60 (dt, J = 7.8, 1.1 Hz, 1H), 7.36 (ddd, J = 7.7, 4.9, 1.2 Hz, 1H), 7.06 (s, 3H), 
5.29 (s, 1H), 3.53 (d, J = 6.3 Hz, 2H), 2.84 (br s, 2H), 2.27 (s, 6H), 2.19–2.09 (m, 2H), 1.92–1.78 
(m, 4H), 1.72–1.59 (m, 3H), 1.58–1.47 (m, 3H), 1.11 (qt, J = 12.9, 3.4 Hz, 2H), 1.00–0.87 (m, 1H), 
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0.56–0.44 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 172.2, 172.0, 155.6, 148.3, 137.4, 135.0, 134.8, 
128.3, 126.6, 124.7, 124.6, 74.2, 54.8, 37.6, 36.4, 31.0, 26.2, 25.6, 23.1, 19.0; HRMS (ESI) m/z 
calcd for C27H36N3O2 [M + H]
+ 434.2802, found 434.2802. 
 
 
          N-(Cyclohexylmethyl)-N-(1-((2,6-dimethylphenyl)carbamoyl)cyclohexyl)nicotinamide. 
Prepared according to the general procedure for Ugi multicomponent reaction, the title compound 
was obtained as a white solid (0.017 g, 0.038 mmol, 9% yield, ≥ 99% purity). Mp = 119–121 ºC; 
IR (neat) 2925, 1678, 1617 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.99 (s, 1H), 8.77–8.68 (m, 2H), 
7.83 (dt, J = 7.8, 1.9 Hz, 1H), 7.41 (ddd, J = 7.9, 4.9, 0.9 Hz, 1H), 7.07 (s, 3H), 3.36 (d, J = 6.0 
Hz, 2H), 2.71 (br s, 2H), 2.32 (s, 6H), 2.17–2.07 (m, 2H), 1.85–1.60 (m, 8H), 1.58–1.42 (m, 3H), 
1.19–1.06 (m, 2H), 1.01–0.87 (m, 1H), 0.62–0.50 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 173.7, 
172.7, 151.4, 149.3, 136.4, 135.0, 134.3, 134.0, 128.4, 126.4, 123.8, 66.5, 55.7, 37.2, 32.7, 31.1, 
26.1, 25.5, 25.3, 22.6, 19.4; HRMS (ESI) m/z calcd for C28H38N3O2 [M + H]






          N-(Cyclohexylmethyl)-N-(1-((2,6-
dimethylphenyl)carbamoyl)cyclopentyl)nicotinamide. Prepared according to the general 
procedure for Ugi multicomponent reaction, the title compound was obtained as a colorless film 
(0.035 g, 0.079 mmol, 20% yield, 98.9% purity). IR (neat) 2925, 1687, 1665 cm-1; 1H NMR (500 
MHz, CDCl3) δ 9.55 (s, 1H), 8.82–8.60 (m, 2H), 7.86 (d, J = 7.9 Hz, 1H), 7.48 (dd, J = 7.7, 5.1 
Hz, 1H), 7.07 (s, 3H), 3.35 (d, J = 6.6 Hz, 2H), 2.82 (br s, 2H), 2.30 (s, 6H), 2.17 (q, J = 8.3 Hz, 
2H), 1.97–1.81 (m, 4H), 1.81–1.44 (m, 6H), 1.19–1.05 (m, 2H), 1.01–0.86 (m, 1H), 0.51 (q, J = 
12.0 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 171.8, 171.2, 149.4, 147.1, 137.2, 134.8, 134.6, 
134.4, 128.5, 126.7, 124.3, 74.3, 56.5, 37.3, 36.4, 31.0, 26.1, 25.5, 22.7, 19.0; HRMS (ESI) m/z 
calcd for C27H36N3O2 [M + H]
+ 434.2802, found 434.2819. 
 
 
          N-(Cyclohexylmethyl)-N-(1-((2,6-
dimethylphenyl)carbamoyl)cyclohexyl)isonicotinamide. Prepared according to the general 
procedure for Ugi multicomponent reaction, the title compound was obtained as a colorless film 
(0.034 g, 0.076 mmol, 19% yield, 95.6% purity). IR (neat) 2921, 1681, 1630 cm-1; 1H NMR (600 
MHz, CDCl3) δ 9.66 (s, 1H), 8.75 (br s, 2H), 7.38 (d, J = 5.4 Hz, 2H), 7.07 (s, 3H), 3.29 (d, J = 
6.1 Hz, 2H), 2.63 (br s, 1H), 2.31 (s, 6H), 2.25–2.15 (m, 2H), 1.88–1.77 (m, 2H), 1.75–1.61 (m, 
4H), 1.60–1.47 (m, 6H), 1.18–1.08 (m, 2H), 1.02–0.92 (m, 1H), 0.91–0.80 (m, 1H), 0.63–0.49 (m, 
2H); 13C NMR (151 MHz, CDCl3) δ 173.3, 172.2, 150.1, 146.3, 134.9, 134.4, 128.5, 126.6, 122.6, 
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66.6, 55.3, 37.4, 32.8, 31.1, 26.1, 25.5, 25.4, 22.8, 19.4; 34 mg, HRMS (ESI) m/z calcd for 
C28H38N3O2 [M + H]
+ 448.2959, found 448.2975. 
 
 
          N-(Cyclohexylmethyl)-N-(1-((2,6-
dimethylphenyl)carbamoyl)cyclopentyl)isonicotinamide.  Prepared according to the general 
procedure for Ugi multicomponent reaction, the title compound was obtained as a white solid 
(0.029 g, 0.065 mmol, 17% yield, 97.7% purity). Mp = 189–191 ºC; IR (neat) 2926, 1656, 1635, 
1506 cm-1;  1H NMR (500 MHz, CDCl3) δ 9.16 (s, 1H), 8.73 (d, J = 5.9 Hz, 2H), 7.39 (d, J = 5.9 
Hz, 2H), 7.08 (s, 3H), 3.26 (d, J = 6.6 Hz, 2H), 2.81 (br s, 1H), 2.30 (s, 6H), 2.22–2.07 (m, 3H), 
1.97–1.79 (m, 4H), 1.78–1.45 (m, 6H), 1.19–1.05 (m, 2H), 1.02–0.90 (m, 1H), 0.53 (q, J = 11.7 
Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 171.6, 171.1, 148.7, 147.2, 134.7, 134.6, 128.5, 126.9, 
122.5, 74.2, 56.0, 37.4, 36.4, 31.0, 26.1, 25.5, 22.8, 19.0; HRMS (ESI) m/z calcd for C27H36N3O2 





          N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclohexyl)-N-(furan-2-ylmethyl)picolinamide. 
Prepared according to the general procedure for Ugi multicomponent reaction, the title compound 
was obtained as a yellow solid (0.106 g, 0.246 mmol, 61% yield, ≥ 99% purity). Mp = 75–78 ºC; 
IR (neat) 2930, 1656 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.59–8.52 (m, 2H), 7.74 (td, J = 
7.7, 1.7 Hz, 1H), 7.54 (dt, J = 7.8, 1.1 Hz, 1H), 7.33 (ddd, J = 7.7, 4.8, 1.2 Hz, 1H), 7.19 (dd, J = 
1.9, 0.8 Hz, 1H), 7.07–6.99 (m, 3H), 6.15 (dd, J = 3.3, 1.9 Hz, 1H), 5.89 (d, J = 3.2 Hz, 1H), 4.93 
(s, 2H), 2.42–2.29 (m, 4H), 2.19 (s, 6H), 1.91– 1.80 (m, 2H), 1.74–1.62 (m, 2H), 1.59–1.50 (m, 
2H); 13C NMR (126 MHz, CDCl3) δ 172.0, 171.9, 155.1, 151.4, 148.1, 142.0, 137.2, 135.4, 134.5, 
128.1, 126.6, 124.8, 124.1, 110.9, 108.2, 67.1, 43.0, 32.9, 25.7, 22.6, 18.8; HRMS (ESI) m/z calcd 
for C26H30N3O3 [M + H]
+ 432.2282, found 432.2280. 
 
 
          N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclopentyl)-N-(furan-2-
ylmethyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a yellow solid (0.067 g, 0.160 mmol, 40% yield, 96.8% 
purity). Mp = 158–161 ºC; IR (neat) 2958, 1661 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.54 
(ddd, J = 4.9, 1.6, 0.9 Hz, 1H), 8.44 (br s, 1H), 7.77 (td, J = 7.7, 1.7 Hz, 1H), 7.57 (dt, J = 7.9, 1.0 
Hz, 1H), 7.34 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 7.22 (dd, J = 1.8, 0.7 Hz, 1H), 7.10–6.98 (m, 3H), 
6.20 (dd, J = 3.2, 1.9 Hz, 1H), 6.01 (d, J = 2.9 Hz, 1H), 4.92 (s, 2H), 4.84 (br s, 1H), 2.76 (br s, 
2H), 2.18 (s, 6H), 2.15–2.10 (m, 2H), 1.93–1.65 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 171.8, 
111 
 
171.0, 154.8, 151.4, 148.0, 142.1, 137.4, 135.5, 134.4, 128.1, 126.8, 124.9, 124.1, 110.9, 108.3, 
74.4, 44.1, 36.5, 23.9, 18.6; HRMS (ESI) m/z calcd for C25H28N3O3 [M + H]




          N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclohexyl)-N-(furan-2-ylmethyl)nicotinamide. 
Prepared according to the general procedure for Ugi multicomponent reaction, the title compound 
was obtained as a white solid (68 mg, 0.158 mmol, 39% yield, ≥ 99% purity). Mp = 180–183 ºC; 
IR (neat) 2930, 1659, 1643 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.89 (s, 1H), 8.64 (s, 1H), 8.57 (d, 
J = 5.2 Hz, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.45–7.39 (m, 1H), 7.27 (dd, J = 1.9, 0.8 Hz, 1H), 7.09–
7.00 (m, 3H), 6.23 (dd, J = 3.3, 1.9 Hz, 1H), 6.07–6.02 (m, 1H), 4.68 (s, 2H), 2.46–2.29 (m, 4H), 
2.19 (s, 6H), 1.90–1.81 (m, 2H), 1.70–1.48 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 171.4, 171.2, 
150.1, 149.1, 146.3, 142.4, 136.7, 135.1, 134.4, 134.2, 128.2, 126.6, 124.2, 111.1, 108.8, 67.1, 
44.5, 32.7, 25.4, 22.6, 18.8; HRMS (ESI) m/z calcd for C26H30N3O3 [M + H]






          N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclopentyl)-N-(furan-2-
ylmethyl)nicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a white solid (0.042 g, 0.101 mmol, 25% yield, 97.0% 
purity). Mp = 206–208 ºC; IR (neat) 2954, 1656, 1640 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.87 
(br s, 1H), 8.60 (dd, J = 5.1, 1.6 Hz, 1H), 8.25 (s, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.49–7.42 (m, 1H), 
7.34 (dd, J = 1.9, 0.8 Hz, 1H), 7.10–7.02 (m, 3H), 6.31 (dd, J = 3.3, 1.8 Hz, 1H), 6.13 (dd, J = 3.3, 
1.0 Hz, 1H), 4.66 (s, 2H), 2.92–2.76 (m, 2H), 2.21 (s, 6H), 2.17–2.10 (m, 2H), 1.92–1.73 (m, 4H); 
13C NMR (126 MHz, CDCl3) δ 171.2, 170.7, 150.4, 148.4, 145.7, 142.7, 137.2, 135.5, 134.3, 134.1, 
128.4, 127.1, 124.4, 111.3, 108.7, 74.4, 46.0, 36.5, 23.8, 18.7; HRMS (ESI) m/z calcd for 
C25H28N3O3 [M + H]




          N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclohexyl)-N-(furan-2-
ylmethyl)isonicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a yellow solid (0.070 g, 0.162 mmol, 41 yield, ≥ 99% 
purity). Mp = 194–197 ºC; IR (neat) 2932, 1662, 1642, 1493 cm-1; 1H NMR (500 MHz, CDCl3) δ 
8.70–8.65 (m, 2H), 8.31 (s, 1H), 7.42–7.37 (m, 2H), 7.30 (dd, J = 1.9, 0.8 Hz, 1H), 7.11–7.01 (m, 
3H), 6.28 (dd, J = 3.3, 1.9 Hz, 1H), 6.07 (dd, J = 3.3, 0.9 Hz, 1H), 4.62 (s, 2H), 2.45–2.36 (m, 2H), 
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2.34–2.25 (m, 2H), 2.19 (s, 6H), 1.92–1.81 (m, 2H), 1.69–1.48 (m, 4H); HRMS (ESI) m/z calcd 
for C26H30N3O3 [M + H]
+ 432.2282, found 432.2288. 
 
 
          N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclopentyl)-N-(furan-2-
ylmethyl)isonicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a white solid (0.046 g, 0.110 mmol, 28% yield, 97.9% 
purity). Mp = 178–180 ºC; IR (neat) 2962, 1663, 1635 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.69–
8.64 (m, 2H), 8.02 (s, 1H), 7.39–7.32 (m, 3H), 7.13–7.02 (m, 3H), 6.33 (dd, J = 3.3, 1.9 Hz, 1H), 
6.14 (dd, J = 3.3, 1.0 Hz, 1H), 4.58 (s, 2H), 2.84–2.75 (m, 2H), 2.21 (s, 6H), 2.19–2.12 (m, 2H), 
1.93–1.74 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 171.5, 171.2, 150.6, 150.0, 145.0, 142.6, 135.4, 
134.2, 128.4, 127.1, 121.1, 111.3, 108.5, 74.2, 45.5, 36.5, 23.9, 18.7; HRMS (ESI) m/z calcd for 
C25H28N3O3 [M + H]





          (±)-N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclohexyl)-N-((tetrahydrofuran-2-
yl)methyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a light yellow film (0.026 g, 0.060 mmol, 15% yield, 
94.4% purity). IR (neat) 2927, 1679, 1640 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.31 (s, 1H), 8.56 
(ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.79 (td, J = 7.7, 1.7 Hz, 1H), 7.63 (dt, J = 7.9, 1.1 Hz, 1H), 7.31 
(ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 7.05 (s, 3H), 4.17–3.69 (m, 3H), 3.55 (dt, J = 8.2, 6.6 Hz, 1H), 3.42 
(br s, 1H), 2.58 (br s, 1H), 2.47–2.37 (m, 1H), 2.31 (s, 6H), 2.29–2.23 (m, 1H), 2.20–2.11 (m, 3H), 
1.97–1.87 (m, 1H), 1.81–1.46 (m, 6H), 1.29–1.18 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 173.1 
(2 carbonyl), 156.1, 148.0, 137.1, 135.6, 135.2, 128.2, 126.4, 124.9, 124.3, 77.9, 67.9, 66.5, 50.4, 
33.4, 32.4, 31.1, 29.3, 25.8, 25.7, 22.8, 22.6, 18.9; HRMS (ESI) m/z calcd for C26H34N3O3 [M + 
H]+ 436.2595, found 436.2610. 
 
 
          (±)-N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclopentyl)-N-((tetrahydrofuran-2-
yl)methyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a yellow film (0.016 g, 0.038 mmol, 9% yield, 95.7% 
purity). IR (neat) 2961, 1677, 1638 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.05 (br, 1H), 8.55 (ddd, 
J = 4.9, 1.7, 0.9 Hz, 1H), 7.80 (td, J = 7.7, 1.8 Hz, 1H), 7.62 (dt, J = 7.9, 1.1 Hz, 1H), 7.31 (ddd, J 
= 7.6, 4.9, 1.2 Hz, 1H), 7.05 (s, 3H), 4.23–2.48 (m, 6H), 2.37–2.19 (m, 7H), 2.15–1.67 (m, 8H), 
1.59–1.19 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 172.6 (2 Carbonyl), 155.9, 147.8, 137.2, 135.6, 
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135.2, 128.1, 126.5, 124.8, 124.2, 74.0, 68.1, 56.1, 50.3, 37.6, 36.2, 29.1, 25.8, 24.7, 24.3, 18.8; 
HRMS (ESI) m/z calcd for C25H32N3O3 [M + H]
+ 422.2438, found 422.2454. 
 
 
          (±)-N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclohexyl)-N-((tetrahydrofuran-2-
yl)methyl)nicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a white solid (0.110 g, 0.253 mmol, 63% yield, 96.4% 
purity). Mp = 115–118 ºC; IR (neat) 2929, 1677, 1637 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.48 
(br, 1H), 8.69 (dd, J = 2.2, 0.9 Hz, 1H), 8.64 (dd, J = 4.9, 1.7 Hz, 1H), 7.77 (dt, J = 7.9, 1.9 Hz, 
1H), 7.37 (ddd, J = 7.8, 4.8, 0.9 Hz, 1H), 7.05 (s, 3H), 4.14–4.04 (m, 1H), 3.63–3.41 (m, 4H), 2.87 
(br s, 1H), 2.35–2.24 (m, 7H), 2.23–2.18 (m, 1H), 1.95–1.63 (m, 6H), 1.59–1.44 (m, 4H), 1.22–
1.11 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 172.6 (2 carbonyl), 150.6, 148.5, 135.7, 135.3, 135.0, 
134.4, 128.2, 126.5, 123.5, 76.9, 68.0, 66.2, 52.3, 32.8, 32.5, 29.3, 25.8, 25.5, 22.7, 22.5, 18.8; 
HRMS (ESI) m/z calcd for C26H34N3O3 [M + H]





         (±)-N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclopentyl)-N-((tetrahydrofuran-2-
yl)methyl)nicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a colorless film (0.049 g, 0.116 mmol, 29% yield, 
98.1% purity). IR (neat) 2948, 1678, 1630 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.10 (s, 1H), 8.71 
– 8.59 (m, 2H), 7.80 (dt, J = 7.7, 1.6 Hz, 1H), 7.44 (dd, J = 7.7, 5.0 Hz, 1H), 7.06 (s, 3H), 4.19 (br 
s, 1H), 3.71–3.41 (m, 4H), 3.01 (br s, 1H), 2.61–2.47 (m, 1H), 2.29 (s, 6H), 2.20–2.05 (m, 2H), 
2.01–1.87 (m, 3H), 1.85–1.70 (m, 3H), 1.64–1.49 (m, 1H), 1.30–1.15 (m, 1H); 13C NMR (126 
MHz, CDCl3) δ 171.9, 170.7, 148.9, 146.7, 136.4, 135.4, 134.9, 134.7, 128.3, 126.7, 124.0, 73.8, 
68.3, 57.9, 52.3, 37.7, 36.3, 29.2, 25.9, 24.3, 23.9, 18.8; HRMS (ESI) m/z calcd for C25H32N3O3 
[M + H]+ 422.2438, found 422.2464. 
 
 
         (±)-N-(1-((2,6-Dimethylphenyl)carbamoyl)cyclohexyl)-N-((tetrahydrofuran-2-
yl)methyl)isonicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a white solid (0.090 g, 0.207 mmol, 52% yield, ≥ 99% 
purity). Mp = 56–59 ºC; IR (neat) 2928, 1680, 1639 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.15 (s, 
1H), 8.77–8.72 (m, 2H), 7.55–7.50 (m, 2H), 7.07 (s, 3H), 4.14–4.08 (m, 1H), 3.67–3.58 (m, 2H), 
3.54–3.46 (m, 1H), 3.39–3.30 (m, 1H), 2.81–2.77 (m, 1H), 2.40–2.23 (m, 8H), 2.17–2.10 (m, 1H), 
1.95–1.72 (m, 4H), 1.72–1.44 (m, 5H), 1.21–1.10 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 171.9, 
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171.3, 156.3, 147.0, 135.2, 134.8, 128.4, 126.8, 123.2, 68.1, 66.6, 52.1, 36.8, 32.8, 32.7, 29.4, 26.0, 
25.5, 22.9, 22.7, 18.9; HRMS (ESI) m/z calcd for C26H34N3O3 [M + H]
+ 436.2595, found 436.2596. 
 
 
          (±)-N-(1-(Cyclohexylcarbamoyl)cyclopentyl)-N-((tetrahydrofuran-2-
yl)methyl)isonicotinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a white solid (0.086 g, 0.215 mmol 54% yield, 96.1% 
purity). Mp = 137–140 ºC; IR (neat) 2929, 1645 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.68–
8.59 (m, 2H), 7.53 (d, J = 6.9 Hz, 1H), 7.23–7.12 (m, 2H), 4.08–3.95 (m, 1H), 3.79–3.69 (m, 1H), 
3.69–3.60 (m, 1H), 3.60–3.50 (m, 1H), 3.41–3.25 (m, 2H), 2.75 (br s, 1H), 2.15–2.11 (m, 1H), 
2.04–1.49 (m, 14H), 1.41–1.27 (m, 2H), 1.24–1.02 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 173.0, 
170.8, 150.0, 145.7, 121.4, 76.6, 73.1, 67.9, 51.6, 48.2, 37.4, 35.9, 32.9, 32.9, 29.0, 25.8, 25.8, 
24.8, 24.7, 24.3, 24.0; HRMS (ESI) m/z calcd for C23H34N3O3 [M + H]





          N-Benzyl-N-(1-(cyclohexylcarbamoyl)cyclohexyl)picolinamide. Prepared according to 
the general procedure for Ugi multicomponent reaction, the title compound was obtained as a white 
solid (0.121 g, 0.288 mmol, 72% yield, 96.3% purity). Mp = 104–107 ºC; IR (neat) 2927, 1652, 
1628 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.57 – 8.50 (m, 1H), 7.65 (tt, J = 7.7, 1.4 Hz, 1H), 7.43 
(dd, J = 7.9, 1.1 Hz, 1H), 7.28 – 7.13 (m, 6H), 7.06 (s, 1H), 4.72 (s, 2H), 3.73–3.61 (m, 1H), 2.27–
2.17 (m, 2H), 2.14–2.05 (m, 2H), 1.89–1.81 (m, 2H), 1.75–1.45 (m, 8H), 1.42–1.27 (m, 3H), 1.26–
1.11 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 172.7, 172.2, 155.5, 148.4, 138.7, 137.0, 128.4, 
127.5, 127.2, 124.5, 123.7, 66.8, 50.3, 48.1, 33.1, 32.9, 25.8, 25.7, 24.8, 22.6; HRMS (ESI) m/z 
calcd for C26H34N3O2 [M + H]
+ 420.2646, found 420.2667. 
 
 
          N-Benzyl-N-(1-(cyclohexylcarbamoyl)cyclopentyl)picolinamide. Prepared according to 
the general procedure for Ugi multicomponent reaction, the title compound was obtained as a white 
solid (0.077 g, 0.190 mmol, 47% yield, 90.8% purity). Mp = 126–129 ºC; IR (neat) 2929, 1650 (v 
br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.51 (dt, J = 4.8, 1.2 Hz, 1H), 7.69 (td, J = 7.6, 1.6 Hz, 
2H), 7.45 (d, J = 7.9 Hz, 1H), 7.30 (dd, J = 8.0, 5.1 Hz, 1H), 7.25–7.14 (m, 5H), 4.79 (s, 2H), 
3.76–3.67 (m, 1H), 2.57 (br s, 2H), 1.97 (br s, 2H), 1.90–1.83 (m, 2H), 1.75–1.51 (m, 7H), 1.43–
1.30 (m, 2H), 1.28–1.12 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 172.7, 171.2, 155.1, 147.6, 138.8, 
137.6, 128.5, 127.3, 127.3, 124.8, 124.0, 74.5, 52.1, 48.3, 36.6, 33.0, 25.8, 24.9, 23.5; HRMS (ESI) 
m/z calcd for C25H32N3O2 [M + H]





          N-Benzyl-N-(1-(cyclohexylcarbamoyl)cyclohexyl)nicotinamide. Prepared according to 
the general procedure for Ugi multicomponent reaction, the title compound was obtained as a white 
solid (0.103 g, 0.245 mmol, 61% yield, ≥ 99% purity). Mp = 50–53 ºC; IR (neat) 2929, 1653, 1624 
cm-1; 1H NMR (500 MHz, CDCl3) δ 8.70 (dd, J = 2.3, 0.9 Hz, 1H), 8.60 (dd, J = 4.9, 1.7 Hz, 1H), 
7.71 (dt, J = 7.8, 1.9 Hz, 1H), 7.32–7.16 (m, 4H), 7.15–7.10 (m, 2H), 7.06 (d, J = 7.6 Hz, 1H), 
4.60 (s, 2H), 3.72–3.61 (m, 1H), 2.30–2.17 (m, 4H), 1.91–1.82 (m, 2H), 1.75–1.43 (m, 9H), 1.43–
1.31 (m, 2H), 1.29–1.15 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 172.3 (2 carbonyl), 150.2, 147.3, 
137.8, 135.7, 134.3, 128.8, 127.7, 127.3, 123.8, 66.8, 51.3, 48.3, 32.9, 32.8, 25.8, 25.6, 24.8, 22.8; 
HRMS (ESI) m/z calcd for C26H34N3O2 [M + H]
+ 420.2646, found 420.2634. 
 
 
          N-Benzyl-N-(1-(cyclohexylcarbamoyl)cyclopentyl)nicotinamide. Prepared according to 
the general procedure for Ugi multicomponent reaction, the title compound was obtained as a 
yellow solid (0.095 g, 0.234 mmol, 59% yield, 98.3% purity). Mp = 75–79 ºC; IR (neat) 2931, 
1639 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.63 (d, J = 1.5 Hz, 1H), 8.58 (dd, J = 5.0, 1.6 Hz, 
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1H), 7.70 (dt, J = 7.9, 1.8 Hz, 1H), 7.32–7.26 (m, 3H), 7.25–7.21 (m, 1H), 7.18–7.12 (m, 2H), 6.67 
(d, J = 7.6 Hz, 1H), 4.64 (s, 2H), 3.82–3.68 (m, 1H), 2.70–2.63 (m, 2H), 2.06–1.96 (m, 2H), 1.95–
1.84 (m, 2H), 1.78–1.65 (m, 6H), 1.64–1.54 (m, 1H), 1.45–1.33 (m, 2H), 1.28–1.13 (m, 3H); 13C 
NMR (126 MHz, CDCl3) δ 172.3, 171.4, 149.1, 146.1, 138.3, 136.0, 134.0, 129.0, 127.7, 126.6, 
123.9, 74.3, 53.1, 48.5, 36.3, 33.0, 25.8, 24.9, 23.3; HRMS (ESI) m/z calcd for C25H32N3O2 [M + 
H]+ 406.2489, found 406.2509. 
 
 
          N-Benzyl-N-(1-(cyclohexylcarbamoyl)cyclohexyl)isonicotinamide. Prepared according 
to the general procedure for Ugi multicomponent reaction, the title compound was obtained as a 
white solid (0.079 g, 0.188 mmol, 47% yield, 97.1% purity). Mp = 89–92 ºC; IR (neat) 2929, 1650 
(v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 5.5 Hz, 2H), 7.40 (d, J = 5.4 Hz, 2H), 7.33–
7.16 (m, 5H), 6.55 (d, J = 8.0 Hz, 1H), 4.55 (s, 2H), 3.82–3.71 (m, 1H), 2.45–2.36 (m, 2H), 2.11–
1.97 (m, 2H), 1.95–1.88 (m, 2H), 1.77–1.68 (m, 2H), 1.67–1.58 (m, 5H), 1.46–1.32 (m, 3H), 1.30–
1.17 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 171.7, 170.8, 148.8, 146.6, 137.7, 129.0, 127.9, 
126.9, 122.2, 67.1, 50.7, 48.6, 33.0, 32.7, 25.8, 25.5, 24.9, 23.0; HRMS (ESI) m/z calcd for 
C26H34N3O2 [M + H]





          N-Benzyl-N-(1-(cyclohexylcarbamoyl)cyclopentyl)isonicotinamide. Prepared according 
to the general procedure for Ugi multicomponent reaction, the title compound was obtained as a 
white solid (0.085 g, 0.210 mmol, 52% yield, 98.9% purity). Mp = 140–142 ºC; IR (neat) 2928, 
1661, 1623 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.57–8.52 (m, 2H), 7.36–7.22 (m, 5H), 7.21–7.15 
(m, 2H), 6.41 (d, J=7.5 Hz, 1H), 4.59 (s, 2H), 3.83–3.72 (m, 1H), 2.67–2.58 (m, 2H), 2.07–1.88 
(m, 4H), 1.78–1.57 (m, 7H), 1.46–1.33 (m, 2H), 1.28–1.15 (m, 3H); 13C NMR (126 MHz, CDCl3) 
δ 172.3, 171.3, 148.0, 146.9, 138.2, 129.1, 127.8, 126.4, 121.5, 74.1, 52.7, 48.6, 36.2, 33.0, 25.7, 
24.9, 23.4; HRMS (ESI) m/z calcd for C25H32N3O2 [M + H]
+ 406.2489, found 406.2500. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-(cyclohexylmethyl)picolinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a colorless film (0.092 g, 0.216 mmol, 54% yield, 96.7% purity). IR (neat) 2925, 1661, 
1617 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.63–8.58 (m, 1H), 8.29 (d, J = 7.4 Hz, 1H), 7.83–7.75 
(m, 1H), 7.61–7.55 (m, 1H), 7.33 (ddd, J = 7.5, 4.9, 1.4 Hz, 1H), 3.83–3.66 (m, 1H), 3.24 (d, J = 
6.9 Hz, 2H), 2.08–1.81 (m, 5H), 1.75–1.04 (m, 23H), 0.99–0.85 (m, 1H), 0.44 (q, J = 11.3 Hz, 2H); 
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13C NMR (126 MHz, CDCl3) δ 174.3, 173.8, 156.0, 148.9, 137.0, 124.7, 124.6, 65.7, 54.5, 48.1, 
37.2, 32.8, 32.7, 31.0, 26.3, 25.8, 25.8, 25.6, 24.8, 22.3; HRMS (ESI) m/z calcd for C26H40N3O2 
[M + H]+ 426.3115, found 426.3116. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclopentyl)-N-(cyclohexylmethyl)picolinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a white solid (0.066 g, 0.160 mmol, 40% yield, 95.8% purity). Mp = 74–76 ºC; IR 
(neat) 2932, 1665, 1615 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 4.3 Hz, 1H), 8.16 (br s, 
1H), 7.83 (t, J = 7.3 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.43–7.32 (m, 1H), 3.83–3.68 (m, 1H), 3.36 
(d, J = 6.7 Hz, 2H), 2.84–2.62 (m, 2H), 2.18–1.49 (m, 17H), 1.45–1.06 (m, 7H), 1.02–0.86 (m, 
1H), 0.63–0.28 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 173.2, 172.1, 155.5, 148.1, 137.6, 124.8, 
124.7, 73.5, 55.4, 48.2, 37.1, 36.2, 32.9, 31.0, 26.3, 25.8, 25.7, 24.9, 22.7; HRMS (ESI) m/z calcd 
for C25H38N3O2 [M + H]





          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-(cyclohexylmethyl)nicotinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a white solid (0.070 g, 0.164 mmol, 41% yield, ≥ 99% purity). Mp = 129–131 ºC; IR 
(neat) 2926, 1676, 1623 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.80–8.69 (m, 2H), 8.28 (d, J = 6.5 
Hz, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.65–7.51 (m, 1H), 3.83–3.68 (m, 1H), 3.18 (d, J = 6.2 Hz, 2H), 
2.51 (br s, 2H), 2.08–1.80 (m, 4H), 1.79–1.06 (m, 22H), 1.02–0.89 (m, 1H), 0.47 (q, J = 11.3 Hz, 
2H); 13C NMR (126 MHz, CDCl3) δ 173.6, 172.0, 148.4, 146.6, 138.8, 135.3, 124.7, 65.8, 55.9, 
48.1, 37.2, 32.7, 32.2, 31.0, 26.1, 25.7, 25.5, 25.4, 24.6, 22.3; HRMS (ESI) m/z calcd for 
C26H40N3O2 [M + H]
+ 426.3115, found 426.3112. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclopentyl)-N-(cyclohexylmethyl)nicotinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a colorless film (0.057 g, 0.138 mmol, 35% yield, 98.0% purity). IR (neat) 2925, 1662, 
1618 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.67–8.62 (m, 1H), 8.61–8.56 (m, 1H), 8.34 (d, J = 8.2 
Hz, 1H), 7.75–7.68 (m, 1H), 7.38–7.31 (m, 1H), 3.78–3.67 (m, 1H), 3.20 (d, J = 6.9 Hz, 2H), 2.67–
2.58 (m, 2H), 2.02–1.47 (m, 17H), 1.42–1.31 (m, 2H), 1.28–1.18 (m, 3H), 1.16–1.04 (m, 2H), 
0.97–0.85 (m, 1H), 0.51–0.31 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 172.8, 172.7, 151.0, 148.8, 
135.8, 133.6, 123.5, 73.3, 56.8, 48.1, 36.8, 36.1, 32.8, 30.8, 26.2, 25.7, 25.5, 24.7, 22.2; HRMS 
(ESI) m/z calcd for C25H38N3O2 [M + H]





          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-(cyclohexylmethyl)isonicotinamide. 
Prepared according to the general procedure for Ugi multicomponent reaction, the title compound 
was obtained as a colorless film (0.024 g, 0.056 mmol, 14% yield, ≥ 99% purity). IR (neat) 2925, 
1684, 1618 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.75 (d, J = 5.5 Hz, 2H), 8.08 (d, J = 7.6 Hz, 1H), 
7.46 (d, J = 5.5 Hz, 2H), 3.81–3.70 (m, 1H), 3.12 (d, J = 6.4 Hz, 2H), 2.48 (s, 2H), 2.00 (br s, 2H), 
1.92–1.83 (m, 2H), 1.80–1.53 (m, 13H), 1.50–1.07 (m, 11H), 1.03–0.91 (m, 1H), 0.55–0.43 (m, 
2H); 13C NMR (126 MHz, CDCl3) δ 173.6, 172.8, 148.6, 148.0, 123.2, 65.9, 55.5, 48.3, 37.3, 32.9, 
32.4, 31.1, 26.2, 25.8, 25.6, 25.6, 24.7, 22.6; HRMS (ESI) m/z calcd for C26H40N3O2 [M + H]
+ 
426.3115, found 426.3122. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclopentyl)-N-(cyclohexylmethyl)isonicotinamide. 
Prepared according to the general procedure for Ugi multicomponent reaction, the title compound 
was obtained as a white solid (0.066 g, 0.160 mmol, 40% yield, ≥ 99% purity). Mp = 138–140 ºC; 
IR (neat) 2921, 1673, 1616 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.75–8.70 (m, 2H), 7.98 (d, J = 
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7.3 Hz, 1H), 7.41–7.35 (m, 2H), 3.81–3.70 (m, 1H), 3.15 (d, J = 7.0 Hz, 2H), 2.70–2.63 (m, 2H), 
2.00–1.94 (m, 2H), 1.92–1.84 (m, 2H), 1.83–1.64 (m, 7H), 1.63–1.54 (m, 5H), 1.46–1.34 (m, 2H), 
1.31–1.10 (m, 6H), 1.02–0.90 (m, 1H), 0.52–0.40 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 172.4, 
172.0, 148.7, 147.3, 122.7, 73.5, 56.5, 48.3, 37.0, 36.1, 32.9, 31.0, 26.2, 25.8, 25.6, 24.8, 22.3; 
HRMS (ESI) m/z calcd for C25H38N3O2 [M + H]
+ 412.2959, found 412.2946. 
 
 
          (±)-N-(1-(Cyclohexylcarbamoyl)-2-methylcyclopentyl)-N-(furan-2-
ylmethyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a colorless film (0.008 g, 0.020 mmol, 5% yield, 
HPLC purity = 92.8%). IR (neat) 2933, 1664 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.58 (ddd, 
J = 4.8, 1.8, 0.9 Hz, 1H), 7.76 (td, J = 7.7, 1.8 Hz, 1H), 7.58–7.50 (m, 1H), 7.38–7.19 (m, 3H), 
6.25–6.16 (m, 1H), 5.94 (d, J = 3.5 Hz, 1H), 5.08 (d, J = 16.9 Hz, 1H), 4.56 (d, J = 16.9 Hz, 1H), 
3.69–3.58 (m, 1H), 3.32–3.22 (m, 1H), 2.39 (br, 1H), 2.13–1.91 (m, 2H), 1.87–1.51 (m, 7H), 1.48–
1.28 (m, 3H), 1.26–1.02 (m, 3H), 0.96 (d, J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 172.6, 
171.5, 155.1, 151.3, 148.2, 141.8, 137.2, 124.8, 124.2, 110.7, 108.4, 76.3, 51.0, 47.9, 45.1, 38.8, 
32.9, 32.1, 30.9, 25.9, 24.8, 24.7, 19.9, 17.7; HRMS (ESI) m/z calcd for C24H32N3O2 [M + H]
+ 





          N-((1S,2S)-rel-1-(Cyclohexylcarbamoyl)-2-methylcyclohexyl)-N-(furan-2-
ylmethyl)picolinamide (trans-1.49)  and N-((1S,2R)-rel-1-(Cyclohexylcarbamoyl)-2-
methylcyclohexyl)-N-(furan-2-ylmethyl)picolinamide (cis-1.49). To a suspension of picolinic 
acid (0.246 g, 2.00 mmol, 1.0 equiv), furfuryl amine (0.194 g, 2.0 mmol, 1.0 equiv), and 2-
methylcyclohexanone (0.224 g, 2.00 mmol, 1.0 equiv) in methanol (5 mL), was added cyclohexyl 
isocyanide (0.218 g, 2.00 mmol, 1.0 equiv) at room temperature. The mixture was stirred at room 
temperature for 24 h. The reaction mixture was quenched with TFA (0.7 mL) followed by 30 min 
of stirring at room temperature, then concentrated in vacuo. Reverse-phase flash column 
chromatography purification afforded two racemic diastereomers trans-1.49 (0.097 g, 0.229 mmol, 
11% yield, 94.9% purity) as a white solid and cis-1.49 (0.083 g, 0.196 mmol, 10% yield, 96.2% 
purity) as a white solid. The relative stereochemistry was assigned by single crystal X-ray 
diffraction crystallography of trans-1.49. Characterization of trans-1.49: Mp = 101–103 ºC; IR 
(neat) 2929, 2856, 1664 (v br) cm-1; 1H NMR (600 MHz, CDCl3) δ 8.58 (dt, J = 4.9, 1.2 Hz, 1H), 
7.75 (td, J = 7.7, 1.8 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.33 (ddd, J = 7.7, 4.8, 1.2 Hz, 1H), 7.20 
(d, J = 1.7 Hz, 1H), 6.15 (dd, J = 3.3, 1.8 Hz, 1H), 5.88 (d, J = 3.2 Hz, 1H), 4.91 (d, J = 16.9 Hz, 
1H), 4.52 (d, J = 16.9 Hz, 1H), 3.68–3.56 (m, 1H), 3.03 (br s, 1H), 2.38 (t, J = 12.4 Hz, 1H), 1.96–
1.01 (m, 20H); 13C NMR (151 MHz, CDCl3) δ 173.5, 171.7, 155.6, 151.2, 148.3, 141.9, 137.1, 
124.8, 124.5, 110.6, 108.4, 69.7, 47.8, 43.2, 33.0, 32.8, 32.5, 29.1, 25.8, 24.8, 24.7, 22.2, 16.7; 
HRMS (ESI) m/z calcd for C25H33N3NaO3 [M + Na]
+ 446.2414, found 446.2411. Characterization 
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of cis-1.49: Mp = 98–100 ºC; IR (neat) 3417, 2927, 2855, 1677 (v br) cm-1; 1H NMR (600 MHz, 
CDCl3) δ 8.55 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 7.70 (td, J = 7.7, 1.7 Hz, 1H), 7.44–7.37 (m, 1H), 
7.29 (ddd, J = 7.7, 4.8, 1.2 Hz, 1H), 6.70 (br s, 1H), 6.21 (dd, J = 3.3, 1.9 Hz, 1H), 5.83 (d, J = 3.3 
Hz, 1H), 5.17 (d, J = 17.3 Hz, 1H), 4.55 (d, J = 17.2 Hz, 1H), 3.81–3.70 (m, 1H), 3.30 (br s, 1H), 
2.51–2.37 (m, 1H), 2.11–0.99 (m, 20H); 13C NMR (151 MHz, CDCl3) δ 172.3, 170.2, 155.8, 152.2, 
148.1, 141.7, 137.0, 124.3, 123.7, 111.0, 107.6, 69.6, 47.9, 42.5, 33.3, 31.2, 29.93, 29.87, 25.9, 
24.9, 23.2, 20.2, 15.3; HRMS (ESI) m/z calcd for C25H33N3NaO3 [M + Na]




          (±)-N-(1-(Cyclohexylcarbamoyl)-3-methylcyclohexyl)-N-(furan-2-
ylmethyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a colorless oil (0.023 g, 0.054 mmol, 14% yield, 96.3% 
purity). IR (neat) 2927, 1666 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.58 (dd, J = 4.8, 1.6 Hz, 
1H), 7.75 (td, J = 7.6, 1.8 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.46–7.30 (m, 2H), 7.25–7.19 (m, 1H), 
6.20–6.12 (m, 1H), 5.86 (d, J = 3.4 Hz, 1H), 4.73 (br s, 2H), 3.63–3.48 (m, 1H), 3.03–2.36 (m, 
2H), 1.93–1.44 (m, 10H), 1.41–0.79 (m, 10H); 13C NMR (126 MHz, CDCl3) δ 173.7, 173.1, 155.3, 
151.0, 148.3, 141.9, 137.2, 125.0, 124.5, 110.7, 108.7, 67.5, 47.9, 43.6, 40.5, 34.5, 32.9, 31.9, 28.1, 
25.9, 24.7, 22.6, 21.9; HRMS (ESI) m/z calcd for C25H34N3O3 [M + H]





          N-((1r,4r)-1-(Cyclohexylcarbamoyl)-4-methylcyclohexyl)-N-(furan-2-
ylmethyl)picolinamide and (trans-1.51) N-((1s,4s)-1-(Cyclohexylcarbamoyl)-4-
methylcyclohexyl)-N-(furan-2-ylmethyl)picolinamide (cis-1.51). To a suspension of picolinic 
acid (0.246 g, 2.00 mmol, 1.0 equiv), furfuryl amine (0.194 g, 2.0 mmol, 1.0 equiv), and 4-
methylcyclohexanone (0.224 g, 2.00 mmol, 1.0 equiv) in methanol (5 mL), was added cyclohexyl 
isocyanide (0.218 g, 2.00 mmol, 1.0 equiv) at room temperature. The mixture was stirred at room 
temperature for 24 h. The reaction mixture was quenched with TFA (0.7 mL) followed by 30 min 
of stirring at room temperature, then concentrated in vacuo. Reverse-phase flash column 
chromatography purification afforded two racemic diastereomers trans-1.51 (0.228 g, 0.538 mmol, 
27% yield, 98.4% purity) as a white solid and cis-1.51 (0.287 g, 0.678 mmol, 34% yield, ≥ 99% 
purity) as a white solid. The relative stereochemistry was assigned by single crystal X-ray 
diffraction crystallography of trans-1.51. Characterization of trans-1.51: Mp = 87–89 ºC; IR (neat) 
3410, 2927, 2856, 1656 (v br) cm-1; 1H NMR (600 MHz, CDCl3) δ 8.54 (d, J = 4.8 Hz, 1H), 7.74 
(td, J = 7.7, 1.6 Hz, 1H), 7.54 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 0.9 Hz, 1H), 7.27 (d, J = 0.9 Hz, 
1H), 6.46 (d, J = 7.6 Hz, 1H), 6.24 (dd, J = 3.1, 1.8 Hz, 1H), 6.02 (d, J = 3.1 Hz, 1H), 4.79 (s, 2H), 
3.79–3.68 (m, 1H), 2.54 (d, J = 12.4 Hz, 2H), 1.91–1.81 (m, 2H), 1.72–1.48 (m, 9H), 1.44–1.28 
(m, 3H), 1.22–1.04 (m, 3H), 0.90 (d, J = 6.5 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 172.3, 170.9, 
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155.6, 151.9, 148.2, 141.8, 137.2, 124.5, 124.0, 110.8, 107.8, 66.0, 48.0, 42.3, 33.2, 32.8, 31.9, 
31.3, 25.9, 24.9, 21.8; HRMS (ESI) m/z calcd for C25H33N3NaO3 [M + Na]
+ 446.2414, found 
446.2413. Characterization of cis-1.51: Mp = 74–76 ºC; IR (neat) 2926, 2854, 1657 (v br) cm-1; 
1H NMR (600 MHz, CDCl3) δ 8.62 – 8.56 (m, 1H), 7.74 (td, J = 7.8, 1.6 Hz, 1H), 7.58 (d, J = 7.8 
Hz, 1H), 7.33 (ddd, J = 7.6, 4.8, 1.2 Hz, 2H), 7.23–7.19 (m, 1H), 6.15 (t, J = 2.9, 1.8 Hz, 1H), 5.86 
(d, J = 2.9 Hz, 1H), 4.77 (s, 2H), 3.63–3.52 (m, 1H), 2.69 (d, J = 13.3 Hz, 2H), 1.93 (td, J = 14.2, 
3.3 Hz, 2H), 1.82–1.73 (m, 2H), 1.71–1.63 (m, 4H), 1.61–1.50 (m, 2H), 1.38–1.29 (m, 2H), 1.29–
1.15 (m, 3H), 1.14–1.05 (m, 2H), 0.96 (d, J = 6.5 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.7, 
173.0, 155.3, 151.2, 148.4, 141.9, 137.0, 124.9, 124.4, 110.7, 108.7, 66.5, 48.0, 43.5, 32.9, 32.1, 
32.0, 30.5, 25.9, 24.8, 22.3; HRMS (ESI) m/z calcd for C25H33N3NaO3 [M + Na]




          N-((1r,4r)-4-(tert-Butyl)-1-(cyclohexylcarbamoyl)cyclohexyl)-N-(furan-2-
ylmethyl)picolinamide (trans-1.52) and N-((1s,4s)-4-(tert-Butyl)-1-
(cyclohexylcarbamoyl)cyclohexyl)-N-(furan-2-ylmethyl)picolinamide (cis-1.52). To a 
suspension of picolinic acid (0.123 g, 1.00 mmol, 1.0 equiv), furfurylamine (0.097 g, 1.0 mmol, 
1.0 equiv), and 4-tert-butylcyclohexanone (0.154 g, 1.00 mmol, 1.0 equiv) in methanol (2.5 mL), 
was added cyclohexyl isocyanide (0.109 g, 1.00 mmol, 1.0 equiv) at room temperature. The 
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mixture was stirred at room temperature for 24 h. The reaction mixture was quenched with TFA 
(0.35 mL) followed by 30 min of stirring at room temperature, then concentrated in vacuo. 
Reverse-phase flash column chromatography purification afforded two racemic diastereomers 
trans-1.52 (0.070 g, 0.150 mmol, 15% yield, 94.7% purity) as a white solid and cis-1.52 (0.082 g, 
0.176 mmol, 18% yield, 97.8% purity) as a white solid. The relative stereochemistry was assigned 
by single crystal X-ray diffraction crystallography of cis-1.52. Characterization of trans-1.52: Mp 
= 103–105 ºC; IR (neat) 2931, 2855, 1660 (v br) cm-1; 1H NMR (600 MHz, CDCl3) δ 8.54 (ddd, J 
= 4.9, 1.7, 0.9 Hz, 1H), 7.73 (td, J = 7.7, 1.7 Hz, 1H), 7.52 (dt, J = 7.9, 1.1 Hz, 1H), 7.32–7.27 (m, 
2H), 6.39 (d, J = 7.8 Hz, 1H), 6.26 (dd, J = 3.1, 1.9 Hz, 1H), 6.07 (d, J = 2.9 Hz, 1H), 4.77 (s, 2H), 
3.75 (dtd, J = 10.3, 7.0, 6.6, 4.1 Hz, 1H), 2.72–2.61 (m, 2H), 1.88 (dd, J = 13.0, 4.1 Hz, 2H), 1.70–
1.52 (m, 9H), 1.40–1.29 (m, 2H), 1.21–1.05 (m, 3H), 1.03–0.94 (m, 1H), 0.84 (s, 9H); 13C NMR 
(151 MHz, CDCl3) δ 172.0, 170.8, 155.6, 152.1, 148.2, 141.7, 137.1, 124.4, 123.7, 110.8, 107.8, 
66.0, 48.0, 47.7, 42.4, 33.6, 33.2, 32.5, 27.7, 25.9, 24.9, 24.2; HRMS (ESI) m/z calcd for 
C28H39N3NaO3 [M + Na]
+ 488.2884, found 488.2882. Characterization of cis-1.52: Mp = 96–98 
ºC; IR (neat) 2935, 2857, 1662 (v br) cm-1; 1H NMR (400 MHz, CDCl3) δ 8.56 (ddd, J = 4.8, 1.7, 
0.9 Hz, 1H), 7.74 (td, J = 7.7, 1.7 Hz, 1H), 7.58 (dt, J = 7.8, 1.0 Hz, 1H), 7.47 (d, J = 6.1 Hz, 1H), 
7.32 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.19 (dd, J = 1.8, 0.8 Hz, 1H), 6.12 (dd, J = 3.2, 1.9 Hz, 1H), 
5.84 (d, J = 3.2 Hz, 1H), 4.71 (s, 2H), 3.65–3.45 (m, 1H), 2.77 (br s, 2H), 1.95–1.46 (m, 9H), 1.41–
0.98 (m, 8H), 0.87 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 173.9, 173.1, 154.8, 150.8, 148.3, 141.9, 
137.1, 125.1, 124.3, 110.6, 108.7, 66.3, 48.0, 47.2, 43.6, 32.8, 32.5, 32.5, 27.5, 25.8, 24.7, 22.5; 
HRMS (ESI) m/z calcd for C28H39N3NaO3 [M + Na]





          N-((1r,4r)-1-(Cyclohexylcarbamoyl)-4-phenylcyclohexyl)-N-(furan-2-
ylmethyl)picolinamide (trans-1.53) and N-((1s,4s)-1-(Cyclohexylcarbamoyl)-4-
phenylcyclohexyl)-N-(furan-2-ylmethyl)picolinamide (cis-1.53). To a suspension of picolinic 
acid (0.123 g, 1.00 mmol, 1.0 equiv), furfurylamine (0.097 g, 1.0 mmol, 1.0 equiv), and 4-
phenylcyclohexanone (0.174 g, 1.00 mmol, 1.0 equiv) in methanol (2.5 mL), was added 
cyclohexyl isocyanide (0.109 g, 1.00 mmol, 1.0 equiv) at room temperature. The mixture was 
stirred at room temperature for 24 h. The reaction mixture was quenched with TFA (0.35 mL) 
followed by 30 min of stirring at room temperature, then concentrated in vacuo. Reverse-phase 
flash column chromatography purification afforded two racemic diastereomers trans-1.53 (0.102 
g, 0.210 mmol, 21% yield, ≥ 99% purity) and cis-1.53 (0.128 g, 0.264 mmol, 26% yield, ≥ 99% 
purity). The relative stereochemistry was assigned by single crystal X-ray diffraction 
crystallography of trans-1.53. Characterization of trans-1.53: Mp = 107–109 ºC; IR (neat) 2929, 
2856, 1658 (v br) cm-1; 1H NMR (400 MHz, CDCl3) δ 8.55 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.76 
(td, J = 7.7, 1.7 Hz, 1H), 7.56 (dt, J = 7.8, 1.1 Hz, 1H), 7.35–7.29 (m, 2H), 7.29–7.21 (m, 4H), 
7.19–7.13 (m, 1H), 6.44 (d, J = 8.1 Hz, 1H), 6.28 (dd, J = 3.2, 1.9 Hz, 1H), 6.06 (dd, J = 3.3, 0.6 
Hz, 1H), 4.85 (s, 2H), 3.78 (tdt, J = 10.5, 8.0, 3.9 Hz, 1H), 2.68 (d, J = 13.1 Hz, 2H), 2.50 (tt, J = 
12.4, 3.5 Hz, 1H), 2.22–2.07 (m, 2H), 1.95–1.53 (m, 9H), 1.43–1.28 (m, 2H), 1.23–1.03 (m, 3H); 
13C NMR (101 MHz, CDCl3) δ 172.2, 170.7, 155.3, 151.8, 148.1, 146.7, 141.9, 137.3, 128.3, 127.1, 
132 
 
126.1, 124.5, 123.9, 110.9, 107.8, 65.5, 48.0, 43.9, 42.2, 33.3, 33.2, 30.7, 25.8, 24.9; HRMS (ESI) 
m/z calcd for C30H35N3NaO3 [M + Na]
+ 508.2571, found 508.2569. Characterization of cis-1.53: 
Mp = 64–66 ºC; IR (neat) 2930, 2855, 1665 (v br)cm-1; 1H NMR (600 MHz, CDCl3) δ 8.68 (ddd, 
J = 4.8, 1.7, 0.9 Hz, 1H), 7.80 (td, J = 7.7, 1.7 Hz, 1H), 7.67 (dt, J = 7.9, 1.1 Hz, 1H), 7.57 (br s, 
1H), 7.40 (ddd, J = 7.5, 4.8, 1.0 Hz, 1H), 7.36 (d, J = 7.3 Hz, 2H), 7.31 (t, J = 7.6 Hz, 2H), 7.23 
(dd, J = 1.9, 0.8 Hz, 1H), 7.22–7.18 (m, 1H), 6.16 (dd, J = 3.1, 1.9 Hz, 1H), 5.88 (d, J = 2.9 Hz, 
1H), 4.77 (s, 2H), 3.66–3.53 (m, 1H), 2.88 (br s, 2H), 2.76–2.67 (m, 1H), 2.14–1.98 (m, 2H), 1.92–
1.73 (m, 6H), 1.72–1.64 (m, 2H), 1.60–1.52 (m, 1H), 1.40–1.30 (m, 2H), 1.27–1.19 (m, 1H), 1.18–
1.09 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 173.7, 173.6, 154.9, 150.8, 148.4, 146.9, 142.1, 
137.4, 128.5, 127.2, 126.3, 125.3, 124.7, 110.8, 108.9, 66.1, 48.1, 43.8, 43.7, 32.8, 32.5, 29.3, 25.9, 
24.7; HRMS (ESI) m/z calcd for C30H35N3NaO3 [M + Na]
+ 508.2571, found 508.2571. 
 
 
          N-(1-(Cyclohexylcarbamoyl)-3,3,5,5-tetramethylcyclohexyl)-N-(furan-2-
ylmethyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a white solid (0.007 g, 0.015 mmol, 4% yield, ≥ 99% 
purity). Mp = 131–133 ºC;  IR (neat) 2930, 1651 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.55 
(ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.74 (td, J = 7.7, 1.7 Hz, 1H), 7.59 (dt, J = 8.0, 1.1 Hz, 1H), 7.45–
7.38 (m, 1H), 7.31 (ddd, J = 7.7, 4.8, 1.3 Hz, 1H), 7.17 (dd, J = 1.9, 0.9 Hz, 1H), 6.13 (dd, J = 3.3, 
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1.8 Hz, 1H), 5.86–5.82 (m, 1H), 4.82 (s, 2H), 3.60–3.49 (m, 1H), 2.39 (d, J = 14.7 Hz, 2H), 2.02 
(d, J = 14.8 Hz, 2H), 1.86–1.72 (m, 3H), 1.70–1.59 (m, 2H), 1.59–1.49 (m, 1H), 1.39–1.08 (m, 
12H), 0.99 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 173.6, 173.4, 155.2, 151.2, 148.1, 141.8, 137.1, 
124.9, 124.8, 110.6, 108.5, 67.7, 51.3, 48.1, 43.9, 42.4, 34.4, 32.7, 31.3, 30.5, 25.9, 24.7; HRMS 
(ESI) m/z calcd for C28H40N3O3 [M + H]
+ 466.3064, found 466.3061. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cycloheptyl)-N-(furan-2-ylmethyl)picolinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a yellow solid (0.010 g, 0.024 mmol, 6% yield, ≥ 99% purity). Mp = 86–89 ºC;  IR 
(neat) 2927, 1664, 1617  cm-1; 1H NMR (500 MHz, CDCl3) δ 8.60–8.51 (m, 1H), 7.73 (td, J = 7.7, 
1.8 Hz, 1H), 7.53–7.45 (m, 1H), 7.37–7.27 (m, 2H), 6.36–6.18 (m, 2H), 5.85 (d, J = 3.3 Hz, 1H), 
4.89 (s, 2H), 3.78–3.66 (m, 1H), 2.55–2.46 (m, 2H), 2.08–1.99 (m, 2H), 1.95–1.44 (m, 13H), 1.39–
1.26 (m, 2H), 1.19–0.97 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 173.9, 170.2, 155.3, 151.9, 147.8, 
142.0, 137.4, 124.6, 124.1, 110.9, 107.7, 69.9, 48.2, 42.4, 35.6, 33.2, 30.3, 25.8, 25.0, 24.1; HRMS 
(ESI) m/z calcd for C25H34N3O3 [M+H]





        N-(1-(Cyclohexylcarbamoyl)cyclooctyl)-N-(furan-2-ylmethyl)picolinamide. Prepared 
according to the general procedure for Ugi multicomponent reaction, the title compound was 
obtained as a colorless film (8 mg, 0.018 mmol, 5% yield, ≥ 99% purity). IR (neat) 2927, 1665, 
1624 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.57–8.51 (m, 1H), 7.70 (td, J = 7.7, 1.8 Hz, 1H), 7.41 
(dt, J = 7.9, 1.2 Hz, 1H), 7.34–7.26 (m, 2H), 6.31 (d, J = 8.1 Hz, 1H), 6.21 (dd, J = 3.3, 1.8 Hz, 
1H), 5.89 (d, J = 3.2 Hz, 1H), 4.94 (s, 2H), 3.82–3.69 (m, 1H), 2.47–2.38 (m, 2H), 2.22–2.13 (m, 
2H), 1.99–0.97 (m, 20H); 13C NMR (126 MHz, CDCl3) δ 173.0, 169.9, 155.6, 152.3, 148.0, 141.7, 
137.1, 124.4, 123.8, 111.0, 107.5, 70.0, 48.1, 42.8, 33.3, 29.8, 28.5, 25.9, 25.4, 24.9, 22.4; HRMS 
(ESI) m/z calcd for C25H34N3O3 [M+H]
+ 438.2751, found 438.2750. 
 
 
          N-(4-(Cyclohexylcarbamoyl)tetrahydro-2H-pyran-4-yl)-N-(furan-2-
ylmethyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a yellow solid (0.100 g, 0.243 mmol, 61% yield, ≥ 
99% purity). Mp = 109–112 ºC; IR (neat) 2926, 1660, 1622 cm-1; 1H NMR (500 MHz, CDCl3) δ 
8.57 (dt, J = 4.9, 1.4 Hz, 1H), 7.85–7.77 (m, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.41–7.32 (m, 1H), 
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7.27 (dd, J = 1.9, 0.9 Hz, 1H), 7.00 (s, 1H), 6.23 (dd, J = 3.3, 1.8 Hz, 1H), 5.98 (d, J = 3.2 Hz, 1H), 
4.80 (s, 2H), 3.97–3.79 (m, 4H), 3.75–3.63 (m, 1H), 2.51–2.42 (m, 2H), 2.19–2.10 (m, 2H), 1.91–
1.51 (m, 5H), 1.41 1.28 (m, 2H), 1.23–1.04 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 171.6, 171.3, 
154.7, 150.9, 147.8, 142.1, 137.9, 125.1, 124.4, 110.9, 108.4, 64.6, 64.0, 48.1, 42.8, 33.5, 33.0, 
25.8, 24.9; HRMS (ESI) m/z calcd for C23H30N3O4 [M+H]
+ 412.2231, found 412.2231. 
 
 
          N-(4-(Cyclohexylcarbamoyl)-1-methylpiperidin-4-yl)-N-(furan-2-
ylmethyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a yellow solid (0.088 g, 0.207 mmol, 52% yield, ≥ 
99% purity). Mp = 91–94 ºC; IR (neat) 2927, 1660, 1628 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.54 
(ddd, J = 5.0, 1.8, 0.9 Hz, 1H), 7.74 (td, J = 7.7, 1.8 Hz, 1H), 7.53 (dt, J = 7.8, 1.0 Hz, 1H), 7.37–
7.23 (m, 2H), 6.85–6.80 (m, 1H), 6.21 (dd, J = 3.2, 1.8 Hz, 1H), 5.96 (d, J = 3.2 Hz, 1H), 4.78 (s, 
2H), 3.72–3.61 (m, 1H), 2.69–2.52 (m, 3H), 2.48–2.15 (m, 8H), 1.86–1.77 (m, 2H), 1.70–1.60 (m, 
2H), 1.59–1.50 (m, 1H), 1.38–1.26 (m, 2H), 1.22–1.01 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 
172.0, 171.5, 155.0, 151.3, 148.2, 141.9, 137.2, 124.8, 124.0, 110.9, 108.1, 64.0, 52.1, 48.0, 45.9, 
42.8, 33.0, 32.5, 25.8, 24.8; HRMS (ESI) m/z calcd for C24H33N4O3 [M+H]






          N-(1-Benzoyl-4-(cyclohexylcarbamoyl)piperidin-4-yl)-N-(furan-2-
ylmethyl)picolinamide. Prepared according to the general procedure for Ugi multicomponent 
reaction, the title compound was obtained as a yellow film (0.135 g, 0.262 mmol, 66% yield, ≥ 99% 
purity). IR (neat) 2929, 1665, 1625 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.54 (ddd, J = 4.9, 1.8, 
0.9 Hz, 1H), 7.78 (td, J = 7.7, 1.7 Hz, 1H), 7.58 (dt, J = 7.8, 1.1 Hz, 1H), 7.41–7.32 (m, 6H), 7.28 
(dd, J = 1.9, 0.8 Hz, 1H), 6.73 (d, J = 8.1 Hz, 1H), 6.24 (dd, J = 3.3, 1.9 Hz, 1H), 5.98 (dd, J = 3.3, 
0.9 Hz, 1H), 4.86–4.74 (m, 2H), 4.32–4.23 (m, 1H), 3.85–3.76 (m, 1H), 3.72–3.61 (m, 1H), 3.59–
3.48 (m, 2H), 2.57–2.49 (m, 1H), 2.36–2.24 (m, 2H), 2.21–2.17 (m, 1H), 1.89–1.72 (m, 3H), 1.68–
1.43 (m, 2H), 1.39–1.21 (m, 2H), 1.20–1.00 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 171.8, 171.4, 
170.4, 154.6, 150.7, 148.2, 142.3, 137.5, 136.0, 129.7, 128.5, 126.9, 125.1, 124.3, 110.9, 108.4, 
64.3, 48.1, 45.0, 42.7, 41.0, 38.7, 33.0, 32.9, 32.7, 25.7, 24.8; HRMS (ESI) m/z calcd for 
C30H35N4O4 [M+H]





          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-(2-fluorobenzyl)picolinamide. To a 
suspension of picolinic acid (0.100 g, 0.081 mmol, 1.0 equiv), 2-fluorobenzylamine (0.102 g, 
0.081 mmol, 1.0 equiv), and cyclohexanone (0.080 g, 0.081 mmol, 1.0 equiv) in methanol (2 mL), 
was added cyclohexyl isocyanide (0.088 g, 0.081 mmol, 1.0 equiv) at room temperature. The 
mixture was stirred at room temperature for 24 h. The reaction mixture was quenched with TFA 
(0.3 mL), stirred for 30 min at room temperature, and then concentrated in vacuo. Reverse-phase 
flash column chromatography purification (0-100% CH3CN/H2O) afforded the title compound as 
yellow solid (0.027 g, 0.062 mmol, 8% yield, ≥ 99% purity). Mp = 95–98 ºC; IR (neat) 2930, 1656 
(v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.58 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.80 (t, J = 7.6 Hz, 
1H), 7.66–7.57 (m, 1H), 7.45–7.33 (m, 1H), 7.25 (dd, J = 1.8, 0.8 Hz, 1H), 7.04 (d, J = 9.8 Hz, 
1H), 6.20 (dd, J = 3.3, 1.8 Hz, 1H), 5.95 (dd, J = 3.2, 0.9 Hz, 1H), 4.78 (s, 2H), 3.71–3.58 (m, 1H), 
2.23–2.11 (m, 3H), 1.78 (ddt, J = 19.3, 12.5, 7.0 Hz, 5H), 1.71–1.42 (m, 8H), 1.40–1.05 (m, 6H); 
13C NMR (126 MHz, CDCl3) δ 172.7, 172.5, 161.6, 159.6, 155.3, 148.3, 137.3, 130.5, 130.4, 129.3, 
129.3, 125.3, 125.2, 124.8, 124.2, 124.2, 115.4, 115.2, 66.6, 48.2, 44.7, 44.7, 32.8, 31.1, 25.9, 25.8, 
24.8, 22.5; HRMS (ESI) m/z calcd for C26H33FN3O2 [M + H]
+ 438.2551, found 438.2539. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-(2-fluorobenzyl)isonicotinamide. To a 
suspension of isonicotinic acid (0.100 g, 0.081 mmol, 1.0 equiv), 2-fluorobenzylamine (0.102 g, 
0.081 mmol, 1.0 equiv), and cyclohexanone (0.080 g, 0.081 mmol, 1.0 equiv) in methanol (2 mL), 
138 
 
was added cyclohexyl isocyanide (0.088 g, 0.081 mmol, 1.0 equiv) at room temperature. The 
mixture was stirred at room temperature for 24 h. The reaction mixture was quenched with TFA 
(0.3 mL), stirred for 30 min at room temperature, and then concentrated in vacuo. Reverse-phase 
flash column chromatography purification (0-100% CH3CN/H2O) afforded the title compound as 
a yellow solid (0.130 mg, 0.297 mmol, 37% yield, ≥ 99% purity). Mp = 108–111 ºC; IR (neat) 
2935, 1660 (v br) cm-1; 1H NMR (500 MHz, CDCl3) δ 8.65 (d, J = 5.0 Hz, 2H), 7.53 (td, J = 7.7, 
1.7 Hz, 1H), 7.37 (d, J = 6.1 Hz, 2H), 7.26–7.21 (m, 1H), 7.13 (td, J = 7.5, 0.9 Hz, 1H), 6.97 (d, J 
= 7.0 Hz, 1H), 6.94–6.88 (m, 1H), 4.55 (s, 2H), 3.58–3.44 (m, 1H), 2.27–2.16 (m, 4H), 1.88–1.77 
(m, 2H), 1.75–1.63 (m, 4H), 1.61–1.47 (m, 5H), 1.41–1.16 (m, 5H); 13C NMR (126 MHz, CDCl3) 
δ 172.8, 172.2, 161.7, 159.8, 149.9, 145.6, 130.3, 130.2, 129.9, 129.9, 124.5, 124.4, 124.2, 124.0, 
121.7, 115.5, 115.4, 66.4, 48.4, 45.9, 45.9, 32.7, 32.4, 25.8, 25.6, 24.7, 22.7; HRMS (ESI) m/z 
calcd for C26H33FN3O2 [M + H]
+ 438.2551, found 438.2556. 
 
 
          N-Butyl-N-(1-(cyclohexylcarbamoyl)cyclohexyl)nicotinamide. To a suspension of 
nicotinic acid (0.100 g, 0.081 mmol, 1.0 equiv), n-butylamine (0.059 g, 0.081 mmol, 1.0 equiv), 
and cyclohexanone (0.080 g, 0.081 mmol, 1.0 equiv) in methanol (2 mL), was added cyclohexyl 
isocyanide (0.088 g, 0.081 mmol, 1.0 equiv) at room temperature. The mixture was stirred at room 
temperature for 24 h. The reaction mixture was quenched with TFA (0.3 mL), stirred for 30 min 
at room temperature, and then concentrated in vacuo. Reverse-phase flash column chromatography 
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purification (0-100% CH3CN/H2O) afforded the title compound as a white solid (0.088 g, 0.228 
mmol, 28% yield, 98.7% purity). Mp = 77–80 ºC; IR (neat) 2921, 1647 (v br) cm-1; 1H NMR (500 
MHz, CDCl3) δ 8.81–8.63 (m, 2H), 7.94 (d, J = 7.2 Hz, 1H), 7.84 (dt, J = 7.8, 1.8 Hz, 1H), 7.42 
(dd, J = 7.7, 5.0 Hz, 1H), 3.86–3.70 (m, 1H), 3.35 (t, J = 7.6 Hz, 2H), 2.51 (d, J = 12.2 Hz, 2H), 
2.05–1.93 (m, 2H), 1.93–1.80 (m, 2H), 1.77–1.54 (m, 6H), 1.50–1.19 (m, 10H), 1.04 (h, J = 7.4 
Hz, 2H), 0.69 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 174.3, 173.0, 150.7, 148.2, 136.1, 
134.2, 123.9, 65.6, 48.7, 48.0, 32.8, 32.5, 32.0, 25.8, 25.7, 24.7, 22.4, 20.2, 13.5; HRMS (ESI) m/z 
calcd for C23H36N3O2 [M + H]
+ 368.2802, found 386.2791. 
 
 
          N-Butyl-N-(1-(cyclohexylcarbamoyl)cyclohexyl)isonicotinamide. To a suspension of 
isonicotinic acid (0.100 g, 0.081 mmol, 1.0 equiv), n-butylamine (0.059 g, 0.081 mmol, 1.0 equiv), 
and cyclohexanone (0.080 g, 0.081 mmol, 1.0 equiv) in methanol (2 mL), was added cyclohexyl 
isocyanide (0.088 g, 0.081 mmol, 1.0 equiv) at room temperature. The mixture was stirred at room 
temperature for 24 h. The reaction mixture was quenched with TFA (0.3 mL), stirred for 30 min 
at room temperature, and then concentrated in vacuo. Reverse-phase flash column chromatography 
purification (0-100% CH3CN/H2O) afforded the title compound as white solid (0.142 g, 0.368 
mmol, 45% yield, ≥ 99% purity). Mp = 133–136 ºC; IR (neat) 2931, 1657 (v br) cm-1; 1H NMR 
(500 MHz, CDCl3) δ 8.78–8.72 (m, 2H), 7.66 (d, J = 8.0 Hz, 1H), 7.42–7.33 (m, 2H), 3.87–3.74 
(m, 1H), 3.33–3.26 (m, 2H), 2.49–2.35 (m, 2H), 2.12–2.03 (m, 2H), 1.96–1.84 (m, 2H), 1.79–1.56 
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(m, 6H), 1.55–1.15 (m, 10H), 1.05 (h, J = 7.4 Hz, 2H), 0.73 (t, J = 7.3 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 173.8, 172.8, 150.1, 146.3, 121.6, 65.7, 48.1, 48.1, 32.8, 32.6, 32.2, 25.8, 25.6, 
24.7, 22.6, 20.1, 13.5; HRMS (ESI) m/z calcd for C23H36N3O2 [M + H]
+ 368.2802, found 386.2812. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-phenethylpicolinamide. To a suspension of 
picolinic acid (0.100 g, 0.081 mmol, 1.0 equiv), 2-phenethylamine (0.098 g, 0.081 mmol, 1.0 
equiv), and cyclohexanone (0.080 g, 0.081 mmol, 1.0 equiv) in methanol (2 mL), was added 
cyclohexyl isocyanide (0.088 g, 0.081 mmol, 1.0 equiv) at room temperature. The mixture was 
stirred at room temperature for 24 h. The reaction mixture was quenched with TFA (0.3 mL), 
stirred for 30 min at room temperature, and then concentrated in vacuo. Reverse-phase flash 
column chromatography purification (0-100% CH3CN/H2O) afforded the title compound as white 
solid (0.155 g, 44% yield, 97.6% purity). Mp = 77–79 ºC; IR (neat) 2931, 1661 (v br) cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.65–8.57 (m, 1H), 7.77 (td, J = 7.7, 1.7 Hz, 1H), 7.56 (d, J = 6.8 Hz, 
1H), 7.41 (d, J = 7.8 Hz, 1H), 7.36 (ddd, J = 7.6, 4.9, 1.0 Hz, 1H), 7.19–7.10 (m, 3H), 6.82 (dd, J 
= 7.2, 1.8 Hz, 2H), 3.89–3.75 (m, 1H), 3.69–3.52 (m, 2H), 2.90–2.76 (m, 2H), 2.46–2.14 (m, 4H), 
1.97–1.84 (m, 2H), 1.78–1.17 (m, 14H); 13C NMR (101 MHz, CDCl3) δ 173.6, 172.5, 155.7, 148.4, 
138.5, 137.4, 128.7, 128.6, 126.5, 124.6, 123.3, 66.1, 48.8, 48.2, 36.9, 33.2, 32.9, 25.8, 25.8, 24.8, 
22.7; HRMS (ESI) m/z calcd for C27H36N3O2 [M + H]





          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-phenethylnicotinamide. To a suspension of 
nicotinic acid (0.100 g, 0.081 mmol, 1.0 equiv), 2-phenethylamine (0.098 g, 0.081 mmol, 1.0 
equiv), and cyclohexanone (0.080 g, 0.081 mmol, 1.0 equiv) in methanol (2 mL), was added 
cyclohexyl isocyanide (0.088 g, 0.081 mmol, 1.0 equiv) at room temperature. The mixture was 
stirred at room temperature for 24 h. The reaction mixture was quenched with TFA (0.3 mL), 
stirred for 30 min at room temperature, and then concentrated in vacuo. Reverse-phase flash 
column chromatography purification (0-100% CH3CN/H2O) afforded the title compound as 
yellow oil (0.156 g, 44% yield, 90.9% purity). IR (neat) 2931, 1656 (v br) cm-1; 1H NMR (400 
MHz, CD2Cl2) δ 8.73 (dd, J = 5.3, 1.4 Hz, 1H), 8.49 (d, J = 1.5 Hz, 1H), 7.81 (dt, J = 7.9, 1.7 Hz, 
1H), 7.62 (dd, J = 7.9, 5.3 Hz, 1H), 7.50 (d, J = 7.2 Hz, 1H), 7.24–7.14 (m, 3H), 6.91–6.83 (m, 
2H), 3.88–3.74 (m, 1H), 3.62 (t, J = 7.3 Hz, 2H), 2.79 (t, J = 7.3 Hz, 2H), 2.41–2.18 (m, 4H), 2.00–
1.86 (m, 2H), 1.80–1.20 (m, 14H); 13C NMR (101 MHz, CD2Cl2) δ 173.1, 170.4, 146.3, 144.1, 
140.1, 138.4, 136.3, 129.4, 129.3, 127.4, 126.0, 66.5, 50.2, 49.0, 36.7, 33.3, 33.2, 26.2, 26.0, 25.2, 
23.3; HRMS (ESI) m/z calcd for C27H36N3O2 [M + H]





          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-phenethylisonicotinamide To a suspension 
of isonicotinic acid (0.100 g, 0.081 mmol, 1.0 equiv), 2-phenethylamine (0.098 g, 0.081 mmol, 1.0 
equiv), and cyclohexanone (0.080 g, 0.081 mmol, 1.0 equiv) in methanol (2 mL), was added 
cyclohexyl isocyanide (0.088 g, 0.081 mmol, 1.0 equiv) at room temperature. The mixture was 
stirred at room temperature for 24 h. The reaction mixture was quenched with TFA (0.3 mL), 
stirred for 30 min at room temperature, and then concentrated in vacuo. Reverse-phase flash 
column chromatography purification (0-100% CH3CN/H2O) afforded the title compound as white 
solid (0.098 g, 0.226 mmol, 28% yield). 99% purity; Mp = 99–102 ºC; IR (neat) 2934, 1657 (v br) 
cm-1; 1H NMR (500 MHz, CDCl3) δ 8.73–8.67 (m, 2H), 7.58 (d, J = 8.0 Hz, 1H), 7.26–7.11 (m, 
5H), 6.79 (dt, J = 6.7, 2.2 Hz, 2H), 3.89–3.77 (m, 1H), 3.55–3.46 (m, 2H), 2.78–2.70 (m, 2H), 
2.50–2.42 (m, 2H), 2.24–2.08 (m, 2H), 1.96–1.87 (m, 2H), 1.76–1.66 (m, 4H), 1.64–1.55 (m, 2H), 
1.54–1.35 (m, 5H), 1.33–1.20 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 173.3, 172.8, 150.4, 145.6, 
137.7, 128.8, 128.6, 126.9, 121.2, 65.8, 49.7, 48.2, 36.6, 32.9, 32.8, 25.8, 25.6, 24.7, 22.7; HRMS 
(ESI) m/z calcd for C27H36N3O2 [M + H]
+ 434.2802, found 434.2831. 
 
 
          N-(1-(Cyclohexylcarbamoyl)cyclohexyl)-N-phenylpicolinamide. To a suspension of 
picolinic acid (0.100 g, 0.081 mmol, 1.0 equiv), aniline (0.076 g, 0.081 mmol, 1.0 equiv), and 
cyclohexanone (0.080 g, 0.081 mmol, 1.0 equiv) in methanol (2 mL), was added cyclohexyl 
isocyanide (0.088 g, 0.081 mmol, 1.0 equiv) at room temperature. The mixture was stirred at room 
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temperature for 24 h. The reaction mixture was quenched with TFA (0.3 mL), stirred for 30 min 
at room temperature, and then concentrated in vacuo. Reverse-phase flash column chromatography 
purification (0-100% CH3CN/H2O) afforded the title compound as white solid (0.216 g, 0.533 
mmol, 66% yield, ≥ 99% yield). Mp = 67–69 ºC; IR (neat) 2929, 1658 (v br) cm-1; 1H NMR (500 
MHz, CDCl3) δ 8.31–8.25 (m, 1H), 7.45 (td, J = 7.6, 1.7 Hz, 2H), 7.38–7.21 (m, 2H), 7.22–7.06 
(m, 4H), 6.99 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 6.70 (d, J = 8.1 Hz, 1H), 3.96–3.84 (m, 1H), 2.49–
2.35 (m, 2H), 2.07–1.95 (m, 2H), 1.78–1.49 (m, 10H), 1.47–1.13 (m, 6H); 13C NMR (126 MHz, 
CDCl3) δ 172.4, 170.0, 155.6, 148.2, 139.4, 136.3, 131.9, 128.3, 127.9, 123.2, 122.6, 66.9, 48.6, 





          N-(4-(cyclohexylcarbamoyl)-1-phenethylpiperidin-4-yl)-N-(furan-2-
ylmethyl)picolinamide. To a suspension of picolinic acid (0.123 g, 1.00 mmol, 1.0 equiv), 
furfurylamine (0.097 g, 1.00 mmol, 1.0 equiv), and 1-phenethyl-4-piperidone (0.203 g, 1.00 mmol, 
1.0 equiv) in methanol (2 mL), was added cyclohexyl isocyanide (0.109 g, 1.00 mmol, 1.0 equiv) 
at room temperature. The mixture was stirred at room temperature for 24 h. The reaction mixture 
was quenched with TFA (0.3 mL), stirred for 30 min at room temperature, and then concentrated 
in vacuo. Reverse-phase flash column chromatography purification (0-100% CH3CN/H2O) 
144 
 
afforded the title compound as brown solid (0.281 g, 0.546 mmol, 55% yield, ≥ 99% purity). Mp 
= 76–78 ºC; IR (neat) 2928, 1651 (v br) cm-1; 1H NMR (400 MHz, CDCl3) δ 8.57 (ddd, J = 4.8, 
1.6, 0.9 Hz, 1H), 7.76 (td, J = 7.7, 1.7 Hz, 1H), 7.56 (dt, J = 7.8, 1.2 Hz, 1H), 7.39–7.15 (m, 7H), 
6.93 (d, J = 7.4 Hz, 1H), 6.24 (dd, J = 3.2, 1.9 Hz, 1H), 5.99 (d, J = 3.1 Hz, 1H), 4.82 (s, 2H), 
3.80–3.62 (m, 1H), 2.90–2.60 (m, 8H), 2.56–2.40 (m, 2H), 2.37–2.20 (m, 2H), 1.94–1.78 (m, 2H), 
1.76–1.50 (m, 3H), 1.42–1.05 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 171.9, 171.7, 155.1, 151.3, 
148.2, 141.8, 140.6, 137.1, 128.8, 128.4, 126.0, 124.7, 124.0, 110.8, 108.1, 64.7, 60.3, 50.0, 47.9, 





          Methyl 3-(4-(cyclohexylcarbamoyl)-4-(N-(furan-2-ylmethyl)picolinamido)piperidin-1-
yl)propanoate (1.69) and 3-(4-(Cyclohexylcarbamoyl)-4-(N-(furan-2-
ylmethyl)picolinamido)piperidin-1-yl)propanoic acid (1.70). To a suspension of picolinic acid 
(0.123 g, 1.00 mmol, 1.0 equiv), furfurylamine (0.097 g, 1.00 mmol, 1.0 equiv), and methyl 3-(4-
oxopiperidin-1-yl)propanoate (0.185 g, 1.00 mmol, 1.0 equiv) in methanol (2 mL), was added 
cyclohexyl isocyanide (0.109 g, 1.00 mmol, 1.0 equiv) at room temperature. The mixture was 
stirred at room temperature for 24 h. The reaction mixture was quenched with TFA (0.3 mL), 
stirred for 30 min at room temperature, and then concentrated in vacuo. Reverse-phase flash 
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column chromatography purification (0-100% CH3CN/H2O) afforded the desired product (1.73) 
which was partially hydrolyzed in the aqueous solution. The partially hydrolyzed mixture was 
further purified with normal phase flash column chromatography (0-20% CH3OH/DCM) to afford 
1.69 (0.185 g, 0.371 mmol, 37% yield, ≥ 99% purity) as a colorless oil and 1.70 (0.035 g, 
0.073mmol, 7% yield, ≥ 99% purity) as a white solid. Characterization of 1.69: IR (neat) 2930, 
1656 (v br) cm-1; 1H NMR (400 MHz, CDCl3) δ 8.54 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.74 (td, J = 
7.7, 1.7 Hz, 1H), 7.53 (dt, J = 7.8, 0.9 Hz, 1H), 7.31 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 7.24 (dd, J = 
1.8, 0.7 Hz, 1H), 6.91 (d, J = 7.4 Hz, 1H), 6.20 (dd, J = 3.2, 1.9 Hz, 1H), 5.94 (d, J = 3.2 Hz, 1H), 
4.76 (s, 2H), 3.73–3.57 (m, 4H), 2.76–2.54 (m, 6H), 2.53–2.35 (m, 4H), 2.31–2.16 (m, 2H), 1.88–
1.74 (m, 2H), 1.71–1.49 (m, 3H), 1.39–1.01 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 173.1, 172.0, 
171.8, 155.1, 151.3, 148.3, 141.9, 137.2, 124.8, 124.1, 110.8, 108.2, 64.6, 53.4, 51.7, 49.8, 48.0, 
42.9, 33.0, 32.6, 32.4, 25.8, 24.8; HRMS (ESI) m/z calcd for C27H37N4O5 [M + H]
+ 497.2758, 
found 497.2760. Characterization of 1.70: Mp = 101–103 ºC;  IR (neat) 2972 (v br), 1716, 1652 (v 
br) cm-1; 1H NMR (400 MHz, CDCl3) δ 8.54 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.78 (td, J = 7.7, 1.7 
Hz, 3H), 7.56 (dt, J = 7.9, 1.1 Hz, 1H), 7.35 (ddd, J = 7.7, 4.8, 1.2 Hz, 1H), 7.29 (d, J = 1.5 Hz, 
1H), 6.67 (d, J = 8.0 Hz, 1H), 6.24 (dd, J = 3.3, 1.9 Hz, 1H), 6.04 (d, J = 3.2 Hz, 1H), 4.83 (s, 2H), 
3.72–3.58 (m, 1H), 3.30–3.22 (m, 2H), 3.20–3.09 (m, 2H), 2.99 (t, J = 6.1 Hz, 2H), 2.58–2.33 (m, 
6H), 1.85–1.74 (m, 2H), 1.71–1.50 (m, 2H), 1.39–1.23 (m, 2H), 1.21–0.98 (m, 3H); 13C NMR (101 
MHz, CDCl3) δ 174.7, 171.8, 171.0, 154.4, 150.8, 148.2, 142.1, 137.4, 124.9, 124.0, 111.0, 108.4, 
62.7, 53.8, 49.1, 48.1, 42.4, 32.9, 31.2, 30.7, 25.6, 24.7; HRMS (ESI) m/z calcd for C26H35N4O5 






ylmethyl)picolinamide ((S)-1.71) and (R)-N-(1-((4-Bromophenyl)amino)-2-methyl-1-
oxobutan-2-yl)-N-(furan-2-ylmethyl)picolinamide ((R)-1.71). To a suspension of picolinic acid 
(0.295 g, 2.40 mmol, 1.0 equiv), furfurylamine (0.233 g, 2.40 mmol, 1.0 equiv), and 2-butanone 
(0.173 g, 2.40 mmol, 1.0 equiv) in methanol (6 mL), was added 4-bromophenyl isocyanide (0.437 
g, 2.40 mmol, 1.0 equiv) at room temperature. The mixture was stirred at room temperature for 24 
h. The reaction mixture was quenched with TFA (0.84 mL) followed by 30 min of stirring at room 
temperature, then concentrated in vacuo. Reverse-phase flash column chromatography purification 
(0-100% CH3CN/H2O) afforded the racemic mixture (0.400 g, 0.877 mmol, 37% yield). Reaction 
was repeated to obtain enough racemic material for chiral separation. The racemic mixture (0.600 
g dissolved in 4 mL of DCM, 0.15 mL for every injection) was separated by Chiral HPLC 
(CHIRALPAK IA SFC Semi-Prep column, 25% EtOH/hexanes) to afford (S)-1.71 (0.250 g, tR = 
16.2 min) as a white solid and (R)-1.71 (0.240 g, tR = 28.0 min) as a white solid. The absolute 
configuration of (S)-1.71 was unambiguously determined by anomalous scattering of the Cu X-
rays of the Br atoms while that of (R)-1.71 was then assigned accordingly. Characterization of (S)-
1.71: [ɑ]𝐷
20 =  ̶ 66.4 (c 1.0, DCM); Mp = 108–110 ºC; Characterization of (R)-1.71: [ɑ]𝐷
20 = +66.1 
(c 1.0, DCM); Mp = 107–109 ºC;  IR (neat) 2982, 1691, 1641cm-1; 1H NMR (600 MHz, CD2Cl2) 
δ 8.57 (ddd, J = 4.8, 1.7, 1.0 Hz, 1H), 8.35 (s, 1H), 7.79 (td, J = 7.8, 1.7 Hz, 1H), 7.54–7.49 (m, 
1H), 7.44–7.35 (m, 6H), 6.28 (dd, J = 3.3, 1.9 Hz, 1H), 5.96 (dd, J = 3.3, 0.9 Hz, 1H), 5.16 (d, J = 
17.3 Hz, 1H), 4.69 (d, J = 17.3 Hz, 1H), 2.32 (dq, J = 13.4, 7.5 Hz, 1H), 1.96 (dq, J = 13.4, 7.5 Hz, 
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1H), 1.51 (s, 3H), 0.98 (t, J = 7.5 Hz, 3H); 13C NMR (151 MHz, CD2Cl2) δ 172.5, 170.8, 155.0, 
152.1, 148.4, 142.7, 138.6, 138.1, 132.2, 125.4, 124.4, 121.8, 116.3, 111.5, 108.2, 67.3, 42.9, 29.4, 
20.7, 8.7; HRMS (ESI) m/z calcd for C22H22BrN3NaO3 [M+Na]
+ 478.0737, found 478.0737. 
 
 
          (S)-N-(1-((4-Bromophenyl)amino)-2,4-dimethyl-1-oxopentan-2-yl)-N-(furan-2-
ylmethyl)picolinamide ((S)-1.72) and (R)-N-(1-((4-Bromophenyl)amino)-2,4-dimethyl-1-
oxopentan-2-yl)-N-(furan-2-ylmethyl)picolinamide ((R)-1.72). To a suspension of picolinic 
acid (0.590 g, 4.80 mmol, 1.0 equiv), furfurylamine (0.466 g, 4.80 mmol, 1.0 equiv), and 4-
methylpentan-2-one (0.481 g, 4.80 mmol, 1.0 equiv) in methanol (12 mL), was added 4-
bromophenyl isocyanide (0.874 g, 4.80 mmol, 1.0 equiv) at room temperature. The mixture was 
stirred at room temperature for 24 h. The reaction mixture was quenched with TFA (1.70 mL) 
followed by 30 min of stirring at room temperature, then concentrated in vacuo. Reverse-phase 
flash column chromatography purification (0-100% CH3CN/H2O) afforded the racemic mixture 
(0.512 g, 1.057 mmol, 22% yield). The racemic mixture (0.512 g dissolved in 4 mL of DCM, 0.25 
mL for every injection) was separated by Chiral HPLC (CHIRALPAK IA SFC Semi-Prep column, 
25% EtOH/hexanes) to afford (S)-1.72 (0.167 g, tR = 11.7 min) as a white solid and (R)-1.72 (0.199 
g, tR = 24.9 min) as a white solid. The absolute configuration of (S)-1.72 was unambiguously 
determined by anomalous scattering of the Cu X-rays of the Br atoms while that of (R)-1.72 was 
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then assigned accordingly. Characterization of (S)-1.72: [ɑ]𝐷
20 = –78.7 (c 1.0, DCM); Mp = 120–
122 ºC. Characterization of (R)-1.72: [ɑ]𝐷
20 = +76.6 (c 1.0, DCM); Mp = 118–121 ºC; IR (neat) 
2958, 1690, 1643 cm-1; 1H NMR (600 MHz,  CD2Cl2) δ 8.62–8.53 (m, 1H), 8.35 (s, 1H), 7.78 (tdd, 
J = 7.8, 1.8, 0.7 Hz, 1H), 7.45–7.33 (m, 6H), 6.28 (ddd, J = 3.1, 1.9, 0.7 Hz, 1H), 6.00–5.90 (m, 
1H), 5.23 (d, J = 17.2 Hz, 1H), 4.69 (d, J = 17.2 Hz, 1H), 2.20 (dd, J = 13.9, 5.7 Hz, 1H), 1.90 (dd, 
J = 13.9, 4.8 Hz, 1H), 1.87–1.79 (m, 1H), 1.55 (s, 3H), 1.00 (d, J = 6.6 Hz, 3H), 0.98 (d, J = 6.6 
Hz, 3H); 13C NMR (151 MHz, CD2Cl2) δ 172.6, 170.7, 155.1, 152.1, 148.5, 142.7, 138.6, 138.0, 
132.2, 125.3, 124.5, 121.8, 116.3, 111.5, 108.3, 67.0, 44.8, 42.8, 25.4, 25.1, 24.4, 21.8; HRMS 
(ESI) m/z calcd for C24H26BrN3NaO3 [M+Na]
+ 506.1050, found 506.1045. 
 
 
          (S)-N-(1-((4-Bromophenyl)amino)-2-methyl-1-oxohexan-2-yl)-N-(furan-2-
ylmethyl)picolinamide ((S)-1.73) and (R)-N-(1-((4-Bromophenyl)amino)-2-methyl-1-
oxohexan-2-yl)-N-(furan-2-ylmethyl)picolinamide ((R)-1.73). To a suspension of picolinic acid 
(0.295 g, 2.40 mmol, 1.0 equiv), furfurylamine (0.233 g, 2.40 mmol, 1.0 equiv), and 2-hexanone 
(0.240 g, 2.40 mmol, 1.0 equiv) in methanol (6 mL), was added 4-bromophenyl isocyanide (0.437 
g, 2.40 mmol, 1.0 equiv) at room temperature. The mixture was stirred at room temperature for 24 
h. The reaction mixture was quenched with TFA (0.84 mL) followed by 30 min of stirring at room 
temperature, then concentrated in vacuo. Reverse-phase flash column chromatography purification 
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(0-100% CH3CN/H2O) afforded the racemic mixture (0.396 g, 0.818 mmol, 34% yield). The 
racemic mixture (0.396 g dissolved in 3 mL of DCM, 0.25 mL for every injection) was separated 
by Chiral HPLC (CHIRALPAK IA SFC Semi-Prep column, 40% Isopropanol/hexanes) to afford 
(S)-1.73 (0.197 g, tR = 12.3 min) as a white solid and (R)-1.73 (0.174 g, tR = 20.0 min) as a white 
solid. The absolute configuration of (S)-1.73 was unambiguously determined by anomalous 
scattering of the Cu X-rays of the Br atoms while that of (R)-1.73 was then assigned accordingly. 
Characterization of (S)-1.73: [ɑ]𝐷
20 =  ̶ 56.7 (c 0.9, DCM); Mp = 98–100 ºC; IR (neat) 2958, 1691, 
1644 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 8.61–8.53 (m, 1H), 8.33 (s, 1H), 7.79 (td, J = 7.7, 1.7 
Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.47–7.33 (m, 6H), 6.28 (dd, J = 3.3, 1.9 Hz, 1H), 5.97 (d, J = 
3.3 Hz, 1H), 5.15 (d, J = 17.2 Hz, 1H), 4.69 (d, J = 17.2 Hz, 1H), 2.29–2.19 (m, 1H), 1.94–1.86 
(m, 1H), 1.52 (s, 3H), 1.42–1.25 (m, 4H), 0.92 (t, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CD2Cl2) 
δ 172.0, 170.4, 154.5, 151.6, 148.0, 142.1, 138.0, 137.4, 131.7, 124.7, 123.8, 121.2, 115.8, 110.9, 
107.6, 66.3, 42.3, 35.9, 26.0, 23.1, 20.7, 13.8; HRMS (ESI) m/z calcd for C24H26BrN3NaO3 
[M+Na]+ 506.1050, found 506.1051. Characterization of (R)-1.73: [ɑ]𝐷
20 = +56.3 (c 1.0, DCM); 
Mp = 100–102 ºC. 
 
Procedure for Chapter 2 
 
          Methyl 2-tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylate. To a suspension of methyl 
1,2,3,4-tetrahydroisoquinoline-6-carboxylate hydrochloride (1.000 g, 4.39 mmol, 1.0 equiv) in 
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anhydrous DCM (12 mL) were added triethylamine (1.33 g, 13.17 mmol, 3.0 equiv) and 4-
methylbenzenesulfonyl chloride (0.837 g, 4.39 mmol, 1.0 equiv) at room temperature, then stirred 
overnight. The reaction mixture was acidified with aqueous HCl (2 N) to pH 3, then extracted with 
DCM (3 × 20 mL). The combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated in vacuo to afford the title compound as a white solid (1.50 g, 4.34 mmol, 99% yield). 
Mp = 143–145 °C; IR (neat) 1718 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.83–7.76 (m, 2H), 7.75–
7.69 (m, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 8.0 Hz, 1H), 4.28 (s, 2H), 3.89 (s, 3H), 3.37 (t, 
J = 5.9 Hz, 2H), 2.97 (t, J = 5.9 Hz, 2H), 2.42 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 166.9, 144.0, 
136.9, 133.5, 133.3, 130.3, 129.9, 128.8, 127.9, 127.5, 126.6, 52.3, 47.8, 43.7, 28.9, 21.7; HRMS 
(ESI) m/z calcd for C18H20NO4S [M+H]
+ 346.1108, found 346.1106. 
 
 
          2-Tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid. To a solution of methyl 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylate (0.660 g, 2.13 mmol, 1.0 equiv) in methanol 
(10 mL) and THF (10 mL) was added aqueous NaOH (1 N, 20 mL) at room temperature. The 
mixture was stirred overnight, and concentrated in vacuo. The concentrated mixture was acidified 
with aqueous HCl (2 N) to pH 2, then filtered to afford the title compound as a white solid (0.100 
g, 0.29 mmol, 90% yield). Mp = 235–237 °C; IR (neat) 1678 cm-1; 1H NMR (400 MHz, DMSO-
d6) δ 12.89 (br s, 1H); 7.74–7.70 (m, 4H), 7.44 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 1H), 4.25 
(s, 2H), 3.30 (t, J = 6.0 Hz, 2H), 2.91 (t, J = 6.0 Hz, 2H), 2.39 (s, 3H); 13C NMR (101 MHz, 
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DMSO-d6,) δ 167.0, 143.7, 136.7, 133.4, 133.0, 129.9, 129.7, 129.1, 127.4, 126.9, 126.7, 47.3, 
43.3, 27.9, 21.0; HRMS (ESI) m/z calcd for C17H16NO4S [M-H]-330.0806, found 330.0807. 
 
General procedure for reductive amination. To a solution of ketone/aldehyde, amine in DCE 
were added NaBH(OAc)3 and AcOH at room temperature. The resulting mixture were stirred for 
12 or 24 h as needed for the completion of reaction. The reaction was quenched at room 
temperature with aqueous NaOH (1 N) to pH 10, then extracted with EtOAc three times. The 
combined organic phase was washed with brine, dried over Na2SO4, concentrated in vacuo.  The 
crude sample was purified with reverse-phase flash column chromatography (0-100% 
CH3CN/H2O) to afford the product. 
 
 
          N-(4-Chlorobenzyl)-2-methylpropan-2-amine. Prepared according to the general 
procedure for reductive amination using 4-chlorobenzaldehyde (5.000 g, 35.57 mmol, 1.0 equiv), 
tert-butylamine (2.602 g, 35.57 mmol, 1.0 equiv), NaBH(OAc)3 (10.56 g, 49.80 mmol, 1.4 equiv), 
AcOH (1 drop) and DCE (50 mL), which was stirred at room temperature for 12 h. Reverse-phase 
flash column chromatography (0 ̶ 100% CH3CN/H2O) afforded the title compound as a light 
yellow oil (5.340 g, 27.01 mmol, 76% yield). IR (neat) 1590 cm-1; 1H NMR (400 MHz, CD2Cl2) 
δ 7.40–7.19 (m, 4H), 3.70 (s, 2H), 1.15 (s, 9H), 0.95 (br s, 1H); 13C NMR (101 MHz, CD2Cl2) δ 
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141.5, 132.6, 130.1, 128.8, 51.1, 46.9, 29.5; HRMS (ESI) m/z calcd for C11H17ClN [M+H]
+ 
198.1044, found 198.1047. 
 
 
          2-(tert-Butyl(4-chlorobenzyl)amino)acetonitrile. To a solution of N-(4-chlorobenzyl)-2-
methylpropan-2-amine (1.970 g, 9.96 mmol, 1.0 equiv) in acetonitrile (25 mL) were added K2CO3 
(2.760 g, 19.97 mmol, 2.0 equiv), KI (1.660 g, 10.00 mmol, 1.0 equiv) and ClCH2CN (0.831 g, 
11.01 mmol, 1.1 equiv) at room temperature. The reaction was stirred at this temperature for 16 h, 
then diluted with saturated aqueous Na2CO3 (50 mL) and extracted with ether (3 × 100 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuo. 
Silica gel chromatography (0-20% EtOAc/hexanes) afforded the title compound as a yellowish oil 
(1.490 g, 6.29 mmol, 63% yield). IR 2975, 1597, 1490, (neat) cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.33–7.27 (m, 4H), 3.80 (s, 2H), 3.43 (s, 2H), 1.28 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 137.4, 
133.3, 129.9, 128.8, 117.9, 55.4, 50.9, 35.8, 27.4; HRMS (ESI) m/z calcd for C13H18ClN2 [M+H]
+ 





          N1-(tert-Butyl)-N1-(4-chlorobenzyl)ethane-1,2-diamine. To a solution of 2-(tert-butyl(4-
chlorobenzyl)amino)acetonitrile (1.360 g, 5.74 mmol, 1.0 equiv) in anhydrous THF (115 mL) was 
added LiAlH4, (1 N in THF, 23 mL, 23.0 mmol, 4.0 equiv) dropwise at room temperature. The 
resulting mixture was stirred at this temperature for 4 h, then quenched with Glaubler’s salt 
(Na2SO4·10H2O, 90 g) at 0 °C. The reaction was warmed to room temperature and stirred for 15 
min, then filtrated and concentrated in vacuo. Reverse-phase flash column chromatography (0-
100% CH3CN/H2O) afforded the title compound as colorless oil (0.967 g, 4.02 mmol, 70% yield). 
IR 2969, 2869, 1488 (neat) cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33–7.18 (m, 4H), 3.63 (s, 2H), 
2.60 (t, J = 6.4 Hz, 2H), 2.44 (t, J = 6.4 Hz, 2H), 1.33 (br s, 2H), 1.10 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ 142.3, 131.9, 129.0, 128.3, 55.2, 54.7, 54.6, 42.2, 27.5;  HRMS (ESI) m/z calcd for 
C13H22ClN2 [M+H]
+ 241.1466, found 241.1462. 
 
 
          N-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)-2-tosyl-1,2,3,4-tetrahydroisoquinoline-
6-carboxamide. To a solution of 2-tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (1.000 
g, 3.02 mmol, 1.0 equiv) in anhydrous DMF (15 mL) were added DIPEA (1.170 g, 9.05 mmol, 3.0 
equiv) and HATU (1.148 g, 3.02 mmol, 1.0 equiv) at room temperature. The mixture was stirred 
for 5 min, followed by addition of N1-(tert-butyl)-N1-(4-chlorobenzyl)ethane-1,2-diamine (0.727 
g, 3.02 mmol, 1.0 equiv). The reaction was stirred for 12 h at room temperature, then concentrated 
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under N2. The crude sample was purified with reverse-phase flash column chromatography (0-100% 
CH3CN/H2O) to afford the title compound as a white solid (1.108 g, 2.00 mmol, 66% yield, ≥ 99% 
purity). Mp = 95–97 ºC; IR (neat) 2969, 1644, 1541, 1489 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.71 (d, J = 8.4 Hz, 2H), 7.53 (m, 2H), 7.45–7.39 (m, 4H), 7.31 (m, 2H), 7.20 (d, J = 8.0 Hz, 1H), 
4.20 (s, 2H), 3.69 (s, 2H), 3.28 (t, J = 6.0 Hz, 2H), 3.04 (m, 2H), 2.87 (t, J = 6.0 Hz, 2H), 2.64 (m, 
2H), 2.39 (s, 3H), 1.09 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 165.5, 143.6, 142.1, 134.6, 132.9, 
132.84, 132.77, 130.5, 129.9, 129.3, 127.8, 127.45, 127.42, 126.3, 124.7, 54.8, 53.4, 49.9, 47.2, 
43.4, 40.4, 28.0, 27.1, 21.0; HRMS (ESI) m/z calcd for C30H37ClN3O3S [M+H]




          N-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)acetamide. To a solution of N1-(tert-butyl)-
N1-(4-chlorobenzyl)ethane-1,2-diamine (0.050 g, 0.208 mmol, 1.0 equiv) in anhydrous DCM (1 
mL) was added trimethylamine (0.064 g, 0.632 mmol, 3.0 equiv) and solution of acetyl chloride 
(0.016 g, 0.208 mmol, 1.0 equiv) in anhydrous DCM (1 mL) at 0 °C. The resulting mixture was 
stirred at room temperature for 3 h, then concentrated in vacuo, diluted with water (10 mL), and 
extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine and dried 
over Na2SO4, concentrated in vacuo. Reverse-phase flash column chromatography (0-100% 
CH3CN/H2O) afforded the title compound as a colorless film (0.025 g, 0.088 mmol, 42% yield, 
94.3% purity).  IR (neat) 3286, 2971, 1648, 1553; 1488 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.36–
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7.25 (m, 4H), 5.42 (br s, 1H), 3.64 (s, 2H), 2.97–2.90 (m, 2H), 2.67 (t, J = 6.3 Hz, 2H), 1.73 (s, 
3H), 1.13 (s, 9H); 13C NMR (151 MHz, CD2Cl2) δ 169.2, 141.9, 132.0, 129.4, 128.3, 55.3, 54.4, 
50.1, 39.8, 27.0, 22.8; HRMS (ESI) m/z calcd for C15H24ClN2O [M+H]
+ 283.1572, found 283.1564. 
 
 
          N-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)benzamide. To a solution of N1-(tert-
butyl)-N1-(4-chlorobenzyl)ethane-1,2-diamine (0.050 g, 0.208 mmol, 1.0 equiv) in anhydrous 
DCM (1 mL) was added trimethylamine (0.064 g, 0.632 mmol, 3.0 equiv) and solution of benzoyl 
bromide (0.038 g, 0.205 mmol, 1.0 equiv) in anhydrous DCM (1 mL) at 0 °C. The resulting mixture 
was stirred at room temperature for 3 h, then concentrated in vacuo, diluted with water (10 mL), 
and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine, 
dried over Na2SO4, concentrated in vacuo. Reverse-phase flash column chromatography (0-100% 
CH3CN/H2O) afforded the title compound as a colorless oil (0.041 g, 0.119 mmol, 57% yield, ≥ 
99% purity). IR (neat) 3327, 2969, 1638, 1541, 1488 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.60–
7.55 (m, 2H), 7.52–7.47 (m, 1H), 7.45–7.40 (m, 2H), 7.36–7.29 (m, 2H), 7.24–7.17 (m, 2H), 6.24 
(br s, 1H), 3.69 (s, 2H), 3.22–3.14 (m, 2H), 2.82 (t, J = 6.2 Hz, 2H), 1.16 (s, 9H); 13C NMR (151 
MHz, CD2Cl2) δ 167.2, 142.4, 135.5, 132.5, 131.6, 129.8, 129.0, 128.9, 127.2, 56.0, 55.0, 50.7, 
40.5, 27.6; IR (neat) 3326, 2971, 1639, 1541 cm-1 HRMS (ESI) m/z calcd for C20H26ClN2O 





          N-iso-Propyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxamide. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.025 g, 0.075 mmol, 1.0 equiv) in 
anhydrous DMF (0.5 mL) were added DIPEA (0.029 g, 0.226 mmol, 3.0 equiv) and HATU (0.029 
g, 0.075 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by 
addition of isopropylamine (0.005 g, 0.085 mmol, 1.1 equiv). The reaction was stirred for 12 h at 
room temperature, then concentrated under N2 stream. The crude sample was purified with reverse-
phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound as a 
colorless film (0.007 g, 0.019 mmol, 25% yield, ≥99% purity). IR (neat) 3318, 2972, 1633, 1543 
cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.69 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.36 (d, J 
= 8.0 Hz, 2H), 7.10 (d, J = 7.9 Hz, 1H), 5.95 (d, J = 7.1 Hz, 1H), 4.23–4.13 (m, 3H), 3.30 (t, J = 
5.9 Hz, 2H), 2.96 (t, J = 5.8 Hz, 2H), 2.41 (s, 3H), 1.21 (d, J = 6.6 Hz, 6H); 13C NMR (151 MHz, 
CD2Cl2) δ 166.2, 144.6, 135.4, 134.0, 133.9, 132.9, 130.2, 128.1, 127.9, 126.9, 124.8, 48.0, 44.1, 
42.3, 29.2, 22.9, 21.8; HRMS (ESI) m/z calcd for C20H25N2O3S [M+H]





          2-(4-Methylbenzoyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid. To a solution of 
methyl 2-(4-methylbenzoyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylate (0.660 g, 2.13 mmol, 
1.0 equiv) in a mixture of THF and methanol (1:1, 20 mL) was added aqueous NaOH (1 N, 20 mL) 
at room temperature. The resulting mixture was stirred at this temperature for 24 h, then acidified 
with aqueous HCl (1 N) to pH 2. Filtration followed by purification with reverse-phase flash 
column chromatography (0-100% CH3CN/H2O) afforded the title compound as a white solid 
(0.520 g, 1.76 mmol, 84% yield). Mp = 70–72 °C IR 1675; 1H NMR (600 MHz, DMSO-d6) δ 
7.84–7.65 (m, 2H), 7.47–7.12 (m, 5H), 4.76 (br s, 2H), 3.63 (m, 2H), 2.91 (s, 2H), 2.35 (s, 3H). 
13C NMR (151 MHz, DMSO-d6) δ 169.6, 167.0, 139.3, 138.2, 134.7, 133.0, 129.6, 128.9, 128.8, 
126.90, 126.87, 126.6, 49.2, 44.4, 28.6, 20.8; HRMS (ESI) m/z calcd for C18H18NO3 [M+H]
+ 
296.1281, found 296.1280. 
 
 
          N-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)-2-(4-methylbenzoyl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of 2-(4-methylbenzoyl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxylic acid (0.030 g, 0.10 mmol, 1.0 equiv) in anhydrous DMF (1 
mL) were added DIPEA (0.039 g, 0.302 mmol, 3.0 equiv) and HATU (0.038 g, 0.10 mmol, 1.0 
equiv) at room temperature. The mixture was stirred for 5 min, followed by addition of N1-(tert-
butyl)-N1-(4-chlorobenzyl)ethane-1,2-diamine (0.034 g, 0.10 mmol, 1.0 equiv). The reaction was 
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stirred for 12 h at room temperature, then concentrated under N2 stream. The crude sample was 
purified with reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the 
title compound as a light yellow film (0.022 g, 0.041 mmol, 53% yield, 98.7% purity).  IR (neat) 
2931, 1667 (v br) cm-1; 1H NMR (600 MHz, DMSO-d6) δ 8.21 (t, J = 5.4 Hz, 1H), 7.66–7.53 (m, 
2H), 7.47–7.19 (m, 9H), 4.72 (br s, 2H), 3.95 – 3.47 (m, 5H), 3.33 (q, J = 6.1 Hz, 2H), 2.87 (s, 
2H), 2.61–2.52 (m, 2H), 2.39–2.28 (m, 5H), 0.83 (s, 9H); 13C NMR (151 MHz, DMSO-d6) δ 169.5, 
165.6, 139.2, 139.0, 136.1, 134.2, 133.0, 132.7, 131.1, 130.1, 128.8, 127.9, 127.4, 126.8, 126.2, 
124.7, 66.4, 59.5, 54.8, 44.4, 40.1, 37.2, 32.7, 28.7, 27.9, 20.8; HRMS (ESI) m/z calcd for 
C31H37ClN3O2 [M+H]
+ 518.2569, found 518.2556. 
 
 
          2-(p-Tolylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid. To a solution of 
methyl ester (0.324 g, 1.00 mmol, 1.0 equiv) in THF (3.3 mL) were added methanol (3.3 mL) and 
aqueous NaOH solution (1 N, 3.3 mL) at room temperature. The mixture was stirred at this 
temperature for 12 h, then concentrated in vacuo, diluted with water (20 mL), and extracted with 
EtOAc (20 mL). The aqueous layer was acidified with aqueous HCl solution (1 N) to pH 2, then 
filtered to afford the title compound as a white solid (0.237 g, 0.76 mmol, 76% yield). Mp = 206–
208 °C; 1H NMR (600 MHz, DMSO-d6) δ 8.54 (s, 1H), 7.80–7.72 (m, 2H), 7.39–7.34 (m, 2H), 
7.29 (d, J = 8.0 Hz, 1H), 7.04 (d, J = 8.3 Hz, 2H), 4.69 (s, 2H), 3.71 (t, J = 5.9 Hz, 2H), 2.90 (t, J 
= 5.8 Hz, 2H), 2.22 (s, 3H); 13C NMR (151 MHz, DMSO-d6) δ 167.2, 155.1, 139.1, 137.8, 135.1, 
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130.6, 129.7, 128.7, 126.9, 126.5, 120.0, 45.7, 41.2, 28.3, 20.4; IR (neat) 3417, 2922, 1668, 1650, 
1517 cm-1; HRMS (ESI) m/z calcd for C18H19N2O3 [M+H]
+ 311.1390, found 311.1391. 
 
 
          N6-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)-N2-(p-tolyl)-3,4-dihydroisoquinoline-
2,6(1H)-dicarboxamide. To a solution of 2-(p-tolylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline-6-
carboxylic acid (0.025 g, 0.080 mmol, 1.0 equiv) in anhydrous DMF (1 mL) were added DIPEA 
(0.031 g, 0.240 mmol, 3.0 equiv) and HATU (0.031 g, 0.082 mmol, 1.0 equiv) at room temperature. 
The mixture was stirred for 5 min, followed by addition of N1-(tert-butyl)-N1-(4-
chlorobenzyl)ethane-1,2-diamine (0.019 g, 0.079 mmol, 1.0 equiv). The reaction was stirred for 
12 h at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
as a colorless oil (0.018 g, 0.034 mmol, 42% yield, ≥99% purity). IR (neat) 3310, 2969, 1635, 
1597, 1517 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.43 (s, 1H), 7.35 (dd, J = 7.9, 1.5 Hz, 1H), 7.33–
7.29 (m, 2H), 7.29–7.25 (m, 2H), 7.23–7.16 (m, 3H), 7.10 (d, J = 8.2 Hz, 2H), 6.49 (s, 1H), 6.21 
(t, J = 4.7 Hz, 1H), 4.68 (s, 2H), 3.74–3.66 (m, 4H), 3.18 (q, J = 5.9 Hz, 2H), 2.96 (t, J = 5.9 Hz, 
2H), 2.81 (t, J = 6.2 Hz, 2H), 2.30 (s, 3H), 1.16 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 167.0, 
155.3, 141.5, 136.8, 136.4, 135.4, 133.4, 133.0, 132.4, 129.6, 129.3, 128.7, 127.3, 126.6, 124.6, 
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120.5, 55.7, 54.7, 50.3, 45.8, 41.7, 40.2, 29.2, 27.5, 20.9; HRMS (ESI) m/z calcd for C31H38ClN4O2 
[M+H]+ 533.2678, found 533.2681. 
 
 
          Methyl 4-((iso-butylamino)methyl)benzoate. Prepared according to the general procedure 
using isobutyraldehyde (0.358 g, 4.96 mmol, 1.0 equiv), methyl 4-(aminomethyl)benzoate 
hydrochloride (1.0 g, 4.96 mmol, 1.0 equiv), NaBH(OAc)3 (1.472 g, 6.94 mmol, 1.4 equiv), and 
DCE (10 ml), stirred at room temperature for 12 h. Reverse-phase flash column chromatography 
(0-100% CH3CN/H2O) afforded the title compound as a light yellow oil (0.670 g, 3.03 mmol, 61% 
yield). IR (neat) 2954, 1722 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.02–7.96 (m, 2H), 7.42–7.37 
(m, 2H), 3.91 (s, 3H), 3.84 (s, 2H), 2.43 (d, J = 6.8 Hz, 2H), 1.82–1.71 (m, 1H), 0.92 (d, J = 6.7 
Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 167.2, 146.4, 129.8, 128.9, 128.0, 57.7, 53.9, 52.2, 28.6, 
20.8; HRMS (ESI) m/z calcd for C13H20ClNO2 [M+H]
+ 222.1489, found 222.1484. 
 
 
          Methyl 4-(((N-iso-butyl-4-methylphenyl)sulfonamido)methyl)benzoate. To a solution of 
methyl 4-((iso-butylamino)methyl)benzoate (0.040 g, 0.181 mmol, 1.0 equiv) and trimethylamine 
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(0.055 g, 0.544 mmol, 3.0 equiv) in anhydrous DCM (1 mL) was added p-toluenesulfonyl chloride 
(0.035 g, 0.184 mmol, 1.0 equiv) at room temperature. The resulting mixture was stirred at this 
temperature for 3 h, then diluted with water, extracted with DCM (2 × 10 mL), washed with brine, 
dried over Na2SO4 and concentrated in vacuo. Reverse-phase flash column chromatography 
afforded the title compound as a colorless oil (0.055 g, 0.146 mmol, 81% yield). IR (neat) 2958, 
1720 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.99–7.94 (m, 2H), 7.74–7.69 (m, 2H), 7.37–7.29 (m, 
4H), 4.33 (s, 2H), 3.91 (s, 3H), 2.89 (d, J = 7.6 Hz, 2H), 2.44 (s, 3H), 1.65–1.56 (m, 1H), 0.73 (d, 
J = 6.7 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 167.0, 143.5, 142.3, 136.9, 129.9, 129.9, 129.7, 
128.4, 127.4, 57.1, 53.0, 52.3, 27.1, 21.7, 20.1; HRMS (ESI) m/z calcd for C20H26NO4S [M+H]
+ 
376.1577, found 376.1574. 
 
 
          4-(((N-iso-Butyl-4-methylphenyl)sulfonamido)methyl)benzoic acid. To a solution of 
methyl 4-(((N-iso-butyl-4-methylphenyl)sulfonamido)methyl)benzoate  (0.043 g, 0.115 mmol, 1.0 
equiv) in a THF (1 mL) was added methanol (1 mL) and aqueous NaOH solution (1 N, 1 mL) at 
room temperature. The resulting mixture was stirred at this temperature for 12 h, then concentrated 
in vacuo, diluted with water, acidified with aqueous HCl solution (1 N) to pH 2. Filtration afforded 
the title compound as a white solid (0.035 g, 0.097 mmol, 85% yield). Mp = 105–108 °C; IR (neat) 
2964, 1708 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 12.93 (s, 1H), 7.93–7.87 (m, 2H), 7.77–7.72 
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(m, 2H), 7.47–7.40 (m, 4H), 4.32 (s, 2H), 2.85 (d, J = 7.4 Hz, 2H), 2.41 (s, 3H), 1.58–1.41 (m, 
1H), 0.66 (d, J = 6.6 Hz, 6H); 13C NMR (101 MHz, DMSO-d6) δ 167.1, 143.3, 142.7, 135.9, 129.9, 
129.9, 129.3, 128.1, 127.1, 57.2, 52.5, 26.5, 21.0, 19.7; HRMS (ESI) m/z calcd for C19H24NO4S 
[M+H]+ 362.1421, found 362.1422. 
 
 
          N-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)-4-(((N-iso-butyl-4-
methylphenyl)sulfonamido)methyl)benzamide. To a solution of 4-(((N-iso-butyl-4-
methylphenyl)sulfonamido)methyl)benzoic acid (0.024 g, 0.067 mmol, 1.0 equiv) in anhydrous 
DMF (1 mL) were added DIPEA (0.026 g, 0.201 mmol, 3.0 equiv) and HATU (0.025 g, 0.067 
mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by addition of 
N1-(tert-butyl)-N1-(4-chlorobenzyl)ethane-1,2-diamine (0.031 g, 0.15 mmol, 1.0 equiv). The 
reaction was stirred for 12 h at room temperature, then concentrated under N2 stream. The crude 
sample was purified with reverse-phase flash column chromatography (0-100% CH3CN/H2O) to 
afford the title compound as a colorless film (0.016 g, 0.027 mmol, 41% yield, ≥ 99% purity). IR 
(neat) 3338, 2965, 1642 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.71 (d, J = 8.2 Hz, 2H), 7.52 (d, J 
= 8.2 Hz, 2H), 7.39–7.29 (m, 6H), 7.20 (d, J = 8.3 Hz, 2H), 6.25 (t, J = 5.4 Hz, 1H), 4.31 (s, 2H), 
3.69 (s, 2H), 3.17 (q, J = 5.9 Hz, 2H), 2.89 (d, J = 7.5 Hz, 2H), 2.81 (t, J = 6.2 Hz, 2H), 2.44 (s, 
3H), 1.64–1.56 (m, 1H), 1.16 (s, 9H), 0.74 (d, J = 6.6 Hz, 6H); 13C NMR (151 MHz, CD2Cl2) δ 
166.8, 144.1, 142.3, 141.0, 137.3, 134.7, 132.5, 130.3, 129.8, 128.9, 128.8, 127.7, 127.3, 57.5, 
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56.0, 55.0, 53.3, 50.7, 40.5, 27.6, 27.4, 21.8, 20.3; HRMS (ESI) m/z calcd for C32H43ClN3O3S 
[M+H]+ 584.2708, found 584.2720. 
 
 
          Methyl (R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate. To a solution of (R)-1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid (1.0 g, 5.64 mmol, 1.0 equiv) in anhydrous methanol (25 
mL) was added sulfuric acid (95-98%, 0.5 mL) at room temperature. The reaction was refluxed 
for 24 h, followed by removal of solvent in vacuo. The residue was diluted with water (100 mL), 
then extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and concentrated in vacuo. Flash column chromatography (0-10% 
CH3OH/CH2Cl2) afforded the title compound as yellowish oil (0.97 g, 5.07 mmol, 90% yield). 
[ɑ]𝐷
20 = +58.3 (c 0.5, MeOH); IR (neat) 3331, 2951, 1739 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.18–7.08 (m, 3H), 7.07–7.00 (m, 1H), 4.19–4.04 (m, 2H), 3.81–3.73 (m, 4H), 3.09 (dd, J = 16.2, 
4.7 Hz, 1H), 2.97 (dd, J = 16.2, 10.1 Hz, 1H), 2.31–2.22 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 
173.6, 134.9, 133.2, 129.3, 126.4, 126.3, 126.2, 56.0, 52.3, 47.4, 31.7; HRMS (ESI) m/z calcd for 
C11H14NO2 [M+H]





          Methyl (R)-2-isopropyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate. To a solution of 
acetone (2.61 g, 44.87 mmol, 1.4 equiv) in DCE (30 mL) were added methyl (R)-1,2,3,4-
tetrahydroisoquinoline-3-carboxylate (6.13 g, 32.05 mmol, 1.0 equiv), NaBH(OAc)3 (9.51 g, 
44.87 mmol, 1.4 equiv) and acetic acid (1.92 g, 32.05 mmol, 1.0 equiv) at room temperature. The 
reaction was stirred at this temperature for 24 h, then basified with aqueous NaOH (1 N) to pH 10. 
The mixture was extracted with EtOAc (3 × 200 mL), washed with brine, dried over Na2SO4 and 
concentrated in vacuo. Reverse-phase flash column chromatography (0-100% CH3CN/H2O) 
afforded the title compound as an orange oil (6.26 g, 26.8 mmol, 84% yield). [ɑ]𝐷
20 =  ̶ 3.3 (c 1.0, 
MeOH); IR (neat) 2966, 1737 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.17–7.04 (m, 4H), 4.09 (d, J 
= 15.2 Hz, 1H), 3.97–3.90 (m, 2H), 3.65 (s, 3H), 3.20–3.03 (m, 3H), 1.19 (d, J = 6.5 Hz, 3H), 1.11 
(d, J = 6.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 174.1, 135.1, 132.4, 128.3, 126.4, 126.1, 126.0, 







          (±)-2-Isopropyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide. The suspension of 
methyl (R)-2-isopropyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (5.69 g, 24.388 mmol, 1.0 
equiv) in aqueous NH3 solution (28-30% NH3 basis, 150 mL) was loaded in Parr reactor. The 
reaction was stirred for 24 h at 60 °C, followed by another 24 h at 90 °C. The solvent was removed 
in vacuo. Reverse-phase column chromatography (0-100% CH3CN/H2O) afforded the title 
compound as a yellow solid (1.120 g, 5.131 mmol, 21% yield). IR (neat) 3414, 2966, 1678 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.26–7.09 (m, 5H), 5.58 (br s, 1H), 3.80–3.72 (m, 2H), 3.52 (dd, J 
= 7.0, 4.4 Hz, 1H), 3.09 (dd, J = 15.1, 4.4 Hz, 1H), 3.05–2.92 (m, 2H), 1.14 (d, J = 6.6 Hz, 3H), 
1.06 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 178.5, 137.3, 135.2, 127.5, 127.2, 126.5, 
125.7, 59.2, 53.6, 47.0, 31.7, 19.8, 18.7; HRMS (ESI) m/z calcd for C13H19N2O [M+H]
+ 219.1492, 
found 219.1490. The compound demonstrated no optical rotation, and was then evidenced as a 
racemate by chiral HPLC (ChiralPak IA column 4.6 × 250 mm, 5% isopropanol/hexanes, UV 






          (±)-(2-Isopropyl-1,2,3,4-tetrahydroisoquinolin-3-yl)methanamine. To a solution of (±)-
2-isopropyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (0.36 g, 1.65 mmol, 1.0 equiv) in 
anhydrous THF (10 mL) was added LiAlH4 (1 N in THF, 6.6 mL, 6.6 mmol, 4.0 equiv) dropwise 
at 0 °C. The reaction was refluxed for 3 h, then quenched with Glauber’s salt at -20 °C and warmed 
to room temperature to stir for 15 min. The mixture was filtered through Celite amd concentrated 
in vacuo. Reverse-phase column chromatography (0-100% CH3CN/0.5% aqueous NH3) afforded 
the title compound as a colorless oil (0.22 g, 1.077 mmol, 65% yield). IR (neat) 2965, 1576, 1456 
cm-1; 1H NMR (400 MHz, CD3OD) δ 7.18–7.04 (m, 4H), 3.79 (AB q, ΔδAB = 0.07, J=15.5 Hz, 
2H), 3.15–2.90 (m, 3H), 2.80–2.69 (m, 2H), 2.52 (dd, J = 12.7, 7.7 Hz, 1H), 1.18 (d, J = 6.5 Hz, 
3H), 1.10 (d, J = 6.4 Hz, 3H); 13C NMR (101 MHz, CD3OD) δ 136.5, 135.4, 129.5, 127.5, 127.2, 
127.0, 57.3, 52.1, 47.4, 43.1, 31.3, 21.4, 18.7; HRMS (ESI) m/z calcd for C13H21N2 [M+H]
+ 
205.1699, found 205.1697. 
 
 
         (±)-N-((2-Isopropyl-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of 2-tosyl-1,2,3,4-tetrahydroisoquinoline-
6-carboxylic acid (0.05 g, 0.15 mmol, 1.0 equiv) in anhydrous DMF (2 mL) were added DIPEA 
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(0.058 g, 0.449 mmol, 3.0 equiv) and HATU (0.057 g, 0.150 mmol, 1.0 equiv) at room temperature. 
The mixture was stirred for 5 min, followed by addition of (2-isopropyl-1,2,3,4-
tetrahydroisoquinolin-3-yl)methanamine (0.031 g, 0.152 mmol, 1.0 equiv). The reaction was 
stirred for 12 h at room temperature, then concentrated under N2 stream. The crude sample was 
purified with reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the 
title compound as a colorless film (0.016 g, 0.031 mmol, 21% yield, HPLC purity = 100%). IR 
(neat) 3330, 2967, 1643, 1537, 1494 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.75–7.70 (m, 2H), 
7.43–7.32 (m, 4H), 7.18–7.05 (m, 5H), 6.65 (br s, 1H), 4.25 (s, 2H), 3.89–3.76 (m, 2H), 3.51–3.31 
(m, 5H), 3.08 (hept, J = 6.5 Hz, 1H), 3.00 (dd, J = 16.2, 5.8 Hz, 1H), 2.95 (t, J = 5.9 Hz, 2H), 2.69 
(dd, J = 16.2, 3.6 Hz, 1H), 2.44 (s, 3H), 1.18 (d, J = 6.5 Hz, 3H), 1.10 (d, J = 6.4 Hz, 3H); 13C 
NMR (151 MHz, CD2Cl2) δ 167.1, 144.6, 136.7, 135.6, 135.2, 134.1, 133.9, 133.6, 130.3, 128.8, 
128.2, 128.0, 127.0, 126.5, 126.4, 126.3, 125.1, 53.7, 51.7, 42.6, 31.5, 29.4, 21.9, 21.8, 18.6; 
HRMS (ESI) m/z calcd for C30H36N3O3S [M+H]
+ 518.2472, found 518.2461. 
 
 
          tert-Butyl (S)-(1-((4-chlorobenzyl)(isopropyl)amino)propan-2-yl)carbamate. To a 
solution of tert-butyl (S)-(1-oxopropan-2-yl)carbamate (0.346 g, 2.0 mmol, 1.0 equiv) in DCE (3 
mL) were added N-(4-chlorobenzyl)propan-2-amine (0.367 g, 2.0 mmol, 1.0 equiv), NaBH(OAc)3 
(0.593 g, 2.8 mmol, 1.4 equiv) and acetic acid (1 drop). The mixture was stirred at room 
temperature for 3 d, then basified with aqueous NaOH (1 N) to pH 10. The mixture was extracted 
with ether (3 × 10 mL), washed with brine, dried over Na2SO4 and concentrated in vacuo. Reverse-
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phase flash column chromatography (0-100% CH3CN/H2O) afforded the title compound as a 
colorless oil (0.550 g, 1.613 mmol, 81% yield). [ɑ]𝐷
20 = –26.4 (c 1.0, CHCl3); IR (neat) 2966, 1698, 
1489 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.28 (q, J = 8.5 Hz, 4H), 4.51 (br s, 1H), 3.65–3.45 (m, 
3H), 2.87 (hept, J = 6.6 Hz, 1H), 2.32 (d, J = 7.0 Hz, 2H), 1.42 (s, 9H), 1.06 (d, J = 6.5 Hz, 3H), 
1.01 (d, J = 6.6 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H); 13C NMR (151 MHz, CD2Cl2) δ 156.1, 140.4, 
132.6, 130.5, 128.7, 79.0, 55.5, 54.2, 50.2, 45.5, 28.8, 19.7, 18.7, 17.4; HRMS (ESI) m/z calcd for 
C18H30ClN2O2 [M+H]
+ 341.1990, found 341.1990. 
 
 
          (S)-N-(1-((4-Chlorobenzyl)(isopropyl)amino)propan-2-yl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of (S)-N1-(4-chlorobenzyl)-N1-
isopropylpropane-1,2-diamine (0.024 g, 0.1 mmol, 1.0 equiv) in DCM (1 mL) was added TFA (1 
mL) at room temperature. The resulting mixture was stirred for 3 h at this temperature, then 
concentrated in vacuo. The obtained crude TFA salt of diamine was used directly in the following 
HATU promoted amide coupling without further purification. To a solution of 2-(p-
tolylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.1 mmol, 1.0 equiv) in anhydrous DMF (1 mL) 
were added DIPEA (0.039 g, 0.3 mmol, 3.0 equiv) and HATU (0.038 g, 0.1 mmol, 1.0 equiv) at 
room temperature. The mixture was stirred for 5 min, followed by addition of crude TFA salt of 
diamine (0.1 mmol, 1.0 equiv). The reaction was stirred for 12 h at room temperature, then 
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concentrated under N2 stream. The crude sample was purified with reverse-phase flash column 
chromatography (0-100% CH3CN/H2O) to afford the title compound as a white solid (0.026 g, 
0.047 mmol, 47% yield, HPLC purity =99.7%). [ɑ]𝐷
20 = –7.8 (c 0.2, CHCl3); Mp = 102–104 °C; 
IR (neat) 2965, 1638, 1536, 1490 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.76–7.67 (m, 2H), 7.43 (d, 
J = 1.8 Hz, 1H), 7.37 (dd, J = 8.0, 1.8 Hz, 1H), 7.35–7.30 (m, 4H), 7.22–7.12 (m, 4H), 7.07 (d, J 
= 8.0 Hz, 1H), 6.17 (d, J = 5.9 Hz, 1H), 4.27 (s, 2H), 4.08–3.93 (m, 1H), 3.58 (d, J = 14.1 Hz, 1H), 
3.42 (d, J = 14.1 Hz, 1H), 3.36 (t, J = 5.9 Hz, 2H), 2.99–2.86 (m, 3H), 2.51 (dd, J = 13.2, 5.6 Hz, 
1H), 2.45–2.36 (m, 4H), 1.18 (d, J = 6.3 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H), 0.99 (d, J = 6.5 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 166.8, 144.0, 139.4, 135.1, 133.6, 133.6, 133.4, 132.5, 130.0, 
129.9, 128.5, 127.8, 127.7, 126.6, 124.6, 54.7, 53.4, 49.7, 47.6, 44.3, 43.7, 29.0, 21.6, 19.4, 19.1, 
16.6; HRMS (ESI) m/z calcd for C30H37ClN3O3S [M+H]
+ 554.2239, found 554.2255. 
 
 
          tert-Butyl (R)-(1-((4-chlorobenzyl)(isopropyl)amino)propan-2-yl)carbamate. To a 
solution of tert-butyl (R)-(1-oxopropan-2-yl)carbamate (0.346 g, 2.0 mmol, 1.0 equiv) in DCE (3 
mL) were added N-(4-chlorobenzyl)propan-2-amine (0.0.367 g, 2.0 mmol, 1.0 equiv), 
NaBH(OAc)3 (0.593 g, 2.8 mmol, 1.4 equiv) and acetic acid (1 drop). The mixture was stirred at 
room temperature for 3 d, then basified with aqueous NaOH (1 N) to pH 10. The mixture was 
extracted with ether (3 × 10 mL), washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Reverse-phase flash column chromatography (0-100% CH3CN/H2O) afforded the title compound 
as a colorless oil (0.555 g, 1.628 mmol, 81% yield). [ɑ]𝐷
20 = +20.4 (c .0, CHCl3); IR (neat) 2967, 
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1701, 1470 cm-1; 1H NMR (400 MHz, CD2Cl2) δ 7.34–7.22 (m, 4H), 4.49 (br s, 1H), 3.53 (q, J = 
14.3 Hz, 3H), 2.87 (hept, J = 6.6 Hz, 1H), 2.32 (d, J = 7.1 Hz, 2H), 1.41 (s, 9H), 1.06 (d, J = 6.5 
Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, CD2Cl2) δ 156.2, 
140.4, 132.6, 130.5, 128.7, 79.1, 55.6, 54.3, 50.3, 45.6, 28.8, 19.7, 18.7, 17.4; HRMS (ESI) m/z 
calcd for C18H30ClN2O2 [M+H]
+ 341.1990, found 341.1990. 
 
 
          (R)-N-(1-((4-chlorobenzyl)(isopropyl)amino)propan-2-yl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of (R)-N1-(tert-butyl)-N1-(4-
chlorobenzyl)-3-methylbutane-1,2-diamine (0.028 g, 0.1 mmol, 1.0 equiv) in DCM (1 mL) was 
added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.1 mmol, 1.0 equiv) in 
anhydrous DMF (1 mL) were added DIPEA (0.039 g, 0.3 mmol, 3.0 equiv) and HATU (0.038 g, 
0.1 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by addition 
of crude TFA salt of diamine (0.1 mmol, 1.0 equiv). The reaction was stirred for 12 h at room 
temperature, then concentrated under N2 stream. The crude sample was purified with reverse-phase 
flash column chromatography (0-100% CH3CN/H2O) to afford the title compound as a white solid 
(0.029 g, 0.052 mmol, 52% yield, 98.5% purity). [ɑ]𝐷
20 = +6.0 (c 0.1, CHCl3); Mp = 73–76 °C; IR 
171 
 
(neat) 2965, 1639, 1537, 1490 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.77–7.69 (m, 2H), 7.43 (d, J 
= 1.7 Hz, 1H), 7.40–7.30 (m, 3H), 7.22–7.12 (m, 4H), 7.07 (d, J = 8.0 Hz, 1H), 6.15 (d, J = 5.7 
Hz, 1H), 4.28 (s, 2H), 4.07–3.94 (m, 1H), 3.59 (d, J = 14.1 Hz, 1H), 3.46–3.30 (m, 3H), 3.03–2.84 
(m, 3H), 2.57–2.36 (m, 5H), 1.19 (d, J = 6.4 Hz, 3H), 1.02 (dd, J = 15.8, 6.6 Hz, 6H); 13C NMR 
(101 MHz, CDCl3) δ 166.9, 144.0, 139.4, 135.2, 133.7, 133.6, 133.4, 132.6, 130.0, 129.9, 128.6, 
127.8, 127.7, 126.6, 124.6, 54.8, 53.4, 49.8, 47.7, 44.3, 43.7, 29.0, 21.6, 19.5, 19.1, 16.5; HRMS 
(ESI) m/z calcd for C30H37ClN3O3S [M+H]
+ 554.2239, found 554.2254. 
 
 
          tert-Butyl (S)-(1-(tert-butyl(4-chlorobenzyl)amino)propan-2-yl)carbamate. To a 
solution of tert-butyl (S)-(1-oxopropan-2-yl)carbamate (0.520 g, 3.0 mmol, 1.0 equiv) in DCE (4 
mL) were added N-(4-chlorobenzyl)-2-methylpropan-2-amine (0.593 g, 3.0 mmol, 1.0 equiv) and 
NaBH(OAc)3 (0.890 g, 4.2 mmol, 1.4 equiv) and acetic acid (1 drop). The mixture was stirred at 
room temperature for 3 d, then basified with aqueous NaOH (1 N) to pH 10. The mixture was 
extracted with ether (3 × 10 mL), washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Reverse-phase flash column chromatography (0-100% CH3CN/H2O) afforded the title compound 
as a colorless oil (0.497 g, 1.400 mmol, 47% yield). [ɑ]𝐷
20 = +14.1 (c 0.4, CHCl3); IR (neat) 2972, 
1699, 1488 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.35–7.28 (m, 2H), 7.27–7.21 (m, 2H), 4.42 (br 
s, 1H), 3.74 (d, J = 16.2 Hz, 1H), 3.64 (d, J = 16.2 Hz, 1H), 3.24 (br s, 1H), 2.53 (dd, J = 13.3, 7.6 
Hz, 1H), 2.45 (dd, J = 13.3, 6.4 Hz, 1H), 1.39 (s, 9H), 1.08 (s, 9H), 1.01 (d, J = 6.4 Hz, 3H); 13C 
172 
 
NMR (151 MHz, CD2Cl2) δ 155.9, 142.8, 132.0, 129.6, 128.6, 79.0, 57.7, 55.8, 55.2, 47.0, 28.7, 
27.5, 19.6; HRMS (ESI) m/z calcd for C19H32ClN2O2 [M+H]
+ 355.2147, found 355.2145. 
 
 
          (S)-N-(1-(tert-Butyl(4-chlorobenzyl)amino)propan-2-yl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (S)-(1-(tert-butyl(4-
chlorobenzyl)amino)propan-2-yl)carbamate (0.035 g, 0.1 mmol, 1.0 equiv) in DCM (1 mL) was 
added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.1 mmol, 1.0 equiv) in 
anhydrous DMF (1 mL) were added DIPEA (0.039 g, 0.3 mmol, 3.0 equiv) and  HATU (0.038 g, 
0.1 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by addition 
of TFA salt of crude diamine (0.1 mmol, 1.0 equiv). The reaction was stirred for 12 h at room 
temperature, then concentrated under N2 stream. The crude sample was purified with reverse-phase 
flash column chromatography (0-100% CH3CN/H2O) to afford the title compound as a white solid 
(0.030 g, 0.053 mmol, 53% yield, 98.9% purity). [ɑ]𝐷
20 = +58.5 (c 0.2, CHCl3) IR (neat) 2971, 
1638, 1536, 1488 cm-1;  1H NMR (400 MHz, CD2Cl2) δ 7.76–7.68 (m, 2H), 7.40–7.34 (m, 3H), 
7.34–7.29 (m, 1H), 7.27–7.19 (m, 2H), 7.12–7.03 (m, 3H), 6.02 (d, J = 6.1 Hz, 1H), 4.33–4.19 (m, 
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2H), 3.80–3.58 (m, 3H), 3.39–3.28 (m, 2H), 2.95 (t, J = 5.9 Hz, 2H), 2.70–2.59 (m, 2H), 2.42 (s, 
3H), 1.17–1.06 (m, 12H); 13C NMR (101 MHz, CD2Cl2) δ 166.9, 144.6, 142.4, 135.6, 134.3, 134.1, 
133.9, 132.2, 130.3, 129.7, 128.7, 128.2, 128.0, 127.0, 124.9, 57.3, 56.0, 55.5, 48.2, 46.6, 44.3, 
29.4, 27.6, 21.8, 19.3; HRMS (ESI) m/z calcd for C31H39ClN3O3S [M+H]




          tert-Butyl (R)-(1-(tert-butyl(4-chlorobenzyl)amino)propan-2-yl)carbamate. To a 
solution of tert-butyl (R)-(1-oxopropan-2-yl)carbamate (0.520 g, 3.0 mmol, 1.0 equiv) in DCE (5 
mL) were added N-(4-chlorobenzyl)-2-methylpropan-2-amine (0.593 g, 3.0 mmol, 1.0 equiv) and 
NaBH(OAc)3 (0.890 g, 4.2 mmol, 1.4 equiv) and acetic acid (1 drop). The mixture was stirred at 
room temperature for 3 d, then basified with aqueous NaOH (1 N) to pH 10. The mixture was 
extracted with ether (3 × 10 mL), washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Reverse-phase flash column chromatography (0-100% CH3CN/H2O) afforded the title compound 
as a colorless oil (0.490 g, 1.381 mmol, 46% yield). [ɑ]𝐷
20 =  ̶ 13.0 (c 0.3, CHCl3); IR (neat) 2972, 
1699, 1489 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.31 (m, 2H), 7.27–7.22 (m, 2H), 4.43 (br s, 1H), 
3.74 (d, J = 16.2 Hz, 1H), 3.63 (d, J = 16.2 Hz, 1H), 3.24 (br s, 1H), 2.53 (dd, J = 13.3, 7.6 Hz, 
1H), 2.45 (dd, J = 13.3, 6.4 Hz, 1H), 1.38 (s, 9H), 1.08 (s, 9H), 1.01 (d, J = 6.4 Hz, 3H); 13C NMR 
(151 MHz, CD2Cl2) δ 156.0, 142.8, 132.0, 129.6, 128.6, 79.0, 57.7, 55.8, 55.2, 47.0, 28.7, 27.5, 
19.6; HRMS (ESI) m/z calcd for C19H32ClN2O2 [M+H]





          (R)-N-(1-(tert-Butyl(4-chlorobenzyl)amino)propan-2-yl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (R)-(1-(tert-butyl(4-
chlorobenzyl)amino)propan-2-yl)carbamate (0.071 g, 0.20 mmol, 1.0 equiv) in DCM (2 mL) was 
added TFA (2 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.066 g, 0.20 mmol, 1.0 equiv) in 
anhydrous DMF (1 mL) were added DIPEA (0.078 g, 0.60 mmol, 3.0 equiv) and  HATU (0.076 
g, 0.20 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by 
addition of crude TFA salt of diamine (0.20 mmol, 1.0 equiv). The reaction was stirred for 12 h at 
room temperature, then concentrated under N2 stream. The crude sample was purified with reverse-
phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound as a 
colorless oil (0.077 g, 0.135 mmol, 68% yield, 92.9% purity). [ɑ]𝐷
20 =  ̶ 61.0 (c 0.2, CHCl3); IR 
(neat) 2970, 1638, 1537, 1489 cm-1; 1H NMR (400 MHz, CD2Cl2) δ 7.76–7.68 (m, 2H), 7.40–7.34 
(m, 3H), 7.31 (dd, J = 8.0, 1.8 Hz, 1H), 7.2 –7.19 (m, 2H), 7.12–7.04 (m, 3H), 5.99 (d, J = 6.0 Hz, 
1H), 4.34–4.18 (m, 2H), 3.80–3.58 (m, 3H), 3.35 (t, J = 6.0 Hz, 2H), 2.95 (t, J = 6.0 Hz, 2H), 2.70–
2.59 (m, 2H), 2.42 (s, 3H), 1.16 – 1.09 (m, 12H); 13C NMR (101 MHz, CD2Cl2) δ 166.9, 144.6, 
142.4, 135.6, 134.3, 134.2, 133.8, 132.2, 130.3, 129.7, 128.7, 128.3, 128.0, 127.0, 124.9, 57.3, 
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56.0, 55.5, 48.2, 46.6, 44.3, 29.4, 27.6, 21.8, 19.3; HRMS (ESI) m/z calcd for C31H39ClN3O3S 
[M+H]+ 568.2395, found 568.2400. 
 
 
          tert-Butyl ((2S)-1-(tert-butyl((4-chlorocyclohexa-1,5-dien-1-yl)methyl)amino)-3-
methylbutan-2-yl)carbamate. To a solution of tert-butyl (S)-(3-methyl-1-oxobutan-2-
yl)carbamate (0.830 g, 4.12 mmol, 1.0 equiv) in DCE (5 mL) were added N-(4-chlorobenzyl)-2-
methylpropan-2-amine (0.815 g, 4.12 mmol, 1.0 equiv) and NaBH(OAc)3 (1.223 g, 5.77 mmol, 
1.4 equiv) and acetic acid (2 drops). The mixture was stirred at room temperature for 7 d, then 
basified with aqueous NaOH (1 N) to pH 10. The mixture was extracted with ether (3 × 10 mL), 
washed with brine, dried over Na2SO4 and concentrated in vacuo. Reverse-phase flash column 
chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil (0.100 g, 
0.261 mmol, 6% yield). [ɑ]𝐷
20 = +10.9 (c 1.1, CHCl3); IR (neat) 2965, 1702, 1489 cm
-1; 1H NMR 
(600 MHz, CD2Cl2) δ 7.36–7.29 (m, 2H), 7.27–7.20 (m, 2H), 4.23 (br s, 1H), 3.69 ( AB q, ΔδAB = 
0.77, J = 16.2 Hz, 2H), 3.24 (br s, 1H), 2.62 (dd, J = 13.6, 6.2 Hz, 1H), 2.38 (dd, J = 13.6, 8.0 Hz, 
1H), 1.95–1.86 (m, 1H), 1.07 (s, 9H), 0.80–0.70 (m, 6H); 13C NMR (151 MHz, CD2Cl2) δ 156.4, 
143.0, 132.0, 129.7, 128.6, 78.8, 56.0, 55.7, 55.2, 53.4, 29.9, 28.8, 27.6, 19.7, 17.0; HRMS (ESI) 
m/z calcd for C21H36ClN2O2 [M+H]





          (S)-N-(1-(tert-Butyl(4-chlorobenzyl)amino)-3-methylbutan-2-yl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl ((2S)-1-(tert-butyl((4-
chlorocyclohexa-1,5-dien-1-yl)methyl)amino)-3-methylbutan-2-yl)carbamate (0.038 g, 0.1 mmol, 
1.0 equiv) in DCM (1 mL) was added TFA (1 mL) at room temperature. The resulting mixture 
was stirred for 3 h at this temperature, then concentrated in vacuo. The obtained crude TFA salt of 
diamine was used directly in the following HATU promoted amide coupling without further 
purification. To a solution of 2-tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 
0.1 mmol, 1.0 equiv) in anhydrous DMF (1 mL) were added DIPEA (0.039 g, 0.3 mmol, 3.0 equiv) 
and  HATU (0.038 g, 0.1 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, 
followed by addition of crude TFA salt of diamine (0.1 mmol, 1.0 equiv). The reaction was stirred 
for 12 h at room temperature, then concentrated under N2 stream. The crude sample was purified 
with reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title 
compound as a colorless oil (0.044 g, 0.074 mmol, 74% yield, 99.0% purity). [ɑ]𝐷
20 = +26.7 (c 0.3, 
CHCl3); IR (neat) 2964, 1643, 1535 cm
-1; 1H NMR (500 MHz, CDCl3) δ 7.76–7.70 (m, 2H), 7.39–
7.28 (m, 4H), 7.20–7.14 (m, 2H), 7.07 (d, J = 8.0 Hz, 1H), 7.05 – 7.00 (m, 3H), 5.69 (d, J = 7.8 
Hz, 1H), 4.29 (AB q, ΔδAB = 0.34, J = 15.6 Hz, 2H), 3.85–3.76 (m, 1H), 3.73 (d, J = 12.5 Hz, 1H), 
3.56 (d, J = 12.5 Hz, 1H), 3.44–3.31 (m, 2H), 2.96 (t, J = 4.7 Hz, 2H), 2.81 (dd, J = 11.1, 4.8 Hz, 
1H), 2.48 (dd, J = 11.1, 6.8 Hz, 1H), 2.42 (s, 3H), 2.11–2.00 (m, 1H), 1.10 (s, 9H), 0.83 (d, J = 6.9 
Hz, 3H), 0.80 (d, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 167.1, 144.0, 141.4, 135.0, 133.8, 
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133.6, 133.2, 131.9, 129.9, 129.3, 128.3, 127.8, 127.7, 126.6, 124.5, 55.7, 55.0, 54.5, 51.9, 47.6, 
43.7, 29.4, 29.0, 27.4, 21.7, 19.1, 17.3; HRMS (ESI) m/z calcd for C33H41ClN3O3S [M-H]
- 




          tert-Butyl (R)-(1-(tert-butyl(4-chlorobenzyl)amino)-3-methylbutan-2-yl)carbamate. To 
a solution of tert-butyl (R)-(3-methyl-1-oxobutan-2-yl)carbamate (0.830 g, 4.12 mmol, 1.0 equiv) 
in DCE (5 mL) were added N-(4-chlorobenzyl)-2-methylpropan-2-amine (0.815 g, 4.12 mmol, 1.0 
equiv), NaBH(OAc)3 (1.223 g, 5.77 mmol, 1.4 equiv) and acetic acid (2 drops). The mixture was 
stirred at room temperature for 7 d, then basified with aqueous NaOH (1 N) to pH 10. The mixture 
was extracted with ether (3 × 10 mL), washed with brine, dried over Na2SO4 and concentrated in 
vacuo. Reverse-phase flash column chromatography (0-100% CH3CN/H2O) afforded the title 
compound as a colorless oil (0.590 g, 1.541 mmol, 37% yield). [ɑ]𝐷
20 =  ̶ 10.1 (c 1.2, CHCl3); IR 
(neat) 2966, 1701, 1489 cm-1; 1H NMR (400 MHz, CD2Cl2) δ 7.35–7.29 (m, 2H), 7.27–7.22 (m, 
2H), 4.23 (br s, 1H), 3.69 (AB q, ΔδAB = 0.78, J = 16.2 Hz, 2H), 3.24 (br s, 1H), 2.63 (dd, J = 13.6, 
6.2 Hz, 1H), 2.38 (dd, J = 13.6, 8.0 Hz, 1H), 1.98–1.82 (m, 1H), 1.41 (s, 9H), 1.07 (s, 9H), 0.81–
0.72 (m, 6H); 13C NMR (101 MHz, CD2Cl2) δ 156.4, 143.0, 132.0, 129.7, 128.6, 78.9, 56.0, 55.7, 
55.1, 53.3, 29.8, 28.8, 27.6, 19.6, 16.9; HRMS (ESI) m/z calcd for C21H36ClN2O2 [M+H]
+ 





          (R)-N-(1-(tert-Butyl(4-chlorobenzyl)amino)-3-methylbutan-2-yl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (R)-(1-(tert-butyl(4-
chlorobenzyl)amino)-3-methylbutan-2-yl)carbamate (0.038 g, 0.1 mmol, 1.0 equiv) in DCM (1 
mL) was added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.1 mmol, 1.0 equiv) in 
anhydrous DMF (1 mL) were added DIPEA (0.039 g, 0.3 mmol, 3.0 equiv) and  HATU (0.038 g, 
0.1 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by addition 
of crude TFA salt of diamine (0.1 mmol, 1.0 equiv). The reaction was stirred for 12 h at room 
temperature, then concentrated under N2 stream. The crude sample was purified with reverse-phase 
flash column chromatography (0-100% CH3CN/H2O) to afford the title compound as a colorless 
oil (0.052 g, 0.087 mmol, 87% yield, ≥ 99% purity). [ɑ]𝐷
20 =  ̶ 26.0 (c 0.2, CHCl3); IR (neat) 2963, 
1640, 1489 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.77–7.69 (m, 2H), 7.39–7.27 (m, 4H), 7.21–7.13 
(m, 2H), 7.10–6.99 (m, 3H), 5.69 (d, J = 7.8 Hz, 1H), 4.31, 4.26 (AB q, ΔδAB = 0.33, J = 15.6 Hz, 
2H), 3.86–3.77 (m, 2H), 3.73 (d, J = 15.6 Hz, 1H), 3.56 (d, J = 15.6 Hz, 1H), 3.45 – 3.30 (m, 2H), 
2.96 (t, J = 6.0 Hz, 2H), 2.81 (dd, J = 13.8, 6.0 Hz, 1H), 2.49 (dd, J = 13.8, 8.4 Hz, 4H), 2.42 (s, 
3H), 2.12–1.99 (m, 1H), 1.10 (s, 9H), 0.82 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 167.1, 143.9, 
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141.5, 135.1, 133.9, 133.7, 133.5, 132.0, 129.9, 129.3, 128.3, 127.8, 127.7, 126.6, 124.5, 55.8, 
55.0, 54.6, 52.0, 47.6, 43.7, 29.5, 29.0, 27.4, 21.6, 19.2, 17.4; HRMS (ESI) m/z calcd for 
C33H43ClN3O3S [M+H]
+ 596.2708, found 596.2716. 
 
 
          Methyl 2-((3-methoxyphenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylate. 
To a suspension of methyl 1,2,3,4-tetrahydroisoquinoline-6-carboxylate hydrochloride (0.273 g, 
1.20 mmol, 1.0 equiv) in anhydrous DCM (12 mL) were added triethylamine (0.364 g, 3.60 mmol, 
3.0 equiv) and 3-methoxybenzenesulfonyl chloride (0.248 g, 1.20 mmol, 1.0 equiv) at room 
temperature, then stirred for overnight. The reaction mixture was acidified with aqueous HCl (2 
N) to pH 3, then extracted with DCM (3 × 50 mL). The combined organic layers were washed 
with brine, dried over Na2SO4 and concentrated in vacuo to afford the title compound as a white 
solid (0.386 g, 1.07 mmol, 89% yield). Mp = 117–119 ºC; IR (neat) 1717, 1596, 1479 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.83–7.75 (m, 2H), 7.47–7.38 (m, 2H), 7.34–7.30 (m, 1H), 7.13–7.07 
(m, 2H), 5.29 (d, J = 0.9 Hz, 2H), 4.32 (s, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.40 (t, J = 5.9 Hz, 2H), 
2.96 (t, J = 5.9 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 166.8, 160.1, 137.5, 136.8, 133.5, 130.4, 
130.3, 128.8, 127.5, 126.6, 119.9, 119.1, 112.7, 55.8, 52.3, 47.7, 43.7, 28.9; HRMS (ESI) m/z 
calcd for C18H20NO5S [M+H]





           6-((3-Methoxyphenyl)sulfonyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid. To a 
solution of methyl 2-((4-methoxyphenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylate 
(0.181 g, 0.50 mmol, 1.0 equiv) in methanol (2 mL) was added aqueous NaOH solution (1 N, 2 
mL) and THF (2 mL). The mixture was stirred overnight and organic solvent was removed in 
vacuo. The concentrated mixture was acidified with aqueous HCl (2 N) to pH 2, then filtered to 
afford the title compound as a white solid (0.107 g, 0.31 mmol, 62% yield). Mp = 161–164 ºC; IR 
(neat) 1683, 1596 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 12.88 (s, 1H), 7.74–7.63 (m, 2H), 7.59–
7.49 (m, 1H), 7.43–7.36 (m, 1H), 7.33–7.22 (m, 3H), 4.30 (s, 2H), 3.82 (s, 3H), 3.35 (t, J = 5.9 Hz, 
2H), 2.89 (t, J = 5.9 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ 167.0, 159.5, 137.3, 136.7, 133.4, 
130.6, 129.7, 129.1, 126.8, 126.7, 119.4, 119.1, 112.1, 55.6, 47.3, 43.3, 27.8; HRMS (ESI) m/z 
calcd for C17H18NO5S [M+H]
+ 348.0900, found 348.0900. 
 
 
          N-(4-Methoxybenzyl)-2-methylpropan-2-amine. Prepared according to the general 
procedure for reductive amination using 4-methoxybenzaldehyde (1.86 g, 13.7 mmol, 1.0 equiv), 
tert-butylamine (1.00 g, 13.7 mmol, 1.0 equiv), NaBH(OAc)3 (4.06 g, 19.2 mmol, 1.4 equiv), 
AcOH (1 drop) and DCE (20 mL), at room temperature for 12 h. Reverse-phase flash column 
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chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil (2.270 g, 
11.74 mmol, 86% yield). IR (neat) 2961, 1613, 1511 cm-1; 1H NMR (400 MHz, CD2Cl2) δ 7.29– 
7.21 (m, 2H), 6.91–6.79 (m, 2H), 3.77 (s, 3H), 3.65 (s, 2H), 1.15 (s, 9H); 13C NMR (101 MHz, 
CD2Cl2) δ 159.0, 134.6, 129.8, 114.1, 55.7, 51.0, 46.9, 29.4; HRMS (ESI) m/z calcd for C12H20NO 
[M+H]+ 194.1539, found 194.1540. 
 
 
          tert-Butyl (2-(tert-butyl(4-methoxybenzyl)amino)ethyl)carbamate. Prepared according 
to the general procedure for reductive amination using N-Boc-2-aminoacetaldehyde (0.159 g, 1.0 
mmol, 1.0 equiv), N-(4-methoxybenzyl)-2-methylpropan-2-amine (0.193 g, 1.0 mmol, 1.0 equiv), 
NaBH(OAc)3 (0.297 g, 1.40 mmol, 1.4 equiv), AcOH (1 drop) and DCE (2 mL), at room 
temperature for 24 h. Reverse-phase flash column chromatography (0-100% CH3CN/H2O) 
afforded the title compound as a colorless oil (0.187 g, 0.56 mmol, 56% yield). IR (neat) 3415, 
2971, 1707, 1612, 1510 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.25–7.20 (m, 2H), 6.86–6.79 (m, 
2H), 4.55 (br s, 1H), 3.78 (s, 3H), 3.59 (s, 2H), 2.88–2.75 (m, 2H), 2.64 (t, J = 6.1 Hz, 2H), 1.38 
(s, 9H), 1.12 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 158.4, 156.1, 134.9, 129.1, 113.8, 78.7, 55.3, 
55.3, 54.5, 50.4, 40.9, 28.5, 27.5; HRMS (ESI) m/z calcd for C19H33N2O3 [M+H]






           N-(2-(tert-Butyl(4-methoxybenzyl)amino)ethyl)-2-((3-methoxyphenyl)sulfonyl)-
1,2,3,4-tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl(4-
methoxybenzyl)amino)ethyl)carbamate (0.039 g, 0.115 mmol, 1.0 equiv) in DCM (1 mL) was 
added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
((3-methoxyphenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.040 g, 0.115 
mmol, 1.0 equiv) in anhydrous DMF (1 mL) were added DIPEA (0.059 g, 0.460 mmol, 4.0 equiv) 
and  HATU (0.044 g, 0.115 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 
min, followed by addition of crude TFA salt of diamine (0.115 mmol, 1.0 equiv). The reaction was 
stirred for 12 h at room temperature, then concentrated under N2 stream. The crude sample was 
purified with reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the 
title compound as a colorless oil (0.027 g, 0.048 mmol, 41% yield, ≥ 99% purity). IR (neat) 3334, 
2955, 1647, 1598, 1510 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.49–7.39 (m, 2H), 7.37–7.32 (m, 
2H), 7.25–7.19 (m, 3H), 7.12 (ddd, J = 7.9, 2.6, 1.4 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.796.71 
(m, 2H), 6.18 (t, J = 4.7 Hz, 1H), 4.30 (s, 2H), 3.86 (s, 3H), 3.70 (s, 3H), 3.61 (s, 2H), 3.40 (t, J = 
5.9 Hz, 2H), 3.21–3.14 (m, 2H), 2.96 (t, J = 5.8 Hz, 2H), 2.84–2.78 (m, 2H), 1.15 (s, 9H); 13C 
NMR (126 MHz, CDCl3) δ 166.8, 160.1, 158.5, 137.5, 134.8, 134.6, 133.5, 133.5, 130.4, 129.2, 
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127.8, 126.5, 124.6, 119.9, 119.2, 114.0, 112.7, 77.4, 55.8, 55.6, 55.3, 54.7, 49.9, 47.7, 43.8, 40.2, 
28.9, 27.5; HRMS (ESI) m/z calcd for C31H40N3O5S [M+H]
 + 566.2683, found 566.2688. 
 
 
          N-(3-Methoxybenzyl)-2-methylpropan-2-amine. Prepared according to the general 
procedure for reductive amination using 3-methoxybenzaldehyde (1.86 g, 13.7 mmol, 1.0 equiv), 
tert-butylamine (1.00 g, 13.7 mmol, 1.0 equiv), NaBH(OAc)3 (4.06 g, 19.2 mmol, 1.4 equiv), 
AcOH (1 drop) and DCE (20 mL), at room temperature for 12 h. Reverse-phase flash column 
chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil (2.260 g, 
11.69 mmol, 86% yield). IR (neat) 2961, 1601, 1489 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.30–
7.18 (m, 1H), 6.96–6.88 (m, 2H), 6.81–6.73 (m, 1H), 3.81 (s, 3H), 3.71 (s, 2H), 1.17 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ 159.8, 143.3, 129.5, 120.6, 113.9, 112.3, 55.3, 50.8, 47.4, 29.3; HRMS 
(ESI) m/z calcd for C12H20NO [M+H]
+ 194.1539, found 194.1540. 
 
 
          tert-Butyl (2-(tert-butyl(3-methoxybenzyl)amino)ethyl)carbamate. Prepared according 
to the general procedure for reductive amination using N-Boc-2-aminoacetaldehyde (0.159 g, 1.00 
mmol, 1.0 equiv), N-(3-methoxybenzyl)-2-methylpropan-2-amine (0.193 g, 1.00 mmol, 1.0 equiv), 
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NaBH(OAc)3 (0.297 g, 1.40 mmol, 1.4 equiv), AcOH (1 drop) and DCE (2 mL), at room 
temperature for 24 h. Reverse-phase flash column chromatography (0-100% CH3CN/H2O) 
afforded the title compound as a colorless oil (0.205 g, 0.61 mmol, 61% yield). IR (neat) 3416, 
2971, 1706, 1600, 1488 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.20 (t, J = 7.8 Hz, 1H), 6.97–6.87 
(m, 2H), 6.77–6.69 (m, 1H), 4.64 (br s, 1H), 3.80 (s, 3H), 3.65 (s, 2H), 2.92–2.79 (m, 2H), 2.67 (t, 
J = 6.1 Hz, 2H), 1.39 (s, 9H), 1.12 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 159.7, 156.1, 144.9, 
129.3, 120.1, 113.3, 112.0, 78.8, 55.3, 55.2, 55.1, 28.5, 27.4; HRMS (ESI) m/z calcd for 
C19H33N2O3 [M+H]
+ 337.2486, found 337.2484. 
 
 
     N-(2-(tert-Butyl(3-methoxybenzyl)amino)ethyl)-2-tosyl-1,2,3,4-tetrahydroisoquinoline-6-
carboxamide. To a solution of tert-butyl (2-(tert-butyl(3-methoxybenzyl)amino)ethyl)carbamate 
(0.101 g, 0.302 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (3 mL) at room temperature. 
The resulting mixture was stirred for 3 h at this temperature, then concentrated in vacuo. The 
obtained crude TFA salt of diamine was used directly in the following HATU promoted amide 
coupling without further purification. To a solution of 2-tosyl-1,2,3,4-tetrahydroisoquinoline-6-
carboxylic acid (0.100 g, 0.302 mmol, 1.0 equiv) in anhydrous DMF (6 mL) were added DIPEA 
(0.155 g, 1.207 mmol, 4.0 equiv) and  HATU (0.114 g, 0.302 mmol, 1.0 equiv) at room temperature. 
The mixture was stirred for 5 min, followed by addition of crude TFA salt of diamine (0.302 mmol, 
1.0 equiv). The reaction was stirred for 12 h at room temperature, then concentrated under N2 
185 
 
stream. The crude sample was purified with reverse-phase flash column chromatography (0-100% 
CH3CN/H2O) to afford the title compound as a colorless film (0.133 g, 0.242 mmol, 80% yield, ≥ 
99% yield). IR (neat) 3327, 2966, 1646, 1599 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.77–7.69 (m, 
2H), 7.39–7.31 (m, 3H), 7.28 (dd, J = 8.0, 1.8 Hz, 1H), 7.18–7.12 (m, 1H), 7.07–7.02 (m, 1H), 
6.96–6.89 (m, 2H), 6.71–6.65 (m, 1H), 6.26 (t, J = 4.9 Hz, 1H), 4.27 (s, 2H), 3.70 (s, 3H), 3.67 (s, 
2H), 3.36 (t, J = 5.9 Hz, 2H), 3.26–3.17 (m, 2H), 2.96 (t, J = 5.8 Hz, 2H), 2.85–2.79 (m, 2H), 2.42 
(s, 3H), 1.15 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 166.7, 159.9, 144.9, 144.0, 134.9, 133.5, 
133.5, 133.2, 129.9, 129.6, 127.9, 127.8, 126.5, 124.6, 120.1, 113.7, 111.8, 55.6, 55.3, 55.2, 50.4, 





          N-(2-(tert-Butyl(4-methoxybenzyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl(4-
methoxybenzyl)amino)ethyl)carbamate (0.101 g, 0.302 mmol, 1.0 equiv) in DCM (3 mL) was 
added TFA (3 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.100 g, 0.302 mmol, 1.0 equiv) in 
anhydrous DMF (6 mL) were added DIPEA (0.155 g, 1.207 mmol, 4.0 equiv) and  HATU (0.114 
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g, 0.302 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by 
addition of crude TFA salt of diamine (0.302 mmol, 1.0 equiv). The reaction was stirred for 12 h 
at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
as a colorless oil (0.131 g, 0.238 mmol, 79% yield, 97.2% purity). IR (neat) 3319, 2965, 1646, 
1579, 1510 cm-1; 1H NMR (500 MHz, CD3Cl) δ 7.79–7.67 (m, 2H), 7.36–7.31 (m, 3H), 7.25–7.19 
(m, 3H), 7.03 (d, J = 8.1 Hz, 1H), 6.77–6.72 (m, 2H), 6.17 (t, J = 5.5 Hz, 1H), 4.26 (s, 2H), 3.70 
(s, 3H), 3.61 (s, 2H), 3.36 (t, J = 5.9 Hz, 2H), 3.20–3.12 (m, 2H), 2.95 (t, J = 5.8 Hz, 2H), 2.83–
2.77 (m, 2H), 2.42 (s, 3H), 1.15 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 166.8, 158.5, 144.0, 134.9, 
134.6, 133.5, 133.2, 132.2, 129.9, 129.2, 127.9, 127.8, 126.5, 124.5, 114.0, 55.6, 55.3, 54.7, 49.9, 





          N-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)-2-((3-methoxyphenyl)sulfonyl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of 2-((3-methoxyphenyl)sulfonyl)-
1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.080 g, 0.230 mmol, 1.0 equiv) in anhydrous 
DMF (4.6 mL) were added DIPEA (0.089 g, 0.689 mmol, 3.0 equiv) and  HATU (0.087 g, 0.229 
mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by addition of 
N1-(tert-butyl)-N1-(4-chlorobenzyl)ethane-1,2-diamine (0.055 g, 0.230 mmol, 1.0 equiv). The 
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reaction was stirred for 12 h at room temperature, then concentrated under N2 stream. The crude 
sample was purified with reverse-phase flash column chromatography (0-100% CH3CN/H2O) to 
afford the title compound as a colorless oil (0.078 g, 0.137 mmol, 59% yield, 91.5% purity). IR 
(neat) 3317, 2970, 1645, 1597 cm-1;  1H NMR (400 MHz, CDCl3) δ 7.38–7.28 (m, 2H), 7.28–7.21 
(m, 2H), 7.20–7.12 (m, 3H), 7.10–6.92 (m, 4H), 6.21–6.05 (m, 1H), 4.20 (s, 2H), 3.74 (s, 3H), 
3.55 (s, 2H), 3.29 (t, J = 5.9 Hz, 2H), 3.09 (q, J = 5.8 Hz, 2H), 2.84 (t, J = 5.8 Hz, 2H), 2.69 (t, J 
= 6.1 Hz, 2H), 1.04 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 166.8, 160.1, 141.5, 137.6, 134.9, 
133.5, 133.4, 132.2, 130.3, 129.2, 128.5, 127.7, 126.5, 124.4, 119.8, 119.0, 112.7, 55.7, 55.6, 54.6, 





          N-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)-2-((4-methoxyphenyl)sulfonyl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of 2-((4-methoxyphenyl)sulfonyl)-
1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.080 g, 0.230 mmol, 1.0 equiv) in anhydrous 
DMF (4.6 mL) were added DIPEA (0.089 g, 0.689 mmol, 3.0 equiv) and  HATU (0.087 g, 0.229 
mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by addition of 
N1-(tert-butyl)-N1-(4-chlorobenzyl)ethane-1,2-diamine (0.055 g, 0.230 mmol, 1.0 equiv). The 
reaction was stirred for 12 h at room temperature, then concentrated under N2 stream. The crude 
sample was purified with reverse-phase flash column chromatography (0-100% CH3CN/H2O) to 
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afford the title compound as a colorless oil (0.061 g, 0.107 mmol, 46% yield, 92.9% purity). IR 
(neat) 3326, 2970, 1644, 1596 cm-1;  1H NMR (600 MHz, CD2Cl2) δ 7.80–7.73 (m, 2H), 7.35 (s, 
1H), 7.32–7.27 (m, 3H), 7.20–7.16 (m, 2H), 7.10 (d, J = 8.0 Hz, 1H), 7.06–6.99 (m, 2H), 6.13 (t, 
J = 5.4 Hz, 1H), 4.26 (s, 2H), 3.86 (s, 3H), 3.68 (s, 2H), 3.35 (t, J = 5.9 Hz, 2H), 3.16 (q, J = 5.9 
Hz, 2H), 2.96 (t, J = 5.8 Hz, 2H), 2.80 (t, J = 6.2 Hz, 2H), 1.15 (s, 9H); 13C NMR (151 MHz, 
CD2Cl2) δ 166.3, 163.2, 141.8, 135.1, 133.6, 133.4, 131.9, 129.8, 129.2, 128.3, 127.8, 127.4, 126.5, 
124.2, 114.3, 55.7, 55.4, 54.5, 50.2, 47.6, 43.7, 40.0, 28.8, 27.1; HRMS (ESI) m/z calcd for 
C30H37ClN3O4S [M+H]
+ 570.2188, found 570.2170. 
 
 
          N-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)-2-((3-hydroxyphenyl)sulfonyl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of compound N-(2-(tert-butyl(4-
chlorobenzyl)amino)ethyl)-2-((3-methoxyphenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinoline-6-
carboxamide (0.025 g, 0.044 mmol, 1.0 equiv) in DCM (6 mL) was added dropwise BBr3 (1 N in 
DCM, 0.68 ml, 0.680 mmol, 17.0 equiv) at -40 °C. The reaction was warmed to 0 °C and stirred 
for 2 h, then quenched with methanol at -20 °C. The organic phase was washed with water, brine, 
dried over Na2SO4 and concentrated in vacuo. Reverse-phase flash column chromatography (0-
100% CH3CN/H2O) afforded the title compound as a colorless film (4 mg, 0.008 mmol, 18% yield, 
HPLC purity = 93.3%). IR (neat) 2970, 1636, 1575, 1542, 1489 cm-1; 1H NMR (600 MHz, CD2Cl2) 
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δ 7.42–7.21 (m, 7H), 7.19–7.13 (m, 2H), 7.09–6.97 (m, 2H), 6.34 (br s, 1H), 4.18 (s, 2H), 3.67 (s, 
2H), 3.26–3.13 (m, 4H), 2.89–2.75 (m, 4H), 1.16 (s, 9H); 13C NMR (151 MHz, CD2Cl2) δ 167.7, 
157.7, 142.2, 137.5, 135.9, 134.3, 133.5, 132.6, 130.9, 129.9, 128.9, 128.1, 127.2, 124.8, 121.0, 
119.8, 114.9, 56.1, 55.1, 50.5, 48.1, 44.2, 40.8, 29.4, 27.6; HRMS (ESI) m/z calcd for 
C29H35ClN3O4S [M+H]
+ 556.2031, found 556.2024. 
 
 
          N-(2-(tert-Butyl(4-chlorobenzyl)amino)ethyl)-2-((4-hydroxyphenyl)sulfonyl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of compound N-(2-(tert-butyl(4-
chlorobenzyl)amino)ethyl)-2-((4-methoxyphenyl)sulfonyl)-1,2,3,4-tetrahydroisoquinoline-6-
carboxamide (0.025 g, 0.044 mmol, 1.0 equiv) in anhydrous DCM (6 mL) was added dropwise 
BBr3 (1 N in DCM, 0.68 mL, 0.680 mmol, 15.0 equiv) at -40 °C. The reaction was warmed to 0 °C 
and stirred for 2 h, then quenched with methanol at -20 °C. The organic phase was washed with 
water, brine, dried over Na2SO4 and concentrated in vacuo. Reverse-phase flash column 
chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil (10 mg, 
0.018mmol, 41% yield, 97.7% purity). IR (neat) 2947, 1637, 1580 cm-1; 1H NMR (500 MHz, 
DMSO-d6) δ 10.54 (br s, 2H), 8.20 (t, J = 5.7 Hz, 1H), 7.68–7.61 (m, 2H), 7.56–7.48 (m, 2H), 
7.43–7.38 (m, 2H), 7.36–7.28 (m, 2H), 7.19 (d, J = 6.4 Hz, 1H), 6.98 – 6.89 (m, 2H), 4.14 (s, 2H), 
3.68 (s, 2H), 3.23 (t, J = 6.0 Hz, 2H), 3.07–3.00 (m, 2H), 2.86 (m, 2H), 2.66–2.60 (m, 2H), 1.09 
(s, 9H); 13C NMR (126 MHz, DMSO-d6) δ 165.6, 161.7, 142.2, 134.8, 133.0, 132.8, 130.6, 129.9, 
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129.4, 127.9, 127.5, 126.4, 124.8, 115.8, 54.8, 53.4, 49.9, 47.3, 43.5, 40.4, 28.1, 27.1; HRMS (ESI) 
m/z calcd for C29H35ClN3O4S [M+H]
+ 556.2031, found 556.2009. 
 
 
          2-Methyl-N-(4-(methylthio)benzyl)propan-2-amine. Prepared according to the general 
procedure for reductive amination using 4-(methylthio)benzaldehyde (0.761 g, 5.00 mmol, 1.0 
equiv), tert-butylamine (0.366 g, 5.00 mmol, 1.0 equiv), NaBH(OAc)3 (1.483 g, 7.00 mmol, 1.4 
equiv), AcOH (1 drop) and DCE (10 mL), at room temperature for 12 h. Reverse-phase flash 
column chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil 
(0.630 g, 3.01 mmol, 60% yield). IR (neat) 2961, 1492 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.30–
7.18 (m, 4H), 3.68 (s, 2H), 2.46 (s, 3H), 1.17 (s, 9H);  13C NMR (101 MHz, CDCl3) δ 138.8, 136.5, 
128.9, 127.2, 50.8, 46.9, 29.3, 16.4; HRMS (ESI) m/z calcd for C13H22N [M+H]




          tert-Butyl (2-(tert-butyl(4-(methylthio)benzyl)amino)ethyl)carbamate. Prepared 
according to the general procedure for reductive amination using N-Boc-2-aminoacetaldehyde 
(0.159 g, 1.00 mmol, 1.0 equiv), 2-methyl-N-(4-(methylthio)benzyl)propan-2-amine (0.209 g, 1.00 
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mmol, 1.0 equiv), NaBH(OAc)3 (0.297 g, 1.40 mmol, 1.4 equiv), AcOH (1 drop) and DCE (2 mL), 
at room temperature for 24 h. Reverse-phase flash column chromatography (0-100% CH3CN/H2O) 
afforded the title compound as a colorless oil (0.238 g, 0.68 mmol, 68% yield).  IR (neat) 2971, 
1709, 1492 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.29–7.23 (m, 4H), 7.22–7.17 (m, 2H), 4.56 (s, 
1H), 3.62 (s, 2H), 2.89–2.80 (m, 2H), 2.65 (t, J = 6.3 Hz, 2H), 2.46 (s, 3H), 2.17 (s, 2H), 1.39 (s, 
9H), 1.12 (s, 9H);  13C NMR (101 MHz, CDCl3) δ 156.1, 140.3, 136.2, 128.5, 127.1, 78.9, 55.4, 





          N-(2-(tert-Butyl(4-(methylthio)benzyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl(4-
(methylthio)benzyl)amino)ethyl)carbamate (0.025 g, 0.071 mmol, 1.0 equiv) in DCM (1 mL) was 
added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.023 g, 0.069 mmol, 1.0 equiv) in 
anhydrous DMF (1.4 mL) were added DIPEA (0.036 g, 0.28 mmol, 4.0 equiv) and  HATU (0.027 
g, 0.071 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by 
addition of crude TFA salt of diamine (0.071 mmol, 1.0 equiv). The reaction was stirred for 12 h 
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at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
as white solid (0.025 g, 0.044 mmol, 63% yield, ≥ 99% purity). Mp = 59–62 ºC; IR (neat) 2992, 
1626, 1542, 1497 cm-1; 1H NMR (500 MHz, CD2Cl2) δ 7.92 (t, J = 5.7 Hz, 1H), 7.78–7.71 (m, 
2H), 7.53–7.44 (m, 2H), 7.43–7.33 (m, 4H), 7.15 (d, J = 8.1 Hz, 1H), 7.08–7.01 (m, 2H), 4.62–
4.50 (m, 1H), 4.26 (s, 2H), 3.83 (dd, J = 12.9, 8.8 Hz, 1H), 3.74–3.65 (m, 1H), 3.58–3.48 (m, 1H), 
3.45–3.31 (m, 3H), 3.16–3.06 (m, 1H), 3.00 (t, J = 6.1 Hz, 2H), 2.45 (s, 3H), 2.28 (s, 3H), 1.59 (s, 
9H); 13C NMR (126 MHz, CD2Cl2) δ 172.0, 144.7, 142.5, 137.2, 134.3, 133.3, 131.9, 130.3, 128.6, 
128.2, 127.2, 126.6, 125.8, 125.1, 66.1, 56.4, 48.2, 44.1, 40.3, 29.3, 25.5, 21.8, 15.0; HRMS (ESI) 
m/z calcd for C31H40N3O3S2 [M+H]
+ 566.2506, found 566.2519. 
 
 
          4-((tert-Butylamino)methyl)-N,N-dimethylaniline. Prepared according to the general 
procedure for reductive amination using 4-(dimethylamino)benzaldehyde (0.746 g, 5.00 mmol, 1.0 
equiv), tert-butylamine (0.366 g, 5.00 mmol, 1.0 equiv), NaBH(OAc)3 (1.483 g, 7.00 mmol, 1.4 
equiv), AcOH (1 drop) and DCE (10 mL), at room temperature for 12 h. Reverse-phase flash 
column chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil 
(0.803 g, 3.89 mmol, 78% yield). IR (neat) 2957, 1613, 1518, 1479 cm-1; 1H NMR (400 MHz, 
CD3OD) δ 7.22–7.14 (m, 2H), 6.79–6.70 (m, 2H), 3.58 (s, 2H), 2.88 (s, 6H), 1.18 (s, 9H); 
13C 
NMR (101 MHz, CD3OD) δ 151.5, 130.5, 129.4, 114.3, 51.9, 47.3, 41.2, 28.7; HRMS (ESI) m/z 
calcd for C13H21N2O [M+H]





          tert-Butyl (2-(tert-butyl(4-(dimethylamino)benzyl)amino)ethyl)carbamate. Prepared 
according to the general procedure for reductive amination using N-Boc-2-aminoacetaldehyde 
(0.159 g, 1.00 mmol, 1.0 equiv), 4-((tert-butylamino)methyl)-N,N-dimethylaniline (0.206 g, 1.00 
mmol, 1.0 equiv), NaBH(OAc)3 (0.297 g, 1.40 mmol, 1.4 equiv), AcOH (1 drop) and DCE (2 mL), 
at room temperature for 24 h. Reverse-phase column chromatography (0-100% CH3CN/H2O) 
afforded the title compound as a colorless oil (0.200 g, 0.57 mmol, 57% yield). IR (neat) 2964, 
1710, 1614, 1518 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.23–7.14 (m, 2H), 6.78–6.69 (m, 2H), 
3.60 (s, 2H), 2.88 (s, 6H), 2.79–2.71 (m, 2H), 2.67–2.59 (m, 2H), 1.38 (s, 9H), 1.15 (s, 9H);  13C 
NMR (101 MHz, CD3OD) δ 158.2, 151.2, 132.1, 130.1, 114.4, 79.7, 56.1, 55.3, 51.0, 42.2, 41.4, 
28.8, 27.7; HRMS (ESI) m/z calcd for C20H36N3O2 [M+H]
+ 350.2802; found 350.2806. 
 
 
          N-(2-(tert-Butyl(4-(dimethylamino)benzyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl(4-
(dimethylamino)benzyl)amino)ethyl)carbamate (0.035 g, 0.100 mmol, 1.0 equiv) in DCM (1 mL) 
was added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
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temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.100 mmol, 1.0 equiv) in 
anhydrous DMF (2 mL) were added DIPEA (0.052 g, 0.402 mmol, 4.0 equiv) and  HATU (0.038 
g, 0.100 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by 
addition of crude diamine (0.100 mmol, 1.0 equiv). The reaction was stirred for 12 h at room 
temperature, then concentrated under N2 stream. The crude sample was purified with reverse-phase 
flash column chromatography (0-100% CH3CN/H2O) to afford the title compound as a colorless 
film (0.030 g, 0.053 mmol, 53% yield, HPLC purity = 96.6%). IR (neat) 3357, 2967, 1645, 1521 
cm-1; 1H NMR (400 MHz, CD2Cl2) δ 7.67–7.58 (m, 2H), 7.31–7.24 (m, 3H), 7.20–7.13 (m, 1H), 
7.12–7.03 (m, 2H), 6.97 (d, J = 8.0 Hz, 1H), 6.54–6.45 (m, 2H), 4.16 (s, 2H), 3.49 (s, 2H), 3.25 (t, 
J = 5.9 Hz, 2H), 3.07–2.98 (m, 2H), 2.90–2.79 (m, 2H), 2.77–2.65 (m, 8H), 2.33 (s, 3H), 1.06 (s, 
9H); 13C NMR (101 MHz, CD2Cl2) δ 166.7, 150.3, 144.6, 135.4, 134.2, 134.0, 133.8, 130.8, 130.3, 
129.3, 128.2, 128.1, 126.9, 125.0, 113.1, 55.8, 55.0, 50.2, 48.2, 44.3, 41.0, 40.5, 29.5, 27.7, 21.8; 
HRMS (ESI) m/z calcd for C32H43N4O3S [M+H]
+ 563.3050, found 563.3027. 
 
 
          N-(4-(Methoxymethyl)benzyl)-2-methylpropan-2-amine. Prepared according to the 
general procedure for reductive amination using 4-(methoxymethyl)benzaldehyde (0.150 g, 1.0 
mmol, 1.0 equiv), tert-butylamine (0.073 g, 1.00 mmol, 1.0 equiv), NaBH(OAc)3 (0.297 g, 1.40 
mmol, 1.4 equiv), AcOH (1 drop) and DCE (2 mL), at room temperature for 12 h. Reverse-phase 
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flash column chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless 
oil (0.150 g, 0.72 mmol, 72% yield). IR (neat) 2963, 1474, 1385 cm-1; 1H NMR (400 MHz, CD3OD) 
δ 7.45–7.32 (m, 4H), 4.46 (s, 2H), 3.88 (s, 2H), 3.37 (s, 3H), 1.30 (s, 9H); 13C NMR (101 MHz, 
CD3OD) δ 139.1, 137.7, 130.2, 129.3, 75.2, 58.3, 54.5, 47.1, 27.6; HRMS (ESI) m/z calcd for 
C13H22NO [M+H]
+ 208.1696; found 208.1694. 
 
 
          tert-Butyl (2-(tert-butyl(4-(methoxymethyl)benzyl)amino)ethyl)carbamate. Prepared 
according to the general procedure for reductive amination using N-Boc-2-aminoacetaldehyde 
(0.054 g, 0.34 mmol, 1.0 equiv), N-(4-(methoxymethyl)benzyl)-2-methylpropan-2-amine (0.070 
g, 0.34 mmol, 1.0 equiv), NaBH(OAc)3 (0.100 g, 0.47 mmol, 1.4 equiv), AcOH (1 drop) and DCE 
(0.68 mL), at room temperature for 24 h. Reverse-phase column chromatography (0-100% 
CH3CN/H2O) afforded the title compound as a colorless oil (0.060 g, 0.17 mmol, 50% yield). IR 
2972, 1710, 1500 (neat) cm-1; 1H NMR (400 MHz, CD3OD) δ 7.36 (d, J = 8.1 Hz, 2H), 7.25 (d, J 
= 8.1 Hz, 2H), 4.42 (s, 2H), 3.71 (s, 2H), 3.35 (s, 3H), 2.85–2.72 (m, 2H), 2.70–2.60 (m, 2H), 1.39 
(s, 9H), 1.14 (s, 9H);  13C NMR (101 MHz, CD3OD) δ 158.2, 143.6, 137.2, 129.2, 129.0, 80.0, 







          N-(2-(tert-Butyl(4-(methoxymethyl)benzyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl(4-
(methoxymethyl)benzyl)amino)ethyl)carbamate (0.035 g, 0.100 mmol, 1.0 equiv) in DCM (1 mL) 
was added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.100 mmol, 1.0 equiv) in 
anhydrous DMF (2 mL) were added DIPEA (0.052 g, 0.402 mmol, 4.0 equiv) and  HATU (0.038 
g, 0.100 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by 
addition of crude TFA salt of diamine (0.100 mmol, 1.0 equiv). The reaction was stirred for 12 h 
at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
as white solid (0.030 g, 0.053 mmol, 53% yield, ≥ 99% purity). Mp = 83–85 ºC; IR (neat) 3341, 
2970, 1645, 1538 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.76–7.68 (m, 2H), 7.44 (dd, J = 8.0, 1.8 
Hz, 3H), 7.42–7.33 (m, 5H), 7.22–7.16 (m, 2H), 7.12 (d, J = 8.1 Hz, 1H), 4.33 (s, 2H), 4.23 (s, 
2H), 3.73 (s, 2H), 3.37–3.28 (m, 2H), 3.18 – 3.09 (m, 2H), 2.89 (t, J = 5.9 Hz, 1H), 2.83–2.74 (m, 
2H), 2.41 (s, 3H), 1.17 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 169.4, 145.4, 143.7, 137.5, 136.7, 
134.8, 134.7, 134.2, 130.9, 129.2, 128.9, 128.9, 128.7, 127.6, 126.0, 75.5, 58.2, 56.3, 55.8, 51.0, 
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          (4-((tert-Butylamino)methyl)phenyl)methanol. Prepared according to the general 
procedure for reductive amination using 4-(hydroxymethyl)benzaldehyde (0.681 g, 5.00 mmol, 
1.0 equiv), tert-butylamine (0.366 g, 5.00 mmol, 1.0 equiv), NaBH(OAc)3 (1.483 g, 7.00 mmol, 
1.4 equiv), AcOH (1 drop) and DCE (10 mL) at room temperature for 12 h. Reverse-phase flash 
column chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil 
(0.700 g, 3.62 mmol, 72% yield). IR (neat) 3260, 2965, 1487, 1390 cm-1; 1H NMR (400 MHz, 
CD3OD) δ 7.37–7.28 (m, 5H), 4.58 (s, 2H), 3.70 (s, 2H), 1.20 (s, 9H); 
 13C NMR (101 MHz, 
CD3OD) δ 141.6, 140.3, 129.7, 128.1, 65.0, 52.1, 47.6, 28.7; HRMS (ESI) m/z calcd for C12H20NO 
[M+H]+ 194.1539; found 194.1538. 
 
 
          tert-Butyl (2-(tert-butyl(4-(hydroxymethyl)benzyl)amino)ethyl)carbamate. Prepared 
according to the general procedure for reductive amination using N-Boc-2-aminoacetaldehyde 
(0.159 g, 1.00 mmol, 1.0 equiv), N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-
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methylpropan-2-amine (0.193 g, 1.00 mmol, 1.0 equiv), NaBH(OAc)3 (0.297 g, 1.40 mmol, 1.4 
equiv), AcOH (1 drop) and DCE (2 mL), at room temperature for 24 h. Reverse-phase flash column 
chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil (0.169 g, 
0.50 mmol, 50% yield). IR (neat) 2972, 1687, 1509 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.35 (d, 
J = 8.1 Hz, 2H), 7.28 (d, J = 8.1 Hz, 2H), 4.57 (s, 2H), 3.71 (s, 2H), 2.86–2.72 (m, 2H), 2.72–2.60 
(m, 2H), 1.39 (s, 9H), 1.14 (s, 9H);  13C NMR (101 MHz, CD3OD) δ 158.2, 143.3, 140.8, 129.1, 
128.0, 79.8, 65.1, 56.1, 55.7, 51.5, 42.2, 28.8, 27.7; HRMS (ESI) m/z calcd for C19H33N2O3 
[M+H]+ 337.2486; found 337.2484. 
 
 
          N-(2-(tert-Butyl(4-(hydroxymethyl)benzyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl(4-
(hydroxymethyl)benzyl)amino)ethyl)carbamate (0.034 g, 0.100 mmol, 1.0 equiv) in DCM (1 mL) 
was added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.100 mmol, 1.0 equiv) in 
anhydrous DMF (2 mL) were added DIPEA (0.052 g, 0.402 mmol, 4.0 equiv) and  HATU (0.038 
g, 0.100 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by 
addition of crude TFA salt of diamine (0.100 mmol, 1.0 equiv). The reaction was stirred for 12 h 
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at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
as a colorless film (0.035 g, 0.064 mmol, 64% yield, ≥ 99% purity). IR (neat) 3371, 2968, 1640, 
1538, 1495 cm-1; 1H NMR (500 MHz, CD3OD) δ 7.77–7.70 (m, 2H), 7.46 (dd, J = 8.0, 1.8 Hz, 
1H), 7.44–7.35 (m, 5H), 7.26–7.20 (m, 2H), 7.16 (d, J = 8.1 Hz, 1H), 4.51 (s, 2H), 4.26 (s, 2H), 
3.75 (s, 2H), 3.36 (t, J = 6.0 Hz, 2H), 3.16 – 3.09 (m, 2H), 2.92 (t, J = 5.9 Hz, 2H), 2.82–2.76 (m, 
2H), 2.42 (s, 3H), 1.17 (s, 9H); 13C NMR (126 MHz, CD3OD) δ 169.5, 145.5, 140.9, 136.8, 134.8, 
134.2, 130.9, 129.3, 128.9, 128.7, 128.0, 127.7, 126.0, 65.1, 56.3, 55.7, 50.9, 48.8, 45.0, 42.1, 29.7, 
27.7, 21.5; HRMS (ESI) m/z calcd for C31H40N3O4S [M+H]
+ 550.2734, found 550.2748. 
 
 
          N-(Benzo[d][1,3]dioxol-5-ylmethyl)-2-methylpropan-2-amine. Prepared according to the 
general procedure for reductive amination using benzo[d][1,3]dioxole-5-carbaldehyde (0.750 g, 
5.00 mmol, 1.0 equiv), tert-butylamine (0.366 g, 5.00 mmol, 1.0 equiv), NaBH(OAc)3 (1.483 g, 
7.00 mmol, 1.4 equiv), AcOH (1 drop) and DCE (10 mL), at room temperature for 12 h. Reverse-
phase flash column chromatography (0-100% CH3CN/H2O) afforded the title compound as a 
colorless oil (0.850 g, 4.10 mmol, 82% yield).  IR (neat) 2962, 1488, 1440 cm-1; 1H NMR (400 
MHz, CDCl3) δ 6.87–6.83 (m, 1H), 6.80–6.71 (m, 2H), 5.91 (s, 2H), 3.63 (s, 2H), 1.16 (s, 9H); 
 
13C NMR (101 MHz, CDCl3) δ 147.7, 146.4, 135.7, 121.2, 109.0, 108.2, 100.9, 50.7, 47.2, 29.3; 
HRMS (ESI) m/z calcd for C13H22N [M+H]





          tert-Butyl (2-((benzo[d][1,3]dioxol-5-ylmethyl)(tert-butyl)amino)ethyl)carbamate. 
Prepared according to the general procedure for reductive amination using N-Boc-2-
aminoacetaldehyde (0.159 g, 1.00 mmol, 1.0 equiv), 2-methyl-N-(4-(methylthio)benzyl)propan-2-
amine (0.207 g, 1.00 mmol, 1.0 equiv), NaBH(OAc)3 (0.297 g, 1.40 mmol, 1.4 equiv), AcOH (1 
drop) and DCE (2 mL), at room temperature for 24 h. Reverse-phase flash column chromatography 
(0-100% CH3CN/H2O) afforded the title compound as a colorless oil (0.240 g, 0.68 mmol, 68% 
yield), at room temperature for 24 h. IR (neat) 2972, 1701, 1487, 1440 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 6.88–6.83 (m, 1H), 6.79–6.67 (m, 2H), 5.92 (s, 2H), 4.56 (br s, 1H), 3.57 (s, 2H), 2.90–
2.80 (m, 2H), 2.65 (t, J = 6.1 Hz, 2H), 1.39 (s, 9H), 1.11 (s, 9H);  13C NMR (101 MHz, CDCl3) δ 
156.1, 147.8, 146.3, 137.1, 120.7, 108.5, 108.1, 100.9, 78.8, 55.3, 55.1, 50.6, 41.0, 28.5, 27.5; 
HRMS (ESI) m/z calcd for C19H31N2O4 [M+H]
+ 351.2278; found 351.2284. 
 
 
          N-(2-((Benzo[d][1,3]dioxol-5-ylmethyl)(tert-butyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-((benzo[d][1,3]dioxol-5-
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ylmethyl)(tert-butyl)amino)ethyl)carbamate (0.025 g, 0.071 mmol, 1.0 equiv) in DCM (1 mL) was 
added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.023 g, 0.069 mmol, 1.0 equiv) in 
anhydrous DMF (1.4 mL) were added DIPEA (0.036 g, 0.279 mmol, 4.0 equiv) and  HATU (0.027 
g, 0.071 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by 
addition of crude TFA salt of diamine (0.071 mmol, 1.0 equiv). The reaction was stirred for 12 h 
at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
as a colorless film (0.020 g, 0.035 mmol, 51% yield, 98.8% purity). IR (neat) 2988, 1627, 1540, 
1495 cm-1; 1H NMR (500 MHz, CD2Cl2) 7.89 (t, J = 5.7 Hz, 1H), 7.77–7.71 (m, 2H), 7.56–7.50 
(m, 2H), 7.44–7.37 (m, 2H), 7.19–7.13 (m, 1H), 6.96 (dd, J = 7.9, 1.9 Hz, 1H), 6.89 (d, J = 1.8 Hz, 
1H), 6.72 (d, J = 7.9 Hz, 1H), 5.86 (d, J = 1.4 Hz, 1H), 5.66 (d, J = 1.4 Hz, 1H), 4.56–4.49 (m, 
1H), 4.27 (s, 2H), 3.78 (dd, J = 13.0, 8.9 Hz, 1H), 3.74–3.65 (m, 1H), 3.56 (dddd, J = 15.7, 7.9, 
5.7, 2.0 Hz, 1H), 3.46–3.30 (m, 3H), 3.17 (dtd, J = 14.9, 6.5, 2.0 Hz, 1H), 3.00 (t, J = 6.0 Hz, 2H), 
2.62 (s, 20H), 2.46 (s, 3H), 1.58 (s, 9H); 13C NMR (126 MHz, CD2Cl2) δ 172.1, 149.7, 148.9, 
144.7, 137.3, 134.4, 133.3, 130.4, 130.3, 128.9, 128.2, 127.2, 126.0, 125.7, 122.4, 111.2, 109.4, 
102.4, 66.0, 56.8, 53.7, 48.2, 44.2, 40.4, 29.3, 25.5, 21.8; HRMS (ESI) m/z calcd for C31H38N3O5S 





          N-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-methylpropan-2-amine. Prepared 
according to the general procedure for reductive amination using 2,3-
dihydrobenzo[b][1,4]dioxine-6-carbaldehyde (0.821 g, 5.00 mmol, 1.0 equiv), tert-butylamine 
(0.366 g, 5.00 mmol, 1.0 equiv), NaBH(OAc)3 (1.483 g, 7.00 mmol, 1.4 equiv), AcOH (1 drop) 
and DCE (10 mL), at room temperature for 12 h. Reverse-phase flash column chromatography (0-
100% CH3CN/H2O) afforded the title compound as a colorless oil (0.970 g, 4.38 mmol, 88% yield).  
IR (neat) 2963, 1591, 1506, 1431 cm-1; 1H NMR (400 MHz, CD3OD) δ 6.87 (dd, J = 1.8, 0.7 Hz, 
2H), 6.84–6.76 (m, 4H), 4.23 (s, 4H), 3.62 (s, 2H), 1.21 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 
144.9, 144.2, 134.0, 122.6, 118.5, 118.1, 65.6, 65.6, 52.3, 47.3, 28.5; HRMS (ESI) m/z calcd for 
C13H20NO2 [M+H]
+ 222.1489; found 222.1485. 
 
 
          tert-Butyl (2-(tert-butyl((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)amino)ethyl) 
carbamate. Prepared according to the general procedure for reductive amination using N-Boc-2-
aminoacetaldehyde (0.159 g, 1.00 mmol, 1.0 equiv), N-((2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)methyl)-2-methylpropan-2-amine (0.221 g, 1.00 mmol, 1.0 equiv), NaBH(OAc)3 (0.297 g, 1.40 
mmol, 1.4 equiv), AcOH (1 drop) and DCE (2 mL) at room temperature for 24 h. Reverse-phase 
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flash column chromatography (0-100% CH3CN/H2O) afforded the title compound as colorless oil 
(0.217 g, 0.60 mmol, 60% yield). IR (neat) 2972, 1701, 1590 cm-1; 1H NMR (400 MHz, CD3OD) 
δ 6.86–6.69 (m, 3H), 4.24–4.15 (m, 4H), 3.58 (s, 2H), 2.84–2.73 (m, 2H), 2.68–2.59 (m, 2H), 1.39 
(s, 9H), 1.13 (s, 9H);  13C NMR (101 MHz, CD3OD) δ 158.2, 144.7, 143.6, 137.2, 121.8, 117.8, 
117.8, 79.8, 65.6, 65.5, 56.1, 55.3, 51.4, 42.2, 28.8, 27.7; HRMS (ESI) m/z calcd for C20H33N2O4 
[M+H]+ 365.2435; found 365.2428. 
 
 
          N-(2-(tert-Butyl((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)amino)ethyl)-2-tosyl-
1,2,3,4-tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl((2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)methyl)amino)ethyl)carbamate (0.036 g, 0.100 mmol, 1.0 equiv). 
in DCM (1 mL) was added TFA (1 mL) at room temperature. The resulting mixture was stirred 
for 3 h at this temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine 
was used directly in the following HATU promoted amide coupling without further purification. 
To a solution of 2-tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.100 mmol, 
1.0 equiv) in anhydrous DMF (2 mL) were added DIPEA (0.052 g, 0.402 mmol, 4.0 equiv) and  
HATU (0.038 g, 0.100 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, 
followed by addition of crude diamine (0.100 mmol, 1.0 equiv). The reaction was stirred for 12 h 
at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
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as colorless film (0.027 g, 0.047 mmol, 47% yield, ≥ 99% purity). IR (neat) 2970, 1646, 1504 cm-
1; 1H NMR (400 MHz, CD3OD) δ 7.76–7.68 (m, 2H), 7.44 (dd, J = 8.0, 1.8 Hz, 1H), 7.42–7.36 
(m, 4H), 7.13 (d, J = 8.1 Hz, 1H), 6.84 (d, J = 1.9 Hz, 2H), 6.79 (dd, J = 8.2, 2.0 Hz, 1H), 6.66 (d, 
J = 8.2 Hz, 1H), 4.24 (s, 2H), 4.13–4.05 (m, 4H), 3.59 (s, 2H), 3.35–3.32 (m, 2H), 3.19–3.10 (m, 
2H), 2.91 (t, J = 5.9 Hz, 2H), 2.81–2.73 (m, 2H), 2.41 (s, 3H), 1.15 (s, 9H); 13C NMR (101 MHz, 
CD3OD) δ 169.4, 145.5, 144.7, 143.6, 137.1, 136.8, 134.9, 134.8, 134.2, 130.9, 128.9, 128.7, 127.7, 
126.1, 121.9, 117.9, 117.9, 65.5, 65.5, 56.3, 55.4, 50.8, 48.8, 45.0, 42.1, 29.7, 27.7, 21.5; HRMS 
(ESI) m/z calcd for C32H40N3O5S [M+H]
+ 578.2683, found 578.2678. 
 
 
          N-(4-((tert-Butylamino)methyl)phenyl)acetamide. Prepared according to the general 
procedure for reductive amination using N-(4-formylphenyl)acetamide (0.816 g, 5.00 mmol, 1.0 
equiv), tert-butylamine (0.366 g, 5.00 mmol, 1.0 equiv), NaBH(OAc)3 (1.483 g, 7.00 mmol, 1.4 
equiv), AcOH (1 drop) and DCE (10 mL), at room temperature for 12 h. Reverse-phase flash 
column chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil 
(0.943 g, 4.28 mmol, 86% yield). IR (neat) 3273, 1603, 1551, 1515 cm-1; 1H NMR (400 MHz, 
DMSO-d6) δ 7.53–7.44 (m, 2H), 7.27–7.19 (m, 2H), 3.57 (s, 2H), 2.02 (s, 3H), 1.07 (s, 9H); 
13C 
NMR (101 MHz, DMSO-d6) δ 167.9, 137.4, 136.7, 128.1, 118.6, 49.9, 45.8, 28.9, 23.9; HRMS 
(ESI) m/z calcd for C13H21N2O [M+H]





          tert-Butyl (2-((4-acetamidobenzyl)(tert-butyl)amino)ethyl)carbamate. Prepared 
according to the general procedure for reductive amination using N-Boc-2-aminoacetaldehyde 
(0.159 g, 1.00 mmol, 1.0 equiv), N-(4-((tert-butylamino)methyl)phenyl)acetamide (0.220 g, 1.00 
mmol, 1.0 equiv), NaBH(OAc)3 (0.297 g, 1.40 mmol, 1.4 equiv), AcOH (1 drop) and DCE (2 mL), 
at room temperature for 24 h. Reverse-phase column chromatography (0-100% CH3CN/H2O) 
afforded the title compound as a colorless oil (0.176 g, 0.48 mmol, 48% yield). IR (neat) 2972, 
1668, 1603, 1510 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.51–7.43 (m, 2H), 7.34–7.26 (m, 2H), 
3.66 (s, 2H), 2.83–2.74 (m, 2H), 2.68–2.60 (m, 2H), 2.10 (s, 3H), 1.38 (s, 9H), 1.13 (s, 9H);  13C 
NMR (101 MHz, CD3OD) δ 171.4, 158.2, 139.9, 138.3, 129.4, 121.0, 79.8, 56.1, 55.4, 51.4, 42.2, 
28.8, 27.7, 23.8; HRMS (ESI) m/z calcd for C20H34N3O3 [M+H]
+ 364.2595; found 364.2594. 
 
 
          N-(2-((4-Acetamidobenzyl)(tert-butyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-((4-
acetamidobenzyl)(tert-butyl)amino)ethyl)carbamate (0.036 g, 0.100 mmol, 1.0 equiv) in DCM (1 
mL) was added TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this 
temperature, then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly 
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in the following HATU promoted amide coupling without further purification. To a solution of 2-
tosyl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.100 mmol, 1.0 equiv) in 
anhydrous DMF (2 mL) were added DIPEA (0.052 g, 0.402 mmol, 4.0 equiv) and  HATU (0.038 
g, 0.100 mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by 
addition of crude TFA salt of diamine (0.100 mmol, 1.0 equiv). The reaction was stirred for 12 h 
at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
as a colorless film (0.037 g, 0.064 mmol, 64% yield, ≥ 99% purity). IR (neat) 3307, 2970, 1641 
cm-1; 1H NMR (400 MHz, CD3CN) δ 8.23 (s, 1H), 7.75–7.67 (m, 2H), 7.42–7.33 (m, 6H), 7.32–
7.24 (m, 2H), 7.14–7.06 (m, 1H), 6.67 (t, J = 5.6 Hz, 1H), 4.22 (s, 2H), 3.64 (s, 2H), 3.30 (t, J = 
5.9 Hz, 2H), 3.06 (dt, J = 7.0, 6.0 Hz, 2H), 2.89 (t, J = 6.0 Hz, 2H), 2.73 (t, J = 6.8 Hz, 2H), 2.39 
(s, 3H), 1.99 (s, 3H), 1.12 (s, 9H); 13C NMR (101 MHz, CD3CN) δ 169.3, 167.1, 145.2, 139.2, 
138.5, 136.0, 134.5, 134.4, 134.4, 130.8, 129.3, 128.7, 128.4, 127.5, 125.5, 120.1, 56.0, 55.2, 50.8, 





          N-(4-Ethylbenzyl)-2-methylpropan-2-amine. Prepared according to the general procedure 
for reductive amination using 4-ethylbenzaldehyde (0.671 g, 5.00 mmol, 1.0 equiv), tert-
butylamine (0.366 g, 5.00 mmol, 1.0 equiv), NaBH(OAc)3 (1.483 g, 7.00 mmol, 1.4 equiv), AcOH 
(1 drop) and DCE (10 mL), at room temperature for 12 h. Reverse-phase flash column 
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chromatography (0-100% CH3CN/H2O) afforded the title compound as a colorless oil (0.370 g, 
1.93 mmol, 39% yield). IR (neat) 2962, 1513 cm-1; 1H NMR (600 MHz, CD3CN) δ 7.23 (d, J = 
8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 3.66 (s, 2H), 2.60 (q, J = 7.6 Hz, 2H), 1.19 (t, J = 7.6 Hz, 
3H), 1.12 (s, 9H);  13C NMR (151 MHz, CD3CN) δ 143.4, 140.6, 129.1, 128.6, 51.1, 47.3, 29.3, 
29.1, 16.2; HRMS (ESI) m/z calcd for C13H22N [M+H]
+ 192.1747; found 192.1746. 
 
 
          tert-Butyl (2-(tert-butyl(4-ethylbenzyl)amino)ethyl)carbamate. Prepared according to 
the general procedure for reductive amination using N-Boc-2-aminoacetaldehyde (0.159 g, 1.00 
mmol, 1.0 equiv), N-(4-ethylbenzyl)-2-methylpropan-2-amine (0.191 g, 1.00 mmol, 1.0 equiv), 
NaBH(OAc)3 (0.297 g, 1.40 mmol, 1.4 equiv), AcOH (1 drop) and DCE (2 mL), at room 
temperature for 24 h. Reverse-phase column chromatography (0-100% CH3CN/H2O) afforded the 
title compound as a colorless oil (0.173 g, 0.52 mmol, 52% yield).  IR (neat) 2966, 1702 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.24 (d, J = 8.1 Hz, 2H), 7.12 (d, J = 8.1 Hz, 2H), 3.64 (s, 2H), 2.88–
2.78 (m, 2H), 2.69–2.56 (m, 4H), 1.39 (s, 9H), 1.23 (t, J = 7.6 Hz, 3H), 1.13 (s, 9H);  13C NMR 
(101 MHz, CDCl3) δ 156.1, 142.5, 140.2, 127.9, 127.9, 78.8, 55.3, 54.9, 50.6, 40.9, 28.6, 28.6, 
27.5, 15.7; HRMS (ESI) m/z calcd for C20H35N2O2 [M+H]





          N-(2-(tert-Butyl(4-ethylbenzyl)amino)ethyl)-2-tosyl-1,2,3,4-tetrahydroisoquinoline-6-
carboxamide. To a solution of tert-butyl (2-(tert-butyl(4-ethylbenzyl)amino)ethyl)carbamate 
(0.023 g, 0.069 mmol, 1.0 equiv) in DCM (1 mL) was added TFA (1 mL) at room temperature. 
The resulting mixture was stirred for 3 h at this temperature, then concentrated in vacuo. The 
obtained crude TFA salt of diamine was used directly in the following HATU promoted amide 
coupling without further purification. To a solution of 2-tosyl-1,2,3,4-tetrahydroisoquinoline-6-
carboxylic acid (0.023 g, 0.069 mmol, 1.0 equiv) in anhydrous DMF (1.4 mL) were added DIPEA 
(0.036 g, 0.279 mmol, 4.0 equiv) and  HATU (0.027 g, 0.071 mmol, 1.0 equiv) at room temperature. 
The mixture was stirred for 5 min, followed by addition of crude TFA salt of diamine (0.069 mmol, 
1.0 equiv). The reaction was stirred for 12 h at room temperature, then concentrated under N2 
stream. The crude sample was purified with reverse-phase flash column chromatography (0-100% 
CH3CN/H2O) to afford the title compound as a white solid (0.020 g, 0.037 mmol, 52% yield, HPLC 
purity = 96.7%). Mp = 133–135 ºC; IR (neat) 3339, 2966, 1644 cm-1; 1H NMR (400 MHz, CD3CN) 
δ 7.76–7.68 (m, 2H), 7.46–7.35 (m, 4H), 7.33–7.23 (m, 2H), 7.18–7.01 (m, 3H), 6.68–6.60 (m, 
1H), 4.24 (s, 2H), 3.69 (s, 2H), 3.33 (t, J = 6.0 Hz, 2H), 3.13 – 3.04 (m, 2H), 2.91 (t, J = 6.0 Hz, 
2H), 2.74 (t, J = 6.8 Hz, 2H), 2.53 (q, J = 7.8 Hz, 2H), 2.40 (s, 3H), 2.15 (s, 2H), 1.45 (s, 1H), 1.27 
(s, 1H); 13C NMR (101 MHz, CD3CN) δ 167.1, 145.2, 143.3, 141.5, 136.1, 134.6, 134.5, 134.4, 
130.8, 128.9, 128.7, 128.6, 128.4, 127.5, 125.5, 55.9, 55.3, 50.8, 48.5, 44.7, 41.1, 29.4, 29.0, 27.7, 
21.5, 16.1; HRMS (ESI) m/z calcd for C32H42N3O3S [M+H]





         tert-Butyl (2-(tert-butyl(pyridin-2-ylmethyl)amino)ethyl)carbamate. To a solution of 
tert-butylamine (0.219 g, 3.00 mmol, 1.0 equiv) and picolinaldehyde (0.321 g, 3.00 mmol, 1.0 
equiv) in DCE (6 mL) was added NaBH(OAc)3 (0.890 g, 4.20 mmol, 1.4 equiv) at room 
temperature. The reaction mixture was stirred at this temperature overnight, prior to the addition 
of N-Boc-2-aminoacetaldehyde (0.478 g, 3.00 mmol, 1.0 equiv), NaBH(OAc)3 (0.890 g, 4.20 
mmol, 1.4 equiv) and DCE (4 mL). The reaction was stirred for 24 h at room temperature, then 
quenched with aqueous NaOH solution (1 N, 12 mL), extracted with EtOAc (3 × 50 ml). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo.  Reverse-phase flash column chromatography (0-100% CH3CN/H2O) afforded the title 
product as a colorless oil (0.450 g, 1.46 mmol, 49% yield). IR (neat) 3348, 2972, 1701 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.53–8.43 (m, 1H), 7.61 (td, J = 7.7, 1.6 Hz, 1H), 7.45 (d, J = 7.6 Hz, 
1H), 7.13–7.04 (m, 1H), 5.26 (br s, 1H), 3.81 (s, 2H), 2.94 (t, J = 6.2 Hz, 2H), 2.73 (t, J = 6.2 Hz, 
2H), 1.40 (s, 9H), 1.08 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 163.4, 156.2, 149.0, 136.4, 122.2, 
121.6, 78.8, 57.1, 55.5, 51.0, 40.8, 28.6, 27.3; HRMS (ESI) m/z calcd for C17H30N3O2 [M+H]
+ 





          N-(2-(tert-Butyl(pyridin-2-ylmethyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl(pyridin-2-
ylmethyl)amino)ethyl)carbamate (0.031 g, 0.100 mmol. 1.0 equiv) in DCM (1 mL) was added 
TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this temperature, 
then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly in the 
following HATU promoted amide coupling without further purification. To a solution of 2-tosyl-
1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.100 mmol, 1.0 equiv) in anhydrous 
DMF (2 mL) were added DIPEA (0.052 g, 0.402 mmol, 4.0 equiv) and  HATU (0.038 g, 0.100 
mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by addition of 
crude TFA salt of diamine (0.100 mmol, 1.0 equiv). The reaction was stirred for 12 h at room 
temperature, then concentrated under N2 stream. The crude sample was purified with reverse-phase 
flash column chromatography (0-100% CH3CN/H2O) to afford the title compound as a colorless 
film (0.031 g, 0.060 mmol, 60% yield, 98.0% purity). IR (neat) 3292, 2970, 1646, 1538 cm-1; 1H 
NMR (400 MHz, CD2Cl2) δ 8.51–8.29 (m, 2H), 7.76–7.68 (m, 2H), 7.67–7.54 (m, 3H), 7.36 (d, J 
= 8.0 Hz, 2H), 7.28 (d, J = 7.7 Hz, 1H), 7.12 (d, J = 7.9 Hz, 1H), 7.11–7.05 (m, 1H), 4.27 (s, 2H), 
3.85 (s, 2H), 3.43 – 3.30 (m, 4H), 2.96 (t, J = 5.8 Hz, 2H), 2.85 (t, J = 5.7 Hz, 2H), 2.42 (s, 3H), 
1.05 (s, 9H); 13C NMR (101 MHz, CD2Cl2) δ 166.7, 163.9, 149.4, 144.6, 136.9, 135.2, 134.6, 
133.9, 133.7, 130.3, 128.4, 128.2, 126.9, 125.3, 122.6, 122.1, 56.0, 55.9, 50.2, 48.2, 44.3, 39.6, 
29.5, 27.5, 21.8; HRMS (ESI) m/z calcd for C29H37N4O3S [M+H]





          tert-Butyl (2-(tert-butyl(pyridin-3-ylmethyl)amino)ethyl)carbamate. To a solution of 
tert-butylamine (0.110 g, 1.50 mmol, 1.0 equiv) and nicotinaldehyde (0.161 g, 1.50 mmol, 1.0 
equiv) in DCE (3 mL) was added NaBH(OAc)3 (0.445 g, 2.10 mmol, 1.4 equiv) at room 
temperature. The reaction mixture was stirred at this temperature overnight, prior to the addition 
of N-Boc-2-aminoacetaldehyde (0.239 g, 1.50 mmol, 1.0 equiv), NaBH(OAc)3 (0.445 g, 2.10 
mmol, 1.4 equiv) and DCE (2 mL). The reaction was stirred for 24 h at room temperature, then 
quenched with aqueous NaOH solution (1 N, 6 mL), extracted with EtOAc (3 × 25 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo.  Reverse-phase flash column chromatography (0-100% CH3CN/H2O) afforded the title 
product as a colorless oil (0.163 g, 0.53 mmol, 35% yield). IR (neat) 3346, 2972, 1702 cm-1; 1H 
NMR (400 MHz, acetone-d6) δ 8.56 (dd, J = 2.3, 0.9 Hz, 1H), 8.40 (dd, J = 4.7, 1.7 Hz, 1H), 7.79 
(dt, J = 7.8, 1.9 Hz, 1H), 7.33–7.21 (m, 1H), 5.69 (br s, 1H), 3.78 (s, 2H), 2.93–2.84 (m, 2H), 2.73–
2.66 (m, 2H), 1.36 (s, 9H), 1.14 (s, 9H); 13C NMR (101 MHz, acetone-d6) δ 156.5, 150.3, 148.6, 
139.4, 136.1, 123.9, 78.3, 55.9, 52.9, 51.5, 42.0, 28.6, 27.6; HRMS (ESI) m/z calcd for C17H30N3O2 




          N-(2-(tert-Butyl(pyridin-3-ylmethyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl(pyridin-3-
ylmethyl)amino)ethyl)carbamate (0.031 g, 0.100 mmol. 1.0 equiv) in DCM (1 mL) was added 
TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this temperature, 
then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly in the 
following HATU promoted amide coupling without further purification. To a solution of 2-tosyl-
1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.100 mmol, 1.0 equiv) in anhydrous 
DMF (2 mL) were added DIPEA (0.052 g, 0.402 mmol, 4.0 equiv) and  HATU (0.038 g, 0.100 
mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by addition of 
crude TFA salt of diamine (0.100 mmol, 1.0 equiv). The reaction was stirred for 12 h at room 
temperature, then concentrated under N2 stream. The crude sample was purified with reverse-phase 
flash column chromatography (0-100% CH3CN/H2O) to afford the title compound as a white solid 
(0.040 g, 0.077 mmol, 77% yield, 95.0% purity). Mp = 120–123 ºC; IR (neat) 3321, 2969, 1647, 
1538 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 8.57 (s, 1H), 8.39–8.31 (m, 1H), 7.71 (d, J = 8.3 Hz, 
2H), 7.66 (d, J = 7.7 Hz, 1H), 7.40–7.29 (m, 4H), 7.13 (dd, J = 7.7, 4.8 Hz, 1H), 7.09 (d, J = 8.0 
Hz, 1H), 6.20 (t, J = 5.5 Hz, 1H), 4.25 (s, 2H), 3.73 (s, 2H), 3.34 (t, J = 5.9 Hz, 2H), 3.18–3.11 (m, 
2H), 2.96 (t, J = 5.8 Hz, 2H), 2.80 (t, J = 6.3 Hz, 2H), 2.42 (s, 3H), 1.15 (s, 9H); 13C NMR (151 
MHz, CD2Cl2) δ 166.8, 150.1, 148.6, 144.6, 138.7, 135.9, 135.6, 134.2, 133.8, 133.6, 130.3, 128.2, 
128.0, 127.0, 124.9, 123.7, 56.1, 53.1, 50.7, 48.1, 44.2, 40.5, 29.4, 27.6, 21.8; HRMS (ESI) m/z 
calcd for C29H37N4O3S [M+H]





          tert-Butyl (2-(tert-butyl(pyridin-4-ylmethyl)amino)ethyl)carbamate. To a solution of 
tert-butylamine (0.110 g, 1.5 mmol, 1.0 equiv) and isonicotinaldehyde (0.161 g, 1.50 mmol, 1.0 
equiv) in DCE (3 mL) was added NaBH(OAc)3 (0.445 g, 2.10 mmol, 1.4 equiv) at room 
temperature. The reaction mixture was stirred at this temperature overnight, prior to the addition 
of N-Boc-2-aminoacetaldehyde (0.239 g, 1.50 mmol, 1.0 equiv), NaBH(OAc)3 (0.445 g, 2.10 
mmol, 1.4 equiv) and DCE (2 mL). The reaction was stirred for 24 h at room temperature, then 
quenched with aqueous NaOH solution (1 N, 6 mL), extracted with EtOAc (3 × 25 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo.  Reverse-phase flash column chromatography (0-100% CH3CN/H2O) afforded the title 
product as a light yellow oil (0.196 g, 0.44 mmol, 43% yield). IR (neat) 3349, 2972, 1703 cm-1; 
1H NMR (400 MHz, acetone-d6) δ 8.51–8.40 (m, 2H), 7.46–7.34 (m, 2H), 5.80 (br s, 1H), 3.78 (s, 
2H), 2.98–2.89 (m, 2H), 2.76–2.66 (m, 2H), 1.37 (s, 9H), 1.11 (s, 9H); 13C NMR (101 MHz, 
acetone-d6) δ 156.5, 153.8, 150.3, 123.5, 78.4, 55.8, 54.6, 51.9, 41.9, 28.6, 27.5; HRMS (ESI) m/z 
calcd for C17H30N3O2 [M+H]





          N-(2-(tert-Butyl(pyridin-4-ylmethyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of tert-butyl (2-(tert-butyl(pyridin-4-
ylmethyl)amino)ethyl)carbamate (0.031 g, 0.100 mmol. 1.0 equiv) in DCM (1 mL) was added 
TFA (1 mL) at room temperature. The resulting mixture was stirred for 3 h at this temperature, 
then concentrated in vacuo. The obtained crude TFA salt of diamine was used directly in the 
following HATU promoted amide coupling without further purification. To a solution of 2-tosyl-
1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (0.033 g, 0.100 mmol, 1.0 equiv) in anhydrous 
DMF (2 mL) were added DIPEA (0.052 g, 0.402 mmol, 4.0 equiv) and  HATU (0.038 g, 0.100 
mmol, 1.0 equiv) at room temperature. The mixture was stirred for 5 min, followed by addition of 
crude TFA salt of diamine (0.100 mmol, 1.0 equiv). The reaction was stirred for 12 h at room 
temperature, then concentrated under N2 stream. The crude sample was purified with reverse-phase 
flash column chromatography (0-100% CH3CN/H2O) to afford the title compound as white solid 
(0.040 g, 0.077 mmol, 77% yield, 99.0% purity). Mp = 89–70 ºC; IR (neat) 3313, 2969, 1646, 
1541 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 8.41 (d, J = 5.9 Hz, 2H), 7.71 (d, J = 8.3 Hz, 2H), 7.41 
– 7.34 (m, 4H), 7.31 (d, J = 5.4 Hz, 2H), 7.10 (d, J = 8.0 Hz, 1H), 6.26 (s, 1H), 4.25 (s, 2H), 3.74 
(s, 2H), 3.34 (t, J = 5.9 Hz, 2H), 3.24–3.15 (m, 2H), 2.95 (t, J = 5.8 Hz, 2H), 2.81 (t, J = 6.1 Hz, 
2H), 2.42 (s, 3H), 1.13 (s, 9H); 13C NMR (151 MHz, CD2Cl2) δ 166.9, 153.2, 150.2, 144.6, 135.7, 
134.2, 133.8, 133.6, 130.3, 128.2, 128.0, 127.1, 124.8, 123.2, 56.0, 54.7, 51.1, 48.1, 44.2, 40.4, 
29.4, 27.5, 21.8; HRMS (ESI) m/z calcd for C29H37N4O3S [M+H]





          N-(4-Chlorobenzyl)-2,2-dimethylpropan-1-amine. Prepared according to the general 
procedure for reductive amination using pivalaldehyde (1.034 g, 12.0 mmol, 1.0 equiv), methyl 4-
chlorobenzylamine (1.70 g, 12.0 mmol, 1.0 equiv), NaBH(OAc)3 (3.56 g, 16.8 mmol, 1.4 equiv), 
AcOH (1 drop) and DCE (20 mL), at room temperature for 12 h. Reverse-phase flash column 
chromatography (0-100% CH3CN/H2O) afforded the title compound as a light yellow oil (1.68 g, 
7.93 mmol, 66% yield). IR (neat) 2952, 1490 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 9.27 (br s, 1H), 
7.56–7.48 (m, 2H), 7.41–7.34 (m, 2H), 4.06 (s, 2H), 2.66 (s, 2H), 1.01 (s, 9H); 13C NMR (151 
MHz, CD2Cl2) δ 136.1, 132.7, 129.8, 129.6, 58.6, 52.0, 31.1, 27.7; HRMS (ESI) m/z calcd for 
C12H19ClN [M+H]




          2-((4-Chlorobenzyl)(neopentyl)amino)acetonitrile. To a solution of N-(4-chlorobenzyl)-
2,2-dimethylpropan-1-amine (1.58 g, 7.46 mmol, 1.0 equiv) in acetonitrile (20 mL) were added 
K2CO3 (2.06 g, 14.9 mmol, 2.0 equiv), KI (1.24 g, 7.46 mmol, 1.0 equiv) and chloroacetonitrile 
(0.62 g, 8.21 mmol, 1.1 equiv) at room temperature. The resulting mixture was stirred at this 
temperature overnight, then diluted with saturated aqueous Na2CO3. The aqueous phase was 
extracted with ether (3 × 50 mL), washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Silica gel chromatography (0-20% EtOAc/hexanes) afforded the title compound as a colorless oil 
(0.996 g, 3.97 mmol, 53% yield). IR (neat) 2953, 1484 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35–
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7.29 (m, 4H), 3.74 (s, 2H), 3.37 (s, 2H), 2.43 (s, 2H), 0.95 (s, 9H); 13C NMR (101 MHz, CDCl3) 
δ 136.4, 133.7, 130.3, 129.0, 115.8, 67.0, 60.1, 44.0, 33.5, 27.9. HRMS (ESI) m/z calcd for 
C14H20ClN2 [M+H]
+ 251.1310, found 251.1310. 
 
 
          N1-(4-Chlorobenzyl)-N1-neopentylethane-1,2-diamine. To a solution of 2-((4-
chlorobenzyl)(neopentyl)amino)acetonitrile (0.687 g, 2.74 mmol, 1.0 equiv) in anhydrous THF (6 
mL) was added LiAlH4, (1 N in THF, 3.0 mL, 3.0 mmol, 1.1 equiv) dropwise at room temperature. 
The resulting mixture was stirred overnight, then gradually quenched with EtOAc and water. The 
solution was acidified with aqueous HCl (2 N) to pH 5, then washed with EtOAc. The aqueous 
phase was basified with aqueous NaOH (2 N) to pH 11, then extracted with EtOAc (3 × 50 mL), 
washed with brine, dried over Na2SO4 and concentrated in vacuo. Flash column chromatography 
(0-10% CH3OH/DCM, CH3OH containing 10% diethylamine) afforded the title compound as 
colorless oil (0.370 g, 1.45 mmol, 53% yield). IR (neat) 2961, 1489 cm-1; 1H NMR (600 MHz, 
CD2Cl2) δ 7.38–7.22 (m, 4H), 3.59 (s, 2H), 2.65 (t, J = 6.3 Hz, 2H), 2.40 (t, J = 6.3 Hz, 2H), 2.28 
(s, 2H), 0.89 (s, 9H); 13C NMR (151 MHz, CD2Cl2) δ 139.9, 132.7, 130.7, 128.7, 67.9, 61.7, 60.3, 





          N-(2-((4-Chlorobenzyl)(neopentyl)amino)ethyl)-2-tosyl-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of 2-tosyl-1,2,3,4-tetrahydroisoquinoline-
6-carboxylic acid (0.025 g, 0.075 mmol, 1.0 equiv) in anhydrous DMF (0.5 mL) were added 
DIPEA (0.029 g, 0.224 mmol, 3.0 equiv) and HATU (0.031 g, 0.082 mmol, 1.0 equiv) at room 
temperature. The mixture was stirred for 5 min, followed by addition of N1-(4-chlorobenzyl)-N1-
neopentylethane-1,2-diamine (0.019 g, 0.075 mmol, 1.0 equiv). The reaction was stirred for 12 h 
at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
as a yellow film (0.014 g, 0.025 mmol, 33% yield, ≥ 99% purity). IR (neat) 2950, 1640 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.3 Hz, 2H), 7.45 (s, 1H), 7.41–7.34 (m, 3H), 7.29 (t, J = 
4.2 Hz, 3H), 7.23 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.0 Hz, 1H), 6.38 (t, J = 4.4 Hz, 1H), 4.32 (s, 
2H), 3.63 (s, 2H), 3.47–3.34 (m, 4H), 3.00 (t, J = 5.8 Hz, 2H), 2.63–2.57 (m, 2H), 2.45 (s, 3H), 
2.37 (s, 2H), 0.94 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 166.9, 144.0, 138.6, 135.3, 133.8, 133.3, 
133.3, 132.9, 130.3, 129.9, 128.7, 127.9, 127.8, 126.7, 124.5, 67.4, 61.0, 54.8, 47.7, 43.7, 38.0, 
33.1, 29.0, 28.6, 21.7; HRMS (ESI) m/z calcd for C31H39ClN3O3S [M+H]






          N6-(2-((4-Chlorobenzyl)(neopentyl)amino)ethyl)-N2-(p-tolyl)-3,4-dihydroisoquinoline-
2,6(1H)-dicarboxamide. To a solution of 2-(p-tolylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline-6-
carboxylic acid (0.025 g, 0.081 mmol, 1.0 equiv) in anhydrous DMF (0.5 mL) were added DIPEA 
(0.031 g, 0.240 mmol, 3.0 equiv) and HATU (0.031 g, 0.082 mmol, 1.0 equiv) at room temperature. 
The mixture was stirred for 5 min, followed by addition of N1-(4-chlorobenzyl)-N1-
neopentylethane-1,2-diamine (0.021 g, 0.082 mmol, 1.0 equiv). The reaction was stirred for 12 h 
at room temperature, then concentrated under N2 stream. The crude sample was purified with 
reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford the title compound 
as a colorless film (0.022 g, 0.040 mmol, 50% yield, HPLC purity = 100%). IR (neat) 3320, 3222, 
2948, 1633 cm-1; 1H NMR (600 MHz, CD2Cl2) δ 7.51 (s, 1H), 7.44 (dd, J = 7.9, 1.2 Hz, 1H), 7.32 
(d, J = 8.3 Hz, 2H), 7.29–7.26 (m, 2H), 7.26–7.21 (m, 3H), 7.10 (d, J = 8.3 Hz, 2H), 6.44 (s, 1H), 
6.37 (t, J = 5.2 Hz, 1H), 4.70 (s, 2H), 3.72 (t, J = 5.9 Hz, 2H), 3.63 (s, 2H), 3.39 (q, J = 5.6 Hz, 
2H), 2.98 (t, J = 5.8 Hz, 2H), 2.61 (t, J = 6.0 Hz, 2H), 2.37 (s, 2H), 2.30 (s, 3H), 0.93 (s, 9H); 13C 
NMR (151 MHz, CD2Cl2) δ 167.0, 155.4, 139.4, 137.5, 137.2, 136.1, 133.8, 133.2, 133.1, 130.9, 
129.8, 128.9, 127.6, 127.0, 125.0, 120.8, 67.7, 61.3, 55.4, 46.3, 42.2, 38.4, 33.3, 29.6, 28.8, 21.0; 
HRMS (ESI) m/z calcd for C32H40ClN4O2 [M+H]





          N-(2-((4-Chlorobenzyl)(neopentyl)amino)ethyl)-2-(4-methylbenzoyl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide. To a solution of 2-(4-methylbenzoyl)-1,2,3,4-
tetrahydroisoquinoline-6-carboxylic acid (0.024 g, 0.080 mmol, 1.0 equiv) in anhydrous DMF (0.5 
mL) were added DIPEA (0.031 g, 0.240 mmol, 3.0 equiv) and HATU (0.030 g, 0.079 mmol, 1.0 
equiv) at room temperature. The mixture was stirred for 5 min, followed by addition of N1-(4-
chlorobenzyl)-N1-neopentylethane-1,2-diamine (0.020 g, 0.078 mmol, 1.0 equiv). The reaction 
was stirred for 12 h at room temperature, then concentrated under N2 stream. The crude sample 
was purified with reverse-phase flash column chromatography (0-100% CH3CN/H2O) to afford 
the title compound as a white solid (0.022 g, 0.041 mmol, 53% yield, HPLC purity = 98.6%). 1H 
NMR (600 MHz, DMSO-d6) δ 8.21 (t, J = 5.4 Hz, 1H), 7.66–7.53 (m, 2H), 7.47–7.19 (m, 9H), 
4.72 (br s, 2H), 3.95–3.47 (m, 5H), 3.33 (q, J = 6.1 Hz, 2H), 2.87 (s, 2H), 2.61–2.52 (m, 2H), 2.39–
2.28 (m, 5H), 0.83 (s, 9H); 13C NMR (151 MHz, DMSO-d6) δ 169.5, 165.6, 139.2, 139.0, 136.1, 
134.2, 133.0, 132.7, 131.1, 130.1, 128.8, 127.9, 127.4, 126.8, 126.2, 124.7, 66.4, 59.5, 54.8, 44.4, 









          (R)-4-Benzyl-3-(2-bromoacetyl)oxazolidin-2-one. To a solution of (R)-4-
benzyloxazolidin-2-one (10.63 g, 60.0 mmol, 1.0 equiv) in THF (300 mL) was added n-BuLi (2.5 
N in hexanes, 25.20 mL, 63.0 mmol, 1.05 equiv) dropwise at –78 °C. The mixture was stirred for 
1 h at this temperature, followed by addition of neat bromoacetyl bromide (12.72 g, 63.0 mmol, 
1.05 equiv) at –78 °C. The reaction was slowly warmed to room temperature and stirred for 3 h, 
followed by quenching with aqueous NH4Cl solution at –20 °C. The aqueous layer was extracted 
with EtOAc (3 × 200 mL), then the combined organic extracts were washed with brine, dried over 
Na2SO4, and concentrated in vacuo. Normal phase flash column chromatography (0-40% 
EtOAc/hexanes) afforded the title compound as yellow oil (15.98 g, 53.6 mmol, 89% yield). [ɑ]𝐷
20 
=  ̵̶ 71.2 (c 1.0, CHCl3); IR (neat) 3029, 1774, 1698 cm
-1; 1H NMR (400 MHz, acetone-d6) δ 7.39–
7.23 (m, 5H), 4.80 (m, 1H), 4.61 (AB q, ΔδAB = 0.10, J = 12.8 Hz, 2H), 4.44 (m, 1H), 4.31 (dd, J 
= 8.9, 3.2 Hz, 1H), 3.20 (dd, J = 13.6, 3.2 Hz, 1H), 2.99 (dd, J = 13.6, 8.2 Hz, 1H); 13C NMR (101 
MHz, acetone-d6) δ 166.5, 154.1, 136.5, 130.5, 129.6, 127.9, 67.5, 56.0, 37.7, 29.6; HRMS (ESI) 
m/z calcd for C12H13BrNO3 [M+H]
+ 298.0073, found 298.0073.  
 
 
          (R)-Diethyl 2-(4-benzyl-2-oxooxazolidin-3-yl)-2-oxoethylphosphonate. A mixture of 
(R)-4-benzyl-3-(2-bromoacetyl)oxazolidin-2-one (15.780 g, 52.90 mmol, 1.0 equiv) and triethyl 
phosphite (17.58 g, 105.8 mmol, 2.0 equiv) was heated under reflux for 2 h. The mixture was 
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cooled to room temperature and loaded directly on silica gel column for purification (0-100% 
EtOAc/hexanes) to afford the title compound as a light yellow oil (14.57 g, 41.0 mmol, 78% yield). 
[ɑ]𝐷
20 =  ̶̵ 44.0 (c 0.5, CHCl3);  IR (neat) 2985, 1776, 1695 cm
-1; 1H NMR (400 MHz, CDCl3) δ 
7.36–7.15 (m, 5H), 4.75–4.64 (m, 1H), 4.26–4.10 (m, 6H), 3.90–3.67 (m, 2H), 3.32 (dd, J = 13.4, 
3.3 Hz, 1H), 2.75 (dd, J = 13.4, 9.8 Hz, 1H), 1.34 (td, J = 7.1, 0.6 Hz, 6H); 13C NMR (101 MHz, 
CDCl3) δ 165.0, 164.9, 153.3, 135.1, 129.4, 128.9, 127.3, 66.0, 62.7, 62.7, 55.4, 37.6, 35.0, 33.7, 
16.3, 16.3; HRMS (ESI) m/z calcd for C16H23NO6P [M+H]
+ 356.1258, found 356.1251. 
 
 
          (R,E)-4-Benzyl-3-(3-(1-methyl-1H-imidazol-5-yl)acryloyl)oxazolidin-2-one. To a 
solution of diethyl (R)-(2-(4-benzyl-2-oxooxazolidin-3-yl)-2-oxoethyl)phosphonate (14.32 g, 40.3 
mmol, 1.05 equiv) in anhydrous THF (200 mL), was added NaH (60% dispersion in mineral oil, 
1.61 g, 40.3 mmol, 1.05 equiv) at 0 °C. The resulting mixture was stirred for 15 min at 0 °C and 
45 min at room temperature. This solution was cooled to  –78 °C prior to addition of 1-methyl-
1H-imidazole-5-carbaldehyde (4.230 g, 38.38 mmol, 1.0 equiv) in anhydrous THF (200 mL). The 
reaction was slowly warmed to room temperature and stirred for 3 h, followed by quenching with 
water at 0 °C. The mixture was extracted with EtOAc (3 × 200 mL), then combined organic layers 
were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified 
via flash column chromatography (0-80% EtOAc/hexanes) to afford title compound as a white 
solid (7.34 g, 23.6 mmol, 61% yield). Mp = 120–122 °C; [ɑ]𝐷
20 = +66.0 (c 1.0, CHCl3);   IR (neat) 
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3029, 1768, 1672, 1607 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.76 (AB q, ΔδAB = 0.03, J = 15.9 
Hz, 2H), 7.57 (s, 1H), 7.55 (s, 1H), 7.39–7.20 (m, 5H), 4.85–4.74 (m, 1H), 4.29–4.17 (m, 2H), 
3.79 (s, 3H), 3.36 (dd, J = 13.4, 3.3 Hz, 1H), 2.84 (dd, J = 13.4, 9.5 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 165.2, 153.7, 141.9, 135.4, 135.0, 131.4, 129.6, 129.2, 129.1, 127.5, 114.3, 66.3, 55.6, 
38.1, 33.0; HRMS (ESI) m/z calcd for C17H18N3O3 [M+H]
+ 312.1343, found 312.1338. 
 
 
          (R)-4-Benzyl-3-(3-(1-methyl-1H-imidazol-5-yl)propanoyl)oxazolidin-2-one. A round-
bottom flask was flushed with N2, then charged with a solution of (R,E)-4-benzyl-3-(3-(1-methyl-
1H-imidazol-5-yl)acryloyl)oxazolidin-2-one (5.00 g, 16.1 mmol, 1.0 equiv) in EtOAc (160 mL) 
and Pd/C (0.500 g, 10 wt%). The resulting suspension was and stirred under an H2 atmosphere 
(balloon) at room temperature for 16 h. The mixture was filtered through Celite, and concentrated 
to afford the title product as a yellow oil (5.03 g, 16.1 mmol, 100% yield). [ɑ]𝐷
20 =  ̶̵ 65.2 (c 0.5, 
CHCl3);  IR (neat) 2982, 1776, 1733, 1697 cm
-1; 1H NMR (400 MHz, CDCl3) δ 7.41–7.23 (m, 4H), 
7.20–7.14 (m, 2H), 6.83 (s, 1H), 4.71–4.61 (m, 1H), 4.27–4.13 (m, 2H), 3.61 (s, 3H), 3.37–3.20 
(m, 3H), 2.95 (t, J = 7.3 Hz, 2H), 2.76 (dd, J = 13.4, 9.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 
171.9, 153.6, 137.9, 135.2, 130.5, 129.5, 129.1, 127.5, 126.7, 66.5, 55.3, 38.0, 34.6, 31.4, 18.7; 
HRMS (ESI) m/z calcd for C17H20N3O3 [M+H]





          (R)-4-Benzyl-3-((R)-2-((1-methyl-1H-imidazol-5-yl)methyl)pent-4-enoyl)oxazolidin-2-
one. To a solution of (R)-4-benzyl-3-(3-(1-methyl-1H-imidazol-5-yl)propanoyl)oxazolidin-2-one 
(5.02 g, 16.0 mmol, 1.0 equiv) in anhydrous THF (140 mL) was added NaHMDS (1 N in THF, 
17.62 mL, 17.62 mmol, 1.1 equiv) dropwise over 10 min at  ̶̵ 78 °C. The resulting mixture was 
warmed to room temperature and stirred for 1 h. The mixture was cooled to  ̶̵ 78 °C, followed by 
slow addition of allyl iodide (4.31 g, 25.6 mmol, 1.6 equiv) at this temperature. The reaction was 
stirred at  ̵̶ 78 °C for 1 h, followed by another 2 h of stirring at  ̵̶ 20 °C. The reaction was quenched 
by the addition of saturated aqueous NH4Cl solution at  ̶̵ 20 °C and slowly warmed to room 
temperature while stirring. The reaction mixture was extracted with EtOAc (3 × 100 mL), then the 
combined organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuo. 
The residue was purified with reverse-phase flash column chromatography (0–100% CH3CN/H2O) 
to afford title product as yellow oil (3.55 g, 10.1 mmol, 63% yield). [ɑ]𝐷
20 =  ̶̵ 95.2 (c 1.1, CHCl3); 
IR (neat) 1770, 1692, 1502 cm-1; 1H NMR (400 MHz, CD2Cl2) δ 7.37–7.23 (m, 4H), 7.23–7.18 
(m, 2H), 6.69 (s, 1H), 5.87 (ddt, J = 17.1, 10.1, 7.0 Hz, 1H), 5.21–5.08 (m, 2H), 4.67–4.53 (m, 
1H), 4.30–4.19 (m, 1H), 4.11–4.03 (m, 2H), 3.56 (s, 3H), 3.20 (dd, J = 13.5, 3.4 Hz, 1H), 2.97 (dd, 
J = 15.0, 9.9 Hz, 1H), 2.79–2.68 (m, 2H), 2.63–2.51 (m, 1H), 2.43–2.32 (m, 1H); 13C NMR (101 
MHz, CD2Cl2) δ 175.2, 153.7, 138.3, 136.0, 135.3, 130.0, 129.8, 129.3, 127.7, 127.6, 118.1, 66.7, 
55.8, 42.3, 38.5, 37.1, 31.7, 26.2; HRMS (ESI) m/z calcd for C20H24N3O3 [M+H]






          (R)-2-((1-Methyl-1H-imidazol-5-yl)methyl)pent-4-enoic acid. To a solution of (R)-4-
benzyl-3-((R)-2-((1-methyl-1H-imidazol-5-yl)methyl)pent-4-enoyl)oxazolidin-2-one (3.00 g, 
8.49 mmol, 1.0 equiv) in THF (42.5 mL), was added a solution of LiOH (0.713 g, 17.0 mmol) and 
H2O2 (30% weight in water, 4.25 mL, 41.6 mmol, 4.9 equiv) in H2O (42.5 mL) at 0 °C. The 
reaction was stirred for 2 h, followed by quenching with saturated aqueous solution of Na2SO3 at 
0 °C, and concentrated in vacuo. The residue was purified with reverse-phase flash column 
chromatography (0 ̶̵ 100% CH3CN/H2O) to afford the title compound as colorless oil. (1.481 g, 
8.49 mmol, 90% yield). [ɑ]𝐷
20 = +6.2 (c 0.5, EtOH); IR (neat) 3364, 1590 cm-1; 1H NMR (600 
MHz, CD3OD) δ 7.45 (s, 1H), 6.76 (s, 1H), 5.91–5.80 (m, 1H), 5.05 (dq, J = 17.1, 1.6 Hz, 1H), 
4.98 (ddt, J = 10.2, 2.2, 1.1 Hz, 1H), 3.61 (s, 3H), 2.86 (dd, J = 15.3, 8.9 Hz, 1H), 2.63 (dd, J = 
15.3, 5.7 Hz, 1H), 2.57–2.49 (m, 1H), 2.44–2.35 (m, 1H), 2.27–2.17 (m, 1H); 13C NMR (151 MHz, 
CD3OD) δ 182.7, 138.4, 138.1, 132.8, 126.7, 116.4, 49.4, 38.5, 31.6, 27.4; HRMS (ESI) m/z calcd 
for C10H15N2O2 [M+H]
+ 195.1128, found 195.1129. 
 
 
          tert-Butyl (1-(allylamino)-2-methyl-1-oxopropan-2-yl)carbamate. To a solution of -
(Boc-amino)isobutyric acid (6.10 g, 30.0 mmol, 1.0 equiv) in DCM (150 mL), were added DIPEA 
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(11.63 g, 90.0 mmol, 3.0 equiv) and HATU (11.41 g, 30.0 mmol, 1.0 equiv) at room temperature. 
The resulting mixture was stirred for 5 min, followed by addition of allylamine (1.71 g, 30.0 mmol, 
1.0 equiv) dropwise at room temperature. The reaction was stirred for 12 h, then diluted with water. 
The aqueous layer was extracted with DCM (2 × 100 mL), then the combined organic layers were 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified with 
reverse-phase flash column chromatography to afford the title compound as a white solid (4.79 g, 
19.8 mmol, 66% yield). Mp = 123 ̶̵ 124 °C; IR (neat) 3321, 1684, 1656 cm-1; 1H NMR (400 MHz, 
CHCl3) δ 6.57 (s, 1H), 5.83 (ddt, J = 17.2, 10.3, 5.5 Hz, 1H), 5.20 (dq, J = 17.2, 1.7 Hz, 1H), 5.11 
(dq, J = 10.3, 1.4 Hz, 1H), 4.89 (s, 1H), 3.88 (tt, J = 5.7, 1.6 Hz, 2H), 1.49 (s, 6H), 1.43 (s, 9H); 
13C NMR (101 MHz, CHCl3) δ 174.6, 154.9, 134.4, 116.2, 80.4, 57.0, 42.1, 28.4, 25.9; HRMS 
(ESI) m/z calcd for C12H22N2NaO3 [M+Na]
+ 265.1523, found 265.1522. 
 
 
          tert-Butyl (S)-2-((1-(allylamino)-2-methyl-1-oxopropan-2-yl)carbamoyl)pyrrolidine-1-
carboxylate. To a solution of tert-butyl (1-(allylamino)-2-methyl-1-oxopropan-2-yl)carbamate 
(3.16 g, 13.0 mmol, 1.0 equiv) in DCM (26 mL) was added TFA (26 mL) at room temperature. 
The resulting mixture was stirred for 3 h at room temperature, then concentrated in vauco to afford 
a crude TFA salt of N-allyl-2-amino-2-methylpropanamide, which was used directly in the 
subsequent HATU promoted amide coupling without further purification. To a solution of N-Boc-
L-proline (2.81 g, 13.0 mmol, 1.0 equiv) in DCM (35 mL), were added DIPEA (6.74 g, 52.2 mmol, 
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4.0 equiv) and HATU (4.96 g, 13.0 mmol, 1.0 equiv) at room temperature. The resulting mixture 
was stirred at room temperature for 5 min, followed by addition of the previously obtained TFA 
salt of N-allyl-2-amino-2-methylpropanamide (13.04 mmol, 1.0 equiv). The reaction was stirred 
for 12 h, then concentrated. The crude sample was purified with reverse-phase flash column 
chromatography (0-100% CH3CN/H2O) to afford the title as a white solid (2.64 g, 7.78 mmol, 60% 
yield). mp = 161 ̶ 164 °C; [ɑ]𝐷
20 =  ̶ 27.0 (c 0.5, DMSO); IR (neat) 3321, 2978, 1674, 1656, 1537 
cm-1; 1H NMR (600 MHz, DMSO-d6, 40 ºC) δ 8.22–7.67 (m, 1H), 7.51 (s, 1H), 5.85–5.65 (m, 1H), 
5.19–5.08 (m, 1H), 5.08–4.94 (m, 1H), 4.14–4.00 (m, 1H), 3.81–3.51 (m, 2H), 3.41–3.26 (m, 2H), 
2.16–1.63 (m, 4H), 1.57–1.14 (m, 15H); major rotamer 13C NMR (101 MHz, DMSO-d6) δ 173.8, 
171.8, 154.1, 135.2, 114.5, 79.1, 59.7, 56.2, 46.8, 41.0, 29.5, 28.1, 26.6, 24.2, 24.2; minor rotamer 
13C NMR (101 MHz, DMSO-d6) δ 173.7, 171.7, 153.3, 135.4, 114.5, 78.4, 59.6, 55.8, 46.5, 41.1, 
30.7, 28.0, 25.5, 24.3, 23.0; HRMS (ESI) m/z calcd for C17H29N3NaO4 [M+Na]




          (S)-N-(1-(Allylamino)-2-methyl-1-oxopropan-2-yl)-1-((R)-2-((1-methyl-1H-imidazol-
5-yl)methyl)pent-4-enoyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate. To a solution of 
tert-butyl (S)-2-((1-(allylamino)-2-methyl-1-oxopropan-2-yl)carbamoyl)pyrrolidine-1-
carboxylate (2.60 g, 7.66 mmol, 1.0 equiv) in DCM (16 mL) was added TFA (16 mL) at room 
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temperature. The resulting mixture was stirred for 3 h. The reaction was concentrated in vacuo to 
afford a TFA salt of (S)-N-(1-(allylamino)-2-methyl-1-oxopropan-2-yl)pyrrolidine-2-carboxamide, 
which was used directly in the subsequent HATU promoted amide coupling without further 
purification. To the solution of (R)-2-((1-methyl-1H-imidazol-5-yl)methyl)pent-4-enoic acid (1.49 
g, 7.66 mmol, 1.0 equiv) and DIPEA (4.95 g, 38.3 mmol, 5.0 equiv) in anhydrous DMF (50 mL) 
was added HATU (2.91 g, 7.66 mmol, 1.0 equiv) at room temperature. The resulting mixture was 
stirred for 5 min, followed by addition of the TFA salt of (S)-N-(1-(allylamino)-2-methyl-1-
oxopropan-2-yl)pyrrolidine-2-carboxamide (7.66 mmol, 1.0 equiv) in anhydrous DMF (20 mL). 
After stirred for 12 h at room temperature, the reaction was concentrated under an N2 stream. The 
residue was purified with reverse-phase flash column chromatography (0 ̶100% CH3CN/0.5% 
TFA in H2O) to afford the title product as a yellow foam (1.969 g, 3.84 mmol, 50% yield). mp = 
42 ̶ 44 °C. [ɑ]𝐷
20  =  ̶ 56.1  (c 1.0, CHCl3); IR (neat) 3326, 2980, 1625 cm
-1; 1H NMR (400 MHz, 
CD3OD) δ 7.53 (br s, 1H), 6.70 (br s, 1H), 5.94–5.76 (m, 2H), 5.26–5.01 (m, 4H), 4.21 (dd, J = 
7.7, 6.3 Hz, 1H), 3.85 (ddt, J = 16.0, 5.2, 1.8 Hz, 1H), 3.71 (ddt, J = 15.9, 5.3, 1.8 Hz, 1H), 3.65–
3.52 (m, 4H), 3.22 (ddd, J = 9.8, 7.3, 5.2 Hz, 1H), 3.02–2.71 (m, 3H), 2.53–2.40 (m, 1H), 2.32–
2.17 (m, 1H), 2.14–1.94 (m, 2H), 1.93–1.81 (m, 1H), 1.78–1.64 (m, 1H), 1.52 (s, 3H), 1.43 (s, 3H); 
13C NMR (151 MHz, CD3OD) δ 176.8, 175.4, 174.3, 138.8, 136.6, 135.6, 131.6, 126.8, 117.8, 
115.8, 61.9, 58.2, 48.9, 44.8, 43.1, 38.0, 31.7, 30.2, 27.4, 26.5, 26.0, 24.3; HRMS (ESI) m/z calcd 
for for C22H34N5O3 [M+H]




          (10R,15aS,E)-3,3-dimethyl-10-((1-methyl-1H-imidazol-5-yl)methyl)-
2,3,5,6,9,10,13,14,15,15a-decahydro-1H-pyrrolo[1,2-a][1,4,7]triazacyclotridecine-1,4,11-
trione (trans-3.23) and (10R,15aS,Z)-3,3-dimethyl-10-((1-methyl-1H-imidazol-5-yl)methyl)-
2,3,5,6,9,10,13,14,15,15a-decahydro-1H-pyrrolo[1,2-a][1,4,7]triazacyclotridecine-1,4,11-
trione (cis-3.23). To a solution of 3.22 (1.960 g, 3.82 mmol, 1.0 equiv) in anhydrous DCM (350 
mL) was added Hoveyda-Grubbs 2 catalyst (0.359 g, 0.574 mmol, 0.15 equiv) at room temperature, 
then stirred for 15 h at this temperature. The reaction was quenched by addition of DMSO (7.470 
g, 96.0 mmol, 25.0 equiv), and stirred for 2 h. The mixture was concentrated in vacuo to remove 
DCM, with residue purified with reverse-phase flash column chromatography (0-100% 
CH3CN/H2O) to afford the majority of products as inseparable mixture of cis/trans isomers (0.460 
g, 1.19 mmol, 31% yield). Only small fraction of trans-3.23 was isolated (0.002 g), which was 
characterized with 1H NMR and HRMS. 1H NMR (600 MHz, CD3OD) δ 7.50 (s, 1H), 6.67 (s, 1H), 
5.68 (ddd, J = 15.1, 10.0, 5.0 Hz, 1H), 5.30 (ddd, J = 15.1, 9.6, 5.2 Hz, 1H), 4.39 (dd, J = 8.5, 3.7 
Hz, 1H), 4.13 (dd, J = 12.7, 5.2 Hz, 1H), 3.72 (dd, J = 6.2, 3.7 Hz, 1H), 3.65 (s, 3H), 3.55 (dt, J = 
10.0, 6.8 Hz, 1H), 3.19 (dd, J = 12.6, 9.7 Hz, 1H), 3.11 (dd, J = 15.2, 10.0 Hz, 1H), 2.72–2.64 (m, 
1H), 2.40 (ddd, J = 13.2, 10.0, 5.3 Hz, 1H), 2.35–2.23 (m, 2H), 2.03 (dq, J = 14.5, 9.3, 8.3 Hz, 
1H), 1.95–1.86 (m, 2H), 1.43 (s, 3H), 1.37 (s, 3H); HRMS (ESI) m/z calcd for for C20H30N5O3 





          (10R,15aS)-3,3-dimethyl-10-((1-methyl-1H-imidazol-5-yl)methyl)dodecahydro-1H-
pyrrolo[1,2-a][1,4,7]triazacyclotridecine-1,4,11-trione. A solution of 3.23 (0.460 g, 1.187 mmol, 
1.0 equiv) in CH3OH (40 mL) was stirred under an H2 atmosphere (balloon) for 18 h. The reaction 
nixture was filtered through Celite, then concentrated in vacuo to afford the title compound as a 
white solid (0.460 g, 1.18 mmol, 100% yield). Mp = 163 ̶ 165 °C. [ɑ]𝐷
20 =  ̶ 24.0 (c 0.5, EtOH); IR 
(neat) 3326, 2944, 1667, 1613 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.52 (s, 1H), 6.71 (s, 1H), 
4.50 (dd, J = 7.8, 5.8 Hz, 1H), 3.64 (s, 3H), 3.59 (ddd, J = 13.8, 5.0, 2.3 Hz, 1H), 3.50 (dt, J = 9.8, 
7.6 Hz, 1H), 3.03–2.68 (m, 5H), 2.17–1.99 (m, 2H), 1.92 (dtd, J = 12.8, 7.0, 5.4 Hz, 1H), 1.81–
1.32 (m, 11H), 1.30–1.01 (m, 2H); 13C NMR (101 MHz, CD3OD) δ 178.0, 176.8, 174.7, 139.0, 
131.5, 127.1, 61.3, 58.8, 48.7, 37.2, 31.6, 30.6, 29.0, 28.3, 27.3, 27.3, 26.3, 23.3, 21.6; HRMS 
(ESI) m/z calcd for for C20H32N5O3 [M+H]
+ 390.2500, found 390.2500. The structure was 
confirmed with single crystal X-ray experiment (see appendices) 
General Procedure for the Kinetic Resolution of Racemic Alcohols. A stock solution of catalyst 
was prepared by dissolving 3.13 (0.025 g, 0.064 mmol) in anhydrous DCM (20 mL). A stock 
solution of DIPEA was prepared by dissolving the base (0.033 g, 0.26 mmol) in anhydrous toluene 
(1 mL). A solution of substrate was prepared by dissolving alcohol (0.128 mmol, 1.0 equiv) in 
anhydrous toluene (12.8 mL). To an oven-dried flask was added 1.0 mL of catalyst solution 
230 
 
(0.0032 mmol, 2.5 mol %), followed by removal of DCM in vacuo. To the flask containing catalyst 
was added the previously prepared substrate solution. The resulting mixture was stirred at 25 °C 
for 30 min, then DIPEA (0.10 mL of stock solution, 0.026 mmol, 0.2 equiv) and Ac2O (0.108 g, 
1.058 mmol, 8.26 equiv) were introduced. During the reaction, aliquot of 0.05 mL were removed 
per 15 min, quenched with 0.05 mL of CH3OH, and directed monitored by chiral HPLC in order 
to estimate an appropriate time to quench the reaction. The reaction was quenched with 10 mL of 
CH3OH, concentrated in vacuo, and purified with reverse-phase flash column chromatography (0 ̶ 
100% CH3CN/H2O) to afford the product and recovered starting material. The enantiomeric excess 
of both product and recovered starting material was obtained by chiral HPLC analysis. Conversion 
and selectivity factor s were calculated by the method of Kagan.22 
 
 
           trans-2-Acetamidocyclohexyl acetate (3.7-Ac). The reaction was quenched at 2.5 h and 
afforded 3.7-Ac (0.010 g, 0.050 mmol, 39%) and recovered 3.7 (0.010 g, 0.064 mmol, 50%) after 
purification. IR (neat) 3282, 1729, 1731, 1642, 1556 cm-1; 1H NMR (600 MHz, CDCl3) δ 5.73 (d, 
J = 8.2 Hz, 1H), 4.62 (ddd, J = 11.2, 10.1, 4.6 Hz, 1H), 3.83 (dddd, J = 11.2, 10.1, 8.2, 4.3 Hz, 
1H), 2.01 (s, 4H), 1.89 (s, 4H), 1.78–1.71 (m, 1H), 1.70–1.61 (m, 1H), 1.5–1.40 (m, 1H), 1.37–
1.20 (m, 2H), 1.19–1.08 (m, 1H); 13C NMR (151 MHz, CDCl3) δ 172.0, 169.8, 74.8, 53.0, 32.2, 
31.2, 24.2, 23.5, 21.3; HRMS (ESI) m/z calcd for C10H18NO3 [M+H]
+ 200.1281, found 200.1278. 
Chiral HPLC analysis of 3.7-Ac: 3.7-Ac was hydrolyzed with NaOH (1 N in 1:1 EtOH-H2O) to 
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free alcohol (3.7) for ee analysis. Chiralpak IA analytical column (4.6 × 250 mm), flow rate 1 
mL/min, isocratic (5% isopropanol/hexanes), detector wavelength (220 nm); tR = 20.3 min (1R, 
2R, minor), 25.9 (1S, 2S, major). Chiral HPLC analysis of recovered 3.7: Chiralpak IA analytical 
column (4.6 × 250 mm), flow rate 1 mL/min, isocratic (5% isopropanol/hexanes), detector 
wavelength (220 nm); tR = 19.7 min (1R,2R, major), 26.5 (1S,2S, minor). The absolute 
configuration was determined by comparing with the tR of (1R,2R)-3.7 (18.9 min) and tR of 
racemic 3.7 (20.2 min, 26.8 min) under the same conditions. 
 
 
          trans-2-Acetamidocycloheptyl acetate (3.24-Ac). The reaction was quenched at 2.5 h and 
afforded 3.24-Ac (0.010 g, 0.047 mmol, 37%) and recovered 3.24 (0.011 g, 0.064 mmol, 50%) 
after purification.IR (neat) 3272, 2931, 1731, 1646 cm-1;1H NMR (400 MHz, CDCl3) δ 5.77 (d, J 
= 7.4 Hz, 1H), 4.84–4.74 (m, 1H), 4.00 (qd, J = 9.0, 3.4 Hz, 1H), 2.02 (s, 3H), 1.91 (s, 3H), 1.86–
1.43 (m, 10H); 13C NMR (101 MHz, CDCl3) δ 171.7, 169.6, 77.6, 55.4, 31.6, 31.5, 27.8, 24.1, 
23.5, 22.6, 21.4; HRMS (ESI) m/z calcd for C11H20NO3 [M+H]
+ 214.1438, found 214.1436. Chiral 
HPLC analysis of 3.24-Ac: 3.24-Ac was inseparable with all methods surveyed, which was then 
hydrolyzed with NaOH (1 N in 1:1 EtOH/H2O) to free alcohol (3.24) for ee analysis. Chiralpak IA 
analytical column (4.6 × 250 mm), flow rate 1 mL/min, isocratic (5% isopropanol/hexanes), 
detector wavelength (220 nm); tR = 21.6 min (1R, 2R, minor), 27.1 (1S, 2S, major). Chiral HPLC 
analysis of recovered 3.24: Chiralpak IA analytical column (4.6 × 250 mm), flow rate 1 mL/min, 
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isocratic (5% isopropanol/hexanes), detector wavelength (220 nm); tR = 21.9 min (1R,2R, major), 
29.3 (1S,2S, minor). The absolute configuration was determined by comparing with the tR of 
(1S,2S)-3.24 (28.4 min) and tR of racemic 3.24 (21.7 min, 28.7 min) at the same conditions. 
 
 
          trans-2-Acetamidocyclooctyl acetate (3.25-Ac). The reaction was quenched at 3.0 h and 
afforded 3.25-Ac (0.014 g, 0.062 mmol, 48%) and recovered 3.25 (0.010 g, 0.054 mmol, 42%) 
after purification. IR (neat) 3287, 2926, 1647, 1556 cm-1; 1H NMR (400 MHz, CD3OD) δ 4.90 
(ddd, J = 10.0, 6.9, 2.1 Hz, 1H), 4.13 (ddd, J = 10.0, 7.2, 2.8 Hz, 1H), 1.98 (s, 3H), 1.90 (s, 3H), 
1.88–1.43 (m, 12H). 13C NMR (101 MHz, CD3OD) δ 172.6, 172.5, 78.1, 53.5, 31.7, 30.0, 26.7, 
26.7, 26.1, 25.3, 22.6, 21.1; HRMS (ESI) m/z calcd for C12H22NO3 [M+H]
+ 228.1594, found 
228.1591. Chiral HPLC analysis of 3.25-Ac: Chiralpak IA analytical column (4.6 × 250 mm), flow 
rate 1 mL/min, isocratic (2% isopropanol/hexanes), detector wavelength (220 nm); tR = 16.8 min 
(1R,2R, minor), 20.1 (1S,2S, major). Chiral HPLC analysis of recovered 3.25: Chiralpak IA 
analytical column (4.6 × 250 mm), flow rate 1 mL/min, isocratic (5% isopropanol/hexanes), 
detector wavelength (220 nm); tR = 18.5 min (1R, 2R, major), 24.3 (1S, 2S, minor). The absolute 
configuration was determined by comparing the specific optical rotation of recovered 3.25 [ɑ]𝐷
20 
=  ̶ 9.1 (c 0.2, EtOH) with reported (1S,2S)-2-amino-cyclooctanol [ɑ]𝐷





          trans-6-Acetamidocyclohex-3enyl acetate (3.26-Ac). The reaction was quenched at 2.0 h 
and afforded 3.26-Ac (0.006 g, 0.030 mmol, 24%) and recovered 3.26 (0.013 g, 0.084 mmol, 65%) 
after purification. IR (neat) 3283, 1729, 1650, 1548 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.69 (d, 
J = 7.1 Hz, 1H), 5.63–5.53 (m, 2H), 4.97 (ddd, J = 9.9, 8.6, 5.9 Hz, 1H), 4.26–4.14 (m, 1H), 2.65–
2.52 (m, 1H), 2.49–2.37 (m, 1H), 2.35 – 2.24 (m, 1H), 2.06 (d, J = 0.4 Hz, 3H), 2.02–1.91 (m, 4H); 
13C NMR (101 MHz, CDCl3) δ 172.0, 170.0, 124.8, 124.1, 71.0, 49.0, 31.8, 30.7, 23.5, 21.3; 
HRMS (ESI) m/z calcd for C10H15NNaO3 [M+Na]
+ 220.0944, found 220.0941. Chiral HPLC 
analysis of 3.26-Ac: Chiralpak IC analytical column (4.6 × 250 mm), flow rate 0.6 mL/min, 
isocratic (10% isopropanol/hexanes), detector wavelength (220 nm); tR = 26.4 min (major), 36.2 
(minor). Chiral HPLC analysis of recovered 3.26: Chiralpak IA analytical column (4.6 × 250 mm), 
flow rate 1.0 mL/min, isocratic (5% isopropanol/hexanes), detector wavelength (220 nm); tR = 
19.4 min (major), 27.0 (minor). The absolute configuration was not determined. 
 
 
          (1S,2S)-rel-2-acetamido-1,2-diphenylethyl acetate (3.27-Ac). The reaction was quenched 
at 5.0 h and afforded 3.27-Ac (0.008 g, 0.027 mmol, 21%) and recovered 3.27 (0.021 g, 0.082 
mmol, 64%) after purification. IR (neat) 3273, 1736, 1649, 1541 cm-1; 1H NMR (400 MHz, 
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CD3OD) δ 7.30–7.13 (m, 10H), 5.98 (d, J = 7.2 Hz, 1H), 5.38 (d, J = 7.2 Hz, 1H), 2.05 (s, 3H), 
1.95 (s, 3H). 13C NMR (101 MHz, CD3OD) δ 172.8, 171.6, 139.9, 139.0, 129.3, 129.2, 129.1, 
128.6, 128.6, 128.1, 79.2, 58.9, 22.4, 20.8; HRMS (ESI) m/z calcd for C16H18NO2 [M+H]
+ 
298.1438, found 298.1439. Chiral HPLC analysis of 3.27-Ac: Chiralpak IA analytical column (4.6 
× 250 mm), flow rate 1.0 mL/min, isocratic (5% isopropanol/hexanes), detector wavelength (220 
nm); tR = 22.8 min (minor), 27.3 (major). Chiral HPLC analysis of recovered 3.27: Chiralpak IC 
analytical column (4.6 × 250 mm), flow rate 0.6 mL/min, isocratic (10% isopropanol/hexanes), 
detector wavelength (220 nm); tR = 26.1 min (minor), 34.6 (major). The absolute configuration 















X-ray crystallographic data of trans-1.49 
Table A1.1.  Crystal data and structure refinement for trans-1.49 
Identification code  v74b 
Empirical formula  C25 H35 N3 O4 
Formula weight  441.56 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 10.9057(9) Å = 90°. 
 b = 18.4019(15) Å = 112.106(2)°. 
 c = 12.5970(10) Å  = 90°. 
Volume 2342.2(3) Å3 
Z 4 
Density (calculated) 1.252 Mg/m3 
Absorption coefficient 0.684 mm-1 
F(000) 952 
Crystal size 0.250 x 0.090 x 0.040 mm3 
Theta range for data collection 4.486 to 68.108°. 
Index ranges -10<=h<=13, -19<=k<=22, -14<=l<=10 
Reflections collected 15007 
Independent reflections 4154 [R(int) = 0.0229] 
Completeness to theta = 66.000° 99.4 %  
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Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.876 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4154 / 0 / 429 
Goodness-of-fit on F2 1.028 
Final R indices [I>2sigma(I)] R1 = 0.0450, wR2 = 0.1168 
R indices (all data) R1 = 0.0497, wR2 = 0.1214 
Extinction coefficient n/a 
Largest diff. peak and hole 0.540 and -0.276 e.Å-3 
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Table A1.2.  Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for trans-1.49.  U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
______________________________________________________________________________  
 x y z U(eq) 
______________________________________________________________________________  
C(1) 3368(2) 1714(1) 3478(2) 28(1) 
C(2) 3842(2) 1210(1) 4548(2) 33(1) 
C(3) 3030(2) 498(1) 4307(2) 41(1) 
C(4) 3159(2) 74(1) 3316(2) 43(1) 
C(5) 2657(2) 529(1) 2228(2) 38(1) 
C(6) 3341(2) 1265(1) 2406(2) 34(1) 
C(7) 3825(2) 1554(1) 5639(2) 37(1) 
N(8) 4293(1) 2342(1) 3631(1) 23(1) 
C(9) 3906(2) 2873(1) 2818(1) 24(1) 
O(10) 2844(1) 2867(1) 1999(1) 30(1) 
C(11) 4788(2) 3527(1) 2940(1) 24(1) 
N(12) 4978(1) 3970(1) 3833(1) 27(1) 
C(13) 5632(2) 4591(1) 3868(2) 30(1) 
C(14) 6131(2) 4787(1) 3052(2) 35(1) 
C(15) 5952(2) 4316(1) 2149(2) 37(1) 
C(16) 5258(2) 3679(1) 2084(2) 30(1) 
C(17) 5700(2) 2292(1) 4401(1) 24(1) 
C(18) 6533(2) 1823(1) 3984(1) 26(1) 
O(19) 6550(1) 1976(1) 2922(1) 31(1) 
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C(20) 7496(2) 1529(1) 2790(2) 38(1) 
C(21) 8048(2) 1111(1) 3721(2) 37(1) 
C(22) 7418(2) 1296(1) 4495(2) 31(1) 
C(23) 1984(2) 2028(1) 3308(1) 27(1) 
O(24) 972(1) 1711(1) 2682(1) 34(1) 
N(25) 1946(2) 2616(1) 3909(1) 28(1) 
C(26) 720(2) 2964(1) 3836(2) 30(1) 
C(27) 293(2) 2685(1) 4787(2) 35(1) 
C(28) -944(2) 3074(1) 4780(2) 44(1) 
C(29) -736(2) 3890(1) 4861(2) 44(1) 
C(30) -365(2) 4164(1) 3883(2) 42(1) 
C(31) 886(2) 3788(1) 3885(2) 35(1) 




Table A1.3.   Bond lengths [Å] and angles [°] for  trans-1.49 
_____________________________________________________  
C(1)-N(8)  1.498(2) 
C(1)-C(23)  1.554(2) 
C(1)-C(2)  1.555(2) 
C(1)-C(6)  1.573(3) 
C(2)-C(7)  1.518(3) 
C(2)-C(3)  1.547(3) 
C(2)-H(2)  1.06(2) 
C(3)-C(4)  1.523(3) 
C(3)-H(3A)  1.02(3) 
C(3)-H(3B)  1.00(2) 
C(4)-C(5)  1.521(3) 
C(4)-H(4A)  1.05(3) 
C(4)-H(4B)  1.11(3) 
C(5)-C(6)  1.522(3) 
C(5)-H(5A)  1.09(2) 
C(5)-H(5B)  1.06(2) 
C(6)-H(6A)  1.06(2) 
C(6)-H(6B)  0.99(2) 
C(7)-H(7A)  1.09(3) 
C(7)-H(7B)  1.00(2) 
C(7)-H(7C)  1.05(3) 
N(8)-C(9)  1.363(2) 
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N(8)-C(17)  1.478(2) 
C(9)-O(10)  1.227(2) 
C(9)-C(11)  1.512(2) 
C(11)-N(12)  1.340(2) 
C(11)-C(16)  1.386(2) 
N(12)-C(13)  1.339(2) 
C(13)-C(14)  1.380(3) 
C(13)-H(13)  0.97(2) 
C(14)-C(15)  1.383(3) 
C(14)-H(14)  0.95(2) 
C(15)-C(16)  1.382(3) 
C(15)-H(15)  0.99(3) 
C(16)-H(16)  0.95(2) 
C(17)-C(18)  1.486(2) 
C(17)-H(17A)  0.98(2) 
C(17)-H(17B)  0.95(2) 
C(18)-C(22)  1.348(2) 
C(18)-O(19)  1.374(2) 
O(19)-C(20)  1.377(2) 
C(20)-C(21)  1.340(3) 
C(20)-H(20)  0.98(3) 
C(21)-C(22)  1.430(3) 
C(21)-H(21)  1.00(3) 
C(22)-H(22)  0.93(2) 
241 
 
C(23)-O(24)  1.236(2) 
C(23)-N(25)  1.330(2) 
N(25)-C(26)  1.453(2) 
N(25)-H(25N)  0.82(2) 
C(26)-C(31)  1.525(3) 
C(26)-C(27)  1.529(2) 
C(26)-H(26)  0.93(2) 
C(27)-C(28)  1.525(3) 
C(27)-H(27A)  1.04(2) 
C(27)-H(27B)  1.07(2) 
C(28)-C(29)  1.516(3) 
C(28)-H(28A)  1.07(3) 
C(28)-H(28B)  1.06(3) 
C(29)-C(30)  1.520(3) 
C(29)-H(29A)  1.00(3) 
C(29)-H(29B)  1.04(2) 
C(30)-C(31)  1.529(3) 
C(30)-H(30A)  1.00(3) 
C(30)-H(30B)  0.94(3) 
C(31)-H(31A)  0.99(2) 
C(31)-H(31B)  0.94(2) 
O(1W)-H(1W1)  0.86(3) 

















































































































































Table A1.4.   Anisotropic displacement parameters (Å2x 103) for trans-1.49. The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 26(1)  26(1) 29(1)  1(1) 6(1)  -5(1) 
C(2) 35(1)  31(1) 29(1)  3(1) 9(1)  -3(1) 
C(3) 49(1)  34(1) 35(1)  2(1) 10(1)  -7(1) 
C(4) 55(1)  31(1) 38(1)  -2(1) 13(1)  -8(1) 
C(5) 43(1)  34(1) 35(1)  -6(1) 12(1)  -6(1) 
C(6) 37(1)  32(1) 34(1)  -1(1) 15(1)  -3(1) 
C(7) 41(1)  34(1) 36(1)  0(1) 12(1)  -3(1) 
N(8) 22(1)  24(1) 22(1)  1(1) 5(1)  -2(1) 
C(9) 26(1)  26(1) 20(1)  0(1) 9(1)  0(1) 
O(10) 27(1)  35(1) 22(1)  3(1) 4(1)  -3(1) 
C(11) 23(1)  25(1) 23(1)  3(1) 6(1)  2(1) 
N(12) 27(1)  26(1) 27(1)  0(1) 10(1)  0(1) 
C(13) 33(1)  24(1) 33(1)  -2(1) 12(1)  -1(1) 
C(14) 40(1)  26(1) 40(1)  3(1) 17(1)  -4(1) 
C(15) 44(1)  35(1) 37(1)  6(1) 22(1)  -3(1) 
C(16) 35(1)  29(1) 28(1)  0(1) 14(1)  0(1) 
C(17) 22(1)  26(1) 21(1)  0(1) 3(1)  -2(1) 
C(18) 27(1)  25(1) 23(1)  -2(1) 5(1)  -2(1) 
O(19) 35(1)  33(1) 25(1)  0(1) 10(1)  7(1) 
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C(20) 39(1)  42(1) 32(1)  -6(1) 13(1)  8(1) 
C(21) 37(1)  35(1) 34(1)  -7(1) 7(1)  10(1) 
C(22) 34(1)  28(1) 26(1)  -1(1) 5(1)  2(1) 
C(23) 27(1)  31(1) 21(1)  4(1) 6(1)  -6(1) 
O(24) 26(1)  42(1) 30(1)  -6(1) 5(1)  -10(1) 
N(25) 22(1)  36(1) 22(1)  -1(1) 4(1)  -6(1) 
C(26) 24(1)  39(1) 24(1)  -3(1) 7(1)  -5(1) 
C(27) 38(1)  40(1) 31(1)  -3(1) 17(1)  -7(1) 
C(28) 42(1)  55(1) 42(1)  -7(1) 24(1)  -8(1) 
C(29) 39(1)  52(1) 40(1)  -5(1) 16(1)  5(1) 
C(30) 39(1)  42(1) 41(1)  2(1) 9(1)  4(1) 
C(31) 31(1)  40(1) 33(1)  5(1) 10(1)  -2(1) 




Table A1.5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for trans-1.49 
______________________________________________________________________________  
 x  y  z  U(eq) 
______________________________________________________________________________  
  
H(2) 4820(20) 1050(12) 4687(17) 35(5) 
H(3A) 2060(30) 605(13) 4170(20) 48(6) 
H(3B) 3240(20) 205(13) 5020(20) 41(6) 
H(4A) 2600(20) -408(14) 3200(20) 51(6) 
H(4B) 4220(30) -59(14) 3510(20) 57(7) 
H(5A) 1600(20) 643(13) 1991(19) 44(6) 
H(5B) 2850(20) 276(11) 1550(17) 33(5) 
H(6A) 4350(20) 1183(12) 2537(18) 36(5) 
H(6B) 2950(20) 1539(11) 1676(18) 33(5) 
H(7A) 4350(30) 1194(14) 6350(20) 57(7) 
H(7B) 4200(20) 2054(13) 5777(18) 38(6) 
H(7C) 2840(30) 1520(14) 5570(20) 56(7) 
H(13) 5780(20) 4892(11) 4535(17) 31(5) 
H(14) 6580(20) 5238(13) 3153(18) 40(6) 
H(15) 6320(20) 4433(14) 1570(20) 51(7) 
H(16) 5070(20) 3338(12) 1472(19) 37(6) 
H(17A) 6058(19) 2788(11) 4502(16) 25(5) 
H(17B) 5800(19) 2128(11) 5148(17) 25(5) 
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H(20) 7640(20) 1566(14) 2070(20) 53(7) 
H(21) 8790(20) 755(14) 3880(20) 50(6) 
H(22) 7570(20) 1108(12) 5220(20) 37(5) 
H(25N) 2620(20) 2796(12) 4370(20) 37(6) 
H(26) 80(20) 2820(11) 3136(18) 29(5) 
H(27A) 1080(20) 2763(12) 5559(19) 38(6) 
H(27B) 130(20) 2112(14) 4650(20) 46(6) 
H(28A) -1210(30) 2879(15) 5460(20) 63(8) 
H(28B) -1730(30) 2988(15) 3980(20) 58(7) 
H(29A) -1560(30) 4139(14) 4830(20) 54(7) 
H(29B) 10(20) 4006(12) 5652(19) 37(5) 
H(30A) -1100(20) 4058(14) 3140(20) 50(6) 
H(30B) -290(20) 4672(15) 3880(20) 45(6) 
H(31A) 1630(20) 3926(11) 4600(18) 32(5) 
H(31B) 1105(19) 3951(11) 3275(17) 25(5) 
H(1W1) 4400(30) 3678(15) 5150(20) 57(8) 

















































































Table A1.7.  Hydrogen bonds for trans-1.49 [Å and °] 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(6)-H(6B)...O(10) 0.99(2) 2.49(2) 3.007(2) 112.2(14) 
 C(17)-H(17A)...N(12) 0.98(2) 2.47(2) 3.199(2) 131.3(14) 
 C(17)-H(17B)...O(10)#1 0.95(2) 2.55(2) 3.241(2) 129.5(15) 
 N(25)-H(25N)...O(1W) 0.82(2) 2.18(2) 2.972(2) 163(2) 
 C(31)-H(31A)...O(1W) 0.99(2) 2.53(2) 3.311(2) 135.7(15) 
 O(1W)-H(1W1)...N(12) 0.86(3) 2.06(3) 2.905(2) 168(3) 
 O(1W)-H(1W2)...O(24)#10.88(3) 1.85(3) 2.7289(18) 176(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  














X-ray crystallographic data of trans-1.51 
Table A2.1.  Crystal data and structure refinement for trans-1.51. 
Identification code  v76b 
Empirical formula  C25 H35 N3 O4 
Formula weight  441.56 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.0174(8) Å = 90°. 
 b = 18.465(3) Å = 90°. 
 c = 21.840(3) Å  = 90°. 
Volume 2426.7(6) Å3 
Z 4 
Density (calculated) 1.209 Mg/m3 
Absorption coefficient 0.660 mm-1 
F(000) 952 
Crystal size 0.590 x 0.050 x 0.025 mm3 
Theta range for data collection 3.134 to 67.990°. 
Index ranges -6<=h<=7, -21<=k<=18, -25<=l<=25 
Reflections collected 13187 
Independent reflections 4283 [R(int) = 0.0275] 
Completeness to theta = 66.000° 99.8 %  
Absorption correction Multi-scan 
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Max. and min. transmission 1.000 and 0.800 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4283 / 0 / 429 
Goodness-of-fit on F2 1.047 
Final R indices [I>2sigma(I)] R1 = 0.0276, wR2 = 0.0700 
R indices (all data) R1 = 0.0286, wR2 = 0.0711 
Absolute structure parameter 0.51(6) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.110 and -0.176 e.Å-3 
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Table A2.2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103) for trans-1.51. U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________  
 x y z U(eq) 
______________________________________________________________________________   
C(1) 5400(3) 5631(1) 6124(1) 20(1) 
C(2) 6828(3) 6279(1) 5915(1) 23(1) 
C(3) 6710(3) 6438(1) 5226(1) 27(1) 
C(4) 4327(3) 6480(1) 4988(1) 29(1) 
C(5) 3090(3) 5788(1) 5159(1) 26(1) 
C(6) 3037(3) 5695(1) 5852(1) 22(1) 
C(7) 4267(4) 6630(1) 4302(1) 40(1) 
N(8) 5264(2) 5618(1) 6810(1) 20(1) 
C(9) 7041(3) 5383(1) 7131(1) 22(1) 
O(10) 8780(2) 5187(1) 6884(1) 26(1) 
C(11) 6897(3) 5339(1) 7821(1) 23(1) 
N(12) 5263(3) 4927(1) 8056(1) 27(1) 
C(13) 5187(3) 4862(1) 8668(1) 31(1) 
C(14) 6668(4) 5200(1) 9059(1) 32(1) 
C(15) 8343(3) 5616(1) 8807(1) 34(1) 
C(16) 8473(3) 5685(1) 8177(1) 30(1) 
C(17) 3452(3) 6012(1) 7124(1) 22(1) 
C(18) 3678(3) 6813(1) 7083(1) 25(1) 
O(19) 5692(2) 7095(1) 7257(1) 32(1) 
C(20) 5490(5) 7837(1) 7184(1) 43(1) 
259 
 
C(21) 3468(5) 8009(1) 6982(1) 47(1) 
C(22) 2271(4) 7346(1) 6914(1) 36(1) 
C(23) 6409(3) 4902(1) 5897(1) 21(1) 
O(24) 7914(2) 4892(1) 5515(1) 25(1) 
N(25) 5404(3) 4303(1) 6104(1) 24(1) 
C(26) 6118(3) 3578(1) 5918(1) 24(1) 
C(27) 4102(3) 3082(1) 5882(1) 31(1) 
C(28) 4788(3) 2308(1) 5706(1) 34(1) 
C(29) 6476(3) 2008(1) 6160(1) 33(1) 
C(30) 8523(3) 2498(1) 6191(1) 34(1) 
C(31) 7874(3) 3280(1) 6352(1) 30(1) 




Table A2.3.   Bond lengths [Å] and angles [°] for trans-1.51 
_____________________________________________________  
C(1)-N(8)  1.501(2) 
C(1)-C(2)  1.543(2) 
C(1)-C(6)  1.545(2) 
C(1)-C(23)  1.558(2) 
C(2)-C(3)  1.534(2) 
C(2)-H(2A)  0.98(3) 
C(2)-H(2B)  1.00(2) 
C(3)-C(4)  1.527(3) 
C(3)-H(3A)  0.98(2) 
C(3)-H(3B)  0.96(2) 
C(4)-C(7)  1.523(3) 
C(4)-C(5)  1.525(3) 
C(4)-H(4)  1.02(2) 
C(5)-C(6)  1.525(2) 
C(5)-H(5A)  0.99(2) 
C(5)-H(5B)  1.00(2) 
C(6)-H(6A)  0.99(2) 
C(6)-H(6B)  0.97(2) 
C(7)-H(7A)  0.99(3) 
C(7)-H(7B)  0.98(3) 
C(7)-H(7C)  1.03(3) 
N(8)-C(9)  1.350(2) 
261 
 
N(8)-C(17)  1.479(2) 
C(9)-O(10)  1.232(2) 
C(9)-C(11)  1.513(2) 
C(11)-N(12)  1.345(2) 
C(11)-C(16)  1.383(3) 
N(12)-C(13)  1.344(3) 
C(13)-C(14)  1.384(3) 
C(13)-H(13)  0.95(2) 
C(14)-C(15)  1.380(3) 
C(14)-H(14)  0.96(3) 
C(15)-C(16)  1.384(3) 
C(15)-H(15)  0.98(3) 
C(16)-H(16)  0.97(3) 
C(17)-C(18)  1.487(2) 
C(17)-H(17A)  0.97(2) 
C(17)-H(17B)  0.99(2) 
C(18)-C(22)  1.349(3) 
C(18)-O(19)  1.373(2) 
O(19)-C(20)  1.385(3) 
C(20)-C(21)  1.333(4) 
C(20)-H(20)  0.93(3) 
C(21)-C(22)  1.429(3) 
C(21)-H(21)  0.96(3) 
C(22)-H(22)  0.95(3) 
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C(23)-O(24)  1.231(2) 
C(23)-N(25)  1.339(2) 
N(25)-C(26)  1.464(2) 
N(25)-H(25N)  0.87(3) 
C(26)-C(27)  1.522(2) 
C(26)-C(31)  1.522(3) 
C(26)-H(26)  0.99(2) 
C(27)-C(28)  1.535(3) 
C(27)-H(27A)  1.04(3) 
C(27)-H(27B)  0.98(3) 
C(28)-C(29)  1.524(3) 
C(28)-H(28A)  1.02(3) 
C(28)-H(28B)  1.03(3) 
C(29)-C(30)  1.529(3) 
C(29)-H(29A)  1.01(3) 
C(29)-H(29B)  0.99(3) 
C(30)-C(31)  1.536(3) 
C(30)-H(30A)  1.00(3) 
C(30)-H(30B)  0.99(2) 
C(31)-H(31A)  0.98(3) 
C(31)-H(31B)  1.01(2) 
O(1W)-H(1W1)  0.89(3) 

















































































































































Table A2.4.   Anisotropic displacement parameters (Å2x 103) for trans-1.51. The anisotropic 
displacement factor exponent takes the form: -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 21(1)  21(1) 19(1)  1(1) 0(1)  -1(1) 
C(2) 21(1)  22(1) 25(1)  2(1) 1(1)  -2(1) 
C(3) 32(1)  23(1) 25(1)  3(1) 4(1)  -3(1) 
C(4) 35(1)  28(1) 23(1)  2(1) 0(1)  6(1) 
C(5) 24(1)  32(1) 23(1)  1(1) -4(1)  3(1) 
C(6) 19(1)  25(1) 23(1)  0(1) 0(1)  0(1) 
C(7) 50(1)  42(1) 28(1)  8(1) -3(1)  2(1) 
N(8) 20(1)  21(1) 19(1)  -1(1) 0(1)  0(1) 
C(9) 22(1)  20(1) 23(1)  1(1) 0(1)  -2(1) 
O(10) 20(1)  31(1) 26(1)  0(1) 0(1)  2(1) 
C(11) 24(1)  22(1) 24(1)  0(1) 0(1)  4(1) 
N(12) 32(1)  25(1) 23(1)  4(1) -1(1)  -2(1) 
C(13) 38(1)  29(1) 26(1)  6(1) 3(1)  -1(1) 
C(14) 44(1)  32(1) 21(1)  2(1) -3(1)  9(1) 
C(15) 33(1)  42(1) 27(1)  -7(1) -7(1)  3(1) 
C(16) 26(1)  36(1) 28(1)  -2(1) -1(1)  0(1) 
C(17) 24(1)  23(1) 21(1)  1(1) 3(1)  2(1) 
C(18) 29(1)  25(1) 22(1)  -4(1) 4(1)  -1(1) 
O(19) 37(1)  28(1) 31(1)  -7(1) 3(1)  -7(1) 
C(20) 67(2)  27(1) 36(1)  -9(1) 11(1)  -14(1) 
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C(21) 73(2)  26(1) 42(1)  -2(1) 4(1)  6(1) 
C(22) 46(1)  28(1) 34(1)  0(1) 0(1)  8(1) 
C(23) 19(1)  23(1) 21(1)  1(1) -3(1)  0(1) 
O(24) 25(1)  27(1) 22(1)  0(1) 4(1)  1(1) 
N(25) 23(1)  22(1) 27(1)  -2(1) 4(1)  1(1) 
C(26) 26(1)  21(1) 26(1)  -3(1) 3(1)  1(1) 
C(27) 26(1)  25(1) 42(1)  -4(1) -5(1)  0(1) 
C(28) 32(1)  25(1) 45(1)  -6(1) -2(1)  -2(1) 
C(29) 35(1)  23(1) 42(1)  2(1) 4(1)  1(1) 
C(30) 30(1)  26(1) 45(1)  -1(1) -1(1)  4(1) 
C(31) 26(1)  25(1) 37(1)  -2(1) -3(1)  0(1) 




Table A2.5. Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for trans-1.51 
______________________________________________________________________________  
 x  y  z  U(eq) 
______________________________________________________________________________  
  
H(2A) 8360(40) 6192(12) 6052(10) 32(6) 
H(2B) 6240(40) 6715(12) 6138(10) 30(6) 
H(3A) 7530(40) 6073(12) 4996(10) 28(5) 
H(3B) 7490(40) 6883(13) 5146(10) 29(5) 
H(4) 3520(40) 6897(12) 5197(10) 28(5) 
H(5A) 1540(40) 5811(11) 5001(10) 27(5) 
H(5B) 3890(40) 5365(12) 4976(10) 30(6) 
H(6A) 2330(30) 6129(12) 6027(9) 20(5) 
H(6B) 2110(40) 5288(12) 5970(10) 27(5) 
H(7A) 4980(50) 6227(15) 4081(12) 47(7) 
H(7B) 5140(50) 7071(15) 4228(12) 51(8) 
H(7C) 2650(50) 6663(15) 4150(12) 54(8) 
H(13) 4050(40) 4568(12) 8836(10) 28(5) 
H(14) 6520(40) 5142(12) 9494(12) 38(6) 
H(15) 9370(40) 5878(13) 9074(12) 43(7) 
H(16) 9620(40) 5978(13) 7987(11) 38(6) 
H(17A) 3460(30) 5872(10) 7551(9) 16(4) 
H(17B) 1990(40) 5864(11) 6959(9) 23(5) 
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H(20) 6780(50) 8078(15) 7306(13) 50(7) 
H(21) 2950(50) 8498(16) 6925(13) 57(8) 
H(22) 780(50) 7283(15) 6783(13) 53(8) 
H(25N) 4450(40) 4341(12) 6401(11) 33(6) 
H(26) 6780(40) 3623(12) 5507(11) 33(6) 
H(27A) 2940(40) 3294(13) 5576(11) 38(6) 
H(27B) 3380(40) 3072(13) 6283(12) 39(6) 
H(28A) 5440(40) 2310(13) 5275(12) 44(7) 
H(28B) 3360(40) 1999(13) 5701(11) 40(6) 
H(29A) 6980(50) 1508(14) 6032(12) 47(7) 
H(29B) 5810(50) 1964(14) 6572(13) 53(8) 
H(30A) 9600(50) 2314(14) 6501(12) 48(7) 
H(30B) 9300(40) 2488(12) 5792(11) 34(6) 
H(31A) 9200(40) 3586(13) 6328(11) 37(6) 
H(31B) 7280(40) 3284(12) 6783(11) 36(6) 
H(1W1) 3080(50) 4434(14) 7462(12) 46(7) 














































































Table A2.7. Hydrogen bonds for trans-1.51  [Å and °] 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2A)...O(10) 0.98(3) 2.61(2) 3.151(2) 115.0(16) 
 C(2)-H(2B)...O(19) 1.00(2) 2.56(2) 3.366(2) 136.8(17) 
 C(14)-H(14)...O(24)#1 0.96(3) 2.26(3) 3.195(2) 165(2) 
 C(17)-H(17A)...N(12) 0.97(2) 2.33(2) 3.057(2) 131.2(15) 
 C(17)-H(17B)...O(10)#2 0.99(2) 2.31(2) 3.240(2) 157.0(17) 
 C(20)-H(20)...O(1W)#3 0.93(3) 2.44(3) 3.192(3) 138(2) 
 N(25)-H(25N)...O(1W) 0.87(3) 2.18(3) 3.040(2) 169(2) 
 O(1W)-H(1W1)...N(12) 0.89(3) 2.06(3) 2.944(2) 175(3) 
 O(1W)-H(1W2)...O(10)#20.94(3) 1.90(3) 2.8313(18) 172(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  









 X-ray crystallographic data of cis-1.52 
 
Table A3.1. Crystal data and structure refinement for cis-1.52 
Identification code  x1611001  
Empirical formula  C28H39N3O3  
Formula weight  465.62  
Temperature/K  100  
Crystal system  triclinic  
Space group  P-1  
a/Å  8.0902(10)  
b/Å  12.2718(16)  
c/Å  13.6660(18)  
α/°  105.567(10)  
β/°  102.637(10)  
γ/°  90.859(10)  
Volume/Å3  1271.4(3)  
Z  2  
ρcalcg/cm
3  1.216  
μ/mm-1  0.625  
F(000)  504.0  
Crystal size/mm3  0.138 × 0.086 × 0.053  
Radiation  CuKα (λ = 1.54178)  
2Θ range for data collection/°  6.902 to 133.352  
Index ranges  -9 ≤ h ≤ 9, -14 ≤ k ≤ 14, -15 ≤ l ≤ 16  
Reflections collected  10318  
Independent reflections  4318 [Rint = 0.0645, Rsigma = 0.0612]  
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Data/restraints/parameters  4318/0/310  
Goodness-of-fit on F2  1.018  
Final R indexes [I>=2σ (I)]  R1 = 0.0532, wR2 = 0.1282  
Final R indexes [all data]  R1 = 0.0765, wR2 = 0.1425  
























Table A3.2. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for cis-1.52. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ 
tensor 
Atom x y z U(eq) 
N1 3431(2) 6658.8(16) 4576.2(15) 22.2(4) 
C2 3203(3) 6052(2) 3578.2(19) 25.4(5) 
C3 3809(3) 6416(2) 2840.6(19) 29.4(6) 
C4 4688(3) 7481(2) 3140.2(19) 28.5(5) 
C5 4906(3) 8138(2) 4156.0(19) 25.3(5) 
C6 4283(3) 7686.2(19) 4846.3(18) 20.6(5) 
C7 4425(3) 8434.3(18) 5948.2(18) 20.5(5) 
O8 3906(2) 9384.3(13) 6059.0(13) 25.6(4) 
N9 5122(2) 8025.4(15) 6768.3(14) 19.2(4) 
C10 6001(3) 6966.2(19) 6588.6(18) 20.9(5) 
C11 7268(3) 6912.7(18) 5934.4(17) 19.9(5) 
O12 8297.4(19) 7890.5(13) 6129.2(12) 23.3(4) 
C13 9432(3) 7622(2) 5503.1(18) 25.4(5) 
C14 9163(3) 6529(2) 4949.6(18) 26.1(5) 
C15 7750(3) 6065(2) 5220.8(18) 24.6(5) 
C16 5056(3) 8741.7(18) 7841.7(17) 20.6(5) 
C17 6061(3) 9912.4(19) 8093.9(17) 21.8(5) 
N18 7447(2) 9904.5(16) 7703.4(16) 24.1(4) 
C19 8532(3) 10923.9(19) 7854.5(18) 22.4(5) 
C20 9354(3) 10784(2) 6931.0(19) 29.5(5) 
C21 10528(3) 11826(2) 7053(2) 31.2(6) 
C22 11850(3) 12129(2) 8095(2) 27.0(5) 
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C23 10990(3) 12275(2) 9002.3(19) 27.2(5) 
C24 9883(3) 11204(2) 8881.7(18) 24.7(5) 
O25 5657(2) 10762.3(13) 8677.5(13) 27.2(4) 
C26 5854(3) 8210.0(19) 8723.3(17) 22.2(5) 
C27 4861(3) 7131(2) 8738.0(18) 23.9(5) 
C28 2971(3) 7289.1(19) 8715.4(17) 21.0(5) 
C29 1973(3) 6171(2) 8680.6(18) 24.2(5) 
C30 2610(3) 5873(2) 9713(2) 36.9(6) 
C31 71(3) 6361(2) 8560(2) 28.5(5) 
C32 2134(3) 5174(2) 7764(2) 36.3(6) 
C33 2218(3) 7794.6(19) 7823.2(17) 21.2(5) 

















Table 3.3. Anisotropic Displacement Parameters (Å2×103) for x1611001. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…] 
Atom U11 U22 U33 U23 U13 U12 
N1 21.3(9) 22.2(10) 23.5(10) 7.9(8) 4.5(8) 2.6(8) 
C2 24.0(11) 24.3(12) 25.4(12) 5.8(10) 1.8(9) 4.7(9) 
C3 31.2(12) 33.1(13) 22.7(12) 5.7(10) 5.9(10) 11.1(11) 
C4 26.5(12) 39.5(14) 29.4(12) 20.1(11) 13.2(10) 13.4(11) 
C5 20.0(11) 26.5(12) 34.6(13) 16.7(11) 6.9(10) 4.5(9) 
C6 15.8(10) 21.8(11) 26.1(11) 10.8(10) 3.5(8) 2.2(8) 
C7 17.5(10) 18.3(11) 27.2(12) 8.5(9) 5.7(9) -1.5(9) 
O8 28.9(8) 18.3(8) 31.6(9) 9.8(7) 7.7(7) 4.2(7) 
N9 18.5(9) 16.3(9) 23(1) 6.1(8) 4.4(7) 2.0(7) 
C10 21.5(11) 18.9(11) 23.4(11) 8.3(9) 4.2(9) 4.4(9) 
C11 18.4(10) 20.0(11) 21.1(11) 7.9(9) 1.2(8) 1.3(9) 
O12 21.9(8) 21.6(8) 25.8(8) 3.5(7) 7.9(6) -0.2(6) 
C13 23.0(11) 33.5(13) 21.6(11) 8.3(10) 8.2(9) 0.1(10) 
C14 27.4(12) 30.1(13) 21.2(11) 4.8(10) 8.8(9) 5.2(10) 
C15 29.2(12) 21.9(11) 21.7(11) 4.2(9) 6.3(9) 2.5(10) 
C16 21.4(11) 17.4(11) 21.8(11) 3.1(9) 5.9(9) 1.2(9) 
C17 20.9(11) 20.5(11) 21.2(11) 3.7(9) 1.6(9) 1.3(9) 
N18 21.3(9) 16.5(9) 31.8(11) 0.0(8) 9.3(8) -1.4(8) 
C19 20.7(10) 18.2(11) 27.6(12) 6.4(9) 4.1(9) 1.8(9) 
C20 30.1(12) 28.7(13) 28.3(12) 7.3(11) 4.2(10) 0.7(10) 
C21 35.3(13) 32.7(13) 31.0(13) 14.1(11) 12.2(11) 1.3(11) 
C22 23.7(11) 21.6(11) 38.3(14) 11.2(11) 9.1(10) -0.6(9) 
C23 22.5(11) 28.9(13) 27.0(12) 6.8(10) 0.9(9) -2.7(10) 
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C24 22.9(11) 26.7(12) 24.9(12) 8.8(10) 4.1(9) -0.5(10) 
O25 27.8(8) 18.9(8) 32.7(9) 1.7(7) 9.4(7) 2.3(7) 
C26 18.8(10) 24.2(11) 22.1(11) 5.0(9) 3.0(9) 2.5(9) 
C27 22.8(11) 27.8(12) 22.3(11) 8.9(10) 5.4(9) 3.7(9) 
C28 20.4(11) 21.5(11) 19.4(11) 3.1(9) 4.3(9) 0.8(9) 
C29 23.8(11) 23.5(12) 26.1(12) 7.2(10) 7.4(9) 0.7(9) 
C30 28.2(12) 45.4(16) 42.4(15) 24.2(13) 4.9(11) -1.4(12) 
C31 23.8(12) 31.0(13) 30.5(13) 9.4(11) 5(1) -1.8(10) 
C32 37.3(14) 21.1(12) 47.8(16) 2.2(12) 14.0(12) -3.1(11) 
C33 16.5(10) 21.7(11) 23.8(11) 4.0(9) 4.2(8) 1.8(9) 



















Table A3.4. Bond Lengths for cis-1.52 
Atom Atom Length/Å  Atom Atom Length/Å 
N1 C2 1.338(3)  C16 C34 1.539(3) 
N1 C6 1.347(3)  C17 N18 1.342(3) 
C2 C3 1.381(4)  C17 O25 1.228(3) 
C3 C4 1.393(4)  N18 C19 1.458(3) 
C4 C5 1.377(4)  C19 C20 1.523(3) 
C5 C6 1.390(3)  C19 C24 1.531(3) 
C6 C7 1.517(3)  C20 C21 1.531(3) 
C7 O8 1.227(3)  C21 C22 1.532(3) 
C7 N9 1.364(3)  C22 C23 1.522(3) 
N9 C10 1.479(3)  C23 C24 1.531(3) 
N9 C16 1.507(3)  C26 C27 1.545(3) 
C10 C11 1.492(3)  C27 C28 1.539(3) 
C11 O12 1.381(3)  C28 C29 1.565(3) 
C11 C15 1.349(3)  C28 C33 1.528(3) 
O12 C13 1.373(3)  C29 C30 1.534(4) 
C13 C14 1.339(3)  C29 C31 1.540(3) 
C14 C15 1.431(3)  C29 C32 1.529(3) 
C16 C17 1.556(3)  C33 C34 1.526(3) 








Table A3.5. Bond Angles for cis-1.52 
Atom Atom Atom Angle/˚  Atom Atom Atom Angle/˚ 
C2 N1 C6 116.4(2)  C34 C16 C26 106.41(18) 
N1 C2 C3 123.8(2)  N18 C17 C16 115.72(18) 
C2 C3 C4 118.7(2)  O25 C17 C16 120.9(2) 
C5 C4 C3 118.9(2)  O25 C17 N18 123.2(2) 
C4 C5 C6 118.1(2)  C17 N18 C19 123.22(19) 
N1 C6 C5 124.1(2)  N18 C19 C20 109.57(19) 
N1 C6 C7 117.5(2)  N18 C19 C24 112.24(19) 
C5 C6 C7 118.2(2)  C20 C19 C24 110.75(19) 
O8 C7 C6 118.2(2)  C19 C20 C21 111.9(2) 
O8 C7 N9 123.0(2)  C20 C21 C22 111.5(2) 
N9 C7 C6 118.82(19)  C23 C22 C21 110.7(2) 
C7 N9 C10 119.99(18)  C22 C23 C24 111.0(2) 
C7 N9 C16 116.92(17)  C19 C24 C23 110.24(19) 
C10 N9 C16 122.95(18)  C16 C26 C27 115.18(18) 
N9 C10 C11 114.99(19)  C28 C27 C26 113.06(18) 
O12 C11 C10 116.37(18)  C27 C28 C29 112.21(18) 
C15 C11 C10 133.5(2)  C33 C28 C27 108.91(18) 
C15 C11 O12 109.9(2)  C33 C28 C29 113.89(18) 
C13 O12 C11 106.25(17)  C30 C29 C28 109.31(19) 
C14 C13 O12 110.5(2)  C30 C29 C31 108.0(2) 
C13 C14 C15 106.8(2)  C31 C29 C28 109.37(19) 
C11 C15 C14 106.6(2)  C32 C29 C28 112.7(2) 
N9 C16 C17 110.27(18)  C32 C29 C30 110.0(2) 
N9 C16 C26 113.55(17)  C32 C29 C31 107.3(2) 
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N9 C16 C34 109.87(17)   C34 C33 C28 112.12(18) 
C26 C16 C17 106.21(17)   C33 C34 C16 112.59(18) 



























Table A3.6. Torsion Angles for cis-1.52 
A B C D Angle/˚  A B C D Angle/˚ 
N1 C2 C3 C4 -1.0(3)  C15 C11 O12 C13 0.5(2) 
N1 C6 C7 O8 -123.7(2)  C16 N9 C10 C11 -126.8(2) 
N1 C6 C7 N9 56.5(3)  C16 C17 N18 C19 179.50(19) 
C2 N1 C6 C5 0.6(3)  C16 C26 C27 C28 -51.8(3) 
C2 N1 C6 C7 174.76(19)  C17 C16 C26 C27 170.00(17) 
C2 C3 C4 C5 -0.7(3)  C17 C16 C34 C33 -171.65(18) 
C3 C4 C5 C6 2.1(3)  C17 N18 C19 C20 -150.9(2) 
C4 C5 C6 N1 -2.2(3)  C17 N18 C19 C24 85.6(3) 
C4 C5 C6 C7 -176.33(19)  N18 C19 C20 C21 -179.32(19) 
C5 C6 C7 O8 50.9(3)  N18 C19 C24 C23 179.83(18) 
C5 C6 C7 N9 -129.0(2)  C19 C20 C21 C22 53.7(3) 
C6 N1 C2 C3 1.0(3)  C20 C19 C24 C23 57.0(2) 
C6 C7 N9 C10 11.0(3)  C20 C21 C22 C23 -54.3(3) 
C6 C7 N9 C16 -173.25(18)  C21 C22 C23 C24 57.0(3) 
C7 N9 C10 C11 48.7(3)  C22 C23 C24 C19 -58.5(2) 
C7 N9 C16 C17 -61.7(2)  C24 C19 C20 C21 -55.0(3) 
C7 N9 C16 C26 179.29(18)  O25 C17 N18 C19 -5.7(4) 
C7 N9 C16 C34 60.3(2)  C26 C16 C17 N18 88.8(2) 
O8 C7 N9 C10 -168.9(2)  C26 C16 C17 O25 -86.2(2) 
O8 C7 N9 C16 6.9(3)  C26 C16 C34 C33 -56.8(2) 
N9 C10 C11 O12 41.7(3)  C26 C27 C28 C29 177.46(18) 
N9 C10 C11 C15 -144.7(2)  C26 C27 C28 C33 50.4(2) 
N9 C16 C17 N18 -34.7(3)  C27 C28 C29 C30 67.0(2) 
N9 C16 C17 O25 150.4(2)  C27 C28 C29 C31 -174.95(19) 
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N9 C16 C26 C27 -68.6(2)  C27 C28 C29 C32 -55.7(3) 
N9 C16 C34 C33 66.5(2)  C27 C28 C33 C34 -55.7(2) 
C10 N9 C16 C17 114.0(2)  C28 C33 C34 C16 61.9(2) 
C10 N9 C16 C26 -5.1(3)  C29 C28 C33 C34 178.22(17) 
C10 N9 C16 C34 -124.1(2)  C33 C28 C29 C30 -168.73(19) 
C10 C11 O12 C13 175.48(18)  C33 C28 C29 C31 -50.6(2) 
C10 C11 C15 C14 -173.7(2)  C33 C28 C29 C32 68.6(2) 
C11 O12 C13 C14 -0.9(3)  C34 C16 C17 N18 -156.3(2) 
O12 C11 C15 C14 0.1(3)  C34 C16 C17 O25 28.8(3) 
O12 C13 C14 C15 1.0(3)  C34 C16 C26 C27 52.3(2) 


















Table A3.7. Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for cis-1.52 
Atom x y z U(eq) 
H2 2590 5330 3365 30 
H3 3630 5949 2143 35 
H4 5131 7750 2652 34 
H5 5466 8878 4379 30 
H10A 5136 6318 6248 25 
H10B 6587 6873 7274 25 
H13 10288 8139 5468 31 
H14 9789 6137 4469 31 
H15 7250 5308 4951 29 
H18 7714 9252 7338 29 
H19 7798 11574 7875 27 
H20A 8454 10658 6282 35 
H20B 10017 10107 6866 35 
H21A 9840 12480 7012 37 
H21B 11117 11672 6472 37 
H22A 12637 11519 8099 32 
H22B 12522 12841 8176 32 
H23A 10276 12927 9033 33 
H23B 11866 12442 9665 33 
H24A 10604 10560 8891 30 
H24B 9325 11321 9474 30 
H26A 5955 8786 9402 27 
H26B 7017 8021 8657 27 
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H27A 4952 6503 8127 29 
H27B 5391 6912 9375 29 
H28 2917 7863 9381 25 
H30A 3792 5681 9776 55 
H30B 1903 5223 9724 55 
H30C 2539 6526 10297 55 
H31A -66 7070 9065 43 
H31B -518 5727 8687 43 
H31C -415 6406 7850 43 
H32A 1840 5399 7115 54 
H32B 1361 4530 7717 54 
H32C 3306 4954 7873 54 
H33A 2234 7240 7150 25 
H33B 1019 7938 7830 25 
H34A 3173 9457 8578 26 













X-ray crystallographic data of trans-1.53 
Table A4.1. Crystal data and structure refinement for trans-1.53  
Identification code  x1605004  
Empirical formula  C30H37N3O4  
Formula weight  503.62  
Temperature/K  100  
Crystal system  tetragonal  
Space group  P42/n  
a/Å  25.908(2)  
b/Å  25.908(2)  
c/Å  8.0598(8)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  5409.8(11)  
Z  8  
ρcalcg/cm
3  1.237  
μ/mm-1  0.659  
F(000)  2160.0  
Crystal size/mm3  0.26 × 0.206 × 0.144  
Radiation  CuKα (λ = 1.54178)  
2Θ range for data collection/°  4.824 to 140.416  
Index ranges  -31 ≤ h ≤ 31, -31 ≤ k ≤ 31, -9 ≤ l ≤ 9  
Reflections collected  48994  
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Independent reflections  5144 [Rint = 0.0352, Rsigma = 0.0162]  
Data/restraints/parameters  5144/0/337  
Goodness-of-fit on F2  1.052  
Final R indexes [I>=2σ (I)]  R1 = 0.0386, wR2 = 0.0945  
Final R indexes [all data]  R1 = 0.0420, wR2 = 0.0970  







Table A4.2. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for trans-1.53. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ 
tensor 
Atom x y z U(eq) 
N1 7067.6(4) 4058.9(4) -640.1(14) 23.9(2) 
C2 7176.7(6) 3792.6(6) -2024.1(18) 29.3(3) 
C3 7564.9(6) 3428.5(6) -2096(2) 34.2(3) 
C4 7848.8(6) 3324.9(6) -681(2) 35.4(3) 
C5 7735.4(5) 3591.9(5) 762.5(19) 28.2(3) 
C6 7347.4(5) 3958.7(5) 719.0(16) 20.7(3) 
C7 7204.5(4) 4248.0(5) 2284.1(16) 18.9(3) 
O8 7088.4(3) 3998.5(3) 3521.9(11) 23.1(2) 
N9 7184.8(4) 4774.6(4) 2233.1(13) 17.3(2) 
C10 7478.9(5) 5055.4(5) 955.5(15) 19.1(3) 
C11 8020.8(5) 5171.8(5) 1462.6(16) 20.3(3) 
O12 8303.9(3) ,,4757.4(3) 2000.3(12) 23.5(2) 
C13 8792.9(5) 4938.5(6) 2283.8(17) 27.3(3) 
C14 8821.9(5) 5444.5(6) 1941.5(18) 29.1(3) 
C15 8317.7(5) 5597.5(5) 1408.6(17) 24.6(3) 
C16 7010.3(5) 5048.7(5) 3768.7(15) 17.0(2) 
C17 7419.1(5) 4995.5(5) 5145.5(15) 18.1(3) 
C18 7318.5(5) 5330.9(5) 6674.8(15) 18.0(2) 
C19 7212.3(5) 5897.6(5) 6234.3(15) 17.9(3) 
C20 7113.7(5) 6210.5(5) 7783.4(16) 18.8(3) 
C21 7494.3(5) 6537.6(5) 8402.4(17) 22.7(3) 
C22 7414.7(6) 6818.7(5) 9845.6(18) 27.9(3) 
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C23 6949.3(6) 6782.5(5) 10688.1(17) 29.0(3) 
C24 6565.8(5) 6458.5(5) 10087.0(17) 26.2(3) 
C25 6650.1(5) 6171.1(5) 8658.6(17) 22.3(3) 
C26 6775.5(5) 5926.6(5) 4957.1(16) 19.4(3) 
C27 6923.3(5) 5626.6(5) 3394.4(15) 18.3(3) 
C28 6480.8(5) 4813.2(4) 4277.9(16) 18.0(3) 
O29 6386.0(3) 4697.2(4) 5720.4(11) 23.8(2) 
N30 6133.1(4) 4778.0(4) 3045.3(13) 19.2(2) 
C31 5662.8(5) 4467.4(5) 3219.9(16) 19.9(3) 
C32 5216.6(5) 4705.6(5) 2262(2) 33.7(4) 
C33 4732.1(5) 4367.7(6) 2401(2) 39.1(4) 
C34 4834.3(6) 3815.3(6) 1844(2) 32.2(3) 
C35 5287.9(5) 3583.0(5) 2766.4(19) 26.2(3) 
C36 5768.3(5) 3920.6(5) 2620.9(18) 25.5(3) 





Table A4.3. Anisotropic Displacement Parameters (Å2×103) for trans-1.53. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…] 
Atom U11 U22 U33 U23 U13 U12 
N1 25.4(6) 22.0(5) 24.2(6) -3.1(4) -1.5(5) -1.5(4) 
C2 33.7(7) 29.0(7) 25.3(7) -5.1(6) -0.5(6) -6.5(6) 
C3 34.3(8) 34.3(8) 34.0(8) -13.7(6) 9.5(6) -5.0(6) 
C4 26.4(7) 32.6(8) 47.3(9) -9.4(7) 6.5(7) 5.3(6) 
C5 21.9(6) 28.5(7) 34.2(8) -2.2(6) 0.0(6) 3.3(5) 
C6 18.6(6) 18.7(6) 24.9(7) -0.4(5) 1.6(5) -3.4(5) 
C7 14.6(5) 20.2(6) 21.9(6) 0.9(5) -1.8(5) -1.1(5) 
O8 26.4(5) 19.3(4) 23.8(5) 2.7(4) 1.6(4) -1.7(4) 
N9 17.4(5) 17.7(5) 16.9(5) 0.5(4) 1.1(4) -1.6(4) 
C10 20.8(6) 19.1(6) 17.4(6) 1.4(5) 2.3(5) -2.2(5) 
C11 22.0(6) 21.0(6) 18.0(6) -0.4(5) 3.2(5) 0.3(5) 
O12 20.9(4) 23.8(5) 25.8(5) 2.0(4) 0.9(4) -0.6(4) 
C13 18.5(6) 36.7(8) 26.7(7) -3.9(6) 0.4(5) -0.7(5) 
C14 22.6(7) 33.1(7) 31.6(8) -8.2(6) 3.4(6) -7.3(6) 
C15 24.5(6) 22.4(6) 26.8(7) -3.1(5) 5.5(5) -3.8(5) 
C16 16.4(6) 17.7(6) 16.9(6) 0.7(5) 0.5(5) -0.7(4) 
C17 16.2(6) 18.0(6) 19.9(6) 0.9(5) -1.1(5) 0.9(4) 
C18 16.4(6) 18.7(6) 18.9(6) 1.0(5) -1.8(5) 0.7(4) 
C19 15.7(6) 17.8(6) 20.1(6) 0.7(5) 1.3(5) -1.6(4) 
C20 20.4(6) 15.8(6) 20.4(6) 2.4(5) -1.6(5) 2.5(5) 
C21 20.2(6) 21.7(6) 26.3(7) 0.3(5) -2.1(5) 0.3(5) 
C22 32.1(7) 23.2(6) 28.5(7) -3.9(6) -7.8(6) 1.0(5) 
C23 42.8(8) 24.0(7) 20.0(7) -1.9(5) -1.1(6) 8.4(6) 
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C24 30.3(7) 24.8(7) 23.6(7) 4.8(5) 6.9(6) 7.4(5) 
C25 22.0(6) 19.3(6) 25.5(7) 1.9(5) 2.2(5) 0.0(5) 
C26 18.2(6) 17.1(6) 22.7(6) 1.5(5) -1.2(5) 1.6(5) 
C27 17.3(6) 17.8(6) 19.8(6) 2.3(5) -1.8(5) -0.8(4) 
C28 18.1(6) 14.9(5) 20.9(6) -0.5(5) 0.9(5) 0.2(4) 
O29 23.6(5) 29.6(5) 18.3(5) 1.9(4) 1.5(4) -6.5(4) 
N30 17.7(5) 20.2(5) 19.8(5) 2.3(4) 0.5(4) -3.4(4) 
C31 17.0(6) 22.4(6) 20.3(6) 0.0(5) 0.8(5) -3.9(5) 
C32 19.7(7) 22.4(7) 59.1(10) 9.2(7) -6.2(7) -1.6(5) 
C33 17.5(7) 30.2(8) 69.6(12) 11.3(8) -8.6(7) -1.8(6) 
C34 27.8(7) 33.2(8) 35.5(8) 3.3(6) -8.8(6) -11.5(6) 
C35 25.0(7) 21.3(6) 32.3(7) -0.6(6) 0.7(6) -4.7(5) 
C36 20.4(6) 21.5(6) 34.7(8) -0.3(6) 1.1(6) -1.5(5) 






Table A4.4. Bond Lengths for trans-1.53 
Atom Atom Length/Å  Atom Atom Length/Å 
N1 C2 1.3418(18)  C17 C18 1.5305(17) 
N1 C6 1.3389(17)  C18 C19 1.5353(16) 
C2 C3 1.380(2)  C19 C20 1.5105(17) 
C3 C4 1.383(2)  C19 C26 1.5316(17) 
C4 C5 1.385(2)  C20 C21 1.3925(18) 
C5 C6 1.3838(19)  C20 C25 1.3965(18) 
C6 C7 1.5133(18)  C21 C22 1.3878(19) 
C7 O8 1.2262(16)  C22 C23 1.387(2) 
C7 N9 1.3657(16)  C23 C24 1.388(2) 
N9 C10 1.4732(15)  C24 C25 1.3884(19) 
N9 C16 1.4969(15)  C26 C27 1.5287(17) 
C10 C11 1.4930(17)  C28 O29 1.2256(16) 
C11 O12 1.3706(15)  C28 N30 1.3441(17) 
C11 C15 1.3453(18)  N30 C31 1.4670(15) 
O12 C13 1.3700(16)  C31 C32 1.5208(18) 
C13 C14 1.342(2)  C31 C36 1.5212(18) 
C14 C15 1.431(2)  C32 C33 1.5345(19) 
C16 C17 1.5402(16)  C33 C34 1.523(2) 
C16 C27 1.5439(16)  C34 C35 1.515(2) 






Table A4.5. Bond Angles for trans-1.53 
Atom Atom Atom Angle/˚  Atom Atom Atom Angle/˚ 
C6 N1 C2 117.80(12)  C18 C17 C16 114.35(10) 
N1 C2 C3 122.67(14)  C17 C18 C19 112.78(10) 
C2 C3 C4 119.05(14)  C20 C19 C18 110.63(10) 
C3 C4 C5 118.88(14)  C20 C19 C26 113.84(10) 
C6 C5 C4 118.40(14)  C26 C19 C18 109.55(10) 
N1 C6 C5 123.18(12)  C21 C20 C19 120.19(11) 
N1 C6 C7 116.97(11)  C21 C20 C25 118.20(12) 
C5 C6 C7 119.78(12)  C25 C20 C19 121.58(11) 
O8 C7 C6 118.49(11)  C22 C21 C20 120.96(12) 
O8 C7 N9 122.81(11)  C23 C22 C21 120.27(13) 
N9 C7 C6 118.61(11)  C22 C23 C24 119.49(13) 
C7 N9 C10 119.68(10)  C23 C24 C25 120.08(13) 
C7 N9 C16 117.40(10)  C24 C25 C20 120.99(12) 
C10 N9 C16 119.99(9)  C27 C26 C19 110.11(10) 
N9 C10 C11 113.25(10)  C26 C27 C16 111.63(10) 
O12 C11 C10 115.58(10)  O29 C28 C16 121.51(11) 
C15 C11 C10 133.98(12)  O29 C28 N30 123.39(11) 
C15 C11 O12 110.26(11)  N30 C28 C16 114.98(10) 
C13 O12 C11 106.22(10)  C28 N30 C31 121.53(10) 
C14 C13 O12 110.62(12)  N30 C31 C32 111.10(10) 
C13 C14 C15 106.33(12)  N30 C31 C36 109.33(10) 
C11 C15 C14 106.57(12)  C32 C31 C36 110.69(11) 
N9 C16 C17 110.21(9)  C31 C32 C33 110.68(12) 
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N9 C16 C27 110.04(10)   C34 C33 C32 111.85(13) 
N9 C16 C28 107.36(9)   C35 C34 C33 111.31(12) 
C17 C16 C27 109.14(10)   C34 C35 C36 111.54(11) 
C17 C16 C28 112.40(10)   C31 C36 C35 111.27(11) 






Table A4.6. Hydrogen Bonds for trans-1.53 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O37 H37A O291 0.87 2.10 2.8794(14) 148.3 






Table A4.7. Torsion Angles for trans-1.53 
A B C D Angle/˚  A B C D Angle/˚ 
N1 C2 C3 C4 1.2(2)  C16 C28 N30 C31 166.58(10) 
N1 C6 C7 O8 122.32(13)  C17 C16 C27 C26 -55.55(13) 
N1 C6 C7 N9 -54.37(15)  C17 C16 C28 O29 13.37(16) 
C2 N1 C6 C5 -0.81(19)  C17 C16 C28 N30 -170.42(10) 
C2 N1 C6 C7 -177.67(11)  C17 C18 C19 C20 179.77(10) 
C2 C3 C4 C5 -0.3(2)  C17 C18 C19 C26 53.47(13) 
C3 C4 C5 C6 -1.1(2)  C18 C19 C20 C21 103.95(13) 
C4 C5 C6 N1 1.7(2)  C18 C19 C20 C25 -74.18(14) 
C4 C5 C6 C7 178.48(12)  C18 C19 C26 C27 -59.02(13) 
C5 C6 C7 O8 -54.65(17)  C19 C20 C21 C22 -178.48(12) 
C5 C6 C7 N9 128.65(13)  C19 C20 C25 C24 179.58(11) 
C6 N1 C2 C3 -0.7(2)  C19 C26 C27 C16 61.73(13) 
C6 C7 N9 C10 -23.12(16)  C20 C19 C26 C27 176.53(10) 
C6 C7 N9 C16 176.24(10)  C20 C21 C22 C23 -0.8(2) 
C7 N9 C10 C11 -87.33(13)  C21 C20 C25 C24 1.42(19) 
C7 N9 C16 C17 69.20(13)  C21 C22 C23 C24 0.7(2) 
C7 N9 C16 C27 -170.38(10)  C22 C23 C24 C25 0.4(2) 
C7 N9 C16 C28 -53.51(13)  C23 C24 C25 C20 -1.5(2) 
O8 C7 N9 C10 160.33(11)  C25 C20 C21 C22 -0.29(19) 
O8 C7 N9 C16 -0.30(17)  C26 C19 C20 C21 -132.18(12) 
N9 C10 C11 O12 52.76(14)  C26 C19 C20 C25 49.69(16) 
N9 C10 C11 C15 -132.79(15)  C27 C16 C17 C18 49.99(13) 
N9 C16 C17 C18 170.94(10)  C27 C16 C28 O29 -106.85(13) 
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N9 C16 C27 C26 -176.60(9)  C27 C16 C28 N30 69.36(13) 
N9 C16 C28 O29 134.72(12)  C28 C16 C17 C18 -69.35(13) 
N9 C16 C28 N30 -49.07(13)  C28 C16 C27 C26 66.71(12) 
C10 N9 C16 C17 -91.37(12)  C28 N30 C31 C32 147.24(12) 
C10 N9 C16 C27 29.04(14)  C28 N30 C31 C36 -90.29(14) 
C10 N9 C16 C28 145.91(10)  O29 C28 N30 C31 -17.29(18) 
C10 C11 O12 C13 175.71(11)  N30 C31 C32 C33 177.97(13) 
C10 C11 C15 C14 -174.52(14)  N30 C31 C36 C35 -179.57(11) 
C11 O12 C13 C14 -0.10(15)  C31 C32 C33 C34 -55.24(19) 
O12 C11 C15 C14 0.14(15)  C32 C31 C36 C35 -56.87(15) 
O12 C13 C14 C15 0.18(16)  C32 C33 C34 C35 54.09(18) 
C13 C14 C15 C11 -0.20(16)  C33 C34 C35 C36 -54.14(17) 
C15 C11 O12 C13 -0.03(14)  C34 C35 C36 C31 55.83(16) 
C16 N9 C10 C11 72.80(13)  C36 C31 C32 C33 56.29(17) 






Table A4.8. Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for trans-1.53 
Atom x y z U(eq) 
H2 6979 3857 -2994 35 
H3 7636 3252 -3103 41 
H4 8117 3075 -699 42 
H5 7920 3525 1758 34 
H10A 7299 5384 704 23 
H10B 7485 4847 -74 23 
H13 9073 4734 2669 33 
H14 9118 5659 2034 35 
H15 8213 5934 1081 29 
H17A 7435 4630 5497 22 
H17B 7761 5088 4680 22 
H18A 7622 5313 7418 22 
H18B 7018 5190 7287 22 
H19 7531 6038 5698 21 
H21 7813 6569 7828 27 
H22 7680 7037 10258 34 
H23 6893 6978 11669 35 
H24 6245 6433 10654 31 
H25 6389 5944 8271 27 
H26A 6456 5780 5438 23 
H26B 6708 6292 4668 23 
H27A 7243 5775 2919 22 
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H27B 6645 5663 2559 22 
H30 6189 4945 2112 23 
H31 5567 4453 4421 24 
H32A 5314 4743 1080 40 
H32B 5142 5054 2707 40 
H33A 4612 4366 3567 47 
H33B 4454 4518 1710 47 
H34A 4523 3603 2045 39 
H34B 4906 3812 638 39 
H35A 5363 3236 2310 31 
H35B 5197 3542 3952 31 
H36A 6050 3768 3289 31 
H36B 5882 3931 1449 31 
H37A 3838 5189 1799 61 











X-ray crystallographic data of (S)-1.71  
Table A5.1. Crystal data and structure refinement for (S)-1.71 
Identification code  q07e 
Empirical formula  C22.50 H25 Br Cl N3 O4 
Formula weight  516.81 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.9999(3) Å  
 b = 12.1506(6) Å  
 c = 16.4980(9) Å  
Volume 1171.90(10) Å3 
Z 2 
Density (calculated) 1.465 Mg/m3 
Absorption coefficient 3.723 mm-1 
F(000) 530 
Crystal size 0.350 x 0.135 x 0.025 mm3 
Theta range for data collection 2.680 to 69.680°. 
Index ranges -7<=h<=6, -14<=k<=12, -20<=l<=20 
Reflections collected 12689 
Independent reflections 5679 [R(int) = 0.0342] 
Completeness to theta = 66.000° 95.0 %  
Absorption correction Multi-scan 
305 
 
Max. and min. transmission 1.000 and 0.645 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5679 / 3 / 732 
Goodness-of-fit on F2 1.025 
Final R indices [I>2sigma(I)] R1 = 0.0297, wR2 = 0.0732 
R indices (all data) R1 = 0.0297, wR2 = 0.0732 
Absolute structure parameter 0.055(8) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.564 and -0.672 e.Å-3 
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Table A5.2. Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for (S)-1.71. U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor 
______________________________________________________________________________ 
 x y z U(eq) 
______________________________________________________________________________ 
C(1A) 255(6) 3333(3) 809(2) 16(1) 
C(2A) -1971(6) 3669(3) 539(2) 18(1) 
C(3A) -1576(7) 4798(3) 124(2) 27(1) 
C(4A) 1603(6) 3057(3) 80(2) 20(1) 
N(5A) -333(5) 2340(2) 1350(2) 15(1) 
C(6A) 1359(6) 2108(3) 1824(2) 16(1) 
O(7A) 3325(4) 2680(2) 1820(2) 20(1) 
C(8A) 806(6) 1161(3) 2419(2) 18(1) 
N(9A) -777(6) 1230(3) 2976(2) 23(1) 
C(10A) -1133(7) 440(4) 3543(2) 29(1) 
C(11A) 30(8) -424(4) 3570(3) 31(1) 
C(12A) 1614(8) -493(4) 2984(3) 35(1) 
C(13A) 2031(7) 318(3) 2396(3) 28(1) 
C(14A) -2462(6) 1483(3) 1200(2) 18(1) 
C(15A) -2451(6) 824(3) 428(2) 22(1) 
O(16A) -594(5) 373(2) 299(2) 26(1) 
C(17A) -1024(8) -241(4) -419(3) 32(1) 
C(18A) -3048(9) -185(4) -733(3) 38(1) 
C(19A) -4003(8) 518(4) -183(3) 32(1) 
C(20A) 1708(6) 4364(3) 1305(2) 17(1) 
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O(21A) 3365(4) 4969(2) 1006(1) 20(1) 
N(22A) 790(5) 4561(2) 2026(2) 16(1) 
C(23A) 1743(6) 5429(3) 2600(2) 17(1) 
C(24A) 4047(6) 5947(3) 2639(2) 20(1) 
C(25A) 4862(7) 6744(3) 3256(2) 23(1) 
C(26A) 3365(7) 6997(3) 3826(2) 21(1) 
C(27A) 1067(7) 6499(3) 3797(2) 21(1) 
C(28A) 255(7) 5721(3) 3171(2) 19(1) 
Br(29) 4543(1) 8040(1) 4690(1) 29(1) 
C(1B) 5344(6) 5965(3) 7789(2) 16(1) 
C(2B) 7804(6) 6099(3) 8128(2) 19(1) 
C(3B) 8474(7) 7021(3) 8788(2) 25(1) 
C(4B) 3585(6) 5415(3) 8406(2) 20(1) 
N(5B) 5107(5) 5276(2) 7012(2) 16(1) 
C(6B) 3353(6) 5335(3) 6497(2) 17(1) 
O(7B) 1932(4) 5887(2) 6668(1) 21(1) 
C(8B) 3220(6) 4751(3) 5672(2) 18(1) 
N(9B) 5152(5) 4912(3) 5239(2) 18(1) 
C(10B) 5000(6) 4451(3) 4490(2) 20(1) 
C(11B) 2993(7) 3806(3) 4149(2) 22(1) 
C(12B) 1016(7) 3658(3) 4599(2) 24(1) 
C(13B) 1127(7) 4146(3) 5375(2) 22(1) 
C(14B) 6141(7) 4280(3) 6967(2) 20(1) 
C(15B) 4782(8) 3302(3) 7409(2) 25(1) 
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O(16B) 2526(5) 2981(2) 7184(2) 31(1) 
C(17B) 1567(10) 2082(4) 7649(3) 40(1) 
C(18B) 3133(11) 1845(4) 8140(3) 47(1) 
C(19B) 5250(9) 2625(4) 7993(2) 37(1) 
C(20B) 5012(6) 7168(3) 7620(2) 18(1) 
O(21B) 3889(4) 7632(2) 8078(1) 21(1) 
N(22B) 6232(5) 7684(3) 6996(2) 19(1) 
C(23B) 6097(6) 8744(3) 6691(2) 18(1) 
C(24B) 4225(7) 9227(3) 6815(2) 21(1) 
C(25B) 4090(7) 10209(3) 6418(2) 23(1) 
C(26B) 5827(6) 10713(3) 5918(2) 22(1) 
C(27B) 7779(7) 10271(3) 5822(2) 21(1) 
C(28B) 7904(6) 9288(3) 6210(2) 20(1) 
Br(2B) 5457(1) 11960(1) 5310(1) 26(1) 
Cl(1S) 6529(2) 8434(1) 1588(1) 63(1) 
Cl(2S) 1872(2) 7951(1) 930(1) 55(1) 
C(1S) 4625(11) 7688(4) 816(4) 53(1) 
O(1W) -2933(5) 3136(2) 2895(2) 22(1) 




Table A5.3. Bond lengths [Å] and angles [°] for (S)-1.71 
_____________________________________________________  
C(1A)-N(5A)  1.500(4) 
C(1A)-C(4A)  1.526(4) 
C(1A)-C(2A)  1.546(5) 
C(1A)-C(20A)  1.562(5) 
C(2A)-C(3A)  1.523(5) 
C(2A)-H(2A)  1.02(4) 
C(2A)-H(2B)  0.92(5) 
C(3A)-H(3A)  0.9800 
C(3A)-H(3B)  0.9800 
C(3A)-H(3C)  0.9800 
C(4A)-H(4A)  0.9800 
C(4A)-H(4B)  0.9800 
C(4A)-H(4C)  0.9800 
N(5A)-C(6A)  1.359(4) 
N(5A)-C(14A)  1.471(4) 
C(6A)-O(7A)  1.229(4) 
C(6A)-C(8A)  1.516(5) 
C(8A)-N(9A)  1.341(5) 
C(8A)-C(13A)  1.388(5) 
N(9A)-C(10A)  1.344(5) 
C(10A)-C(11A)  1.385(6) 
C(10A)-H(10A)  1.03(7) 
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C(11A)-C(12A)  1.377(7) 
C(11A)-H(11A)  1.01(8) 
C(12A)-C(13A)  1.387(6) 
C(12A)-H(12A)  0.95(6) 
C(13A)-H(13A)  0.87(6) 
C(14A)-C(15A)  1.486(5) 
C(14A)-H(14A)  0.95(5) 
C(14A)-H(14B)  0.87(5) 
C(15A)-C(19A)  1.352(6) 
C(15A)-O(16A)  1.363(5) 
O(16A)-C(17A)  1.373(5) 
C(17A)-C(18A)  1.331(7) 
C(17A)-H(17A)  0.84(6) 
C(18A)-C(19A)  1.438(6) 
C(18A)-H(18A)  0.93(7) 
C(19A)-H(19A)  0.97(7) 
C(20A)-O(21A)  1.215(4) 
C(20A)-N(22A)  1.352(4) 
N(22A)-C(23A)  1.416(5) 
N(22A)-H(22N)  0.80(5) 
C(23A)-C(24A)  1.385(6) 
C(23A)-C(28A)  1.396(5) 
C(24A)-C(25A)  1.392(5) 
C(24A)-H(24A)  1.01(5) 
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C(25A)-C(26A)  1.382(6) 
C(25A)-H(25A)  1.02(5) 
C(26A)-C(27A)  1.377(6) 
C(26A)-Br(29)  1.902(3) 
C(27A)-C(28A)  1.388(5) 
C(27A)-H(27A)  0.91(6) 
C(28A)-H(28A)  0.84(7) 
C(1B)-N(5B)  1.500(4) 
C(1B)-C(4B)  1.530(5) 
C(1B)-C(2B)  1.546(5) 
C(1B)-C(20B)  1.551(5) 
C(2B)-C(3B)  1.525(5) 
C(2B)-H(2C)  0.97(5) 
C(2B)-H(2D)  1.06(5) 
C(3B)-H(3D)  0.9800 
C(3B)-H(3E)  0.9800 
C(3B)-H(3F)  0.9800 
C(4B)-H(4D)  0.9800 
C(4B)-H(4E)  0.9800 
C(4B)-H(4F)  0.9800 
N(5B)-C(6B)  1.362(4) 
N(5B)-C(14B)  1.479(4) 
C(6B)-O(7B)  1.227(4) 
C(6B)-C(8B)  1.509(4) 
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C(8B)-N(9B)  1.347(5) 
C(8B)-C(13B)  1.384(6) 
N(9B)-C(10B)  1.337(5) 
C(10B)-C(11B)  1.386(6) 
C(10B)-H(10B)  1.07(6) 
C(11B)-C(12B)  1.385(6) 
C(11B)-H(11B)  0.99(5) 
C(12B)-C(13B)  1.391(5) 
C(12B)-H(12B)  0.97(6) 
C(13B)-H(13B)  0.86(6) 
C(14B)-C(15B)  1.495(6) 
C(14B)-H(14C)  0.95(6) 
C(14B)-H(14D)  0.95(4) 
C(15B)-C(19B)  1.352(6) 
C(15B)-O(16B)  1.367(6) 
O(16B)-C(17B)  1.375(5) 
C(17B)-C(18B)  1.319(9) 
C(17B)-H(17B)  0.99(10) 
C(18B)-C(19B)  1.433(8) 
C(18B)-H(18B)  0.9500 
C(19B)-H(19B)  0.99(6) 
C(20B)-O(21B)  1.224(4) 
C(20B)-N(22B)  1.355(5) 
N(22B)-C(23B)  1.413(5) 
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N(22B)-H(22B)  0.77(6) 
C(23B)-C(24B)  1.393(5) 
C(23B)-C(28B)  1.404(5) 
C(24B)-C(25B)  1.395(6) 
C(24B)-H(24B)  0.98(5) 
C(25B)-C(26B)  1.379(6) 
C(25B)-H(25B)  0.99(6) 
C(26B)-C(27B)  1.401(5) 
C(26B)-Br(2B)  1.893(4) 
C(27B)-C(28B)  1.387(6) 
C(27B)-H(27B)  0.89(5) 
C(28B)-H(28B)  1.04(4) 
Cl(1S)-C(1S)  1.787(7) 
Cl(2S)-C(1S)  1.762(6) 
C(1S)-H(1SA)  1.03(8) 
C(1S)-H(1SB)  1.12(7) 
O(1W)-H(1W1)  0.81(6) 
O(1W)-H(1W2)  0.92(7) 
O(2W)-H(2W1)  0.81(5) 
















































































































































































































Table A5.4. Anisotropic displacement parameters  (Å2x 103) for (S)-1.71.  The anisotropic 
displacement factor exponent takes the form: -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1A) 12(2)  17(2) 19(1)  2(1) -2(1)  3(1) 
C(2A) 12(2)  20(2) 23(2)  2(1) -4(1)  5(1) 
C(3A) 23(2)  29(2) 30(2)  11(2) -2(1)  9(2) 
C(4A) 17(2)  22(2) 20(1)  -1(1) 3(1)  4(1) 
N(5A) 10(2)  16(1) 18(1)  2(1) -2(1)  4(1) 
C(6A) 14(2)  16(2) 20(2)  0(1) -1(1)  8(1) 
O(7A) 12(1)  20(1) 28(1)  3(1) -2(1)  4(1) 
C(8A) 15(2)  17(2) 23(2)  3(1) -2(1)  3(1) 
N(9A) 21(2)  24(2) 24(1)  2(1) -1(1)  8(1) 
C(10A) 30(2)  32(2) 25(2)  7(2) 1(2)  6(2) 
C(11A) 30(2)  29(2) 35(2)  14(2) -1(2)  6(2) 
C(12A) 30(3)  26(2) 53(3)  15(2) 5(2)  13(2) 
C(13A) 19(2)  24(2) 43(2)  9(2) 4(2)  9(2) 
C(14A) 10(2)  18(2) 25(2)  2(1) -2(1)  2(1) 
C(15A) 16(2)  17(2) 31(2)  2(1) -4(1)  3(1) 
O(16A) 20(2)  22(1) 34(1)  -5(1) -3(1)  6(1) 
C(17A) 33(3)  24(2) 37(2)  -11(2) -1(2)  6(2) 
C(18A) 47(3)  33(2) 33(2)  -13(2) -10(2)  7(2) 
C(19A) 31(3)  28(2) 35(2)  -6(2) -12(2)  6(2) 
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C(20A) 12(2)  16(2) 23(2)  3(1) -2(1)  5(1) 
O(21A) 15(1)  19(1) 24(1)  0(1) 1(1)  1(1) 
N(22A) 11(2)  16(1) 21(1)  1(1) 0(1)  1(1) 
C(23A) 19(2)  14(2) 19(2)  2(1) -3(1)  7(1) 
C(24A) 16(2)  21(2) 24(2)  1(1) -2(1)  6(1) 
C(25A) 16(2)  23(2) 31(2)  1(1) -4(1)  3(1) 
C(26A) 25(2)  16(2) 21(2)  -2(1) -7(1)  5(1) 
C(27A) 21(2)  20(2) 22(2)  1(1) 2(1)  8(1) 
C(28A) 14(2)  19(2) 25(2)  3(1) 0(1)  2(1) 
Br(29) 31(1)  27(1) 26(1)  -8(1) -7(1)  1(1) 
C(1B) 14(2)  19(2) 16(1)  -1(1) -1(1)  6(1) 
C(2B) 17(2)  23(2) 18(2)  -1(1) -3(1)  9(1) 
C(3B) 22(2)  28(2) 26(2)  -6(2) -6(1)  10(2) 
C(4B) 17(2)  22(2) 23(2)  3(1) 1(1)  8(1) 
N(5B) 15(2)  18(1) 18(1)  0(1) -2(1)  8(1) 
C(6B) 12(2)  18(2) 21(2)  2(1) -1(1)  6(1) 
O(7B) 17(1)  26(1) 22(1)  0(1) -3(1)  10(1) 
C(8B) 18(2)  17(2) 20(2)  3(1) 2(1)  10(1) 
N(9B) 13(2)  21(2) 19(1)  2(1) -2(1)  6(1) 
C(10B) 19(2)  23(2) 21(2)  6(1) 2(1)  10(1) 
C(11B) 29(2)  21(2) 18(2)  1(1) 1(1)  13(2) 
C(12B) 20(2)  26(2) 25(2)  -3(2) -5(1)  7(1) 
C(13B) 15(2)  28(2) 23(2)  0(1) 0(1)  7(1) 
C(14B) 19(2)  22(2) 20(2)  -1(1) -3(1)  12(1) 
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C(15B) 40(3)  21(2) 20(2)  -1(1) 0(1)  16(2) 
O(16B) 31(2)  25(1) 35(1)  4(1) 8(1)  3(1) 
C(17B) 52(3)  24(2) 43(2)  6(2) 20(2)  4(2) 
C(18B) 78(4)  29(2) 35(2)  6(2) 19(2)  16(2) 
C(19B) 58(3)  35(2) 25(2)  5(2) 1(2)  25(2) 
C(20B) 13(2)  20(2) 22(2)  -1(1) -5(1)  7(1) 
O(21B) 21(1)  23(1) 22(1)  1(1) 3(1)  11(1) 
N(22B) 17(2)  18(2) 24(1)  2(1) 0(1)  10(1) 
C(23B) 19(2)  14(2) 19(1)  -1(1) -4(1)  5(1) 
C(24B) 23(2)  19(2) 24(2)  4(1) -1(1)  10(1) 
C(25B) 23(2)  17(2) 31(2)  2(1) -2(1)  10(1) 
C(26B) 21(2)  19(2) 24(2)  -3(1) -7(1)  4(1) 
C(27B) 19(2)  19(2) 25(2)  0(1) -2(1)  4(1) 
C(28B) 15(2)  20(2) 24(2)  1(1) -3(1)  6(1) 
Br(2B) 30(1)  18(1) 34(1)  6(1) 0(1)  10(1) 
Cl(1S) 35(1)  39(1) 112(1)  34(1) -7(1)  -2(1) 
Cl(2S) 43(1)  48(1) 74(1)  -9(1) -13(1)  15(1) 
C(1S) 53(4)  27(2) 80(4)  8(2) 21(3)  11(2) 
O(1W) 15(1)  23(1) 28(1)  0(1) -2(1)  6(1) 




Table A5.5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for (S)-1.71 
______________________________________________________________________________ 
 x  y  z  U(eq) 
______________________________________________________________________________ 
  
H(2A) -2990(70) 3700(40) 1030(20) 13(9) 
H(2B) -2840(90) 3130(40) 190(30) 21(10) 
H(3A) -561 4788 -337 33(12) 
H(3B) -870 5405 511 29(12) 
H(3C) -3043 4928 -70 32(12) 
H(4A) 2895 2755 268 33(13) 
H(4B) 2174 3745 -220 33(13) 
H(4C) 604 2493 -275 19(10) 
H(10A) -2360(120) 480(50) 3960(40) 49(16) 
H(11A) -160(140) -970(70) 4030(50) 60(20) 
H(12A) 2300(100) -1130(50) 2990(30) 40(14) 
H(13A) 3010(100) 290(50) 2020(30) 33(13) 
H(14A) -3750(90) 1820(40) 1210(30) 23(11) 
H(14B) -2570(80) 1010(40) 1590(30) 18(10) 
H(17A) 70(100) -520(40) -570(30) 24(12) 
H(18A) -3590(120) -580(60) -1210(40) 51(17) 
H(19A) -5480(120) 710(50) -170(30) 41(14) 
H(22N) -340(90) 4120(40) 2160(30) 17(10) 
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H(24A) 5090(90) 5750(40) 2210(30) 22(11) 
H(25A) 6570(90) 7090(40) 3270(30) 18(10) 
H(27A) 110(100) 6630(50) 4190(30) 36(13) 
H(28A) -1150(120) 5410(50) 3130(30) 35(14) 
H(2C) 8840(90) 6220(40) 7680(30) 23(11) 
H(2D) 7890(90) 5290(40) 8340(30) 26(12) 
H(3D) 7413 6860 9239 15(9) 
H(3E) 8408 7753 8566 44(15) 
H(3F) 10032 7044 8983 14(10) 
H(4D) 2041 5335 8178 40(14) 
H(4E) 3751 5891 8902 20(11) 
H(4F) 3836 4669 8533 19(10) 
H(10B) 6600(90) 4570(40) 4190(30) 30(12) 
H(11B) 3030(90) 3500(50) 3590(30) 29(13) 
H(12B) -420(110) 3200(50) 4400(30) 34(13) 
H(13B) -100(90) 4060(40) 5660(30) 24(11) 
H(14C) 7680(100) 4500(40) 7170(30) 26(12) 
H(14D) 6270(80) 4100(40) 6410(30) 14(9) 
H(17B) -50(170) 1700(80) 7520(50) 80(20) 
H(18B) 2898 1263 8523 56 
H(19B) 6770(110) 2750(50) 8270(30) 35(13) 
H(22B) 7050(90) 7380(40) 6770(30) 16(10) 
H(24B) 2940(90) 8830(40) 7130(30) 22(11) 
H(25B) 2660(110) 10480(50) 6470(30) 38(14) 
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H(27B) 8930(90) 10620(40) 5520(30) 22(11) 
H(28B) 9180(70) 8850(30) 6120(20) 12(9) 
H(1SA) 4480(130) 6830(60) 890(40) 56(18) 
H(1SB) 5220(130) 7960(60) 200(40) 59(18) 
H(1W1) -2440(90) 2570(50) 2860(30) 19(10) 
H(1W2) -4270(120) 2940(50) 2590(40) 36(14) 
H(2W1) 7900(90) 6240(40) 5600(30) 11(10) 



































































































































Table A5.7. Hydrogen bonds for (S)-1.71  [Å and °] 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2A)-H(2A)...O(7A)#1 1.02(4) 2.66(4) 3.553(4) 147(3) 
 C(4A)-H(4A)...O(7A) 0.98 2.58 3.122(4) 115.1 
 C(14A)-H(14A)...O(7A)#10.95(5) 2.45(5) 3.340(4) 157(4) 
 C(14A)-H(14B)...N(9A) 0.87(5) 2.50(5) 3.134(5) 131(4) 
 C(18A)-H(18A)...O(21B)#20.93(7) 2.59(7) 3.425(5) 148(5) 
 N(22A)-H(22N)...O(1W) 0.80(5) 2.15(5) 2.919(4) 162(4) 
 C(24A)-H(24A)...O(21A)1.01(5) 2.31(5) 2.901(4) 116(3) 
 C(2B)-H(2C)...O(7B)#3 0.97(5) 2.60(5) 3.517(4) 159(4) 
 C(4B)-H(4D)...O(7B) 0.98 2.60 3.134(4) 114.3 
 C(14B)-H(14D)...N(9B) 0.95(4) 2.35(4) 3.059(4) 131(3) 
 C(14B)-H(14D)...Br(2B)#40.95(4) 3.07(4) 3.823(3) 137(3) 
 N(22B)-H(22B)...O(2W) 0.77(6) 2.14(5) 2.877(4) 159(4) 
 C(24B)-H(24B)...O(21B) 0.98(5) 2.32(5) 2.863(4) 114(4) 
 C(28B)-H(28B)...O(2W) 1.04(4) 2.52(4) 3.270(4) 129(3) 
 C(1S)-H(1SA)...O(21A) 1.03(8) 2.23(8) 3.245(6) 168(6) 
 O(1W)-H(1W1)...N(9A) 0.81(6) 2.10(6) 2.900(4) 168(4) 
 O(1W)-H(1W2)...O(7A)#10.92(7) 1.88(7) 2.793(4) 169(6) 
 O(2W)-H(2W1)...N(9B) 0.81(5) 2.10(5) 2.901(4) 171(5) 




Symmetry transformations used to generate equivalent atoms:  
#1 x-1,y,z    #2 x-1,y-1,z-1    #3 x+1,y,z    #4 x,y-1,z       
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 X-ray crystallographic data of (S)-1.72 
Table A6.1.  Crystal data and structure refinement for (S)-1.72 
Identification code  v13b 
Empirical formula  C24 H28 Br N3 O4 
Formula weight  502.40 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 10.961(3) Å = 90°. 
 b = 6.1312(17) Å = 104.859(7)°. 
 c = 18.282(5) Å  = 90°. 
Volume 1187.5(6) Å3 
Z 2 
Density (calculated) 1.405 Mg/m3 
Absorption coefficient 2.646 mm-1 
F(000) 520 
Crystal size 0.240 x 0.060 x 0.030 mm3 
Theta range for data collection 4.280 to 67.972°. 
Index ranges -12<=h<=13, -7<=k<=4, -21<=l<=21 
Reflections collected 7711 
Independent reflections 3031 [R(int) = 0.0182] 
Completeness to theta = 66.000° 98.3 %  
Absorption correction Multi-scan 
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Max. and min. transmission 1.000 and 0.798 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3031 / 1 / 378 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0198, wR2 = 0.0511 
R indices (all data) R1 = 0.0203, wR2 = 0.0515 
Absolute structure parameter 0.077(8) 
Extinction coefficient 0.0013(3) 
Largest diff. peak and hole 0.318 and -0.395 e.Å-3 
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Table A6.2.  Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for (S)-1.72. U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor 
______________________________________________________________________________ 
 x y z U(eq) 
______________________________________________________________________________ 
C(1) 3505(2) 2119(4) 1685(1) 24(1) 
C(2) 2924(2) 118(4) 1203(1) 26(1) 
C(3) 1845(3) 650(5) 494(2) 30(1) 
C(4) 552(2) 67(5) 616(2) 33(1) 
C(5) 2049(3) -581(6) -190(2) 42(1) 
C(6) 4229(2) 3546(4) 1252(1) 27(1) 
N(7) 4360(2) 1351(3) 2412(1) 23(1) 
C(8) 4682(2) 2816(5) 2988(1) 25(1) 
O(9) 4291(2) 4715(3) 2934(1) 30(1) 
C(10) 5500(2) 2068(4) 3745(1) 27(1) 
N(11) 5136(2) 288(4) 4058(1) 28(1) 
C(12) 5826(2) -294(5) 4756(2) 32(1) 
C(13) 6873(3) 862(6) 5146(2) 37(1) 
C(14) 7229(2) 2695(8) 4814(2) 40(1) 
C(15) 6531(3) 3316(5) 4103(2) 36(1) 
C(16) 5121(2) -640(4) 2418(1) 25(1) 
C(17) 6139(2) -328(4) 2022(1) 27(1) 
O(18) 6924(2) 1408(3) 2267(1) 32(1) 
C(19) 7760(3) 1445(5) 1820(2) 39(1) 
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C(20) 7529(3) -201(6) 1324(2) 39(1) 
C(21) 6473(3) -1366(5) 1451(2) 32(1) 
C(22) 2403(2) 3451(4) 1840(1) 24(1) 
O(23) 2032(2) 5106(3) 1476(1) 34(1) 
N(24) 1832(2) 2565(4) 2354(1) 24(1) 
C(25) 990(2) 3689(4) 2692(1) 23(1) 
C(26) 411(2) 5648(4) 2412(2) 27(1) 
C(27) -290(2) 6790(5) 2822(2) 30(1) 
C(28) -437(2) 5937(5) 3492(2) 30(1) 
C(29) 40(2) 3916(5) 3747(1) 30(1) 
C(30) 758(2) 2790(6) 3345(1) 28(1) 
Br(31) -1265(1) 7696(1) 4083(1) 38(1) 




Table A6.3. Bond lengths [Å] and angles [°] for  (S)-1.72 
_____________________________________________________  
C(1)-N(7)  1.493(3) 
C(1)-C(6)  1.531(3) 
C(1)-C(22)  1.543(3) 
C(1)-C(2)  1.549(3) 
C(2)-C(3)  1.548(3) 
C(2)-H(2A)  1.01(3) 
C(2)-H(2B)  0.98(4) 
C(3)-C(5)  1.527(4) 
C(3)-C(4)  1.533(4) 
C(3)-H(3)  0.96(4) 
C(4)-H(4A)  0.9800 
C(4)-H(4B)  0.9800 
C(4)-H(4C)  0.9800 
C(5)-H(5A)  0.9800 
C(5)-H(5B)  0.9800 
C(5)-H(5C)  0.9800 
C(6)-H(6A)  0.9800 
C(6)-H(6B)  0.9800 
C(6)-H(6C)  0.9800 
N(7)-C(8)  1.360(3) 
N(7)-C(16)  1.477(3) 
C(8)-O(9)  1.236(4) 
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C(8)-C(10)  1.515(3) 
C(10)-N(11)  1.340(3) 
C(10)-C(15)  1.382(4) 
N(11)-C(12)  1.354(3) 
C(12)-C(13)  1.382(4) 
C(12)-H(12)  0.95(3) 
C(13)-C(14)  1.381(6) 
C(13)-H(13)  0.99(3) 
C(14)-C(15)  1.382(4) 
C(14)-H(14)  0.91(4) 
C(15)-H(15)  0.84(4) 
C(16)-C(17)  1.490(3) 
C(16)-H(16A)  0.93(3) 
C(16)-H(16B)  0.97(3) 
C(17)-C(21)  1.351(4) 
C(17)-O(18)  1.370(3) 
O(18)-C(19)  1.375(3) 
C(19)-C(20)  1.337(5) 
C(19)-H(19)  0.95(5) 
C(20)-C(21)  1.428(4) 
C(20)-H(20)  0.93(4) 
C(21)-H(21)  1.02(3) 
C(22)-O(23)  1.225(3) 
C(22)-N(24)  1.368(3) 
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N(24)-C(25)  1.414(3) 
N(24)-H(24N)  0.86(4) 
C(25)-C(26)  1.394(4) 
C(25)-C(30)  1.396(3) 
C(26)-C(27)  1.392(4) 
C(26)-H(26)  0.99(3) 
C(27)-C(28)  1.379(4) 
C(27)-H(27)  0.90(4) 
C(28)-C(29)  1.379(4) 
C(28)-Br(31)  1.913(3) 
C(29)-C(30)  1.391(4) 
C(29)-H(29)  0.98(3) 
C(30)-H(30)  0.94(3) 
O(1W)-H(1W1)  0.85(4) 





















































































































Table A6.4. Anisotropic displacement parameters  (Å2x 103) for (S)-1.72. The anisotropic 
displacement factor exponent takes the form: -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 32(1)  14(1) 26(1)  -1(1) 11(1)  -2(1) 
C(2) 34(1)  15(1) 30(1)  -3(1) 12(1)  -2(1) 
C(3) 39(1)  22(1) 29(1)  3(1) 9(1)  -4(1) 
C(4) 33(1)  32(1) 32(1)  -2(1) 7(1)  0(1) 
C(5) 46(2)  51(2) 32(1)  -5(1) 14(1)  -6(2) 
C(6) 37(1)  18(1) 29(1)  0(1) 16(1)  -5(1) 
N(7) 30(1)  16(1) 26(1)  -1(1) 13(1)  -2(1) 
C(8) 31(1)  18(1) 31(1)  -5(1) 16(1)  -6(1) 
O(9) 42(1)  15(1) 35(1)  -4(1) 15(1)  -3(1) 
C(10) 30(1)  25(1) 29(1)  -4(1) 14(1)  -2(1) 
N(11) 32(1)  27(1) 27(1)  -1(1) 11(1)  -2(1) 
C(12) 36(1)  34(2) 30(1)  1(1) 12(1)  4(1) 
C(13) 35(1)  46(2) 30(1)  -7(1) 8(1)  7(1) 
C(14) 33(1)  49(2) 38(1)  -12(2) 8(1)  -7(2) 
C(15) 40(1)  34(2) 38(1)  -6(1) 15(1)  -10(1) 
C(16) 33(1)  17(1) 28(1)  0(1) 13(1)  0(1) 
C(17) 28(1)  22(1) 31(1)  3(1) 10(1)  0(1) 
O(18) 31(1)  30(1) 35(1)  1(1) 7(1)  -8(1) 
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C(19) 29(1)  41(2) 48(2)  12(1) 12(1)  -8(1) 
C(20) 34(1)  42(2) 47(2)  8(1) 24(1)  2(1) 
C(21) 36(1)  26(1) 37(1)  -2(1) 18(1)  -1(1) 
C(22) 34(1)  13(1) 29(1)  0(1) 14(1)  -3(1) 
O(23) 47(1)  20(1) 41(1)  8(1) 24(1)  6(1) 
N(24) 32(1)  16(1) 25(1)  2(1) 11(1)  2(1) 
C(25) 24(1)  20(1) 25(1)  -3(1) 8(1)  -4(1) 
C(26) 29(1)  25(1) 29(1)  0(1) 9(1)  0(1) 
C(27) 28(1)  25(1) 38(1)  0(1) 10(1)  3(1) 
C(28) 27(1)  31(1) 33(1)  -10(1) 12(1)  -4(1) 
C(29) 32(1)  34(2) 28(1)  0(1) 12(1)  -4(1) 
C(30) 32(1)  24(1) 29(1)  2(1) 10(1)  -1(1) 
Br(31) 38(1)  34(1) 47(1)  -14(1) 23(1)  -5(1) 




Table A6.5. Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for (S)-1.72 
______________________________________________________________________________ 
 x  y  z  U(eq) 
______________________________________________________________________________ 
  
H(2A) 2600(20) -950(50) 1527(15) 22(7) 
H(2B) 3600(30) -690(70) 1066(19) 49(9) 
H(3) 1840(30) 2170(60) 375(17) 38(8) 
H(4A) 393 960 1027 43(9) 
H(4B) 540 -1479 750 39(8) 
H(4C) -106 348 150 35(8) 
H(5A) 2080 -2152 -87 35(7) 
H(5B) 2847 -117 -290 48(9) 
H(5C) 1352 -267 -633 50(10) 
H(6A) 4888 2675 1116 42(7) 
H(6B) 4618 4771 1572 44(9) 
H(6C) 3645 4105 791 39(8) 
H(12) 5540(30) -1570(60) 4958(16) 34(8) 
H(13) 7310(30) 370(60) 5665(18) 39(9) 
H(14) 7890(30) 3580(70) 5030(18) 45(9) 
H(15) 6790(30) 4390(70) 3895(17) 35(8) 
H(16A) 4610(20) -1800(50) 2215(13) 14(6) 
H(16B) 5450(30) -1000(50) 2947(17) 28(7) 
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H(19) 8330(30) 2650(80) 1922(17) 47(8) 
H(20) 7940(30) -390(70) 942(19) 48(9) 
H(21) 6090(20) -2760(50) 1184(15) 26(7) 
H(24N) 2130(30) 1350(70) 2564(19) 42(9) 
H(26) 530(30) 6300(50) 1940(17) 31(8) 
H(27) -640(30) 8090(60) 2674(16) 32(8) 
H(29) -90(20) 3230(50) 4204(15) 31(7) 
H(30) 1090(30) 1400(50) 3506(16) 28(7) 
H(1W1) 3470(40) -1060(70) 3510(20) 51(10) 









































































Table A6.7.  Hydrogen bonds for (S)-1.72 [Å and °] 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2A)...O(23)#1 1.01(3) 2.49(3) 3.301(3) 137(2) 
 C(6)-H(6B)...O(9) 0.98 2.61 3.141(3) 114.5 
 C(15)-H(15)...Br(31)#2 0.84(4) 2.90(4) 3.619(3) 144(3) 
 C(16)-H(16A)...O(9)#1 0.93(3) 2.58(3) 3.205(3) 125.5(18) 
 C(16)-H(16B)...N(11) 0.97(3) 2.29(3) 3.048(3) 135(2) 
 N(24)-H(24N)...O(1W) 0.86(4) 2.09(4) 2.943(3) 169(3) 
 C(26)-H(26)...O(23) 0.99(3) 2.16(3) 2.785(3) 119(2) 
 C(29)-H(29)...Br(31)#3 0.98(3) 3.12(3) 3.919(3) 140(2) 
 C(30)-H(30)...O(1W) 0.94(3) 2.61(3) 3.384(4) 139(2) 
 O(1W)-H(1W1)...N(11) 0.85(4) 2.02(4) 2.860(3) 169(4) 
 O(1W)-H(1W2)...O(9)#1 0.80(6) 2.42(5) 3.079(3) 140(4) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x,y-1,z    #2 x+1,y,z    #3 -x,y-1/2,-z+1       
354 
 
X-ray crystallographic data of (S)-1.73  
Table A7.1. Crystal data and structure refinement for (S)-1.73 
Identification code  q15e 
Empirical formula  C24 H28 Br N3 O4 
Formula weight  502.40 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 10.8713(2) Å = 90°. 
 b = 10.2542(2) Å = 99.8400(10)°. 
 c = 11.1197(2) Å  = 90°. 
Volume 1221.35(4) Å3 
Z 2 
Density (calculated) 1.366 Mg/m3 
Absorption coefficient 2.573 mm-1 
F(000) 520 
Crystal size 0.210 x 0.045 x 0.030 mm3 
Theta range for data collection 4.035 to 69.911°. 
Index ranges -13<=h<=13, -10<=k<=11, -13<=l<=12 
Reflections collected 13304 
Independent reflections 3648 [R(int) = 0.0219] 
Completeness to theta = 66.000° 98.8 %  
Absorption correction Multi-scan 
355 
 
Max. and min. transmission 1.000 and 0.809 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3648 / 1 / 401 
Goodness-of-fit on F2 1.067 
Final R indices [I>2sigma(I)] R1 = 0.0245, wR2 = 0.0608 
R indices (all data) R1 = 0.0250, wR2 = 0.0611 
Absolute structure parameter 0.037(6) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.515 and -0.265 e.Å-3 
356 
 
Table A7.2. Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for (S)-1.73.  U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor 
______________________________________________________________________________ 
 x y z U(eq) 
______________________________________________________________________________ 
C(1) -66(2) 2570(3) 1653(2) 17(1) 
C(2) -561(2) 3963(2) 1793(2) 19(1) 
C(3) -1982(2) 4073(3) 1610(2) 21(1) 
C(4) -2392(3) 5408(3) 1995(2) 24(1) 
C(5) -3804(3) 5523(3) 1881(3) 27(1) 
C(6) -291(2) 1687(3) 2709(2) 19(1) 
N(7) 1293(2) 2616(2) 1592(2) 16(1) 
C(8) 1799(2) 1493(2) 1239(2) 17(1) 
O(9) 1158(2) 540(2) 876(2) 20(1) 
C(10) 3192(2) 1398(3) 1284(2) 19(1) 
N(11) 3756(2) 2320(2) 720(2) 22(1) 
C(12) 4988(2) 2181(3) 743(3) 28(1) 
C(13) 5678(2) 1159(3) 1317(3) 31(1) 
C(14) 5080(3) 212(3) 1872(3) 32(1) 
C(15) 3806(3) 322(3) 1856(3) 25(1) 
C(16) 2081(2) 3609(3) 2322(2) 19(1) 
C(17) 2279(2) 3333(3) 3654(3) 22(1) 
O(18) 2801(2) 2144(2) 3991(2) 28(1) 
C(19) 2879(3) 2054(4) 5230(3) 36(1) 
357 
 
C(20) 2431(3) 3136(4) 5669(3) 37(1) 
C(21) 2042(3) 3986(3) 4650(3) 30(1) 
C(22) -798(2) 2038(2) 437(2) 16(1) 
O(23) -1686(2) 1297(2) 442(2) 21(1) 
N(24) -517(2) 2564(2) -601(2) 17(1) 
C(25) -1249(2) 2466(3) -1771(2) 17(1) 
C(26) -2500(2) 2073(2) -1989(2) 20(1) 
C(27) -3176(2) 2081(3) -3160(2) 23(1) 
C(28) -2616(2) 2487(4) -4118(2) 27(1) 
C(29) -1377(3) 2868(3) -3934(3) 30(1) 
C(30) -697(2) 2858(3) -2766(2) 25(1) 
Br(31) -3566(1) 2479(1) -5726(1) 43(1) 




Table A7.3. Bond lengths [Å] and angles [°] for  (S)-1.73 
_____________________________________________________  
C(1)-N(7)  1.492(2) 
C(1)-C(6)  1.536(3) 
C(1)-C(2)  1.544(4) 
C(1)-C(22)  1.546(3) 
C(2)-C(3)  1.527(3) 
C(2)-H(2A)  1.03(4) 
C(2)-H(2B)  0.99(4) 
C(3)-C(4)  1.524(4) 
C(3)-H(3A)  0.96(4) 
C(3)-H(3B)  0.91(4) 
C(4)-C(5)  1.523(4) 
C(4)-H(4A)  0.98(4) 
C(4)-H(4B)  0.90(5) 
C(5)-H(5A)  0.95(3) 
C(5)-H(5B)  0.97(4) 
C(5)-H(5C)  0.92(6) 
C(6)-H(6A)  0.97(4) 
C(6)-H(6B)  0.97(4) 
C(6)-H(6C)  0.87(4) 
N(7)-C(8)  1.363(3) 
N(7)-C(16)  1.481(3) 
C(8)-O(9)  1.228(3) 
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C(8)-C(10)  1.509(3) 
C(10)-N(11)  1.339(4) 
C(10)-C(15)  1.387(4) 
N(11)-C(12)  1.343(3) 
C(12)-C(13)  1.380(5) 
C(12)-H(12)  0.96(4) 
C(13)-C(14)  1.373(5) 
C(13)-H(13)  0.92(4) 
C(14)-C(15)  1.386(4) 
C(14)-H(14)  0.87(5) 
C(15)-H(15)  0.89(4) 
C(16)-C(17)  1.487(4) 
C(16)-H(16A)  0.96(3) 
C(16)-H(16B)  0.96(4) 
C(17)-C(21)  1.356(4) 
C(17)-O(18)  1.370(4) 
O(18)-C(19)  1.369(4) 
C(19)-C(20)  1.336(5) 
C(19)-H(19)  0.86(5) 
C(20)-C(21)  1.434(5) 
C(20)-H(20)  0.86(4) 
C(21)-H(21)  0.99(5) 
C(22)-O(23)  1.229(3) 
C(22)-N(24)  1.356(3) 
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N(24)-C(25)  1.408(3) 
N(24)-H(24N)  0.83(4) 
C(25)-C(26)  1.399(3) 
C(25)-C(30)  1.404(3) 
C(26)-C(27)  1.382(4) 
C(26)-H(26)  0.87(4) 
C(27)-C(28)  1.379(4) 
C(27)-H(27)  1.00(3) 
C(28)-C(29)  1.385(4) 
C(28)-Br(31)  1.906(2) 
C(29)-C(30)  1.380(4) 
C(29)-H(29)  1.00(4) 
C(30)-H(30)  0.99(4) 
O(1W)-H(1W1)  0.68(5) 

















































































































Symmetry transformations used to generate equivalent atoms:  
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Table A7.4. Anisotropic displacement parameters (Å2x 103) for (S)-1.73. The anisotropic 
displacement factor exponent takes the form: -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 17(1)  13(1) 20(1)  1(1) 3(1)  -1(1) 
C(2) 22(1)  14(1) 21(1)  0(1) 4(1)  0(1) 
C(3) 24(1)  17(1) 22(1)  2(1) 6(1)  2(1) 
C(4) 27(1)  22(1) 24(1)  -4(1) 6(1)  4(1) 
C(5) 30(2)  25(2) 26(1)  0(1) 6(1)  8(1) 
C(6) 21(1)  19(1) 17(1)  2(1) 2(1)  0(1) 
N(7) 17(1)  13(1) 18(1)  0(1) 2(1)  -1(1) 
C(8) 21(1)  16(1) 15(1)  1(1) 1(1)  1(1) 
O(9) 20(1)  14(1) 26(1)  -2(1) 3(1)  -2(1) 
C(10) 18(1)  18(1) 21(1)  -6(1) 1(1)  -2(1) 
N(11) 19(1)  21(1) 27(1)  -4(1) 6(1)  -2(1) 
C(12) 21(1)  30(2) 34(1)  -10(1) 8(1)  -5(1) 
C(13) 18(1)  37(2) 37(2)  -16(1) 2(1)  0(1) 
C(14) 24(1)  30(2) 38(2)  -7(1) -5(1)  9(1) 
C(15) 23(1)  21(1) 31(1)  -1(1) 1(1)  1(1) 
C(16) 20(1)  15(1) 23(1)  -2(1) 3(1)  -2(1) 
C(17) 20(1)  22(1) 25(1)  -1(1) 3(1)  -4(1) 
O(18) 29(1)  32(1) 23(1)  5(1) 2(1)  4(1) 
C(19) 32(2)  53(2) 22(1)  9(1) 0(1)  -2(1) 
366 
 
C(20) 32(2)  57(2) 19(1)  -2(1) 1(1)  -15(1) 
C(21) 32(1)  34(2) 26(1)  -9(1) 7(1)  -10(1) 
C(22) 15(1)  13(1) 21(1)  1(1) 3(1)  2(1) 
O(23) 20(1)  19(1) 23(1)  2(1) 2(1)  -3(1) 
N(24) 17(1)  14(1) 20(1)  0(1) 2(1)  -1(1) 
C(25) 22(1)  11(1) 18(1)  -3(1) 3(1)  2(1) 
C(26) 20(1)  19(1) 23(1)  2(1) 6(1)  3(1) 
C(27) 21(1)  21(1) 26(1)  -2(1) 1(1)  0(1) 
C(28) 30(1)  31(1) 18(1)  -2(1) -3(1)  1(1) 
C(29) 33(1)  39(2) 20(1)  1(1) 7(1)  -6(1) 
C(30) 25(1)  26(2) 23(1)  2(1) 4(1)  -6(1) 
Br(31) 37(1)  69(1) 19(1)  4(1) -4(1)  -7(1) 




Table A7.5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) 
for (S)-1.73 
______________________________________________________________________________ 
 x  y  z  U(eq) 
______________________________________________________________________________ 
  
H(2A) -220(30) 4310(40) 2650(30) 27(9) 
H(2B) -230(30) 4560(40) 1230(30) 28(8) 
H(3A) -2320(30) 3900(30) 770(30) 22(8) 
H(3B) -2300(30) 3460(40) 2060(30) 22(8) 
H(4A) -2000(30) 5590(40) 2840(40) 29(9) 
H(4B) -2060(40) 6010(40) 1570(40) 39(10) 
H(5A) -4210(30) 5310(30) 1080(30) 11(6) 
H(5B) -4130(40) 4910(40) 2410(40) 34(9) 
H(5C) -4040(40) 6350(50) 2070(40) 52(12) 
H(6A) 10(30) 820(40) 2600(30) 15(7) 
H(6B) -1180(40) 1650(40) 2740(40) 35(9) 
H(6C) 150(30) 1930(30) 3400(30) 20(8) 
H(12) 5330(30) 2900(40) 350(30) 24(8) 
H(13) 6510(40) 1090(40) 1240(40) 39(10) 
H(14) 5480(40) -430(50) 2280(40) 49(12) 
H(15) 3350(30) -240(40) 2200(30) 22(7) 
H(16A) 2870(30) 3650(30) 2030(30) 22(8) 
H(16B) 1710(30) 4460(40) 2190(30) 26(8) 
368 
 
H(19) 3210(40) 1340(50) 5530(40) 50(12) 
H(20) 2440(40) 3250(40) 6440(40) 36(10) 
H(21) 1640(40) 4850(50) 4620(40) 43(10) 
H(24N) 140(30) 3000(30) -520(30) 19(8) 
H(26) -2860(30) 1870(40) -1370(40) 30(9) 
H(27) -4080(30) 1840(30) -3290(30) 19(7) 
H(29) -980(40) 3170(40) -4640(40) 40(10) 
H(30) 150(30) 3230(40) -2620(30) 28(8) 
H(1W1) 2360(40) -6540(40) -620(40) 31(11) 









































































Table A7.7. Hydrogen bonds for (S)-1.73 [Å and °] 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2B)...O(9)#1 0.99(4) 2.59(4) 3.345(3) 133(3) 
 C(6)-H(6A)...O(9) 0.97(4) 2.47(3) 3.020(3) 116(2) 
 C(13)-H(13)...O(23)#2 0.92(4) 2.30(4) 3.183(3) 160(3) 
 C(16)-H(16A)...N(11) 0.96(3) 2.32(4) 3.057(3) 132(3) 
 N(24)-H(24N)...O(1W)#30.83(4) 2.23(3) 3.010(3) 155(3) 
 C(26)-H(26)...O(23) 0.87(4) 2.28(4) 2.812(3) 120(3) 
 C(30)-H(30)...O(1W)#3 0.99(4) 2.40(4) 3.246(3) 144(3) 
 O(1W)-H(1W1)...N(11)#40.68(5) 2.27(5) 2.941(3) 171(5) 
 O(1W)-H(1W2)...O(23)#50.94(5) 1.83(5) 2.760(3) 169(4) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x,y+1/2,-z    #2 x+1,y,z    #3 x,y+1,z    #4 x,y-1,z       




X-ray crystallographic data of 3.13 
Table A8.1. Crystal data and structure refinement for 3.13 
Identification code  x1605008  
Empirical formula  C21H33N5O3Cl2  
Formula weight  474.42  
Temperature/K  100  
Crystal system  orthorhombic  
Space group  C2221  
a/Å  14.8861(3)  
b/Å  14.8873(3)  
c/Å  21.3167(5)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  4724.08(17)  
Z  8  
ρcalcg/cm
3  1.334  
μ/mm-1  2.738  
F(000)  2016.0  
Crystal size/mm3  0.27 × 0.148 × 0.108  
Radiation  CuKα (λ = 1.54178)  
2Θ range for data collection/°  8.296 to 144.632  
Index ranges  -18 ≤ h ≤ 16, -18 ≤ k ≤ 18, -26 ≤ l ≤ 25  
Reflections collected  22334  
Independent reflections  4587 [Rint = 0.0370, Rsigma = 0.0348]  
Data/restraints/parameters  4587/0/283  
374 
 
Goodness-of-fit on F2  1.037  
Final R indexes [I>=2σ (I)]  R1 = 0.0267, wR2 = 0.0653  
Final R indexes [all data]  R1 = 0.0278, wR2 = 0.0660  
Largest diff. peak/hole / e Å-3  0.25/-0.20  







Table A8.2. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for 3.13. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ 
tensor. 
Atom x y z U(eq) 
C1 3705.3(13) 6790.6(14) 3030.9(9) 21.7(4) 
N2 2867.6(12) 7113.3(12) 2879.2(8) 22.5(4) 
C3 2357.4(14) 6900.6(14) 3357.0(9) 21.2(4) 
N4 2816.6(12) 6463.7(11) 3811.9(8) 18.5(3) 
C5 2449.5(15) 6117.5(14) 4401.7(10) 25.2(4) 
C6 3693.2(13) 6385.8(12) 3609.5(9) 17.9(4) 
C7 4424.1(14) 5984.2(13) 3999.2(10) 19.6(4) 
C8 5003.0(13) 6696.9(12) 4335.7(9) 17.0(4) 
C9 5552.6(12) 7200.2(12) 3844.5(8) 15.1(4) 
O10 6083.8(9) 6781.4(9) 3506.3(6) 17.7(3) 
N11 5488.9(10) 8097.7(11) 3802.5(7) 16.6(3) 
C12 4889.7(15) 8696.9(13) 4166.3(10) 22.8(4) 
C13 5295.6(15) 9626.7(14) 4055.9(10) 25.0(4) 
C14 5731.9(14) 9556.0(13) 3405.9(10) 22.5(4) 
C15 6098.7(13) 8588.3(12) 3378.4(8) 16.9(4) 
C16 7056.8(13) 8514.8(12) 3643.3(9) 16.6(4) 
O17 7229(1) 8828.5(9) 4164.8(7) 22.4(3) 
N18 7656.2(10) 8083.6(11) 3283.6(7) 16.8(3) 
C19 8567.9(13) 7871.3(13) 3504.0(9) 19.4(4) 
C20 9103.7(15) 8726.1(15) 3638.8(11) 29.0(5) 
C21 9034.4(13) 7323.0(16) 2992.6(10) 25.3(4) 
C22 8555.3(14) 7265.9(13) 4095.8(9) 19.6(4) 
376 
 
O23 9215.3(11) 7235.6(12) 4440.4(7) 31.4(4) 
N24 7835.4(11) 6741.0(11) 4168.6(7) 17.9(3) 
C25 7759.8(14) 6096.9(13) 4680.8(9) 20.1(4) 
C26 7253.0(14) 6467.7(13) 5252.3(9) 19.4(4) 
C27 6338.9(13) 6884.9(12) 5092.3(8) 18.1(4) 
C28 5671.6(14) 6231.2(13) 4782.4(9) 19.2(4) 
Cl1 6243.8(4) 5614.6(4) 6839.7(3) 35.18(14) 
Cl2 8169.8(4) 5257.0(4) 6866.9(3) 34.21(14) 






Table A8.3. Anisotropic Displacement Parameters (Å2×103) for 3.13. The Anisotropic 
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…] 
Atom U11 U22 U33 U23 U13 U12 
C1 19.2(9) 29.8(9) 16.1(9) 2.5(8) 1.0(7) -4.1(7) 
N2 23.6(8) 27.9(9) 16.0(7) 1.1(6) -1.1(7) -0.5(6) 
C3 21.5(10) 23.0(9) 19.2(9) -2.3(7) -0.5(7) 0.1(7) 
N4 22.5(8) 18.2(7) 14.8(7) -1.3(6) 3.1(7) -3.1(6) 
C5 31.6(11) 23.4(9) 20.5(10) 3.1(8) 10.9(8) 0.4(8) 
C6 19.0(9) 18.4(8) 16.3(9) -1.8(7) -0.4(7) -6.0(7) 
C7 21.0(9) 17.8(9) 20.1(9) 1.8(7) -2.1(7) -4.9(7) 
C8 18.5(9) 16.7(9) 15.9(8) 0.8(7) 0.6(7) -3.3(7) 
C9 15.1(8) 18.3(9) 12.0(8) 0.2(7) -3.4(7) -3.2(7) 
O10 21.1(7) 16.8(6) 15.1(6) -1.9(5) 2.1(5) -1.5(5) 
N11 19.0(7) 17.1(7) 13.9(7) 0.7(6) 2.5(6) -0.3(6) 
C12 26.3(10) 19.1(9) 23(1) 1.6(7) 8.3(8) 4.5(7) 
C13 32.1(11) 18.1(9) 24.8(10) 0.2(8) 7.6(8) 4.2(8) 
C14 27.5(11) 17.9(9) 22.1(9) 5.5(7) 1.8(8) 2.0(7) 
C15 20.8(9) 16.9(8) 13.1(8) 2.6(6) 0.8(7) -1.8(7) 
C16 22.7(10) 12.7(8) 14.4(9) 3.1(6) 0.2(7) -3.6(7) 
O17 30.2(8) 21.4(7) 15.7(7) -3.0(5) -4.0(6) 0.8(5) 
N18 17.0(7) 19.9(7) 13.3(7) 0.5(6) -1.1(6) -3.8(6) 
C19 16.1(9) 23.6(9) 18.5(9) 3.0(7) -1.8(7) -4.3(7) 
C20 23.2(10) 31.6(11) 32.1(12) 5.9(9) -6.9(9) -12.6(8) 
C21 17.9(9) 37.9(11) 20(1) 4.5(8) 1.8(8) 2.0(8) 
C22 20.7(9) 22.4(9) 15.6(9) -1.3(7) -1.8(7) -2.1(7) 
378 
 
O23 27.7(8) 41.5(9) 25.2(8) 9.3(6) -12.4(7) -11.1(7) 
N24 18.9(8) 18.9(8) 15.9(7) 1.3(6) -2.4(6) -0.2(6) 
C25 23.2(10) 17.2(9) 19.9(10) 3.2(7) -0.9(8) 1.2(7) 
C26 23.7(10) 19.2(9) 15.4(8) 1.8(7) -3.2(8) -1.3(7) 
C27 22.3(9) 18.2(8) 13.7(8) 0.3(7) -0.2(7) -0.2(8) 
C28 23.8(10) 17.1(8) 16.8(9) 3.0(7) -0.6(8) -3.0(7) 
Cl1 28.9(3) 36.3(3) 40.4(3) -6.2(2) -6.8(2) 5.1(2) 
Cl2 24.7(2) 43.7(3) 34.2(3) -3.2(2) 1.2(2) -4.9(2) 






Table A8.4. Bond Lengths for 3.13 
Atom Atom Length/Å  Atom Atom Length/Å 
C1 N2 1.375(3)  C14 C15 1.542(3) 
C1 C6 1.373(3)  C15 C16 1.538(3) 
N2 C3 1.309(3)  C16 O17 1.233(2) 
C3 N4 1.353(3)  C16 N18 1.340(3) 
N4 C5 1.465(3)  N18 C19 1.471(2) 
N4 C6 1.379(3)  C19 C20 1.529(3) 
C6 C7 1.494(3)  C19 C21 1.529(3) 
C7 C8 1.544(3)  C19 C22 1.550(3) 
C8 C9 1.525(3)  C22 O23 1.227(3) 
C8 C28 1.542(3)  C22 N24 1.335(3) 
C9 O10 1.238(2)  N24 C25 1.458(2) 
C9 N11 1.343(3)  C25 C26 1.535(3) 
N11 C12 1.481(2)  C26 C27 1.534(3) 
N11 C15 1.475(2)  C27 C28 1.540(3) 
C12 C13 1.529(3)  Cl1 C29 1.765(2) 






Table A8.5. Bond Angles for 3.13 
Atom Atom Atom Angle/˚  Atom Atom Atom Angle/˚ 
C6 C1 N2 110.66(18)  N11 C15 C14 102.80(15) 
C3 N2 C1 104.99(17)  N11 C15 C16 108.09(14) 
N2 C3 N4 112.38(18)  C16 C15 C14 112.40(16) 
C3 N4 C5 126.57(18)  O17 C16 C15 119.80(18) 
C3 N4 C6 107.11(16)  O17 C16 N18 123.99(18) 
C6 N4 C5 126.30(18)  N18 C16 C15 116.19(16) 
C1 C6 N4 104.86(18)  C16 N18 C19 122.31(16) 
C1 C6 C7 131.75(19)  N18 C19 C20 111.26(17) 
N4 C6 C7 123.28(17)  N18 C19 C21 107.82(16) 
C6 C7 C8 112.95(16)  N18 C19 C22 111.95(15) 
C9 C8 C7 108.55(15)  C20 C19 C22 109.71(16) 
C9 C8 C28 107.37(15)  C21 C19 C20 109.97(17) 
C28 C8 C7 109.77(15)  C21 C19 C22 105.98(16) 
O10 C9 C8 119.65(16)  O23 C22 C19 119.91(18) 
O10 C9 N11 120.48(17)  O23 C22 N24 123.46(19) 
N11 C9 C8 119.79(16)  N24 C22 C19 116.38(17) 
C9 N11 C12 127.38(16)  C22 N24 C25 122.27(17) 
C9 N11 C15 119.37(16)  N24 C25 C26 113.32(16) 
C15 N11 C12 113.17(15)  C27 C26 C25 113.88(16) 
N11 C12 C13 103.10(16)  C26 C27 C28 114.31(15) 
C12 C13 C14 104.14(17)  C27 C28 C8 113.40(15) 




Table A8.6. Hydrogen Bonds for 3.13 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
N18 H18 N21 0.88 2.13 2.973(2) 161.3 





Table 7 Torsion Angles for 3.13 
A B C D Angle/˚  A B C D Angle/˚ 
C1 N2 C3 N4 0.4(2)  C12 N11 C15 C14 -9.8(2) 
C1 C6 C7 C8 77.3(3)  C12 N11 C15 C16 109.18(18) 
N2 C1 C6 N4 0.3(2)  C12 C13 C14 C15 -35.9(2) 
N2 C1 C6 C7 -175.89(19)  C13 C14 C15 N11 27.8(2) 
N2 C3 N4 C5 -178.82(18)  C13 C14 C15 C16 -88.16(19) 
N2 C3 N4 C6 -0.2(2)  C14 C15 C16 O17 51.1(2) 
C3 N4 C6 C1 0.0(2)  C14 C15 C16 N18 -130.33(17) 
C3 N4 C6 C7 176.54(17)  C15 N11 C12 C13 -12.1(2) 
N4 C6 C7 C8 -98.3(2)  C15 C16 N18 C19 -172.92(15) 
C5 N4 C6 C1 178.55(18)  C16 N18 C19 C20 -63.4(2) 
C5 N4 C6 C7 -4.9(3)  C16 N18 C19 C21 175.94(17) 
C6 C1 N2 C3 -0.4(2)  C16 N18 C19 C22 59.7(2) 
C6 C7 C8 C9 -69.1(2)  O17 C16 N18 C19 5.6(3) 
C6 C7 C8 C28 173.85(16)  N18 C19 C22 O23 -159.16(19) 
C7 C8 C9 O10 -59.6(2)  N18 C19 C22 N24 26.5(2) 
C7 C8 C9 N11 123.63(18)  C19 C22 N24 C25 176.00(17) 
C7 C8 C28 C27 174.54(16)  C20 C19 C22 O23 -35.1(3) 
C8 C9 N11 C12 -3.6(3)  C20 C19 C22 N24 150.49(18) 
C8 C9 N11 C15 172.90(16)  C21 C19 C22 O23 83.5(2) 
C9 C8 C28 C27 56.7(2)  C21 C19 C22 N24 -90.8(2) 
C9 N11 C12 C13 164.57(19)  C22 N24 C25 C26 94.8(2) 
C9 N11 C15 C14 173.18(16)  O23 C22 N24 C25 1.8(3) 
C9 N11 C15 C16 -67.8(2)  N24 C25 C26 C27 51.3(2) 
O10 C9 N11 C12 179.61(18)  C25 C26 C27 C28 59.9(2) 
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O10 C9 N11 C15 -3.9(3)  C26 C27 C28 C8 -150.55(16) 
N11 C12 C13 C14 29.1(2)  C28 C8 C9 O10 59.0(2) 
N11 C15 C16 O17 -61.7(2)  C28 C8 C9 N11 -117.77(18) 






Table A8.8 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for 3.13 
Atom x y z U(eq) 
H1 4221 6841 2771 26 
H3 1735 7038 3382 25 
H5A 1817 6293 4439 38 
H5B 2790 6367 4755 38 
H5C 2496 5461 4406 38 
H7A 4816 5615 3727 24 
H7B 4153 5582 4317 24 
H8 4612 7124 4574 20 
H12A 4896 8539 4618 27 
H12B 4265 8666 4009 27 
H13A 5749 9770 4380 30 
H13B 4824 10096 4060 30 
H14A 6224 9999 3360 27 
H14B 5284 9659 3070 27 
H15 6067 8343 2942 20 
H18 7499 7922 2902 20 
H20A 9150 9085 3255 43 
H20B 9707 8565 3784 43 
H20C 8798 9076 3964 43 
H21A 8688 6776 2910 38 
H21B 9640 7160 3132 38 
H21C 9074 7681 2608 38 
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H24 7391 6785 3898 21 
H25A 8370 5913 4813 24 
H25B 7445 5555 4526 24 
H26A 7160 5974 5557 23 
H26B 7631 6929 5458 23 
H27A 6436 7400 4807 22 
H27B 6066 7121 5483 22 
H28A 5330 5916 5115 23 
H28B 6013 5774 4544 23 
H29A 6988 4300 7050 32 
H29B 7099 4992 7621 32 
 
 
